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1. Central cholinergic neurotransmission 
 
The presence of cholinergic transmission in the central nervous system (CNS) was 
hypothesized by Henry Dale from his demonstration of the evanescence of the action 
of acetylcholine (ACh) by the action of the acetylcholinesterase (AChE) (EC-3.1.1.7) in 
the CNS (Dale, 1937). Nevertheless, Otto Loewi in 1921 had demonstrated the 
existence of cardiac neurotransmission by a substance that he called "vagusstoff", and 
which was later identified as ACh. These findings led Felderg (1945) to postulate that 
“the central nervous system is built of cholinergic and non-cholinergic neurons”, 
distributed in a particular and organized fashion. Further studies demonstrated the 
presence of ACh and choline acetyltransferase (ChAT) (EC-2.3.1.6), ACh synthesis 
and release in the CNS, and the central and peripheral effects of muscarinic agonists 
and anticholinesterases (Stedman and Stedman, 1937; Feldberg, 1945, 1950; 
Karczmar, 1967; Barker et al., 1972).  
 
 
1.1. Acetylcholine metabolism  
 
 The main components of ACh synthesis are acetyl coenzyme A (acetyl-CoA), 
choline (Ch), Ch uptake system and ChAT whose gene is located in human 
chromosome 10q11.23 (Figure 1). ChAT is the enzime responsible for the synthesis of 
ACh from acetyl-CoA and choline in the neuronal perikarya. This reaction is reversible, 
but under conditions of equilibrium, the concentrations of ACh and CoA are higher than 
the concentrations of choline and acetyl-CoA (reviewed in Blusztajn and Wurtman, 
1983). At physiological concentrations of acetyl-CoA and Ch, the activity of ChAT is 
much lower than its maximal rate of activity at saturation concentrations of the 
substrates. Thus, it is possible that, under certain conditions, ChAT activity may be 
insufficient to maintain the rate of ACh synthesis that would be needed to compensate 
for ACh release at high levels of synaptic activity (Tucek, 1984). 
 
Choline originating from released ACh 
 The ACh released from cholinergic terminals can bind to cholinergic receptors 
and be hydrolyzed in the synaptic cleft by the enzyme AChE. Although ACh can be 
spontaneously hydrolyzed, the metabolic process is 100 million times faster when it is 
degraded by the enzyme AChE (each molecule of AChE is able to degrade about 
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25,000 molecules of ACh per second). AChE is found in high concentrations in the 
postsynaptic membrane, and is expressed in neurons, erythrocytes and lymphocytes 
(Brimijoin, 1983). Once the ACh is bound to AChE, the hydrolytic reaction occurs at a 
region of the active site called the esteratic subsite. Here, the ester bond of ACh is 
broken and acetate and Ch are released. Ch is then immediately uptaken by the 
sodium-dependent high affinity Ch uptake (SDHACU) system located on the 
presynaptic membrane (Figure 1). Acetate, however, becomes covalently bonded to 
serine residues within the esteratic subsite, forming a temporary acetylated form of 
AChE  
 
Choline from diet 
 Nerve tissue needs sufficient amounts of “external” Ch for effective release of 
ACh, and Ch obtained from the diet is needed for homeostatic nerve function. High 
levels of dietary Ch and/or certain phospholipids increase the levels of plasma Ch 
which is then transported across the blood-brain barrier into the brain itself, and this is 
consistent with findings which show that an increased intake of Ch leads to behavioral 
and functional benefits (Wurtman, 1987).  
 
Choline from brain phospholipids  
 The synthesis of ACh depends on the levels of Ch, and when it is in short 
supply, membrane phospholipids must provide an alternative source from which Ch 
can be synthesized de novo (Millington and Wurtman, 1982). Phospholipids present in 
the brain include phosphatidylethanolamine (PE), phosphatidylcholine (PC) and 
phosphatidylserine (PS) among other related compounds, and, as will be seen later, all 
of them can be potential sources for the de novo synthesis of Ch via complex 
enzymatic pathways (Hattori and Kanfer, 1984). Changes in the composition of 
membrane phospholipids caused by neurodegenerative processes may affect Ch 
availability for the synthesis of ACh. 
 
Choline transport and uptake 
 There are two Ch reuptake systems, one with high affinity for Ch and the other 
with low affinity. The high affinity Ch transporter is an integral membrane protein with 
13 transmembrane (TM) segments, which belongs to the Na+/glucose co-transporter 
family, and which captures Ch for the synthesis of ACh (Haga, 1971; Okuda and Haga, 
2003) (Figure 1). The second reuptake system captures Ch with very low affinity, 
displays its maximum capacity of transportation independently of Na+, and does not 
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use Ch in the synthesis of ACh. The availability of the irreversible inhibitor of both 
transporters, hemicholinium-3 (HC-3), demonstrated the presence of both types of Ch 
transporters (Yamamura and Snyder, 1973; Haga and Noda, 1973). The low affinity 
transporters are ubiquitous and are found in multiple cell types, whereas the SDHACU 
is specific to cholinergic terminals (Misawa et al., 2001; Kobayashi et al., 2002). The 
early observation that SDHACU levels were decreased in the hippocampus after 
dennervation of the septo-hippocampal pathway and that most of the Ch transported 
via SDHACU was converted to ACh, suggested that SDHACU is not only a unique 
constituent of cholinergic nerve terminals, but also a rate-limiting component for 
synaptic ACh synthesis and availability (Amara and Kuhar, 1993). 
 
 
Figure 1. Schematic representation of a cholinergic synapse. The endogenous ligand, ACh, is 
synthesized in cholinergic neurons (left neuron) by the enzyme ChAT and can be stored in 
synaptic vesicles by the vesicular ACh transporter (vAChT). The ACh released into the synaptic 
cleft can bind to pre- and postsynaptic receptors, and be hydrolysed by AChE. Choline uptake is 
mediated by presynaptic SDHACU. (Modified from Jones et al., 2012).  
 
 
1.2. Central cholinergic pathways 
 
 The central cholinergic pathways have been studied and described over the last 
decades by detection of the presence and activities of ChAT and AChE, or by 
analysing drug binding to cholinergic receptors, and by using different experimental 
models, e.g., specific cholinergic lesions and retrograde staining techniques. In vivo 
neuroimaging techniques such as the PET scanner, functional magnetic resonance 
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imaging and tensor diffusion tractography in humans, monkeys, apes, marmosets, 
raccoons, chickens, rabbits, rodents, and cats have also been applied to the study of 
the cerebral cholinergic pathways, and have shown a high conservation between 
different animal species (Mesulam et al., 1983a,b; Mesulam, 2004; van Dalen et al., 
2016). 
 The cholinergic cells in the brain include projection neurons that innervate distal 
areas and local interneurons that are intermingled with their cellular targets. 
Cholinergic projection neurons are grouped in nuclei throughout the brain, such as in 
the pedunculopontine and laterodorsal tegmental areas (PPTg and LDTg), the medial 
habenula (MHb) (Ren et al., 2011) and the basal forebrain complex (reviewed in Woolf 
et al., 1991). These cholinergic neurons project widely and diffusely, innervating 
cortical and subcoprtical regions throughout the CNS (Figure 2; pathways in purple and 
in green). Cholinergic interneurons are typified by the tonically active ACh neurons of 
the striatum and nucleus accumbens (Mesulam, 1995; Benagiano et al., 2003; von 
Engelhardt et al., 2007) (Figure 2; pathways in blue).   
 Mesulam proposed a useful way of subdividing the cholinergic system in the 
brain of mammals into 8 “major sectors” named Ch1 to Ch8 (Mesulam et al., 1983a; 
Mesulam, 1990). The cholinergic neurons from the different Ch1 to Ch8 subdivisions 
differ in size and shape, are interspersed among non-cholinergic neurons, the ratio of 
cholinergic versus non-cholinergic neurons differs among sectors and the perikarya of 
the cholinergic neurons, as well as non-cholinergic radiations to these neurons, contain 
AChE. 
 
Basal forebrain cholinergic system 
 The Ch1 to Ch4 clusters of cholinergic cells constitute the basal forebrain 
cholinergic system (Mesulam et al., 1983a). The basal forebrain cholinergic neurons 
(BFCN) located in the Ch1 to Ch4 subdivisions provide the main source of cortical and 
hippocampal cholinergic innervation. Ch1 neurons are contained in the medial septal 
nucleus or medial septum (MS), particularly along the midline and the outer edge of the 
septum and 80% of them are non-cholinergic (Mesulam et al., 1983a). Ch1 form a 
bean-shaped continuum with the Ch2 sector, which consists of neurons located within 
the vertical limb of the diagonal band of Broca (VDB); more than 70% of Ch2 neurons 
are BFCN. The main projections of the Ch1-Ch2 BFCN are to the hippocampus, 
hypothalamus and occipital cortex. The Ch3 sector is comprised of neurons of the 
horizontal limb of the diagonal band of Broca (HDB), with approximately 25% of 
neurons displaying a cholinergic phenotype innervating the olfactory bulb. The Ch4 
sector of both human and monkey brain is the major source of cholinergic projections 
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to the cortical mantle (Mesulam et al., 1983b) (Figure 2; pathways in purple). The Ch4 
sector is also denominated nucleus basalis of Meynert (nbM) and it has been 
described as containing the cells which are most vulnerable to neurodegeneration in 
Alzheimer's disease patients. The nbM is explained in detail later and specifically 
analyzed in the present manuscript. 
 
Pedunculopontine, laterodorsal tegmental and habenular areas  
 The Ch5 sector is a heterogeneous nucleus located in the pontomesencephalic 
reticular formation and is comprised of neurons within the pedunculopontine nucleus. 
The Ch5 sector radiates to several thalamic nuclei and sends a minor projection to the 
neocortex. The Ch6 cluster, which is located in the laterodorsal tegmental nucleus, 
innervates various thalamic nuclei (Mesulam et al., 1989). The Ch7 sector is located in 
the medial habenula and projects to the interpeduncular nucleus (Kasa, 1986). Finally, 
the Ch8 sector corresponds to the parabigeminal nucleus of the pontomesencephalic 
region, and its neurons project to the superior colliculus and the lateral geniculate 
(Mesulam et al., 1989) (Figure 2; pathways in green). 
 
 
Figure 2. Basal forebrain cholinergic nuclei and networks in rodent CNS. NBM, nucleus basalis 
magnocellularis; BLA, basolateral amygdala; DR, dorsal raphe; EC, entorhinal cortex; HDB, 
horizontal diagonal band nucleus; Icj, islands of Calleja; IPN, interpeduncular nucleus; LC; locus 
ceruleus; ldt, laterodorsal tegmental nucleus; LH, lateral hypothalamus; MS, medial septal 
nucleus; PPN, pedunculopontine nucleus; SI, substantia innominata; SN, substantia nigra; VDB, 
vertical diagonal band nucleus. (Modified from Woolf et al., 1997). 
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1.3. The nucleus basalis of Meynert  
 
Anatomy and histology of Ch4  
 More than 100 years ago Theodor Meynert first described a group of 
magnocellular hyperchromic neurons located in the human basal forebrain, naming it 
the nucleus of the ansa lenticularis (Meynert, 1872). This structure was later renamed 
as the nucleus basalis of Meynert and was considered to be homologous with the 
nucleus basalis magnocellularis (NBM) of the rat (Kölliker, 1896). The nbM is 
distributed in the sagittal plane extending from the anterior tubercle to the most rostral 
parahippocampal gyrus, and has the greatest cross-sectional diameter in the 
substantia innominata (Mesulam and Geula, 1988). The HDB (Ch3) is the inferior and 
rostral limit. Dorsally, the nbM is limited by the ventral globus pallidus, and laterally by 
the anterior commissure (Figures 2 and 3) (Gratwicke et al., 2013). The nbM is 
evolutionarily conserved in human and non-human primates, as well as in rodents. 
Although it is a well-defined anatomical structure, in rodents it is more rudimentary, and 
BFCN are more interspersed with other neuronal types inside the globus pallidus 
(Gorry, 1963). Histochemical studies in humans reveal the predominant presence of 
BFCN which are estimated to be 210,000 cells in each hemisphere (Gilmor et al., 
1999). These are cholinergic magnocellular hyperchromic neurons, fusiform to 
multipolar in shape and 40–50 × 60–70 μm in size, with no particular pattern of 
dendritic arborisation (Mufson et al., 2003; Mesulam and Geula, 1988). 
Immunochemical studies show that 90% of the magnocellular neurons in the nbM 
express ChAT, AChE and the low affinity nerve-growth factor receptor (p75NTR), 
revealing their cholinergic phenotype. Moreover, a mosaic of smaller non-cholinergic, 
non-galaninergic but GABAergic neurons are also present (Gritti et al., 1993; Mesulam 
and Geula, 1988; Mufson et al., 2003).  
 
 
 
Introduction 
 
10 
 
 
 
Figure 3.  (A) Anatomical diagram of the left hemisphere showing the location of the nbM and 
its major projecting cholinergic pathways in the human brain. A = amygdala; AC = anterior 
commissure (lateral aspect); C = caudate; Cg = Cingulate gyrus; F = frontal lobe (medial 
surface); GPi = globus pallidus (internal part); IN = insular cortex; nbM = nucleus basalis of 
Meynert; Oc = occipital lobe (medial surface); OF = orbitofrontal cortex; P = putamen; Pr = 
parietal lobe (medial surface). (Modified from Gratwicke et al., 2013). (B) Anatomical diagram of 
the human brain showing the location of the medial septum (ms) which innervates the 
hippocampus and the amygdala (red dashed line), and the nucleus basalis of Meynert which 
innervates the entire cortical mantle (red line) (Modified from Perry et al., 1999).  
 
Connectivity. Afferent projections to the nbM 
 Direct axonal tracing experiments in non-human primates and in rodents reveal 
the preponderance of efferent innervations to the almost entire cortical mantle and 
amygdala. However, the afferent connections which reach to the nbM are not 
symmetrical and are restricted to several well-known limbic and paralimbic areas (i.e. 
parahippocampal and entorhinal regions, amygdala, hypothalamus, septal nuclei and 
nucleus accumbens) (Figure 4) (Jones et al., 1976; Mesulam and Geula, 1988; 
Mesulam and Mufson, 1984; Russchen et al., 1985). Immunohistochemical studies in 
rodents reveal a substantial number of catecholaminergic projections from the ventral 
tegmental area and substantia nigra pars compacta, serotonergic projections from the 
dorsal raphe and ventral tegmental area and cholinergic innervations from the 
pedunculopontine nucleus and laterodorsal tegmental area (Figure 4) (Jones and 
Cuello, 1989). The afferent projections to the nbM were demonstrated at the 
subcellular level by the ultrastructural localization of different markers. Dendrites of 
Ch4 BFCN receive innervations from cholinergic (ChAT-positive), GABAergic (glutamic 
acid decarboxylase-positive) and dopaminergic (tyrosine hydroxylase-positive) neurons 
(Smiley and Mesulam, 1999; Reviewed in Mesulam, 2013). The cholinergic contacts 
usually form asymmetric synapses and could represent local collaterals or projections 
from Ch5–Ch6. The GABAergic input occurs through symmetric synapses and could 
represent input from inhibitory neurons within the basal forebrain. The human nbM 
contains numerous dopaminergic, serotonergic, and noradrenergic axons from the 
Introduction 
 
11 
 
neurons of the ventral tegmental area/substantia nigra, the midbrain raphe and the 
nucleus locus coeruleus, respectively. In the rat, all of these nuclei, together with the 
cholinergic Ch5–Ch6 cell groups, have been shown to project to Ch4 (Jones and 
Cuello, 1989). Galanin, glutamate and estrogen receptors have also been found in the 
human Ch4 sector as postsynaptic components of extrinsic afferents to Ch4 (Mufson et 
al., 2003). 
 
Connectivity. Efferent projections from the nbM 
 The human and primate nbM and the NBM in rodents provides the main source 
of cortical cholinergic innervation (Mesulam et al., 1983a,b). Thus, both electrical or 
optogenetic stimulation of the rodent NBM evokes the release of ACh in neocortex 
(Kurosawa et al., 1989, Kalmbach et al., 2012). Moreover, specific depletion of BFCN 
in the Ch4 of rodents and primates significantly reduces the cortical densities of ACh 
and AChE (Wenk et al., 1994; McGeer et al., 1986). At present, the cortical cholinergic 
innervation is being topographically segmented in subsectors of the nbM by using 
retrograde tracing experiments, BFCN lesion models, neuropathological studies in 
brain samples from AD patients and in anatomical studies carried out with diffusion 
tensor imaging and tractography (van Dalen et al., 2016). The most rostral sector, 
designated as the Ch4a, is born posterior to the olfactory tubercle and can be divided 
into anteromedial (Ch4am), anterolateral (Ch4al) and anterointermediate (Ch4ai) 
subsectors. The intermediate sector (Ch4i), which can be segmented into 
superior/dorsal (Ch4id) and inferior/ventral (Ch4iv) subsectors, is caudally limited by 
the ansa peduncularis (ventral amygdalofugal pathway). The most posterior sector 
(Ch4p) is limited by the parahippocampal gyrus (Mesulam and Geula, 1988; Mesulam 
et al., 1983a,b).  
 Ch4a mainly innervates the most rostral part of the brain. The neurons from 
Ch4am provide the major cholinergic innervation to frontal, parietal and cingulate 
cortices. A more modest number of projections are directed to the inferior parietal 
lobule including hypothalamus, hippocampus, somatosensory cortex, amygdala and 
parahippocampal regions among others. The Ch4al subsector mainly projects to the 
frontoparietal cortex and the amygdala and, to a lesser degree, to the olfactory bulb, 
motor cortex, ventrolateral orbital cortex, insular and parahippocampal areas. The 
BFCN of the Ch4i subsector are located in the middle of the nucleus and send 
projections to orbital, insular, periarcuate, peristriate, inferotemporal and 
parahippocampal areas, and to the inferior parietal lobule, but project more modestly to 
the medial frontal pole, dorsomedial motor cortex, amygdala, anterior auditory cortex 
and the temporal pole. Lastly, the BFCN from the Ch4p subsector mainly innervate the 
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superior temporal pole and few projections are directed to inferotemporal and posterior 
insular regions (Jones et al., 1976; Mesulam and Geula, 1988; Mesulam et al., 1983b). 
The same regions can be innervated by different Ch4 subsectors which show that 
there is a considerable overlap among BFCN from individual subsectors. The lack of 
anatomical separation of BFCN in discrete subpopulations would represent a challenge 
for the identification of the degeneration of a specific Ch4 subsector if we were able to 
observe pathological alterations in a particular innervated area of the basal forebrain 
cholinergic system. Immunohistochemical studies in postmortem brain samples from 
human subjects show that cholinergic innervations from the nbM are mostly 
unmyelinated (Wainer and Mesulam, 1990) and leave the nucleus in two highly 
discrete organized fibre bundles which form the medial and lateral cholinergic 
pathways (Figure 3A) (Selden et al., 1998).  
 Axonal tracing experiments must be performed in vivo or ex vivo in animals but 
the recently developed diffusion tensor tractography technique allows us to identify the 
brain´s anatomical connections in vivo in human subjects, and the use of this technique 
has revealed that there are similar connectivity patterns in humans as those observed 
in non-human species. Both the studies in postmortem samples and those performed 
in vivo in healthy volunteers demonstrate that the medial pathway leaves the nbM 
anteriorly and enters through the cingulum, travels posteriorly to the splenium and 
enters the retrosplenial white matter, where it merges with fibres of the lateral pathway 
in the occipital lobe, thereby innervating almost the entire cortical mantle (Hong and 
Jang, 2010; Selden et al., 1998). Moreover, the pathways from the nbM to the cortex 
have been tracked in 87 cognitively impaired patients in an attempt to clarify the 
relationship between symptoms of cholinergic deficiency and degradation of the 
cortical cholinergic projections (van Dalen et al., 2016). Therefore, it is reasonable to 
compare human connectivity with that found in primates and rodents and, indeed, 
human pathological data give indirect support to this assumption (Mesulam and Geula, 
1988). The cholinergic innervation fibres form a dense plexus in all regions of the 
human neocortex displaying synaptic specializations, as they are often in close contact 
with cortical cholinoceptive neurons (Mesulam and Geula, 1988). Overall, the 
heterogeneous neural input to the nucleus from predominantly limbic structures, 
combined with the massive cholinergic output to the almost entire neocortical mantle, 
makes the nbM the principal candidate for the modulation or influence of several 
aspects of complex and organized behavior such as learning, executive functions and 
working memory (Mesulam, 1987; Gratwicke et al., 2013). 
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Figure 4. The proposed major connections of the human nbM with cortical and subcortical 
structures. Major afferent projections (bright green arrows) are inputs to the nbM as a whole: 
catecholaminergic, serotonergic and cholinergic projections. Major efferent projections (bright 
red arrows) are shown according to their subsector of origin. All efferent projections are 
cholinergic. Cx = cortex; Retic. Formation = brainstem reticular formation; SNpc = substantia 
nigra pars compacta; VTA = ventral tegmental area. (Extracted from Gratwicke et al., 2013). 
 
1.4. Central cholinergic signaling 
  
 The acetylcholine receptors are divided into metabotropic muscarinic receptors 
and ionotropic nicotinic receptors. 
 
Muscarinic acetylcholine receptors 
Structure of muscarinic acetylcholine receptors 
 Muscarinic ACh receptors (mAChR) are constituted by seven-transmembrane 
(TM) spanning domains and belong to the guanine nucleotide-binding protein coupled 
receptor (GPCR) superfamily. There are five subtypes of mAChR which mediate 
multiple actions of ACh in the CNS and the periphery. All five subtypes of mAChR are 
expressed in the CNS and are thought to play a relevant role in the signaling 
mechanism for learning and memory processes, REM sleep, attention, control of 
movement and thermoregulation. Riker and Wescoe (1951) suggested the existence of 
different subtypes of mAChR when they observed a cardioselective inhibition of 
mAChR by gallamine and a few years later, some cholinergic compounds were 
described as showing selectivity for mAChR located in sympathetic ganglia 
(Roszkowski, 1961). The introduction of the antagonist pirenzepine demonstrated the 
selectivity of this compound for mAChR subtypes in radioligand binding and functional 
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assays, thereby demonstrating the existence of at least two distinct mAChR subtypes 
(Hammer et al., 1980; Brown et al., 1980; Hammer and Giachetti, 1982). 
 
Muscarinic acetylcholine receptor subtypes 
 M1 and M2 mAChR subtypes were the first to be cloned (Kubo et al., 1986), 
followed by the cloning of the M3, M4 and M5 genes (Bonner et al., 1987, 1988), which 
confirmed that the mAChR are glycoproteins which belong to the superfamily of GPCR 
(Hulme et al., 1990; Wess, 1993). The chromosomal localization of the human mAChR 
genes are as follows: M1, 11q12–13; M2, 7q35–36; M3, 1q43–44; M4, 11p12–11.2; M5, 
15q26, and phylogenetic analyses reveal that the mAChR have evolved from a 
common ancestor (Bonner et al. 1991; Horn et al., 2000). The amino acid composition 
of the human mAChR subtypes ranges from 460 amino acids for M1, 466 for M2, 589 
for M3, 479 for M4, to 532 for M5. Primary sequence alignment reveals that the 
individual subtypes share approximately 145 invariant amino acid residues and show 
between 89% and 98% common amino acid identity in various mammalian species 
(Wess, 1993; Bonner, 1989). Within the TM segments, there is 63% common identity in 
all mAChR subtypes, but it is even higher among the M1, M3, and M5, and between the 
M2 and M4 subtypes. 
 In addition, the preferential coupling of M1, M3 and M5 subtypes is to Gαq/11 
proteins activates phospholipase C (PLC). PLC hydrolyzes phosphatidylinositol 4,5-
bisphosphate (PIP2) to diacyl glycerol (DAG) and inositol trisphosphate (IP3) which act 
as intracellular secondary messengers; DAG activates protein kinase C (PKC) and IP3 
contributes to the phosphorylation of some proteins and the movilization of intracellular 
Ca2+. 
  M2 and M4 mAChR subtypes are preferentially coupled to Gαi/o proteins, whose 
activation mainly inhibits the cAMP dependent pathway by inhibiting adenylate cyclase 
activity which decreases the activity of cAMP-dependent protein kinases (Caulfield and 
Birdsall, 1998)  (Figures 1 and 5).  
 
Distribution of muscarinic acetylcholine receptor subtypes 
 Radioligand binding, immunoprecipitation, immunohistochemistry and in situ 
hybridization techniques have contributed to determining the precise anatomical 
localization and relative abundance of mAChR in the CNS. The earliest studies focused 
on the distribution of central mAChR subtypes were performed by means of radioligand 
binding using the non-subtype selective compound [3H] quinuclidinyl benzilate ([3H] 
QNB) (Snyder et al., 1975). Subsequent refinements in the radioligand-based 
approach to map specific mAChR subtypes involved the use of the radioligand [3H] N-
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methylscopolamine ([3H] NMS), as well as [3H] QNB, in conjunction with relatively 
subtype-selective antagonists (see Ehlert et al., 1994). In situ hybridization and 
quantitative autoradiographic studies with optimized labeling conditions have also 
significantly contributed to quantifying and anatomically locating the mAChR subtypes 
in the CNS (Smith et al., 1991; Rodriguez-Puertas et al., 1997; Flynn et al., 1995). The 
combination of both kinetic and equilibrium labeling approaches provides selective 
labeling of the five mAChR subtypes by using specific cocktails of subtype-selective 
antagonists to “mask” the presence of all mAChR subtypes except the desired 
receptor. Although mRNA-based techniques are very sensitive, the levels and the 
location of mRNA measured cannot be precise since the presence of mRNA does not 
mean that the protein is specifically expressed at an equivalent level in that location or 
that it will be transported to its final destination. The generation of mAChR subtype-
selective antibodies has permitted us to establish the anatomical distribution in discrete 
brain regions and cell compartments and has provided us with a more profound 
understanding of their physiological role in relation to neuronal networks (Levey et al., 
1991). 
 M1 mAChR mRNA transcript is mainly localized in the cerebral cortex, 
hippocampus, thalamus, caudate-putamen, amygdala, olfactory bulb, olfactory tubercle 
and dentate gyrus, whereas M2 mAChR mRNA is more abundantly detected in the 
basal forebrain, caudate-putamen, hippocampus, hypothalamus, amygdala and 
pontine nuclei (Buckley et al., 1988; Vilaro et al., 1994). At the cellular level, M1 
mAChR-immunoreactivity is restricted to neuronal bodies and neurites which is 
consistent with its role as the major postsynaptic mAChR subtype. In the basal 
forebrain, M2 mAChR is expressed at high levels in the BFCN which suggests that M2 
mAChR can act as an autoreceptor. However, M2 mAChR is also present in non-
cholinergic cortical and subcortical structures, thus providing evidence that this subtype 
may presynaptically modulate the release of ACh and other neurotransmitters and may 
also operate postsynaptically (Levey et al., 1991, 1995). Quantitative autoradiographic 
experiments reveal the highest levels of M1 mAChR in the hippocampus, nucleus 
accumbens and caudate-putamen. More modest labeling is also noted in the molecular 
layer of the dentate gyrus and in the olfactory tubercle (Flynn et al., 1997). M2 mAChR 
labeling is observed in the occipital region of the cerebral cortex, the dorsal region of 
the caudate, the olfactory tubercle, the nucleus accumbens, the superficial layers of the 
superior and inferior colliculi, the pontine and parabrachial nuclei, the motor trigeminal 
and the facial nuclei in the brainstem, and some labeling is also present in the 
cerebellum. In general, these findings are consistent with previous studies (Mash and 
Potter, 1986; Levey et al., 1991), but not with in situ experiments that failed to find M2 
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mRNA in the cortex and striatum (Buckley et al, 1988; Vilaro et al., 1994). M3 mRNA 
transcription occurs in the olfactory tubercle, cerebral cortex, hippocampus, thalamus, 
caudate-putamen, and amygdala, whereas M4 mRNA is highest in the olfactory bulb, 
olfactory tubercle, hippocampus, and striatum (Buckley et al., 1988; Caulfield, 1993), 
which is consistent with the quantitative autoradiographic results obtained by Flynn et 
al. (1997), and with those of immunohistochemical studies carried out by Levey et al. 
(1991). M5 mRNA has been detected in the substantia nigra pars compacta (Weiner et 
al., 1990). M5 mAChR binding is observed in the most external layers of the cortex, in 
the caudate-putamen, nucleus accumbens, CA1 and CA2 hippocampal regions and in 
the polymorphic layer of the dentate gyrus (Flynn et al., 1997; Reever et al., 1997). 
 
Nicotinic acetylcholine receptors 
 Nicotinic acetylcholine receptors (nAChRs) are ligand-gated ion channels, 
sensitive to activation by nicotine and whose activity is induced in the micro- to 
submicrosecond range. They can be divided into two types; muscle receptors, which 
are found at the skeletal neuromuscular junction where they mediate neuromuscular 
transmission, and neuronal receptors, which are found throughout the peripheral and 
central nervous systems where they are involved in fast synaptic transmission (Gotti et 
al., 2004).  
 
Structure of nicotinic acetylcholine receptors 
 nAChRs are pentameric structures that are made up of combinations of 
individual subunits closely related to an extended family of cDNAs that in mammals 
encode 16 structurally homologous subunits with primary structural identity. All 
subunits have the following: 1) an extracellular large NH2-terminal domain of ~200 
amino acids; 2) three TM domains; 3) a cytoplasmic loop of variable size and an amino 
acid sequence; and 4) a fourth TM domain with a relatively short and variable 
extracellular COOH-terminal sequence (Lukas et al., 1999). Neuronal nAChRs can be 
homopentamers or heteropentamers composed of different subunits of α2, α3, α4, α5, 
α6, α7, α9, and α10; and 3 non-α subunits (termed β2, β3, and β4), which have been 
cloned from neuronal tissues (Gotti et al., 2004). The receptor channel is also 
permeable to selected ions such as Na+, K+, Ca2+ and Mg2+ (Figures 1 and 5). 
 
Localization and distribution of nicotinic ACh receptors 
 nAChRs can be located at the cell soma, dendrites, preterminal axon regions, 
axon terminals and myelinated axons (reviewed in Albuquerque et al, 2009). Binding 
experiments in human brain have been performed by using [3H]-nicotine, [3H]-cytisine, 
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[3H]-methylcarbamylcholine and, in a few cases, [125I]α-bungarotoxin. Nicotine labels all 
nAChRs; cytisine labels those containing the α3, α4 and β2 or β4 subunits; α-
bungarotoxin labels α7 receptors. [3H]-nicotine and [3H]-cytisine binding studies show 
the highest density of nAChR in the periacqueductal grey matter, putamen, substantia 
nigra pars compacta, dentate gyrus of hippocampus, thalamus and dorsal raphe, and 
moderate densities in the cortex, claustrum, cingulated gyrus, hippocampal pyramidal 
and molecular layers, subiculum, tegmentum, nbM, parahippocampal area, cerebellum 
and substantia nigra pars reticulata. [125I]α-bungarotoxin binding studies show high 
density in the sympathetic ganglia; moderate density in the hippocampal granular layer, 
subiculum, cerebellum, cortex, medial and lateral geniculate and reticular thalamic 
nucleus; and low density in the stratum lacunosum molecular, entorhinal cortex and 
cerebellum (Reviewed in Gotti et al., 1997). The distribution of nAChR has also been 
analyzed in the human CNS by using in situ hybridization and PET and these 
techniques have reported a similar distribution to that described using binding studies 
(Rubboli et al., 1994; Nordberg at al., 1992, 1995). 
 
 
Figure 5. Structure and intracellular signaling of mAChR and nAChR. Each mAChR subtype is 
a seven-TM protein, which belongs to two major functional classes based on the different G-
protein coupling. The M1, M3, and M5 mAChR are selectively coupled to the Gαq/11-type G-
proteins resulting in the generation of IP3 and DAG through activation of the phosphoinositide-
specific PLCβ, leading to increased intracellular Ca
2+
 levels. The M2 and M4 mAChR 
preferentially activate Gαi/o-type G-proteins, thereby inhibiting adenylate cyclase, reducing 
intracellular concentration of cAMP and prolonging the potassium channel opening (Modified 
from Jones et al., 2012). 
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2. The endocannabinoid system 
 
 Marijuana, a derivative of the plant Cannabis sativa, has been used for 
recreational and therapeutic purposes for thousands of years. Ancient Indian and 
Chinese medical writers described the physiological and psychological effects of this 
plant (Mechoulam, 1986). The therapeutic value of cannabis was scientifically 
assessed for the first time in the early 19th century, demonstrating the clinical utility of 
cannabis in several disorders including cholera, rheumatic diseases, delirium tremens 
and infantile convulsions (O‟Shaughnessy, 1843). O‟Shaughnessy‟s work probably 
marks the beginning of „endocannabinoid research‟ (Di Marzo, 2006).  
 The mechanism of action and therapeutic possibilities of cannabis would not 
have been discovered if its active principles had not been purified and chemically 
characterized. At the end of the 19th century resin extraction from Cannabis sativa 
allowed to isolate cannabinol, whose structure was then further elucidated, leading to 
the full chemical characterization of this compound (Wood et al., 1899; Jacob and 
Todd, 1940). However, Δ9-tetrahydrocannabinol (Δ9-THC) would prove to be the most 
pharmacologically interesting compound of cannabis since it is responsible for its 
psychotropic activity. Δ9-THC was isolated from hashish and its chemical structure was 
established by the pioneering studies of Gaoni and Mechoulam (1964). 
 The affinity of Δ9-THC for lipid membranes and its properties of lipid solubility 
erroneously suggested that its effects were induced by a direct modification of cell 
membrane fluidity, rather than by the activation of cell-surface specific receptors 
(Lawrence and Gil, 1975). Experience with opioid receptors and enkephalins led to the 
idea that endogenous cannabinoid ligands and the associated enzymatic machinery 
must be present in mammalians, because such receptors would not have been 
selected by evolution merely to be activated by a plant product (Freund et al., 2003). 
The existence of specific cannabinoid-receptor interaction was confirmed when Howlett 
showed decreased cAMP levels in Δ9-THC-treated neuroblastoma cultures, suggesting 
the existence of functional coupling to G proteins of the Gαi/o subtype (Howlett and 
Fleming, 1984; Howlett, 1984; 1985; Howlett et al., 1986). In 1988 the presence of 
high-affinity binding sites for cannabinoid agonists in rat brain membranes was 
described and, indeed, this was coupled to the inhibition of adenylyl cyclase activity 
which confirmed the findings of Howlett´s pioneering work (Devane et al., 1988; 
Howlett et al., 1990). In 1990 the first receptor for cannabinoids was cloned, thereby 
identifying a DNA sequence encoding for a GPCR (Matsuda et al., 1990). 
[3H]CP55,940 autoradiography showed the first CB1 receptor distribution in mammalian 
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brain (Herkenham et al., 1990). A second cannabinoid receptor expressed in 
immunitary cells, at present known as the CB2 receptor, was cloned a few years later 
and pharmacologically characterized as an inhibitor of adenylyl cyclase activity (Munro 
et al., 1993; Galiegue et al., 1995). 
 Binding studies in rat brain slices demonstrated the displacement of 
[3H]CP55,940 binding elicited by the Ca2+-induced release of an endogenous 
cannabinoid ligand, but failed to detect and characterize it (Evans et al., 1992 and 
1994). Based on the reasoning that endogenous cannabinoids could well be as 
hydrophobic as Δ9-THC, the fractioned lipid extract from porcine brain was used to 
search for cannabinoid-like binding activity. The researchers were able to isolate and 
characterize the first endogenous lipid-based cannabinoid-like component 
(endocannabinoid; eCB) which was given the name of “anandamide” (AEA) and which 
had similar in vitro pharmacological effects to those observed for cannabinoid agonists 
(Devane et al., 1992; Fride and Mechoulam, 1993). However, additional lipid fractions 
from the rat brain contained cannabinoid-binding activity in addition to AEA and, a 
second eCB, 2-araquidonoylglycerol (2-AG), was simultaneously isolated from cat gut 
and rat brain (Mechoulam et al., 1995; Sugiura et al., 1995). The distribution of eCB in 
the CNS has been investigated using different approaches, e.g. by exposing rat brain 
slices to [14C]-AEA and measuring the distribution of radioactivity by autoradiography 
(Giuffrida et al., 2001). Other compounds which produce the classical cannabimimetic 
effects in vivo may also serve as eCB, like O-arachidonoylethanolamine (virodhamine), 
isolated from rat brain, which weakly activates CB1 receptors (Hanus et al., 2001; 
Porter et al., 2002). Other possible eCBs are 2-arachidonoilglycerol ether (noladin 
ether) isolated from porcine brain, N-arachidonoyldopamine (NADA), N-dihomo-γ-
linolenoylethanolamine and N-docosatetraenoylethanolamine (Bisogno et al., 2000; 
Pertwee, 2005). 
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2.1. Endocannabinoids 
 
 Lipid signaling molecules (neurolipids) are emerging as key modulatory 
elements in CNS neurotransmission in which GPCR for multiple neurolipid systems are 
being identified. Lipids represent the main structural components of the cell 
membranes, but some phospholipid species present in the membranes of neurons, glia 
and other cells may serve as precursors for the synthesis of neurolipids, such as the 
eCB. The eCB are defined as endogenous compounds, generated by different tissues 
and organs, capable of binding to and activate cannabinoid receptors. They are 
synthesized through cleavage of phospholipid precursors and may be released on 
demand when evoked by postsynaptic depolarization or GPCR activation (Di Marzo et 
al., 1994; Maejima et al., 2001). The molecular structure of the eCB share two common 
structural motifs: a polyunsaturated fatty acid moiety i.e., arachidonic acid (AA) and a 
polar head group consisting of ethanolamine or glycerol.  
 
Biosynthesis, reuptake and degradation of AEA 
 AEA belongs to the family of the N-acylethanolamines, which are 
biosynthesized via a membrane phospholipid-dependent pathway, i.e. the enzymatic 
hydrolysis of the corresponding N-acyl-phosphatidylethanolamines (NAPE) by a 
phospholipase D selective for NAPE (NAPE-PLD); (EC-3.1.4.4) (Schmid et al. 1996; 
Hansen et al. 1998). The AEA precursor (NAPE) is produced from the transfer of an 
acyl group such as AA, from the sn-1 position of phospholipids (e.g., PC) to the N-
position of PE, catalyzed by a Ca2+-dependent trans-acylase (Di Marzo et al. 1994). 
The finding of a similar distribution of N-arachidonoyl-phosphatidylethanolamine 
(NArPE; the NAPE precursor of AEA) and AEA in nine different brain areas (Bisogno et 
al. 1999), and of increasing levels of both NArPE and AEA in rat brain at different 
stages of development (Berrendero et al. 1999), confirms a precursor/product 
relationship for the two compounds, and suggest that this pathway is probably the one 
mainly responsible for AEA biosynthesis. In addition, the Ca2+ sensitivity of both the 
trans-acylase and NAPE-PLD is in agreement with the fact that AEA biosynthesis is 
triggered by neuronal depolarization and other Ca2+-mobilizing stimuli. However, an 
alternative way for NAPE to be transformed into AEA involves both phospholipase A1 
(PLA1) and the secretory phospholipase A2 (PLA2), with the formation of N-acyl-1-
acyl-lyso-PE, followed by the action of a lyso-PLD enzyme distinct from the already 
known NAPE-PLD (Sun et al. 2004). Finally, two additional pathways for the AEA 
release from NAPE have been proposed; a sequential double deacylation of NAPE by 
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alpha/beta-hydrolase domain-containing 4 (ABHD4), followed by the cleavage of 
glycerolphosphoanandamide to yield AEA and the hydrolysis of NAPE to yield 
phosphoanandamide by PLCβ, plus a subsequent dephosphorilation by phosphatases 
(Fisar, 2009) (Figure 6). 
 Although most of the neurotransmitters are water-soluble and require specific 
TM proteins to transport them across the cell membrane,  the eCB are non-charged 
lipids that readily cross lipid membranes and it is reasonable to hypothesize that there 
is no need for an eCB carrier. However, several structural analogs of AEA have been 
reported to inhibit the AEA uptake (Beltramo et al., 1997), but there is some 
controversy about AEA reuptake since the molecular identity of the carrier has not yet 
been clarified (Beltramo et al., 1997). Nevertheless, AEA transport meets four key 
criteria of a carrier-mediated process: saturability, fast rate, temperature dependence 
and substrate selectivity (reviewed in Freund et al., 2003). The uptake of AEA does not 
require cellular energy or external Na+, suggesting that it is mediated through facilitated 
diffusion and its immediate intracellular hydrolyzation probably contributes to the rate of 
AEA transport. To date, four models have been proposed: 1) AEA uptake occurs by 
facilitated diffusion through a membrane carrier; 2) AEA crosses the membrane by 
enzyme-mediated cleavage of AEA; 3) AEA undergoes endocytosis through a 
caveolae-related uptake process; 4) Simple diffusion driven by intracellular 
sequestration of AEA (reviewed in Di Marzo, 2008).  
 The enzymatic degradation of AEA was first reported in neuroblastoma and 
glioma cells as anandamide amidase (Deutsch and Chin, 1993). Later it was identified 
as anandamide amidohydrolase in the brain, and finally renamed as fatty acid amide 
hydrolase (FAAH) (EC-3.5.1.99) when purified and cloned from rat liver (Cravatt et al., 
1996). Rat, mouse, and human FAAH proteins are all 579 amino acids in length and 
the gene was mapped to human chromosome 1p34-p35. FAAH is detected in many 
organs including brain and recognizes a variety of fatty acid amides, but its preferred 
substrate is AEA. FAAH also catalyzes the hydrolysis of the ester bond of 2-AG in vitro. 
FAAH-knockout mice, created by Cravatt et al. (2001), exhibit an increased 
responsiveness to exogenous administration of AEA, further demonstrating the direct 
involvement of FAAH in AEA degradation.   
 
Biosynthesis, uptake and degradation of 2-AG  
 The levels of 2-AG in tissues, cells or cerebrospinal fluid (CSF) are usually 
much higher than those of AEA, and may be sufficient to permanently activate 
cannabinoid receptors (Sugiura et al. 1995; Stella et al. 1997). Similarly to AEA, the 
enhancement of intracellular Ca2+ induces the synthesis of 2-AG. However, several 
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stimuli have been shown to induce the biosynthesis of 2-AG in intact neuronal and non-
neuronal cells, including lipopolysaccharides (in macrophages), glutamate or carbachol 
(in neurons), carbachol or thrombin (in endothelial cells), endothelin (in astrocytes) or 
the platelet activating factor (in macrophages) (reviewed in Sugiura et al., 2002). The 
most important biosynthetic precursors of 2-AG are the sn-1-acyl-2-
arachidonoylglycerols (DAG) from membrane phospholipids. Two metabolic pathways 
lead to 2-AG biosynthesis in neurons; hydrolysis of membrane lipids containing AA by 
the action of diacylglycerol lipase (DAGL-α) and the hydrolysis of lysophospholipids by 
lyso-PLC activity (Sugiura et al., 1995). In most cases, the DAG necessary for 2-AG 
biosynthesis is obtained from the hydrolysis of 2-arachidonate-containing 
phosphoinositides, catalyzed by a phosphoinositide-selective PLCβ or, alternatively, 
from the hydrolysis of 2-arachidonate-containing phosphatidic acid, catalyzed by a 
phosphohydrolase (Di Marzo et al., 1996; Bisogno et al. 1999) (Figure 6).  
 The main enzyme responsible for the degradation of 2-AG is the 
monoacylglycerol lipase (MAGL) (EC-3.1.1.23), identified by Tornqvist and Belfrage 
(1976) (Dinh et al., 2002). The MAGL was cloned from a mouse adipocyte cDNA 
library (Karlsson et al., 1997). The 303 amino acid length sequence of the MAGL is 
well conserved in different mammalian species such as mouse, rat, and human 
(Karlsson et al., 1997). Several studies suggest the existence of additional 2-AG 
hydrolyzing enzymes in brain microglial cells (Muccioli et al., 2007). A functional 
proteomic strategy estimates that MAGL hydrolyzes 85% of 2-AG, whereas the 
remaining 15% is mostly catalyzed by two serine hydrolases; alpha/beta-hydrolase 
domain-containing 6 (ABHD6) and alpha/beta-hydrolase domain-containing 12 
(ABHD12) (Blankman et al., 2007). 
 The mechanism for 2-AG uptake is also unclear. Some studies propose that 
that 2-AG and AEA are transported by the same system (Piomelli et al., 1999; Bisogno 
et al., 2001). Evidence for this assumption is that cold 2-AG prevents [3H]-AEA uptake, 
suggesting that both eCB may compete for the same transport system. AEA and 2-AG 
also share similar kinetic properties, and their transport is inhibited by AM404, 
(reviewed in Freund et al. 2003).  
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Figure 6.  (A) AEA biosynthesis begins with the formation of NArPE by the transfer of AA from 
phosphatidylcholine (PC) to the primary amine of PE acting a Ca
2+
-dependent trans-acylase 
(step 1). Multiple pathways have been postulated for the release of AEA from NArPE (steps 2–
8). (B) 2-AG is generated from PIP2 by PLCβ followed by cleavage of DAG by DAGLα and 
DAGLβ (Extracted from Blankman and Cravatt, 2013). 
 
 
 
2.2. CB1 receptor 
 
 Subtype 1 of cannabinoid receptors (CB1 receptor) is a member of the 
rhodopsin-like family of seven TM domain receptors that are coupled to G proteins at 
their intracellular surface. This receptor was initially cloned in the rat brain (473 amino 
acids) and subsequently in human (472 amino acids) and in mouse (473 amino acids) 
sharing a 97-99% amino acid sequence homology (Matsuda et al., 1990; Gerard et al., 
1990; Chakrabarti et al., 1995). The gene for the CB1 receptor in humans is located in 
the 6q14-q15 chromosome (Gerard et al., 1990). 
 
CB1 receptor distribution in the CNS and its physiological relevance 
 Howlett (1984) provided the first evidence for the existence of specific receptors 
sensitive to cannabinoid compounds, but the subsequent development of highly 
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selective synthetic cannabinoid agonists accelerated the pharmacological 
characterization of the CB1 receptor (Devane et al., 1988; Gerard et al., 1991). The 
development of the [3H]CP55,940 radioligand allowed the anatomical localization of 
cerebral cannabinoid receptors by using autoradiographic techniques (Herkenham et 
al., 1990). The mapping of [3H]CP55,940 binding sites showed a preferential 
localization of CB1 receptors in specific areas of gray matter, thereby predicting the 
action of cannabinoids reported in behavioral experiments, and this led to intense 
research into eCB signaling (Freund et al., 2003). The highest levels of [3H]CP55,940 
binding were observed in the olfactory bulb, the nigrostriatal pathway including the 
globus pallidus, the cerebellar molecular layer and specific layers of the hippocampus. 
Ligand binding pointed to CB1 receptors as one of the most abundant GPCR in CNS.  
 Regarding the physiological actions mediated by CB1 receptors, the tetrad test 
has been used for screening drugs that induce cannabimimetic effects, consisting of 
four behavioral components: spontaneous activity, catalepsy, hypothermia and 
analgesia (Little et al., 1988). Two brain regions that are intimately involved in the 
control of movement, the basal ganglia and the cerebellum, display very high densities 
of cannabinoid binding sites which are compatible with the effects of cannabinoids on 
both motor and cognitive functions, according to the first behavioral paradigm of the 
tetrad test. The moderate levels of CB1 receptors reported in basal forebrain-emerging 
pathways, including the frontal, parietal, and cingulated cortices, septum and amygdala 
may be an indication of the effects of the cannabinoids on cognitive functions, such as 
learning, memory and emotional behavior. 
 On the other hand, the moderate levels of binding in the hypothalamus, lateral 
subnucleus of interpeduncular nucleus, parabrachial nucleus, nucleus of solitary tract 
and spinal dorsal horn are probably related to the potent analgesic and 
antihyperalgesic properties of cannabinoid agonists and their orexigenic effects 
(Freund et al., 2003). In contrast, the reported low levels of cannabinoid ligand binding 
in the brainstem areas that control cardiovascular and respiratory functions may 
explain the tolerability to high doses of cannabinoids (Kano et al., 2009, Mailleux et al., 
1992). These overall binding properties are preserved in mammals (Herkenham et al., 
1990). During the last decade, there has been increasing evidence of the presence of 
CB1 receptors at other locations such as postsynaptic terminals, intracellular 
organelles, such as the mitochondria which regulate cell metabolism and memory 
(Hebert-Chatelain et al., 2016), and also in astrocytes which regulate gliotransmission 
(Navarrete and Araque, 2008).  
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CB1 receptor-mediated signaling in the CNS 
 
Intracellular signaling pathways 
 Agonist stimulation of CB1 receptors activates multiple signal transduction 
pathways mainly through the Gαi/o family of G proteins, and is responsible for 
decreases in cAMP and protein kinase A (PKA) activity (reviewed in Howlett et al., 
2002). CB1 receptors have shown a measurable constitutive activity, indicative of G 
protein activation in the absence of agonists, which could be related to their high 
abundance and localization in the presynaptic axon terminals (Kendall and Yudowski, 
2017). Therefore, inverse agonists specific for CB1 receptors such as SR141716A, 
have also been described (Bouaboula et al., 1997; Nie and Lewis, 2001). 
 The coupling of CB1 receptors to Gs and the consequent increase in cAMP 
levels may also be possible in specific conditions, suggesting that different types of 
adenylyl cyclase isoforms may influence the outcome of CB1 receptor activation (Glass 
and Felder, 1997; Maneuf and Brotchie, 1997; Rhee et al., 1998). However, a reduced 
activation of Gαi/o attenuating the inhibitory tone on the major isoforms of adenylyl 
cyclase, could partially explain the apparent coupling of CB1 receptors to Gs proteins 
(Eldeeb et al., 2016). The signaling promiscuity of CB1 receptors may be related to the 
agonist trafficking exhibited by structurally different classes of cannabinoid compounds 
that could be selective for specific intracellular signaling pathways, depending on the 
CB1 receptor conformation that they induce (Hudson et al., 2010). The complexity of 
eCB signaling can be explained by the phenomena of functional selectivity or biased 
agonism i.e., the ability of ligands to activate a subset of the full repertoire of signaling 
cascades available to individual GPCR (Urban et al., 2007). Moreover, prolonged 
activation of CB1 receptors results in rapid attenuation of behavioral responsiveness 
due to a decrease in the ability of the receptor to activate effector pathways (i.e., 
desensitization) and/or a reduction in the population of cell surface-expressed GPCR 
(i.e., internalization), leading to the development of tolerance in humans as well as in 
animal models (Howlett et al., 2004). 
  The internalized GPCR finally become a substrate for specific phosphorilation 
processes through unique GPCR kinases, and they are converted to high affinity 
targets for β-arrestins (Jin et al., 1999). CB1 receptors and β-arrestins mediate the 
activation of several signaling cascades, including ERK1/2, JNK1/2/3, CREB and 
P38a, and the consequent regulation of gene expression and protein synthesis 
(Delgado-Peraza et al., 2016). 
 To further increase the complexity of eCB signaling, CB1 receptors frequently 
associate with other GPCR to form heteromeric complexes, as has been detected by 
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fluorescence resonance energy transfer or bioluminescence resonance energy transfer 
(reviewed in Pertwee et al., 2010). Heterodimers of CB1 receptors have been observed 
with dopamine D2 receptors (Kearn et al., 2005), µ-opioid receptors (Rios et al., 2006) 
or OX1 orexin receptors (Ellis et al., 2006). Other studies suggest that CB1 receptors 
may form additional receptor heteromers based upon pharmacological cross-talk data, 
pointing to GABAB receptors (Pacheco et al., 1993), α2-adrenoceptors and 
somatostatin receptors (Pan et al., 1998; Vásquez and Lewis, 1999). The recent 
crystallization of the CB1 receptor bound to the antagonist AM6538 should not only 
provide new opportunities to better understand the structure-function relationship of 
this receptor, but should also be helpful when designing specific new drugs (Hua et al., 
2016). 
 CB1 receptor activation also stimulates different enzymes such as the mitogen 
activated protein kinase (MAPK) pathway which leads to immediate early gene 
expression (Howlett et al., 2002; Bouaboula et al., 1995). The activation of CB1 
receptors is critically involved in many cellular functions such as cell growth, 
transformation and apoptosis (Galve-Roperh et al., 2002), but the CB1 receptor also 
activates other intracellular kinases including the phosphatidylinositol 3-kinase 
(Bouaboula et al., 1997), the focal adhesion kinase (Derkinderen et al., 1996), and 
some enzymes involved in energy metabolism (Guzmán et al., 2001; Guzmán and 
Sanchez, 1999). CB1 receptor activation is also able to evoke a transient Ca
2+ elevation 
that may be related to phospholipase C (PLC) activity modulated by Gα i/o or Gαq/11 
proteins (Sugiura et al., 1997; Lauckner et al., 2005). Moreover, the CB1 receptor 
modulates various types of ion channels and enzymes in a cAMP-dependent or –
independent manner, such as A-type, inwardly rectifying K+ currents and inhibition of N- 
and P/Q-type Ca2+ currents (Mackie et al., 1995; Twitchell et al., 1997). 
The particular distribution of CB1 receptors and the biosynthesis of eCB in the 
CNS induced after the activation of multiple signaling systems e.g., dopaminergic 
(Giuffrida et al., 1999), cholinergic (Kim et al., 2002; Ohno-Shosaku et al., 2003), 
glutamatergic (Ohno-Shosaku et al., 2002) or GABAergic (Wilson and Nicoll, 2001; 
Wilson et al., 2001), further support the involvement of the eCB system in the 
modulation of CNS neurotransmission and control of neuronal network activity. To 
better understand the specific mechanisms of eCB signaling, it is necessary to 
determine the precise localization of CB1 receptors at cellular, subcellular and 
ultrastructural levels in relation to other systems of neurotransmission.  
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Presynaptic localization of neuronal CB1 receptors  
 GPCR, such as the CB1 receptor, are embedded within the lipid bilayer of the 
plasma membrane. Indirect anatomical evidence was first provided by in situ 
hybridization (Matsuda et al., 1990) and receptor binding experiments (Herkenham et 
al., 1990), which showed the somatic distribution of CB1 receptor mRNA in the neurons 
within the striatum (Matsuda et al., 1990), whereas [3H]CP55,940 binding displays the 
highest densities of the whole brain in the globus pallidus and the substantia nigra pars 
reticulata (Herkenham et al., 1990), suggesting that the axonal terminals are the final 
destination of CB1 receptors (Freund et al., 2003).  
 The first clues about the presynaptic localization of CB1 receptors were 
obtained after provoking specific lesions in the CNS. Ibotenic acid lesioning of the rat 
striatum produced a marked decrease in cannabinoid receptor binding in the globus 
pallidus and the substantia nigra pars reticulata (Herkenham et al., 1991). Similarly, 
cannabinoid receptor binding decreased in the dorsal horn of the spinal cord after 
resection of the dorsal root (Hohmann et al., 1999a,b). Different immunohistochemical 
studies indicated that CB1 receptors are predominantly found in axon terminals, where 
they may be involved in the presynaptic regulation of neurotransmitter release 
(reviewed in Freund et al., 2003). The first light microscopy studies revealed the 
existence of numerous CB1 receptor-immunoreactive fibers in basket-like formations 
around CB1 receptor-negative cell bodies throughout the brain, which largely coincides 
with the findings of radioligand binding experiments (Egertova and Elphick, 2000). At 
the ultrastructural level, the first electron microscopy studies carried out in rodents, as 
well as in human CNS, suggested that CB1 receptors are located in specific types of 
axon terminals (Katona et al. 1999, 2000, 2001).  Boutons engaged in asymmetrical 
(excitatory) synapses seem to be devoid of CB1 receptors, whereas symmetrical 
(inhibitory) synapses display a profuse distribution of CB1 receptors, indicating that 
GABAergic, but not glutamatergic, axon terminals contain CB1 receptors. However, 
further studies demonstrated that CB1 receptors are also present in glutamatergic 
synapses, but at much lower levels (Katona et al., 2006; Kawamura et al., 2006). 
 
ECB mediated retrograde synaptic modulation 
 Although anatomical studies may reveal the precise localization of CB1 
receptors, they only enable us to make predictions about their functional role. 
Pharmacological, electrophysiological and neurochemical studies have all shown that 
CB1 receptors are located presynaptically and regulate the release of certain types of 
neurotransmitters. CB1 receptor-mediated suppression of neurotransmitter release 
leads to several forms of synaptic plasticity such as transiently short-term depression 
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(STD) or persistently long-term depression (LTD) and long-term potentiation (LTP) 
Both, STD and LTD are mediated by 2-AG (Figure 7).   
 
Ca2+-driven eCB release-dependent STD 
 STD which is dependent on Ca2+-driven eCB release requires a large Ca2+ 
elevation in postsynaptic neurons induced by the activation of voltage-gated Ca2+ 
channels or NMDA receptors which leads to postsynaptic eCB synthesis in a DAGLα-
dependent manner. 2-AG is then released, binds to presynaptic CB1 receptors whose 
activation suppresses transmitter release by inhibiting presynaptic voltage-gated Ca2+ 
channels (Figure 7a). This form of eCB-mediated synaptic plasticity includes the 
following mechanisms: 1) Depolarization-induced suppression of inhibition (DSI) (Llano 
et al., 1991; Pitler and Alger, 1992; Wilson and Nicoll, 2001); 2) Depolarization-induced 
suppression of excitation (DSE) (Kreitzer and Regehr, 2001); 3) Presynaptic 
suppression caused by Ca2+ influx through NMDA-type glutamate receptors (Ohno-
Shosaku et al., 2007).  
 
1) DSI or modulation of GABAergic neurotransmission via CB1 receptor activation  
 The inhibitory effects of cannabinoids on GABA release were first reported in 
neurons in the basal ganglia, hippocampus, cerebellum, amygdala, nucleus 
accumbens and cortex. Evidence of these effects is further supported by the fact that 
cannabinoid agonists modulate presynaptic GABA release, decrease amplitude and 
frequency of GABAA receptor-mediated inhibitory postsynaptic currents and fail to block 
the postsynaptic response induced by GABA or muscimol. This process is specifically 
mediated by CB1 receptor-dependent activation because it is blocked by two 
independent antagonists of CB1 receptors, e.g., rimonabant (SR141716A) and AM251, 
and is completely absent in CB1 receptor knockout mice (see reviews from Freund et 
al., 2003; Kano et al., 2009; Kano, 2014). The lack of effect of FAAH inhibitors 
(increased endogenous levels of AEA) in the hippocampal DSI indicates that AEA is 
apparently not involved in the CB1 receptor-mediated modulation of GABA release 
(Kim and Alger, 2004). On the other hand, the genetic inhibition of MAGL (increased 
levels of 2-AG) enhances short-term synaptic depression or DSI (Pan et al., 2011)  
whereas the genetic inactivation of DAGL-α (decreased levels of 2-AG) completely 
abolishes all forms of eCB-mediated synaptic plasticity in the prefrontal cortex (Yoshino 
et al., 2011), hippocampus (Gao et al., 2010), striatum and cerebellum (Tanimura et 
al., 2010). Taking into account that DAGL-α is mainly located postsynaptically in 
several brain areas, whereas MAGL is consistently found presynaptically in axon 
terminals throughout the CNS (see review from Katona and Freund, 2012), 2-AG is 
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synthesized and released postsynaptically to bind to CB1 receptors located 
presynaptically. These findings point to 2-AG as the eCB which is most probably 
responsible for DSI.  
 
2) DSE or modulation of glutamatergic neurotransmission by CB1 receptor activation  
Kreitzer and Regehr (2001) discovered that depolarization of cerebellar Purkinje 
cells induced a transient suppression of excitatory transmission by a presynaptic CB1-
mediated mechanism. Cannabinoid agonists failed to reduce postsynaptic responses 
to glutamate or kainate and SR141716A prevented the suppression of excitatory 
transmission (Shen et al., 1996; Auclair et al., 2000). DSE has also been reported in 
many other brain regions including the hippocampus, cerebral cortex, hypothalamus, 
ventral tegmental area and dorsal cochlear nucleus (reviewed in Kano et al., 2014). 
Surprisingly, cannabinoid agonists are able to reduce glutamatergic-mediated 
responses in CB1 receptor knockout mice to the same levels as they do in wild-type 
mice (Hájos et al., 2001), suggesting that glutamatergic axon terminals must contain a 
novel cannabinoid-sensitive site which is indeed blocked by SR141716A, but it would 
be molecularly distinct from the cloned CB1 receptor (Freund et al., 2003). 
 
3) Presynaptic suppression caused by Ca2+ influx by NMDA-type glutamate receptors  
In addition to DSE, the stimulation of NMDA receptors induces a transient 
suppression of inhibitory transmission in cultured hippocampal neurons which requires 
postsynaptic eCB synthesis in a Ca2+-dependent manner and CB1 receptor activation 
(Ohno-Shosaku et al., 2007). 
 
GPCR-driven eCB release-dependent STD 
 The synthesis and release of eCB in a Ca2+ independent manner can be 
induced by the postsynaptic activation of Gαq/11-coupled GPCRs such as Group I 
metabotropic glutamate receptors (mGluR1 and mGluR5). The activation of Group I 
mGluR leads to a transient suppression of the excitatory transmission to Purkinje cells 
which can be abolished when the Gαq/11-signaling pathway is blocked by the 
application of GTPγS or GDPβS, whereas no effects are observed with high 
concentrations of the Ca2+ chelator BAPTA (Maejima et al., 2001). The mGluR-driven 
eCB-STD has been reported in many regions of the brain, including the hippocampus, 
striatum, nucleus accumbens, medial nucleus of the trapezoid body, and 
periaqueductal gray (reviewed in Kano, 2014). The same phenomenom occurs with 
other Gαq/11-coupled GPCRs including M1/M3 mAChR (mAChR1 and mAChR1) (Kim et 
al., 2002), 5-HT2-type serotonin receptors (5HT2R) (Best and Regehr, 2008), orexin 
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receptors (Haj-Damene and Shen, 2005) and oxytocin receptors (Hirasawa et al., 
2004). When postsynaptic Gαq/11-coupled GPCRs are stimulated, DAG is produced 
through PLCβ, and converted to 2-AG by DAGL-α (reviewed in Kano et al., 2009; 
Katona and Freund, 2012; Kano, 2014). 2-AG is then released, activates presynaptic 
CB1 receptors and the transmitter release is suppressed by inhibiting presynaptic 
voltage-gated Ca2+ channels.  
 
Ca2+ assisted GPCR-driven eCB release-dependent STD  
 This form of short-term plasticity induces the synthesis and release of eCB by a 
small increase in Ca2+ and a weak Gαq/11-coupled GPCR activation, including that of 
mGluR1 and mGluR5, mAChR1 and mAChR3, (Kim et al., 2002; Narushima et al, 2007; 
Hashimotodani et al., 2005; Maejima et al., 2001; Maejima et al., 2005). This 
phenomenom shares similar molecular mechanisms of eCB synthesis and release as 
those described immediately above. 
 
The eCB release-dependent LTD 
 Long-term synaptic plasticity phenomenon which occurs in both inhibitory and 
excitatory synapses is mainly induced by repetitive afferent stimulation with or without 
postsynaptic depolarization, but also by postsynaptic firing. Presynaptic release of 
glutamate activates AMPA receptors and mGluR on the postsynaptic membrane and 
induces 2-AG release which activates CB1 receptors in the same presynaptic terminals 
which release glutamate (homosynaptic) or neighboring presynaptic terminals 
(heterosynaptic). This phenomenon has not only been observed in excitatory synapses 
in the dorsal striatum, nucleus accumbens, cerebral cortex, dorsal cochlear nucleus, 
cerebellum, and hippocampus, and in inhibitory synapses in the hippocampus, 
amygdala and ventral tegmental area, but also in cholinergic synapses (reviewed in 
Heifets and Castillo, 2009) (Figure 7b).  
 
The eCB release-dependent LTP 
 CB1 receptor-mediated short-term DSI and DSE may contribute to additional 
forms of neuronal plasticity and synaptic strengthening, such as in LTP (Carlson et al. 
2002). The development of cell-type specific CB1 receptor-knockout models has helped 
us to study how eCB signaling in specific neuronal circuits (i.e. CB1 receptor-mediated 
regulation of GABAergic or glutamatergic transmission) contributes to neuronal 
network activity, synaptic plasticity and behavior. Some studies have revealed that the 
lack of CB1 receptors in glutamatergic neurons (Glu-CB1-KO) facilitates hippocampal 
LTP formation (Monory et al., 2015), or the inactivation of CB1 receptors exclusively in 
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forebrain GABAergic neurons (GABA-CB1-KO) leads to diminished hippocampal LTP 
formation (Monory et al., 2015). The activation of CB1 receptors specifically in 
GABAergic neurons inhibits LTD in the amygdala (Marsicano et al., 2002). Moreover, 
object exploration (Häring et al., 2011), impulsiveness (Lafenêtre et al., 2009), feeding 
response (Bellocchio et al., 2010), and active fear coping (Metna-Laurent et al., 2012), 
are decreased in Glu-CB1-KO animals, whereas these behavioral outcomes are 
increased in GABA-CB1-KO animals.  
 
Figure 7. Schematic diagram of eCB-mediated contol of retrograde signaling. a) In Ca
2+
-driven 
eCB-STD, Ca
2+
 influx through voltage-gated Ca
2+
-channels (VGCC) stimulates an unidentified 
enzymatic pathway (denoted by a question mark) to produce DAG. In GPCR-driven eCB-STD, 
activation of Gαq/11-coupled receptors stimulates PLCβ1 to yield DAG. In eCB-STD and eCB-
LTD, DAG is converted to 2-AG by DAGL-α activates presynaptic CB1 receptors to transiently 
suppress transmitter release and is degraded by MAGL. In synaptically driven eCB-STD, 
glutamate released from excitatory presynaptic terminals causes Ca
2+
 influx through both AMPA 
receptors and VGCC, and/or activation of group I mGluR or mAChR1/3 inducing 2-AG release 
which binds to CB1 receptors located either on the stimulated terminals releasing glutamate 
(homosynaptic) or on neighboring terminals (heterosynaptic). b) The released 2-AG activates 
CB1 receptors on either of the stimulated terminals releasing glutamate. In addition to CB1 
receptor activation, presynaptic electrical activity, Ca2+ influx through VGCCs and Ca2+ influx 
through NMDA-type glutamate receptors (not shown) can each play a part in the induction of 
eCB-mediated long-term depression (eCB-LTD). (Modified from Soltesz et al., 2015). 
 
 
2.3. Modulation of cholinergic neurotransmission through CB1 receptors 
 
 Since cortical cholinergic innervation controls cognitive processes, which can be 
strongly modulated by cannabinoid agonists, the crosstalk between eCB and 
cholinergic systems has been analyzed by different approaches. There is both 
histological and pharmacological evidence of the eCB-driven modulation of cholinergic 
neurotransmission through CB1 receptor activation. 
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Histological evidence 
 BFCN mediated control of learning and memory processes suggests the 
existence of finely-tuned modulations of synaptic transmission involving eCB signaling. 
There are only a few immunohistochemical studies in which the anatomical distribution 
of the different elements of the eCB system in the mammalian central cholinergic 
system is described.  These studies indicate that rodent BFCN of the NBM are devoid 
of CB1 receptors, but contain the AEA degrading enzyme FAAH and display a fine 
receptor fiber meshwork surrounding the perikarya which further suggests that BFCN 
may utilize eCB for the retrograde control of neurotransmission (Harkany et al., 2003). 
Similar results were obtained in the gray mouse lemur, revealing evolutionarily 
conserved networks (Harkany et al., 2005). However, there are controversial 
anatomical data regarding the CB1 receptor expression in BFCN (Freund et al., 2003). 
Previous light and electron microscopy studies reported a dense labeling of CB1 
receptors in ChAT positive neurons in monkey, and the existence of differentiated 
BFCN in the medial septum of the rat where cholinergic innervation of the 
hippocampus originates, some of which express CB1 receptors (Lu et al., 1999; Nyíri et 
al., 2005).  
 
Pharmacological evidence 
 There is pharmacological evidence of the eCB-driven modulation of cholinergic 
neurotransmission through CB1 receptor activation by mAChR-driven eCB release-
dependent STD and mAChR-driven eCB release-dependent LTD. 
 
mAChR-driven eCB release-dependent STD  
 A significant decrease of electrically evoked ACh release in rodent brain can be 
induced by various cannabinoid receptor agonists (Gifford et al., 1996; Kathman et al., 
2001). This effect is completely blocked by the CB1 receptor antagonists SR141716A 
and AM281, and absent in CB1 receptor knockout mice (Gifford et al., 2000). Moreover, 
the eCB-mediated ACh release is increased in “knockdown” experiments with 
antisense oligonucleotides complementary to CB1 receptor mRNA and in the 
hippocampus and the neocortex of CB1 receptor knockout mice (Kathmann et al., 
2001). Comparable effects had been described in hippocampal slices in a CB1 receptor 
activation-dependent manner (Gifford and Ashby, 1996). However, in vivo 
administration of cannabinoid compounds reveals contradictory results; e.g., the 
administration of Δ9-THC or the synthocannabinoid WIN55,212-2 reduces hippocampal 
ACh release (Gessa et al., 1997; Carta et al., 1998), whereas Acquas et al. (2000, 
2001) report increased rates of ACh release. Interestingly, cannabinoid agonists, in a 
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dose-dependent manner, trigger biphasic effects on functional responses (Margulies 
and Hammer, 1991), cortical evoked potentials (Turkanis and Karler, 1981), locomotion 
(Sulcova et al., 1998) and on the CB1 receptor-mediated release of ACh (Tzavara et 
al., 2003a). This study shows that a low dose of WIN55,212-2 (0,5 mg/kg) induces a 
transient stimulation, whereas a higher dose (5 mg/kg) triggers persistent inhibition of 
hippocampal ACh release, probably involving dopamine D1 and D2 receptors. Such an 
“inverted U” dose-response relationship requires further investigation, but may be 
explained by the activation of CB1 receptors located on non-described local neuronal 
networks which may enhance or reduce the intrinsic activity of BFCN (Freund et al., 
2003). 
 On the other hand, the cholinergic agonist carbachol transiently suppresses 
inhibitory synaptic transmission in CA1 pyramidal cells in a CB1 receptor activation-
dependent manner (Kim et al., 2002), specifically through mAChRs with the 
involvement of nitric oxide (Makara et al., 2007). Moreover, in genetically modified mice 
lacking each subtype of mAChR, it has been demonstrated that Gαq/11-coupled mAChR 
activation is responsible for the PLCβ-mediated stimulation of 2-AG synthesis, which 
finally induces short-term plasticity (DSI) in cholinergic synapses (Fukudome et al., 
2004). The mAChR-driven eCB-mediated STD is also found in hippocampal excitatory 
synapses and in striatal inhibitory synapses, leading to the phenomena of DSE and 
DSI, respectively (Straiker and Mackie, 2007; Narushima et al., 2007). 
 
mAChR-driven eCB release-dependent LTD 
 CB1 receptor-mediated LTD dependent on mAChR stimulation has been 
described in both inhibitory synapses (Younts et al., 2013), and excitatory synapses 
(Zhao and Tzounopoulos, 2011). A recent study provides evidence of a 2-AG mediated 
LTD of glutamatergic synaptic transmission in the prefrontal cortex induced by specific 
stimulation of M1 mAChR, since it is abolished by selective M1 mAChR antagonism 
(Martin et al., 2015). 
 The above mentioned findings represent different examples of the crosstalk 
between both systems which reveal the CB1 receptor-mediated short- and long term 
cholinergic synaptic plasticity, pointing to 2-AG as the eCB responsible for these 
phenomena. 
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2.4. CB2 receptor 
 
 In 1993 the second subtype of cannabinoid receptors, named the CB2 receptor 
was identified (Munro et al., 1993). A human cDNA cloning revealed that it is a GPCR 
consisting of 360 amino acids, located in chromosome 1p35-p36 and that it shares a 
44% homology with the human CB1 receptor. It was subsequently cloned in several 
mammalian species, including mouse (347 amino acids) (Shire et al., 1996) and rat 
(410 amino acids) (Brown et al., 2002). 
 
Distribution of CB2 receptors 
 CB2 receptors are widely distributed in peripheral tissues, and particularly in 
immune system cells. CB2 mRNA has been identified in many immune tissues 
displaying the highest levels in macrophages, CD4+ T cells, CD8+ T cells, B cells, 
natural killer cells, monocytes and polymorphonuclear neutrophils. Interestingly, CB2 
mRNA has been found in CNS microglia, regulating its migration (Walter et al., 2003), 
with variations in CB2 receptor level expression depending on the state of activation of 
the cell in response to specific damage such as neurodegenerative processes (Ashton 
and Glass, 2007). In healthy brain, microglia does not express the CB2 receptor (Stella, 
2004). However, CB2 receptors can be detected in neuritic plaque-associated microglia 
in AD brain tissue (Benito et al., 2003). In addition, there is molecular and 
pharmacological evidence of the distribution of CB2 receptors in several tissues 
including pulmonary endothelial cells, bone tissue, the gastrointestinal system, mouse 
spermatogonias, mature and precursor adipocytes, cirrhotic liver, cardiomyocytes, 
pancreas and spleen (reviewed in Atwood and Mackie, 2010).  
 Regarding CB2 receptor expression in the CNS, data obtained during the CB2 
receptor knockout mouse characterization confirmed earlier reports, which led to the 
conclusion that it is absent in the intact CNS. When CB2 was first cloned, in situ 
hybridization demonstrated the absence of a CB2 mRNA signal in rat brain (Munro et 
al., 1993; Hohmann and Herkenham, 1999b; Howlett et al., 2002; Beltramo et al., 
2006). Consistent with these observations, northern blot analyses on mouse and rat 
brain also failed to detect CB2 receptors (Schatz et al., 1997). Further RT-PCR-based 
studies reported undetectable levels of CB2 in human brain and in the pituitary gland 
(Galiegue et al., 1995), or in mouse brain using RT-PCR/southern blot analysis (McCoy 
et al., 1999). In addition to the above mentioned molecular evidence, pharmacological 
approaches based on receptor binding and GTPyS binding studies also failed to detect 
CB2 receptors or G protein-mediated activity in the rat CNS (Griffin et al., 1999).  
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 In summary, the distribution of CB2 in the CNS remains controversial. In 
addition to its expression in the microglia under particular circumstances, more recent 
studies provide immunohistochemical, pharmacological and physiological evidence of 
its presence in astrocytes (Sanchez et al., 2001), brainstem neurons (Van Sickle et al., 
2005) and in culture neurons of Purkinje and granular cells of mice cerebellum (Skaper 
et al., 1996), as well as in neural progenitor cells (Palazuelos et al., 2006). The 
presence of CB2 receptors in the CNS at detectable and functionally relevant levels has 
been detected in rodent and human whole brain, brainstem, cerebellum, cortex, 
hippocampus, thalamus, olfactory bulb, thalamic nuclei and in several additional brain 
regions (reviewed in Atwood and Mackie, 2010). Interestingly, recent work also 
indicates that CB2 receptors expressed in neurons modulate the rewarding sensations 
obtained from cocaine (Xi et al., 2011) and mediate hippocampal synaptic function 
(Stempel et al., 2016).  
 
CB2 receptor-mediated signaling pathways    
 Similarly to CB1, the CB2 receptor has been characterized by different research 
groups as a Gαi/o coupled receptor (Bayewitch et al., 1995; Felder et al., 1995; Slipetz 
et al., 1995; Gonsiorek et al., 2000; Sugiura et al., 2000). The CB2 receptor-mediated 
intracellular signaling mechanisms include MAPK and PI3K activation, gene 
transcription and ceramide production, which is associated with a decrease in 
proliferation and apoptosis (Bouaboula et al., 1996; Shire et al., 1996; Guzmán et al., 
2001a,b; Howlett et al., 2002; Herrera et al., 2005; Romero-Sandoval et al., 2009). One 
of the main differences in relation to CB1 receptors, is that CB2 receptors appear to 
poorly modulate Ca2+ channels or inwardly rectifying K+ channels (Felder et al., 1995).  
 
 
2.5. Phytocannabinoids, synthocannabinoids and indirect agonists 
 
Phytocannabinoids 
 Cannabis plants produce a unique mixture of chemical constituents; the most 
well-known of which are the C21 terpenophenolic compounds, collectively called 
phytocannabinoids. Detailed chemical analysis has identified approximately 70 
molecular species (ElSohly and Slade, 2005). Δ9-THC was isolated by Yechiel Gaoni 
and Raphael Mechoulam (1964), and its psychotropic effects were assessed in 
primates (Mechoulam et al., 1970). Using the chemically defined Δ9-THC molecule, 
researchers were able to obtain qualitatively and quantitatively reproducible 
pharmacological, physiological or behavioral data which led to the uncovering of the 
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neurobiological substrates of eCB signaling. Another important phytocannabinoid 
based on its abundance in the plant (up to 40% plant extract) is cannabidiol. The 
absence of affinity for cannabinoid receptors, together with modest cannabimimetic 
actions and its lack of toxicity, point to this compound as a promising therapeutic agent. 
Some studies suggest possible interactions with other GPCR e.g., antagonist of 
GPR55 (Ryberg et al., 2007), the partial agonist of 5-HT1A receptor (Russo et al., 
2005), or the allosteric modulator of δ-opioid receptors (Kathmann et al., 2006).  
 
Synthocannabinoid agonists 
 Synthetic cannabinoid agonists or synthocannabinoids can be divided into four 
groups according to their chemical structures. The first group (classical cannabinoids) 
involves dibenzopyran derivatives that are both natural constituents of cannabis (e.g., 
Δ9-THC and Δ8-THC) and their synthetic analogues (HU 210). The first generation of 
classical cannabinoids lacked CB1/CB2 receptor selectivity, as they were synthesized 
by inducing minor modifications of the Δ9-THC molecule. CB2 receptor-selective 
agonists such as JWH-133 and HU-308 were also synthesized (Hanuš et al., 1999; 
Huffman et al., 1996). The second group (non-classical cannabinoids) was developed 
as bicylic and tricyclic analogues of Δ9-THC lacking the pyran ring (Melvin et al., 1993). 
This group includes CP55,940, which binds to both CB1 and CB2 receptors with a 
similar affinity. The administration of CP55,940 in mouse revealed that it is 10 to 50 
times more potent than Δ9-THC (Johnson and Melvin, 1986). CP55,940 is a full agonist 
for both receptor types and significantly contributed to both the in vitro and in vivo 
pharmacological characterization of CB1 receptors. The third group of cannabimimetic 
compounds consists of the aminoalkylindoles. This series is represented by 
WIN55,212-2 which also displays a high affinity for both cannabinoid receptors. Some 
of these aminoalkylindoles, such as JWH-015, display significant selectivity for the CB2 
receptors (Showalter et al., 1996). The prototype of the fourth eicosanoid group, which 
involves arachidonic acid derivatives, is AEA, the first eCB isolated from mammalian 
brain (Devane et al., 1992). Some examples of eicosanoid-based cannabinoid agonists 
are AM356, arachidonyl-2´-chloroethylamide (ACEA) and arachidonylcyclopropyl-
amida (ACPA). 
 Some synthetic agonists display more selectivity for the CB1 receptor subtype 
including (+)-methanandamide, ACEA and ACPA. Examples of the CB2 receptor-
selective agonists most frequently used are JWH-133, HU-308, JWH-015 and AM-
1241 (Reviewed in Pertwee, 2008). 
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Synthocannabinoid antagonists 
  The first specific cannabinoid antagonist developed and pharmacologically 
characterized was SR141716A (Rinaldi-Carmona et al., 1994). It blocks the actions of 
various cannabinoid agonists both in vitro and in vivo (see reviews from Kano et al., 
2009; Freund et al., 2003). This compound is a pure antagonist at nanomolar 
concentrations but it is not CB1 receptor-specific and it blocks both CB1 and CB2 
receptors (Pertwee, 1999). It displays inverse agonism under certain experimental 
conditions. Two analogues of SR141716A have also been developed, AM251 and 
AM281 (Howlett et al., 2002). Some selective antagonists for CB2 receptors are 
SR144528, AM630 and surinabant, which display considerably more affinity for CB2 
receptors than for CB1 receptors (Rinaldi-Carmona et al., 1998). However, most of the 
pharmacodynamic features were studied in cell cultures which overexpressed CB2 
receptors, but not by using in vivo experiments. One in vivo experiment on 
cannabinoid-induced antinociception demonstrated that low doses of both SR141716A 
and SR144528 contributed to prolonging and enhancing pain induced by tissue 
damage, which indicates that peripheral CB1 and CB2 receptors are participating in the 
intrinsic control of pain (Calignano et al., 1998).  
 
Indirect agonists 
 Inhibitors of AEA and 2-AG degradation offer an alternative strategy to stimulate 
the eCB system. Indeed, despite the structural similarity shared by AEA and 2-AG, 
distinct enzymes inactivate these lipids and serve as key points of control over specific 
eCB signaling events in vivo. FAAH knockout mice or animals treated with selective 
FAAH inhibitors exhibit more than ten-fold elevations in brain levels of AEA and other 
N-acyl ethanolamines, but no alterations in 2-AG. Conversely, mice treated with 
selective MAGL inhibitors show 8 to 10-fold increases in brain 2-AG levels without 
changes in AEA content. Pharmacological studies have revealed that selective FAAH 
and MAGL inhibitors produce an intriguing subset of the behavioral effects observed 
with direct CB1 receptor agonists. To date several FAAH and MAGL and dual 
FAAH/MAGL inhibitors have been developed (see review from Blankman and Cravatt, 
2013).  
 AEA degradation inhibitors. The FAAH inhibitors with improved selectivity and in 
vivo activity can be divided into α-ketoheterocycles (OL-135), carbamates (URB597, 
URB694), alkylsufonylfluorides (AM3506) and aryl ureas, (PF-3845, LY-2183240). 
  2-AG degradation inhibitors. The first generation of MAGL inhibitors were 
carbamates that displayed low potencies and included URB602, NAM and OMDM169. 
The next O-aryl carbamates showed more capacity to increase brain 2-AG levels. 
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JZL184, which will be used in this work, is about 100-fold more selective for MAGL 
than for FAAH, and has been extensively used to further understand the physiological 
roles of 2-AG (Long et al., 2009). One of the most recently developed MAGL inhibitors 
is based on O-hexafluorisopropyl carbamates is KML29. 
 Dual AEA and 2-AG degradation inhibitors. Dual FAAH/MAGL inhibitors include 
organophosphates (isopropyl-dodecylfluorophosphonate), O-aryl carbamates (JZL195) 
and O-hydroxyacetamide carbamates (SA-57). 
 Blockers of eCB uptake. Some of the molecules that seem to block the uptake 
of eCB include AM404, UCM707, VDM11 and OMDM-2. 
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3. Neurotransmission in AD 
 
 The hypothesis which links age-related memory loss to cholinergic 
neurotransmission impairment was originally based on the observation that cognitive 
deficits related to learning and memory were pharmacologically induced when 
cholinergic neurotransmission was blocked. Antagonists of mAChR disrupt higher 
cognitive functions and induce transient amnestic states. When scopolamine, a 
centrally active and non-selective mAChR antagonist, was administered to young adult 
volunteers, the drug caused selective deficits in recent memory (Drachman and Leavitt, 
1974). The basal forebrain cholinergic pathways play functional roles in conscious 
awareness, attention, working memory and additional mnemonic processes (Perry et 
al., 1999).  In addition, a specific cholinergic deficit involving the projections from the 
basal forebrain to the cortex, hippocampus and amygdala, is consistently found in 
postmortem material from AD patients and in in vivo neuroimaging studies 
(Whitehouse et al., 1982; McGeer et al., 1986).  
 This anatomical and pharmacological evidence indicated a pivotal role for 
cholinergic dysfunction in age-related memory disturbances and lead to the 
“cholinergic hypothesis of geriatric memory dysfunction” (Bartus et al., 1982). The 
cholinergic brain areas involved in the control of the cognitive processes impaired in 
AD patients include the basal forebrain and its main afferent and efferent pathways to 
the cortex, hippocampus and amygdala.  
 
  
3.1. The cholinergic neurotransmitter system in AD 
 
The cholinergic pathways affected in AD 
 Morphological (Hedreen et al., 1984; McGeer, 1986), neurochemical (Sparks et 
al., 1992) and functional studies (Neary et al., 1986; Collerton, 1986; McGeer et al., 
1986) showed that the atrophy of nbM, designated as the Ch4 cell group (Mesulam et 
al., 1983a), played a significant role in the progression of AD. Postmortem and in vivo 
studies have reported marked alterations related to all components of the cholinergic 
neurotransmission system in AD. The loss of BFCN in the nbM is one of the main 
hallmark features of AD brains and was originally described by Davies and Maloney 
(Davies and Maloney, 1976), and corroborated in subsequent studies (Whitehouse et 
al., 1981, 1982; Arendt et al 1983; Vogels et al., 1990; Lehericy et al., 1993; Cullen and 
Halliday, 1998; Geula et al., 2008). The loss of cortical cholinergic innervation in AD 
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can be attributed to the loss of BFCN present in the nbM (Whitehouse et al., 1981, 
1982; McGeer et al., 1984; Rogers et al., 1985; Saper et al., 1985; Etienne et al., 1986; 
Vogels et al., 1990). The profound reductions in ChAT and AChE activities in 
cholinergic projecting areas of AD patients could result from impaired synthesis of 
these enzymes, from an abnormality in their axonal transport from BFCN bodies to 
terminals in the cortex or from degeneration or atrophy of BFCN. The primary source of 
cholinergic innervation to cortex and hippocampal formation is derived from large 
BFCN in the nbM and the complex MS-diagonal band of Broca respectively, and these 
cholinergic nuclei have been extensively examined in patients with AD. This is the case 
of a 74 year-old man who died after a period of progressive loss of memory and 
impairment of judgment. Notably, his father and paternal aunt and uncle suffered from 
a dementia beginning at approximately 60 years of age (Whitehouse et al., 1981). 
Histological analysis of the brain revealed the presence of neuritic plaques and 
neurofibrillary tangles diagnostic of AD. The histochemical studies carried out in serial 
slices, including the forebrain, were compared with slices from an age-matched control. 
The patient with AD exhibited a profound and selective loss of BFCN within the nbM 
(Figure 8), whereas the neurons in the adjacent structures were not affected by the 
degenerative process. 
 Several studies provided evidence of a significant decrease in ChAT and AChE 
activity in AD patients compared to non-demented control subjects, leading to a 
decrease in the synaptic availability of ACh in areas innervated by BFCN (Perry et al., 
1977 and 1978a,b; Davies, 1979; Sims et al., 1981; McGeer et al., 1986). However, 
some immunohistochemical studies reported only changes in size, but not in the 
number of BFCN, and no significant loss of cortical ChAT was found in postmortem 
studies of mild AD patients (Pearson et al., 1983; DeKosky et al. 2002). Further 
quantitative analyses of ChAT-positive cells revealed a similar number of BFCN in the 
nbM in early AD patients and the healthy elderly (Gilmor et al. 1999). However, 
comparable numbers of BFCN do not necessarily reflect an intact and fully functional 
cholinergic system because shrinkage of BFCN has also been observed in AD 
patients, and this is likely to cause a significant loss of cortical synaptic contacts 
(Vogels et al. 1990). A comparison of the estimated BFCN density in the nbM with 
ChAT activity revealed that, when the enzyme activity was reduced by 90%, the BFCN 
density was decreased by 33% (Perry et al., 1982), 35% (Candy et al., 1983), 50% 
(Lehéricy et al., 1993) or 70% (Arendt et al., 1983), demonstrating both the loss of 
BFCN and atrophic BFCN processes (Cummings and Benson, 1987; Pearson et al., 
1983). An in situ hybridization study demonstrated that there was a significant 
reduction in the expression of ChAT mRNA per remaining BFCN in AD patients, 
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supporting the hypothesis that the expression of the ChAT gene might be down-
regulated in the surviving BFCN, suggesting the possibility of the functional restoration 
of ChAT synthesis (Strada et al., 1992). 
 
Figure 8. Photomicrographs from the midportion of the nbM of an age-matched control (A and 
B) and a patient with AD (C and D). (A and C) Normal density of BFCN in the control and the 
profound loss of neurons in the AD patient. At higher magnification, the BFCN in the control 
subject (B) appear as large cells with densely stained Nissl substance. Few neurons are 
present in the nbM of the patient with AD (D). Magnifications: (A and C) x 10; (B and D) x 25. 
Scale bar is 200 µm in (A) and 100 µm in (B). (Original figure extracted from Whitehouse et al., 
1982). 
 
 
 Additional studies demonstrated that BFCN display hypertrophy in the early 
stages of AD, and gradually become atrophic in the advanced stages (Kobayashi et al., 
1991). Interestingly, the relationship between the loss of BFCN in the nbM and the 
formation of neuritic plaques in the cortex of AD patients was examined and a 
correlation between the number of neuritic plaques in several neocortical areas and the 
loss of BFCN was found (Arendt et al. 1984), whilst others concluded that the 
dysfunction and death of BFCN was associated with extensive tangle formation 
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(Rasool et al., 1986). Thus, by using AChE-staining histochemical assay, a marked 
decrease in the density of stained BFCN, together with abundant neurofibrillary tangles 
were found in the nbM of AD patients (McGeer et al., 1986).  
 Due to the large number of neurochemical, neuropathological and functional 
observations which have been made in postmortem samples from AD patients, it is 
reasonable to think that the nbM is deeply involved in the manifestation and 
progression of AD. ChAT activity and AChE-positive fibers are markedly reduced in the 
frontal, parietal, temporal and visual cortices in AD. The depletion of cholinergic 
structures in the temporal lobe, including its limbic, paralimbic and associated 
components is similar to the distribution of the senile plaques (Mesulam and Geula, 
1994). The different subdivisions of the BFCN also seem to be affected in a different 
way in AD which correlates with the cortical areas that are predominantly innervated by 
these BFCN subnuclei (reviewed in Kása et al., 1997). 
 The cholinergic innervation of the hippocampal formation is thought to play an 
important role in memory processes and there is a large body of evidence which 
supports that the basal forebrain cholinergic innervation of the hippocampus becomes 
reduced in the elderly as well as in AD patients. The distribution of AChE in AD 
hippocampal samples revealed reduced levels of both AChE activity and stained fiber 
densities (Henke and Lang, 1983; Green and Mesulam, 1988; Perry et al., 1992; De-
Lacalle et al, 1994). However, the distribution and density of senile plaques is different 
from the density of AChE-positive fibers in the hippocampus from AD patients, despite 
some studies which demonstrate the presence of a large number of senile plaques 
intermingled with positively-stained fibers in the molecular layer of the dentate gyrus 
(Vágvölgyi et al., 1991). Regarding ChAT levels in AD hippocampal samples, different 
studies reported loss to an extent ranging from 25% up to 97%, depending on the area 
and layer examined (Perry et al., 1977; Davies, 1979; Rossor et al., 1982; Henke and 
Lang, 1983; Araujo et al., 1988; Sakurada et al., 1990). 
 The amygdaloid complex is relatively large and is composed of discrete 
neuronal nuclei located deeply within the temporal lobes of the brain. It is involved in 
the processing of memory, decision-making, and emotional reactions (Mishkin, 1978). 
The amygdala is considered part of the limbic system and a major locus of pathology 
associated with AD (Herzog and Kemper, 1980; Kromer-Vogt et al., 1990; Benzing et 
al., 1993; Emre et al., 1993). The cholinergic innervation of the amygdaloid complex 
from patients with AD has been studied by AChE histochemistry (Svendsen and Bird, 
1985; Benzing et al., 1993), and ChAT immunohistochemistry (Benzing et al., 1993; 
Emre et al., 1993). In postmortem samples from AD patients, ChAT activity has been 
found to be significantly reduced in the amygdala (Rossor et al., 1982). The highest 
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reduction was found specifically in the basolateral nucleus (Emre et al. 1993). The 
density of senile plaques and the extent of neurofibrillary tangles in the amygdala do 
not apparently correlate with the loss of either the cholinergic innervation or BFCN 
density (Tago et al., 1987; Benzing et al., 1993; Emre et al., 1993). 
 
Neuroimaging studies in AD  
 Neuroimaging techniques such as in vivo studies using PET markers of ChAT 
and AChE activity (Herholz et al., 2004), or cortical glucose metabolism (Peppard et 
al., 1990), demonstrated a significant reduction of cortical cholinergic function in AD 
patients. Additional functional imaging studies using PET revealed cortical cholinergic 
deficits in both AD and Parkinson´s disease patients, using a radioligand to label AChE 
(Bohnen et al., 2003). In vivo quantification of morphological changes in the nbM using 
magnetic resonance imaging (MRI), demonstrated that the thickness of the substantia 
innominata in the coronal plane provided a very close estimate of atrophy (Hanyu et 
al., 2002). These MRI measurements also proved to be predictive of response to 
treatments with AChE inhibitors (Tanaka et al., 2003). By using a volumetric pixel-
based morphometry approach based on proton-diffusion-weighted images, Teipel et al. 
(2005) found a reduction of the signal intensity in the anterior lateral nbM (Ch4al) of AD 
patients, which may be related to the loss or degeneration of BFCN. Moreover, a 
positive correlation between decreased volumetric measurements in the nbM and 
reduced cortical gray matter density in several regions was observed, suggesting an 
anatomical degenerative link (Grothe et al., 2012 and 2013). Other studies have 
reported a reduced volume of specific nbM compartments associated with cognitive 
decline in MCI patients (Grothe et al., 2010). Additional volumetric neuroimaging 
studies confirmed that the degree of basal forebrain cholinergic degeneration in AD 
patients significantly correlated with cognitive decline by using the Mini-Mental State 
Examination (MMSE) (Choi et al., 2012). Moreover, atrophy of the nbM also predicted 
the development of dementia in Parkinson´s disease patients (Lee et al., 2013). 
  The development of neuroimaging techniques has led to the emergence of 
combined MRI and diffusion tensor imaging analyses which provide a powerful tool to 
identify neural tracts in vivo. Recent studies have used diffusion tensor MRI to identify 
the nbM and its projections in an attempt to relate the atrophy observed in MCI patients 
with either memory and/or attentional deficits, cognitive decline and conversion to AD 
(Brueggen et al. 2015; Grothe et al. 2016; van Dalen et al., 2016). These findings in 
neuroimaging, together with the neurochemical evidence found in postmortem samples 
from AD patients, support the hypothesis that damage to the integrity of the nbM may 
underlie the cognitive deficits associated with AD. 
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 Regarding the areas innervated by the nbM, functional MRI in AD patients after 
a single dose of rivastigmine showed increased cortical activity which indicates a 
specific effect of cholinergic tone enhancement on cortical neuronal activity (Rombouts 
et al., 2002). Chronic administration of rivastigmine to early AD patients also increased 
cortical activation and increased MMSE scores (McGeown et al., 2008; Miettinen et al., 
2011; 2015). Similar findings are observed in a functional MRI study carried out in MCI 
and AD patients following a chronic treatment with the AChE inhibitor donepezil 
(Saykin et al., 2004; Kircher et al., 2005). 
 Hippocampal volumetric measurement is recognized as one of the core in vivo 
neuroimaging biomarkers of AD as the hippocampus already undergoes 
neurodegenerative and atrophic processes during predementia stages of AD (Kaye et 
al., 1997). MRI volumetric studies have shown consistent patterns of hippocampal and 
basal forebrain cholinergic system atrophy in AD patients (Grothe et al., 2012; Teipel et 
al., 2005), and in those with amnestic (Grothe et al., 2010), or amyloid positive MCI 
(Teipel et al., 2014). Based on these findings, hippocampal volume has been analyzed 
as a biomarker of cognitive decline and response to cholinergic treatment in AD 
dementia and prodromal AD (Erten-Lyons et al., 2006; Jack et al., 1999; Macdonald et 
al., 2013). In addition, in a study conducted on patients with mild AD dementia, smaller 
hippocampal volume predicted cognitive decline during donepezil therapy (Csernansky 
et al., 2005). Additional evidence supporting the loss of hippocampal volume as a 
predictor of global cognitive decline in a prodromal AD cohort has recently been 
reported (Teipel et al., 2016). Nevertheless, the hippocampal volume does not seem to 
be a useful biomarker for predicting responses to AChE inhibitors. 
 Volumetric studies performed in the whole amygdala by using MRI techniques 
have consistently found reductions in patients with AD (Basso et al., 2006; Horínek et 
al., 2007). A more recent study reported significantly smaller amygdaloid volumes in 
both hemispheres in AD patients. Interestingly, structural differences were found when 
the different nuclei were individually mapped, highlighting a significant tissue loss in the 
central, medial, lateral and basolateral medial nuclei (Cavedo et al., 2011).  
 
Cholinergic receptors in AD 
 When the supply of cortical ACh is interrupted as a consequence of BFCN 
degeneration and/or ChAT down-regulation, the cholinergic receptors located in 
projecting areas are devoid of the endogenous ligand and one should expect to 
observe a regulation to compensate for that loss of cholinergic input. The two classes 
of cholinergic receptors, the G protein-coupled mAChR and the ligand-gated ion 
channel nAChR, are not equally affected in AD. Nicotinic receptors are generally 
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decreased in AD, but both binding studies with non-selective muscarinic agonists and 
antagonists, and histochemical studies show either decreased levels, unchanged 
levels or even increased levels of mAChR in AD (reviewed in Kása et al., 1997; 
Ferreira-Vieira et al., 2016). 
 
Muscarinic acetylcholine receptors in AD 
 The majority of the mAChR is located postsynaptically, and only a proportion of 
them are autoreceptors distributed in presynaptic membranes of BFCN (Mash et al., 
1985; Gulya et al., 1989; Quirion et al., 1989a).  
  The studies performed in tissue homogenates using radioligands selective for 
mAChR have shown discrepancies in brain tissue samples from AD patients. 
[3H]pirenzepine, a relatively selective M1 mAChR radioligand, shows that binding 
parameters are generally unaltered in brain tissue samples from AD patients (Araujo et 
al., 1988; Giacobini, 1990). Since M1 mAChR are mainly located in postsynaptic 
cholinoceptive neurons, they are probably conserved after the loss of BFCN. 
Regarding the M2 mAChR subtype, different experimental designs make it possible to 
label these receptors by selectively blocking M1 mAChR sites, such as 
[3H]oxotremorine-M binding in the presence of pirenzepine (Vogt et al., 1992), or by 
using [3H]AF-DX 116, a relatively selective M2 mAChR antagonist (Quirion et al., 
1989b). A significant loss of M2 mAChR has been observed in specific brain areas of 
postmortem AD patients, including cortical areas and the hippocampal formation, and 
this is consistent with the idea that M2 mAChR could be located on degenerating BFCN 
nerve terminals (Mash et al., 1985; Quirion et al., 1989a,b; Giacobini et al., 1990; 
Reinikainen et al., 1990; Nordberg, 1992). Due to the selective loss of M2 mAChR in 
the brain regions of patients with AD which contain senile plaques, it has been 
suggested that presynaptic M2-mediated signaling may be involved in the non-
amyloidogenic processing pathway leading to maintain amyloid peptide homeostatic 
levels (Kása et al., 1997). However, the postsynaptic location of M2 in cortical and 
hippocampal regions has also been described and this could mask the reductions in 
the presynaptic M2 mAChR component (Levey et al., 1991 and 1995; Rossner et al., 
1997).  
 Autoradiography represents a powerful pharmacological tool with which to 
analyze the radioligand binding in discrete and small brain areas or subfields in brain 
slices. Moreover, the density and distribution of receptors can readily be correlated with 
the density of neurons, neuritic plaques and neurofibrillary tangles, or with the degree 
of cholinergic dysfunction in the brain area of interest on slices consecutive to those 
processed for autoradiography. The first autoradiographic studies for mAChR in AD 
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patients showed that the densities and the proportions of the M1 and M2 mAChR 
subtypes in autopsied AD brain samples were not significantly different in slices of 
hippocampal tissue compared to those observed in non-demented controls (Griffiths et 
al., 1994; Probst et al., 1988). Conversely, further autoradiographic studies showed 
significant reductions of both [3H]pirenzepine binding in the presence of cold 
oxotremorine (M1 mAChR subtype) and [
3H]oxotremorine binding in the presence of an 
excess of cold pirenzepine (M2 mAChR subtype) in entorhinal cortex and in most 
hippocampal strata in AD brain slices (Rodríguez-Puertas et al., 1997).   
 Immunohistochemical approaches have been used to anatomically describe the 
mAChR cellular distribution in postmortem brain samples from AD patients and have 
found a decrease in the M1 protein in the cortex and hippocampus (Flynn et al., 1995). 
In neocortical and hippocampal regions, M1 mAChR is mainly expressed in all 
pyramidal neurons where it displays a somatodendritic distribution (Levey et al., 1991; 
Levey, 1995). Behavioral studies have demonstrated deficits in learning and memory in 
mice lacking M2 mAChR which suggests that the M2 mAChR subtype plays a crucial 
role in cognitive processes (Tzavara et al., 2003b). In this sense, hippocampal 
muscarinic activation, through the high affinity M2 mAChR subtype, promotes a rise in 
AMPA receptor sensitivity to glutamate which finally leads to the so-called „muscarinic 
long term potentiation‟, essential to explain hippocampal neuronal plasticity (Segal and 
Auerbach, 1997). Regarding the distribution of the M2 mAChR subtype, and consistent 
with radioligand binding assays, a decrease in protein levels was also found in AD 
patients that could probably be explained by the loss of BFCN during the disease. 
Cortical M4 mAChR, which are expressed in the neuropil and in scattered perikarya, 
have been found to be significantly up-regulated in AD patients (Flynn et al., 1995). 
The M4 loss in rodents leads to dysfunction in hippocampal synaptic transmission, 
suggesting that this subtype could be involved in neuronal plasticity-associated with 
memory formation (Mulugeta et al., 2006).  
 The expression of the genes for M1 and M2 mAChR were found to be 
unchanged in AD patients (Ohara et al., 1994). However, other authors reported 
increased mRNA levels of the M1 mAChR subtype in the temporal and occipital 
cortices (Harrison et al., 1991).  
 In reference to the functionality of mAChR, the first studies analyzed radioligand 
binding in the presence of guanine nucleotides, in order to measure the “active 
receptors” (Warpman et al., 1993). A significant loss of high-affinity agonist binding to 
M1 mAChR was described in the frontal cortex of patients with AD (Flynn et al., 1991). 
The decreased ability of the agonist carbachol to stimulate GTP-dependent 
[3H]phosphatidylinositol-4,5-bisphosphate hydrolysis indicated defective mAChR-Gαq/11 
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protein/PLCβ coupling in the disease (Ferrari-DiLeo and Flynn, 1993; Jope et al., 
1997). The first evidence of the relationship between cholinergic muscarinic activation 
and amyloid precursor protein processing was demonstrated in carbachol-treated cell 
cultures which overexpressed M1 and M3 mAChR (Nitsch et al., 1992a). In fact, the 
activation of PKC and MAPK signal transduction pathways significantly decreased the 
generation of Aβ fragment in cultured human cells, and Aβ has been shown to induce 
the uncoupling of M1 mAChR from G-protein, blocking the function of M1 mAChR under 
the pathological conditions of AD (Kelly et al., 1996). More recent studies found that 
the attenuation of G-protein coupling to M1 mAChR in the neocortex was associated 
with dementia severity, and indeed correlated with reductions in PKC activity and 
NMDA receptor density, suggesting a postsynaptic cholinergic dysfunction in AD 
(Tsang et al., 2007). [35S]GTP gamma S binding to G proteins combined with 
immunoblot analysis of G protein subunits also revealed that the receptor-mediated 
activation of G proteins was reduced in brain cortex of AD patients (Wang and 
Friedman, 1994). Oxotremorine-M-mediated activation of the M2 mAChR subtype did 
not trigger any change in the functional coupling of M2 mAChR to G protein in the 
neocortex of patients with AD (Hernández-Hernández et al., 1995). Further studies 
have provided evidence of the loss of muscarinic receptor-G protein coupling in AD 
and support the hypothesis that muscarinic receptor-mediated cortical activation may 
be compromised in this disease (Ferrari-DiLeo et al., 1995). 
 
Nicotinic acetylcholine receptors in AD 
 Different studies suggest that brains from AD patients present reduced densities 
of binding sites for nicotinic ligands such as [3H]ACh, [3H](-)nicotine, 
[3H]methylcarbamylcholine and [125I]α-bungarotoxin, in comparison with brain samples 
from age-matched patients (reviewed in Kàsa et al., 1997).  
 The partial loss of nAChR in AD brains was confirmed by autoradiographic 
methods. For example, marked reductions in nicotinic binding (laminar binding 
distribution of [3H]nicotine, [3H]epibatidine, and [3H]cytosine) throughout the cortical 
layers of the temporal cortex, the presubiculum and parahippocampal gyrus were 
observed in AD patients, which usually correlates with a decrease in ChAT activity 
(reviewed in Kása et al., 1997). 
The detection of nicotinic receptor-specific mRNA sequences in brain slices by in situ 
hybridization showed a differential distribution of the mRNAs for the α3- and α4-
subunits (Wevers et al., 1994). However, no alterations in the localization of the α4-
subunit expressing neurons were detected in cortical regions of AD patients (Schröder 
et al., 1991). 
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The choline transporter (SDHACU) in AD 
 SDHACU is a classical presynaptic marker of the cholinergic terminals and 
pharmacological studies have reported contradictory results in the specific binding of 
[3H]-HC-3, a highly specific competitive inhibitor, in postmortem samples from AD 
patients. Some authors described significantly decreased densities in tissue membrane 
homogenates by using binding methods which are very sensitive and precise, but poor 
in anatomical resolution (Pascual et al., 1991). Consistent with these results, a 
significant decrease in [3H]-HC-3 binding sites was also found in the hippocampus, 
entorhinal cortex and layers I-III of the frontal cortex of AD brains (Rodríguez-Puertas 
et al., 1994). However, other authors have described an increase in [3H]-HC-3 binding 
in membrane homogenates from AD frontal cortex (Slotking et al., 1994, Bissete et al., 
1996). Choline uptake, rather than ChAT activity, is rate-limiting in ACh synthesis 
(Happe and Murrin, 1993), therefore, an increase in [3H]-HC-3 binding together with a 
decline in the number of presynaptic terminals could represent a compensatory 
mechanism in the early stages of the disease, resulting in the maintenance of the total 
uptake capacity in order to increase both the synaptic ACh availability and finally the 
activity of the remaining BFCN. However, more recent studies have demonstrated 
differences in the distribution of the vesicular acetylcholine transporter by using single 
photon computed tomography. A significant decrease in [123I]-IBVM binding (47-62%) 
was reported in AD subjects in cingulate cortex and parahippocampal-amygdaloid 
complex, suggesting that cholinergic degeneration occurs in the early stages of AD 
(Mazère et al., 2008). 
 
Neurotrophic factors in AD 
NGF and receptors 
 The nerve growth factor (NGF) and its high tyrosine kinase (TrkA) and low 
p75NTR affinity receptors play a crucial role in BFCN function, and a deregulation of the 
levels of NGF and its receptors is an important factor underlying BFCN degeneration in 
AD (Mufson et al., 1999). NGF is synthesized as a precursor proNGF molecule that is 
proteolytically cleaved to a mature and biologically active neurotrophin peptide. TrkA 
receptor activation through mature NGF (mNGF) binding stimulates signal transduction 
pathways of NGF, thereby triggering the majority of its effects for survival and growth. 
However, p75NTR has multiple additional functions, including apoptosis or cell death 
(Miller and Kaplan, 2001). The physiological effects of TrkA and p75NTR signaling 
depend on their interactions with either proNGF or mNGF. In this context, 
immunoblotting studies demonstrated that proNGF is the predominant form of NGF 
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present in the cortex of elderly and cognitively healthy humans (Fahnestock et al., 
2001). ProNGF levels are increased in the cortex of patients diagnosed with MCI or 
mild AD, compared to subjects who have no cognitive impairment (Peng et al., 2004). 
Interestingly, reduced TrkA levels in the cortex were positively associated with lower 
cognitive performance as assessed by MMSE scores (Counts et al., 2004), whereas 
increased cortical proNGF levels were negatively correlated with MMSE performance 
(Peng et al., 2004). Thus, the concomitant reduction of TrkA and the accumulation of 
proNGF in the cortex may be an early pathological marker of the onset of AD. Several 
studies indicate that increases in cortical proNGF may result in proapoptotic signaling 
through binding to the p75NTR receptor. Moreover, significantly increased levels of NGF 
are detectable in CSF of AD patients, demonstrating the potential utility of NGF as a 
diagnostic biomarker (Blasko et al., 2006).  
 
Neurotrophin-based treatments in AD 
 A clinical trial with NGF was assayed by its intracerebroventricular (i.c.v.) 
administration to AD patients, but acute side effects such as pain, Schwann cell 
migration to the spinal cord and weight loss were reported and the trial finally had to be 
halted (Eriksdotter et al., 1998). In 2001, a new clinical trial based on using either in 
vivo or ex vivo NGF gene therapy was initiated to check for long-term effects on BFCN 
degeneration (Tuszynski et al., 2015). Trophic responses to NGF persisted up to ten 
years after gene transfer, revealing BFCN hypertrophy and CREB activation. 
Furthermore, no adverse pathological effects were observed over this period. 
 
 
3.2. Rat model of basal forebrain cholinergic lesion 
  
 The first neurochemical deficit identified in AD was the observation that BFCN 
were selectively affected in AD patients, which has motivated the development of 
experimental animal models which imitate this impairment (Davies and Maloney, 1976; 
Perry et al., 1977). Further observations led to the “cholinergic hypothesis of geriatric 
memory dysfunction” (Bartus et al., 1982), and to the development of cholinergic 
enhacement therapies using AChE inhibitors. The effects of specific lesions of BFCN in 
learning and memory have been investigated in animal models of basal forebrain 
cholinergic dysfunction. 
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Excitotoxin-based approaches 
 Initially, the most common approach used in functional studies was the infusion 
of excitatory amino acid analogues. However, a few studies used non-specific 
electrolytic lesions (Motohashi et al., 1986; Pirch et al., 1986) or the infusion of 
ethylcholine aziridinium (AF64A) (Eva et al., 1987; Chrobak et al., 1988). The 
excitotoxic hypothesis of neurodegeneration that was predominant during the nineties 
led to the development of lesion models based on a stereotaxic injection of excitotoxins 
into the basal forebrain to produce a reduction in BFCN and cortico-hippocampal 
cholinergic neurotransmission dysfunction. The most commonly used excitotoxins were 
kainic acid (Stewart et al., 1985; Rigdon and Pirch, 1986; Reed et al., 1990), ibotenic 
acid (Flicker et al., 1983; Hepler et al., 1985; Whishaw et al., 1985) and quisqualic acid 
(Aaltonen et al., 1991; Riekkinen et al., 1991a,b; Zupan et al., 1993). One of the most 
important limitations of these lesion paradigms is the fact that, in the rodent, basal 
forebrain BFCN are surrounded by other different cell populations, especially GABA-
containing neurons of the dorsal and ventral pallidum and non-cholinergic 
magnocellular corticopetal neurons (Zaborsky et al., 1999). The above-mentioned 
excitotoxins are far from selective for BFCN and trigger non-specific lesions, masking 
the specific neurochemical and behavioral effects of the basal forebrain cholinergic 
dysfunction. This is emphasized by studies which demonstrate that basal forebrain 
lesion-induced behavioral effects depend on the toxin used (Wenk et al., 1992). 
Therefore, additional methods are required to produce an efficient and selective BFCN 
lesion to mimic the specific basal forebrain cholinergic dysfunction extensively 
described in AD. Immunotoxins provide the opportunity to produce neurotoxic lesions 
of specific neurochemically-characterized neuronal populations by targeting cell-
surface antigens that are exclusively expressed by the cells of interest.  
 
192IgG-saporin 
 During the early nineties, 192IgG-saporin, a powerful tool for selective BFCN 
lesioning, was developed by Wiley et al. (1991) and revolutionized research on the 
cognitive functions of the basal forebrain cholinergic system. This compound consists 
of a monoclonal antibody (192IgG) which is armed with a ribosome inactivating protein 
(saporin) coupled to the antibody via a disulfide bond and specifically directed to the 
low-affinity nerve growth factor receptor p75NTR. P75NTR is abundantly and specifically 
expressed in BFCN during the whole life of rodents (Springer et al., 1987; Woolf et al., 
1989). The toxin follows receptor binding and internalization like the endogenous ligand 
of p75NTR, and enzymatically inactivates the large ribosomal subunit, thereby blocking 
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protein synthesis and ultimately resulting in cell death by apoptosis; the 
neurodegenerative process can be considered complete in about 2 weeks (Wrenn and 
Wiley, 1998). Lesions of this selectivity and extent had proven impossible to produce 
using any other technique. 
 After an i.c.v. injection of 192IgG-saporin, the immunotoxin is taken up by 
cholinergic terminals and retrogradely transported to cell soma in the basal forebrain 
(Heckers et al., 1994). Thus, the i.c.v. administration of 192IgG-saporin results in 
massive BFCN loss, including those from the medial septum, vertical and horizontal 
limb of the diagonal band of Broca and nucleus basalis magnocellularis, whereas 
cholinergic cells in the adjacent ventral pallidum and cholinergic interneurons within the 
caudate putamen are not affected (Rossner et al., 1995a). The immunolesions keep 
loci of cholinergic degeneration free from mechanical damage and do not affect 
parvalbumin, calbindin or calretinin containing GABAergic neurons of the basal 
forebrain. The only additional non-cholinergic neurons known to be affected by the 
i.c.v. administration of 192IgG-saporin application are cerebellar Purkinje cells which 
also express p75NTR (Heckers et al., 1994; Waite et al., 1995). Lesions restricted to 
these cells can trigger substantial deficits in spatial learning in the Morris water maze 
(Waite et al., 1999). However, such damage results in impairments in a cued version of 
the water maze in which spatial learning is not required, suggesting that there is also a 
sensory or motor impairment associated with the loss of cerebellar Purkinje cells 
(Waite et al., 1995). 
 The basal forebrain cholinergic system is composed of different rostrocaudally 
distributed cholinergic nuclei (Ch1-Ch4) with particular innervating networks (Mesulam, 
1983a). Intraparenchymal injections of 192IgG-saporin directly into specific nuclei of 
the basal forebrain allow us to understand the specific role of the different BFCN 
populations in behavioral and neurochemical aspects. The infusion of 192IgG-saporin 
in the distinct nuclei induces profound specific BFCN losses and cholinergic 
hypoactivity in the innervated areas and permits us to assess the contributions of 
single projection systems in a variety of learning and memory tests, thereby 
demonstrating the effectiveness of 192IgG-saporin (Wenk et al., 1994). It has been 
widely described that 192IgG-saporin, in a dose-dependent manner, induces dramatic 
and permanent decreases in the number of ChAT- and AChE-positive BFCN in the 
NBM (Torres et al., 1994; Wenk et al., 1994). Two weeks after an intraparenchymal 
injection into the NBM, significant, long-lasting decreases in the densities of AChE-
positive fibers and ChAT activity in several cortical regions of adult rats are observed 
(Wenk et al., 1994; Szigeti et al., 2013). 
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Neurochemical effects of BFCN immunolesions in the NBM 
Effects on cholinergic neurotransmission 
 The effects on cholinergic and non-cholinergic neurotransmission of 192IgG-
saporin-induced BFCN depletion in the NBM have been extensively analyzed. Multiple 
neurotransmitter systems are affected in this lesion model, but cortical cholinergic 
neurotransmission becomes especially impaired. Profound alterations have been 
reported, such as reductions in several cortical cholinergic presynaptic markers 
including ChAT activity (up to 80%) and density (up to 50%), or AChE density (up to 
90%) and SDHACU density ([3H]HC-3 binding by up to 45%) (Waite et al., 1994; Wenk 
et al., 1994; Rossner et al., 1995a,b; Gil-Bea et al., 2005; Ljubojevic et al., 2014). As a 
consequence of interruption in the cortical ACh supply, specific adaptations related to 
neurotransmitter receptors are observed. Autoradiographic studies demonstrate that 
M1 mAChR density is increased by up to 35% in the parietal cortex one week after the 
192IgG-saporin infusion, whereas M2 mAChR density is less affected (an increase of 
approximately 20%) which is in parallel with great reductions in AChE levels and 
choline uptake sites (Rossner et al., 1995a,b; Rossner et al., 1997). Cortical 
postsynaptic M1 mAChR, which are mainly expressed in pyramidal cells in layers II/III 
and VI, have been found to be upregulated after the 192IgG-saporin lesion, and these 
receptors may be compensating for the loss of basal forebrain cholinergic input. 
Terminals located in cortical layer IV and at the border between layers V and VI exhibit 
strong M2 mAChR labeling, in agreement with the dense cholinergic innervation of 
these cortical layers and the role of M2 mAChR as an autoreceptor (Eckenstein et al., 
1988; Mechawar et al. 2000). The fact that M2 mAChR is increased after 
immunolesions (having lost up to 80% of BFCN terminals) supports the hypothesis that 
a significant population of M2 mAChR could exist postsynaptically to cholinergic 
terminals in the cerebral cortex (Rossner et al., 1997; Mesulam, 1998). However, the 
expression of M2 receptors in BFCN terminals still remains controversial. Ex vivo 
autoradiographic studies have confirmed significant and widespread decreases in 
cortical presynaptic terminals by using [123I]BVM, a radioligand which targets the 
VAChT (Quinlivan et al., 2007). More recently, in vivo PET neuroimaging studies, 
carried out in rats with a 192IgG-saporin-induced lesion of the NBM, have 
demonstrated a significant decrease in fronto-cortical cholinergic terminals (Parent et 
al., 2012 and 2013), glucose metabolism (Mehlhorn et al., 1998; Jeong et al., 2016), 
and neuronal metabolic activity (Gelfo et al., 2013) by using 
[18F]fluoroethoxybenzovesamicol to label the vesicular ACh transporter and [¹⁸F]-2-
fluoro-2-deoxyglucose and cytochrome oxidase activity assays. 
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Effects on other different neurotransmitter systems 
 As previously mentioned, specific basal forebrain cholinergic immunolesions 
also affect other neurotransmitter systems, including the glutamatergic, GABAergic, 
serotonergic and adrenergic systems. While NMDA receptors are reduced by 
approximately 20%, AMPA and kainate binding sites are increased by up to 30% in 
several cortical regions seven days after the 192IgG-saporin-induced lesion of the 
NBM. Moreover, when the BFCN from the medial septum, which innervate 
hippocampus, are eliminated, NMDA receptor binding sites are reduced by up to 35% 
in CA1, but with no significant changes in AMPA or kainate receptor binding, 
demonstrating that there are different effects depending on which of the basal forebrain 
cholinergic nuclei have been lesioned (Rossner et al., 1995c). Interestingly, 
upregulation of AMPA receptor expression after NBM lesion is prevented with the 
NMDA receptor antagonist MK-801 (Garrett et al., 2006). This effect is more 
pronounced in the frontal cortex of 192IgG-saporin-treated young adult rats than in 
middle-aged and aged rats, suggesting that cholinergic projections from the basal 
forebrain cholinergic system play a critical role in cortical plasticity and also that there 
are age-related differences in lesion-induced expression of AMPA receptors (Kim et al., 
2005). Regarding GABAergic neurotransmission, the binding of [3H]muscimol, but not 
[3H]flunitrazepam, is increased by up to 20% after 192IgG-saporin administration in 
cortical regions, revealing a modulation of cortical inhibition (Rossner et al., 1995c). 
The selective BFCN damage in the NBM may be associated with a functional decline in 
cortical GABAergic neurotransmission and cognitive deficits (Jeong et al., 2011). 
Moreover, deep brain stimulation of the remaining BFCN after NBM lesion improves 
spatial memory performance and partially restores the two isoforms of glutamic acid 
decarboxylase, GAD65kDa and GAD67kDa and glutamate to control levels (Lee et al., 
2016). These findings clearly demonstrate that basal forebrain cholinergic innervation 
has a pivotal role in cognitive processes by fine-tuning the cortical excitatory-inhibitory 
balance. 
 Basal forebrain cholinergic immunolesions do not alter α1-adrenoceptor and 
5HT1A receptor binding in the neocortex, but α2 and β-adrenoceptor and 5HT2A display 
significant reductions in neocortical brain regions in parallel with the loss of BFCN 
terminals (Heider et al., 1997). More recent studies show that NBM cholinergic 
deafferentation triggers a significant down-regulation of 5HT2A receptor levels in the 
frontal cortex, together with changes in serotonin and 5-hydroxytryptophan levels, 
suggesting a down-regulation of the rate-limiting enzyme for the synthesis of serotonin 
in combination with the cholinergic deficit (Severino et al., 2007). However, 5-HT1A and 
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5-HT1B receptors do not seem to mediate this process (Heider et al., 1997; Garcia-
Alloza et al., 2006).  
 
Effects on neurotrophin homeostasis  
 NGF plays a pivotal role in the development and maintenance of BFCN and 
neuronal plasticity (Conner et al. 1992). BFCN depletion in the NBM does not modify 
NGF protein levels in the basal forebrain but considering that much of this protein is 
located in BFCN cell bodies, the remaining BFCN probably compensate for the loss of 
cholinergic innervation (Rossner et al., 1997). Interestingly, when NGF is administered 
i.c.v. to 192IgG-saporin-lesioned rats, it displays a limited capacity to enhance the 
functioning of residual BFCN and increases fear-related behavior and adverse 
neuroproliferative changes (Winkler et al., 2000). However, a more recent study shows 
contradictory results as not only was BFCN rescued two weeks after 192IgG-saporin 
infusion, but learning and memory were also improved (Lee et al., 2013). The brain-
derived neurotrophic factor (BDNF) has also been studied because of its role in 
survival, differentiation and the functioning of neurons (Huang and Reichardt, 2001; 
Mattson, 2008). Two weeks after a 192IgG-saporin-induced lesion of NBM, cortical 
BDNF protein levels are significantly reduced (Angelucci et al., 2011). The fact that 
NGF levels are increased, whereas BDNF is reduced after 192IgG-saporin lesioning of 
BFCN, suggests that there is a different regulation. Growth factors are very promising 
molecules, but neurotrophin-based therapeutic strategies should be handled cautiously 
until there is a complete understanding of their regulation in neurodegeneration since 
some clinical trials have had to be halted because of safety-issues (Eriksdotter et al., 
1998). 
 
Effects on neurogenesis and neuronal plasticity 
 Although the adult mammalian brain has limited capacity for structural repair 
after injury, adult neurogenesis has been demonstrated and promotes the proliferation 
of progenitor cells, migration to the target area and differentiation into mature neurons 
(Biebl et al., 2000; Winner, 2002). Adult neurogenesis is specifically restricted to the 
lateral ventricle wall and to the border between the hilus and the granule cell layer in 
the hippocampal dentate gyrus (Luskin, 1993; Kuhn et al., 1996). The i.c.v. 
administration of 192IgG-saporin in adult rats impairs adult neurogenic processes, 
increasing cell death in both the dentate gyrus and the olfactory bulb (Cooper-Kuhn et 
al., 2004). Impairment in spatial memory performance has also been observed in this 
lesion model, which is reverted by the systemic administration of physostigmine, 
presumably through M1 and M4 mAChR expressed in newly born cells (Mohapel et al., 
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2005). Moreover, a 192IgG-saporin-induced lesion of BFCN in the NBM disrupts 
cortical map reorganization and impairs motor learning, supporting the hypothesis that 
cortical plasticity is a key substrate for enabling an animal to effectively learn a skilled 
motor behavior (Conner et al., 2003). Further studies have demonstrated that following 
focal cortical injury, the basal forebrain cholinergic system is required for the 
neccessary plasticity that behavioral recovery requires (Conner et al., 2005). These 
findings support the hypothesis that the basal forebrain cholinergic system is 
selectively required for modulating complex forms of cortical plasticity driven by 
behavioral experiences (Ramanathan et al., 2009). 
 
Effects on gene regulation 
 Acquisition of new information is associated with changes in the cortical 
expression of several genes, some of which have been identified as playing a major 
role in learning and memory processes (Gusev and Gubin, 2010). The 
intraparenchymal administration of 192IgG-saporin directly in the NBM triggers 
profound regressive changes in dendritic morphology of frontal cortical neurons 
(Harmon and Wellman, 2003), and impairment of neuronal plasticity (Wellman and 
Sengelaub, 1991). When cDNA microarrays and qRT-PCR have been used to screen 
for the cortical gene expression profile in 192IgG-saporin-lesioned rats, specific 
changes in mRNA expression were reported in those behaviorally impaired animals, 
associated with the loss of BFCN in the NBM (Paban et al., 2011). It has been 
proposed that these genes are involved in biological processes such as intracellular 
signaling processes, transcription regulation (Gusev and Gubin, 2010),  glial and 
vascular remodeling and cytoskeleton organization, dendritic proliferation and axon 
guidance (Maysami et al., 2006). 
 
Behavioral effects of BFCN immunolesions in the NBM 
 It has been previously shown that a single intraparenchymal injection of 
192IgG-saporin in the NBM results in an extensive and selective loss of BFCN, long-
lasting cortical cholinergic hypoactivity and deficits in recognition memory capacity 
(nonmatching-to-position task, object recognition task and object location task), in 
delayed matching to position (T-maze task), configural association learning (operant 
conditioning task), spatial learning (Morris water maze) and aversive learning and 
memory (passive avoidance test) (Berger-Sweeney et al., 1994; Torres et al., 1994; 
Baxter et al., 1995; McGaughy et al., 1996; Butt et al., 2002; Pizzo et al., 2002; Bailey 
et al., 2003; Paban et al., 2005; Gibbs et al., 2007; Dashniani et al., 2009; Lee et al., 
2013; Rastogi et al., 2014; Lee et al., 2016).  
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 Further studies involving the lesioning of the NBM with 192IgG-saporin support 
the role of BFCN in an array of attentional functions including vigilance, reorienting of 
spatial attention and attentional resources directed at environmental stimuli (Bucci et 
al., 1998; Chiba et al., 1995 and 1999). All these previous results allow us to conclude 
that the NBM plays a major role in attention and that could have an influence on effects 
on learning and memory (Baxter and Chiba, 1999; McGaughy et al., 1996; Baxter et 
al., 2013).  
 Conversely, the results of other studies based on 192IgG-saporin-induced 
lesion of the NBM indicate that the role of the basal forebrain cholinergic system in 
cognitive functions is considerably more limited than was previously believed. Thus, 
impairments in spatial learning and memory, which are commonly observed after basal 
forebrain lesions produced with less selective methods (excitotoxins), are not observed 
following selective immunotoxic lesions of specific BFCN. Some authors report 
impairment in spatial learning and memory by lesions of the basal forebrain which are 
frequently attributed to BFCN loss, despite the lack of selectivity of the lesion method 
employed (reviewed in Baxter 2001 and Baxter et al., 2013). Several studies using the 
intraparenchymal infusion of 192IgG-saporin in the NBM have failed to show 
impairment in spatial learning tasks, or have produced only mild performance deficits 
(Wenk et al., 1994; Baxter et al, 1996). In contrast, when 192IgG-saporin is 
administered i.c.v., more consistent impairments in spatial learning and memory are 
reported (Berger-Sweeney et al., 1994; Waite et al., 1995; Walsh et al., 1995). Some 
authors have reported a higher depletion of cortical ChAT activity following i.c.v. 
192IgG-saporin administration than with intraparenchymal injections, leading them to 
propose that a severe loss of cortical cholinergic input is required to induce deficits in 
learning and memory (Baxter et al., 2001).  
 In conclusion, the controversial behavioral findings suggest that the surgical 
procedures as well as the dose of immunotoxin used are critical variables when 
192IgG-saporin is administered intraparenchymally. This model of basal forebrain 
cholinergic dysfunction, induced by the administration of 192IgG-saporin in the NBM, 
produces neurochemical perturbations related to ACh-related enzymatic machinery, 
neurotransmitter receptors, neurotrophin homeostasis and neuronal plasticity, leading 
to learning, memory and attentional deficits similar to the cognitive impairment 
observed in AD patients. Therefore, this model is useful to assay a wide range of 
pharmacological interventions aimed at modulating or partially restoring basal forebrain 
cholinergic neurotransmission. 
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3.3. Triple transgenic mice model (3xTg-AD mice) 
 
 As mentioned above, the basal forebrain cholinergic system which innervates 
the hippocampus and the entire cortical mantle plays a key role in cognitive processes 
and seems to be one of the most and one of the earliest atrophied brain areas in AD. 
However, there are identified familial mutations which contribute to the accumulation of 
the histopathologiocal markers of AD. Histopathologically, AD is characterized by the 
accumulation of senile plaques containing amyloid-β (Aβ), produced by the abnormal 
cleavage of the amyloid precursor protein (APP) due to β- and γ-secretases, and by 
the presence of hyperphosphorylated tau and neurofibrillary tangles. 3xTg-AD mice 
harboring βPPSwe, PS1M146V and tauP301L transgenes, have been extensively used as a 
model which shows some of the neuropathological markers of AD during the 
development of the familial type of the disease. These animals accumulate 
extracellular Aβ deposits prior to tangle formation and exhibit deficits in synaptic 
plasticity, including long-term potentiation, which coincides with intracellular 
accumulation of Aβ in brain areas related to the control of memory and emotional 
processing, such as cortex, hippocampus and amygdala (Oddo et al., 2003).  
 Cholinergic neurotransmission in 3xTg-AD mice also seems to be affected. 
Thus, hippocampal and cortical cholinergic neuritic dystrophy was first observed in 
middle-aged (8-10 month-old) mice with increasing levels in an age-dependent 
manner, together with a significant reduction (up to 23%) in the number of BFCN in the 
basal forebrain cholinergic system between young (2-4 month-old) and old (18-20 
month-old) 3xTg-AD mice (Perez et al., 2011). Other authors report a decrease in the 
density of BFCN in the medial septum and deficits in the length of hippocampal 
cholinergic axons in 3xTg-AD mice which starts at 4 months of age (Girão da Cruz et 
al., 2012). Furthermore, the number of ChAT-immunoreactive neurons is decreased in 
the NBM, accompanied by a loss of cholinergic fibers in the frontal motor cortex and 
hippocampal CA1 area in 11-month-old 3xTg-AD-mice (Orta-Salazar et al., 2014). 
These results demonstrate a cholinergic dysfunction in the septo-hippocampal pathway 
and in cortical projections arising from the NBM. Interestingly, 192IgG-saporin-induced 
depletion of BFCN in 12-month-old transgenic mice leads to drastic increased levels of 
Aβ-plaques and hyperphosphorylated tau together with enhanced gliosis, which 
demonstrates that the basal forebrain cholinergic dysfunction contributes to worsen 
AD-like pathology in the 3xTg-AD mouse model, and, as Härtig et al. (2014) support, 
“drugs targeting the cholinergic neurotransmission remain justified as a potential 
treatment strategy of AD”. 
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 The activation of M1 mAChR with AF267B was enough to ameliorate spatial 
learning and memory impairment in 8 month-old transgenic mice. The cognitive 
impairment of 3xTg-AD mice was exacerbated by dicyclomine, a M1 mAChR 
antagonist. Moreover, hippocampal plaque pathology was decreased by AF267B and 
increased after dicyclomine administration (Caccamo et al., 2006). An 
electrophysiological study reported a reduction in burst firing in response to carbachol 
application in 3xTg-AD mice. Thus, a moderate decrease was observed in 5 month-old 
transgenic mice whereas the difference was significantly higher in 10 month-old mice, 
suggesting a decline in cholinergic neurotransmission in an age-dependent manner 
(Akay et al., 2009). A more recent study analyzes the functional coupling of Gα i/o 
protein to M2 and M4 mAChR in 4-month-old (prodromal) and 15-month-old (advanced 
stages) 3xTg-AD mice (Manuel et al., 2016). A decrease in functional coupling was 
found in the posterior amygdala and an increase in the motor cortex in prodromal and 
advanced stages, respectively, suggesting that deregulated signaling in limbic areas in 
the prodromal stages underlie the anxious-like behaviour of these mice.  
 Several studies have evaluated cognition and emotional behavior by using 
passive avoidance or the novel object recognition tests, and have reported deficits in 
learning and memory (Caccamo et al., 2006; Clinton et al., 2007; Filali et al., 2012; 
Rasool et al., 2013). Modulation of anxiety, fear and phobias has also been reported in 
other types of tasks including the open field or the elevated plus maze (Nelson et al., 
2007; Pietrapaolo et al., 2014). 
 As we have seen, 3xTg-AD mice progressively develop and manifest several 
features of AD, including senile plaque formation, intracellular tangle accumulation, 
cholinergic dysfunction, and cognitive impairment and, therefore, represent a useful 
model with which to evaluate therapeutic strategies for familial AD patients.  
 
 
3.4. Endocannabinoid signaling in AD 
 
Neuroanatomical and pharmacological evidence 
 The eCB system is made up of the eCB substances, the enzymatic machinery 
required for their synthesis and degradation, and the cannabinoid receptors that 
modulate the neuronal activity in different brain areas. CB1 receptors are abundantly 
expressed in the CNS, including in areas related to learning and memory processes, 
such as the basal forebrain cholinergic system and innervation to cortex, amygdala and 
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hippocampus. Data obtained from human postmortem samples from AD patients 
suggest that the eCB system is modulated during the course of disease. 
 Westlake and colleagues analyzed both the mRNA expression for CB1 
receptors and [3H]CP55,940 binding in postmortem brain samples from AD patients 
(Westlake et al., 1994). [3H]CP55,940 binding was reduced in cortex, but no alterations 
in levels of CB1 mRNA expression were observed in comparison with aged-matched 
controls. Although [3H]CP55,940 binding was reduced, it was not selectively associated 
with AD-pathology and failed to dissociate changes in CB1 receptor expression from 
normal aging. Other research groups found that both cortical and hippocampal CB1 
receptor levels remain unaltered in AD (Benito et al., 2003; Lee et al., 2010; Mulder et 
al., 2011; Ahmad et al., 2014). In contrast, other authors reported decreased levels of 
highly nitrosylated CB1 receptor expression in cortical areas containing activated 
microglia (Ramirez et al., 2005), which did not correlate with any AD molecular marker 
or cognitive status (Solas et al., 2013). Receptor nitrosylation could indicate impaired 
coupling of CB1 receptors to downstream effectors (Ramirez et al., 2005). Furthermore, 
autoradiographic studies using the selective CB1 receptor radioligand [
125I]SD7015 
revealed increased levels of CB1 receptor expression in the frontal cortex in the early 
stages of AD (I-II), and a decline during the later stages (V-VI), which indicates that 
CB1 receptor density inversely correlate with Braak tau pathology (Farkas et al., 2012). 
A recent detailed autoradiographic study showed increased levels of [3H]CP55,940 
binding in the frontal cortex during the middle stages of AD (III-IV), but no changes in 
the early stages (Manuel et al., 2014). Manuel et al. also reported a similar 
phenomenon within the hippocampus and in the caudate-putamen, showing that CB1 
receptor density inversely correlates with tau accumulation, according to the Braak 
classification. Moreover, the functional coupling of CB1 receptors to Gαi/o protein was 
also analyzed by [35S]GTPγS autoradiography in the same study. Data revealed a 
similar modulation of hippocampal CB1 receptor activity to that observed in 
[3H]CP55,940 binding and increased cortical CB1 receptor activity during the initial 
stages of AD (I-II), preceding the increase in CB1 receptor density (Manuel et al., 
2014). Increased CB1 receptor activity during the initial stages of AD might be an 
indication of neuroprotective mechanisms mediated by eCB signaling in response to 
initial neuronal damage.  
 With regards to CB2 receptors, increased levels have been found in brain tissue 
samples from AD patients which seem to be associated with the activation of the 
microglia surrounding senile plaques (Ramirez et al., 2005). These results suggest a 
positive correlation with the density of both the glial fibrilar acidic protein (GFAP) 
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marker for astrocytes and senile plaques, but not with the cognitive status (Solas et al., 
2013).  
 Moreover, FAAH density and activity is significantly increased and is associated 
with the overexpression of glial CB2 receptors which probably contributes to 
inflammatory processes by increasing arachidonic acid as a consequence of the 
increased AEA metabolism in senile plaque enriched brain areas (Benito et al., 2003; 
Jung et al., 2012). Similarly to what has been observed in CB1 receptor studies, the 
literature fails to report consistent results related to the regulation of eCB metabolism in 
AD. The increased levels of FAAH in AD brains support the idea that eCB and/or their 
precursors could be regulated in some way. Some studies reported decreased brain, 
but not plasmatic, levels of AEA and its precursor NArPE in cortical regions from AD 
patients, which positively correlated with cognitive deficiencies and, inversely, with 
senile plaque pathology, suggesting a possible involvement of AEA deregulated 
metabolism in cognitive dysfunction (Koppel et al., 2009; Jung et al., 2012). In these 
studies no alterations were observed in the levels of 2-AG in brain samples from AD 
patients. However, Mulder et al. (2011) reported that 2-AG-mediated signaling in the 
late stages of AD was deregulated in postmortem brain samples. The increased 
expression of DAGL-α, together with the decreased activity of MAGL and ABHD6, 
could contribute to 2-AG signaling-mediated synapse silencing. The absence of altered 
eCB plasmatic levels means that we cannot consider them as plasmatic biomarkers for 
AD. 
 
Cannabinoids as therapeutic agents for AD 
 The effects of cannabinoid receptor agonists in reducing excitotoxicity, Ca2+ 
influx, neuroinflammatory processes, oxidative stress and apoptosis make the 
cannabinoid system a potential target for the treatment of neurodegenerative diseases. 
The eCB are modulators of other signaling pathways, and are involved in the activation 
of the phosphatidylinositol 3-kinase/protein kinase B pathway, the induction of 
phosphorylation of extracellularly regulated kinases and the expression of transcription 
factors and neurotrophins.   
 The synthesis of eCB is stimulated after neuronal damage, and their protective 
effects may be mediated by CB1 receptors, as indicated by the increase of neuronal 
vulnerability when the CB1 receptor is absent (Stella et al., 1997; Marsicano et al., 
2003; van der Stelt et al., 2001a). The neuroprotective effects of cannabinoids (phyto 
and synthocannabinoids) have been demonstrated in in vitro models of excitotoxicity, 
in both neuronal (Skaper et al., 1996) and in organotypic brain cultures (Grabiec et al., 
2012; Koch et al., 2011), as well as in vivo (van der Stelt et al., 2001b). The CB1 
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receptor antagonists, SR141716A and AM251, but not the CB2 antagonist, AM630, 
attenuate the neuroprotective effects of WIN55,212-2 and NADA on NMDA-mediated 
excitotoxicity models of cortical neurons (Kim et al., 2006) or organotypic brain cultures 
(Koch et al., 2011; Grabiec et al., 2012). Moreover, the negative excitotoxic effects are 
increased in CB1 receptor knockout mice. The CB1 receptor-mediated protection has 
been demonstrated to be sensitive to the pertussis toxin and PKA inhibition which 
leads to inhibition of presynaptic glutamate release or DSE (Marsicano et al., 2003), 
blockage of voltage-gated Ca2+ channels (Mackie and Hille et al., 1992; Twitchell et al., 
1997; Koch et al., 2011) and inhibition of Ca2+ release from ryanodine sensitive stores 
(Zhuang et al., 2005). Excitotoxicity may be underlying or contributing to the 
neurodegenerative processes and memory impairment described in AD (Sonkusare et 
al., 2005). The reduction of glutamatergic neurotransmission through NMDA receptors 
or decreased levels of Ca2+ influx may confer neuroprotective effects. Thus, 
memantine, a noncompetitive antagonist of NMDA receptors, is used for the treatment 
of moderate-to-severe AD. The synthetic cannabinoid HU-210, in addition to acting as 
a full agonist of CB1 receptors, also inhibits NMDA receptors and its beneficial effects 
against excitotoxicity have previously been described (Nadler at al., 1993). The 
activation of CB1 receptors specifically located in glutamatergic networks by either the 
administration of exogenous cannabinoids or by the modulation of the eCB levels (e.g. 
through the inactivation of the degrading enzymes), may represent an alternative 
therapeutic approach to attenuate this neuropathological feature related to the 
excitatory imbalance described in AD.  
 
Clinical evidence of therapeutic properties of cannabinoids in AD 
 Clinical data modestly support the beneficial effects of nabilone or dronabinol 
(cannabinoid agonist analog of Δ9-THC) for some behavioral symptoms related to AD. 
One clinical trial including 15 AD patients resulted in a decrease in the severity of 
altered behavior after 6 weeks of dronabinol treatment, with its side effects limited to 
euphoria and somnolence (Volicer et al., 1997). Further clinical trials including eight 
patients with dementia reported a reduction in nighttime agitation and behavioral 
disturbances, without adverse effects during the trial periods with dronabinol (Walther 
et al., 2006, 2011). Moreover, the administration of nabilone to an advanced AD patient 
who was refractory to antipsychotic and anxiolytic medications, promptly and 
significantly improved the agitation and aggressiveness (Passmore, 2008). However, 
no evidence of cannabinoid-based improvement of dementia has yet been observed 
(Krishnan et al., 2009). Recently, a clinical trial with Δ9-THC in 24 patients with 
dementia and relevant neuropsychiatric symptoms, revealed the absence of side 
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and/or beneficial effects after its daily oral administration for 3 weeks, suggesting that 
higher doses could be efficacious and equally well tolerated (van der Elsen et al., 
2015). The number of patients included in these trials was limited and none of the trials 
evaluated cognitive or neurodegenerative markers, but the positive behavioral results 
are promising and provide us with valuable information, especially considering that no 
notable side effects were reported (Aso et al., 2014). 
 
 
3.5. Lipids and AD 
 
General considerations 
 There is increasing evidence that lipid metabolism alterations may underlie the 
onset or contribute to the progression of several neurodegenerative disorders, 
including AD, but the precise molecular mechanisms involved remain unclear. In 
addition, work is in progress to discover lipid-related prognostic markers with which to 
predict not only the risk of developing AD, but also the onset and progression of the 
disease. Thus, plasmatic (Mapstone et al., 2014; Fiandaca et al., 2015), cerebrospinal 
fluid (Koal et al., 2015; Fonteh et al., 2015) and brain (Mendis et al., 2016) lipid levels 
have been quantified in AD and compared with that of control subjects. Nevertheless, 
over the last few years, the development of matrix-assisted laser desorption/ionization 
imaging mass spectrometry (MALDI-IMS), has permitted the investigation of the 
anatomical distribution of small molecules, including lipids, within biological systems 
through the in situ analysis of tissue slices (Sugiura et al, 2009). Recently published 
studies have identified the distribution pattern of lipid species in hippocampal (Mendis 
et al., 2016) and frontal cortex slices from AD patients and age-matched control 
subjects by using MALDI-IMS (González de San Roman et al., 2017). However, it was 
Alois Alzheimer (1911) who firstly reported “the extraordinarily strong accumulation of 
lipoid material” or fatty deposits in his papers first describing the human brain of a 
demented patient (reviewed in Foley, 2010). In accordance with these original findings, 
subsequent studies have confirmed altered levels of brain and plasma lipid species 
thereby revealing a plausible link between aberrant lipid metabolism and 
neurodegeneration in AD (Ellison et al., 1987; Mulder et al., 2003; Mapstone et al., 
2014; Mendis et al., 2016).  
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Structural lipid profile changes in AD 
 The different lipid species present in the brain can be grouped into three major 
categories: cholesterol, glycerophospholipids and sphingolipids (Jackson et al., 2005). 
The glycerophospholipids category includes the following classes of lipids: PC, PE, 
phosphatidylinositol mono, bis and trisphosphates and phosphatidylserines (PS) 
among others. Specifically, PC (Nitsch et al., 1992b; Martin et al., 2010), and PE 
(Ellison et al., 1987; Martin et al., 2010) species seem to be decreased in AD. 
Moreover, a modulation in the ratio between saturated and unsaturated fatty acids has 
been reported (Mulder et al 2003; Soderberg et al., 1991). Under normal physiological 
conditions, PS species are preferentially located in the inner leaflet of the plasma 
membrane, but the loss of asymmetry is an early indicator of apoptosis (Fadok et al., 
1992), and/or glia-mediated synaptic pruning to remodel the neural circuit (reviewed in 
Bevers and Williamson, 2016). The loss of PS asymmetry with increased 
externalization to the outer leaflet of the lipid bilayer has been described in samples 
from AD patients probably indicating apoptosis rather than synaptic remodeling (Bader 
Lange et al., 2008). The sphingolipids category contains sphingomyelin (SM), 
cerebrosides, ceramides (Cer), sulfatides (SF) and gangliosides. Early studies reported 
an increase in levels of SF in AD (Majocha et al., 1989). There is now evidence of a 
significant SF depletion (up to 58% and 93% in gray and white matter, respectively), 
even at the onset of the clinical manifestations of the disease (Han et al., 2002). 
Moreover, a consequent elevation in ceramide (He et al., 2010) and GM levels was 
found in the entorhinal cortex and dentate gyrus of AD brain samples (Chan et al., 
2012; Pernber et al., 2012). However, results are contradictory as a previous study 
reported decreased GM levels in the hippocampus of early-onset AD (Svennerholm 
and Gottfries, 1994). 
 As previously mentioned, the MALDI-IMS technique allows us to anatomically 
locate and further analyze many small molecules (e.g., lipids). The findings of Mendis 
et al. (2016) showed reduced levels of some PE species in regions of both gray and 
white matter in hippocampus, whereas the levels of some PC, PS, SM, Cer and SF are 
increased. Very recently, the depletion of different SF lipid species has been identified 
from the earliest stages of the disease in both white and gray matter areas of the 
frontal cortex (González de San Roman et al., 2017). The different classes of lipids 
mentioned above, which are deregulated in AD, constitute a large pool of Ch that can 
potentially be used for ACh synthesis when the demand for choline needed to sustain 
ACh release is enhanced (i.e. BFCN death in AD). 
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Choline metabolism and eCB in AD 
 BFCN do have a unique metabolic capability that might contribute to their 
selective vulnerability in AD, and perhaps in other cholinergic disorders (Blusztajn and 
Wurtman, 1983; Wurtman et al., 1985; Wurtman, 1992). BFCN, like any cell of the 
body use Ch to form phosphocholine after a process of phosphorylation, which is then 
further transformed into membrane PC, but additionally, these neurons acetylate it to 
form a compound designated for export; the neurotransmitter ACh (Wurtman, 1992). 
The biosynthesis of ACh is produced by the enzyme ChAT using Ch and acetyl-CoA 
(White and Wu, 1973).  
 As Wurtman noticed in 1992, the first element, Ch, is a metabolically, 
'expensive' molecule due to the presence of three methyl groups. Ch is obtained from 
the diet and delivered to BFCN via the blood stream, whereas acetyl-CoA is a co-
substrate involved in many metabolic pathways and, therefore, not specific for 
cholinergic neurotransmission (reviewed in Blusztajn and Wurtman, 1983). ACh 
hydrolysis provides approximately 50% of Ch, which is finally uptaken by the SDHACU. 
Interestingly, ChAT exhibits low affinity for its substrates (White and Wu, 1973). 
Consequently, the rates at which phosphocholine and ACh are formed in BFCN 
depend on the concentration of Ch (Millington and Wurtman, 1982). A secondary 
source of Ch derived from the hydrolysis of certain lipid species, such as membrane 
phospholipids has been described, and this led to the autocannibalism (autophagy) 
hypothesis as an adaptative response to stress provoked by the cholinergic 
dysfunction present in AD (Wurtman et al., 1985). In the synthetic pathway, PE from 
any specific membrane pool can be sequentially methylated to PC (Bremer et al., 
1960a,b), which are then hydrolyzed to free Ch (Blusztajn et al., 1987), by membrane-
associated phospholipase D (PLD) activation (Hattori and Kanfer, 1984; Exton, 1999). 
PIP2, PKC and phorbol esters stimulate PLD activity (reviewed in Exton, 1999). 
Furthermore, PLD is reduced by up to 63% in homogenates of brain tissue samples 
from AD patients (Kanfer et al., 1986).  
 The relation between muscarinic neurotransmission and PC metabolism has 
previously been studied (Dolezal and Tucek, 1984; Qian et al., 1989). Thus, the 
stimulation of cortical synaptosomes with cholinergic agonists, including ACh, 
carbachol and muscarine, is able to increase PLD activity, which is also dependent on 
PKC activity involving PIP2 and DAG, leading to the accumulation of free Ch (Qian et 
al., 1989). The effect of muscarinic-induced PLD activity is antagonized by atropine 
(Dolezal and Tucek, 1984). Consequently, Gαq/11 protein-coupled muscarinic receptors 
such as M1 and/or M3 subtypes may be involved in these PC-related metabolic 
pathways. By using postmortem brain samples from AD patients, it was found that PC 
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turnover is accelerated and Ch availability decreased (Blusztajn et al., 1990; Nitsch et 
al., 1991, 1992). How changes in membrane phospholipid metabolism might relate to 
BFCN death, which is characteristic of AD, is a question that requires a more detailed 
research to be properly answered. In addition, abnormal Ch metabolism together with 
impaired muscarinic signaling might have a relevant role in the progression of AD. 
 As previously mentioned, cholinergic neurotransmission can be modulated by 
eCB signaling by the presynaptic activation of CB1 receptors driven via the 
postsynaptic release of eCB. Both the synthesis of eCB and de novo synthesis of Ch 
share common membrane phospholipid precursors and metabolic pathways involving 
Gαq/11-coupled mAChRs, different phospholipases and PIP2-DAG metabolism. The 
BFCN which remain alive in AD patients probably increase their activity, and the 
membrane phospholipids may represent the only alternative pool to synthesize Ch de 
novo in an attempt to maintain the cholinergic tone in the brain areas innervated by the 
basal forebrain. If certain precursors for the synthesis of eCB in cholinergic synapses 
and in the basal forebrain are being exploited to maintain cortical cholinergic 
neurotransmission under neurodegenerative conditions the modulation of the eCB 
signaling may be useful in maintaining the homeostasis of both neurotransmitter 
systems. The analysis of the lipid profile in the basal forebrain cholinergic system and 
in the projection areas could not only provide new evidence of the relationship between 
the cholinergic and eCB systems, but also contribute to the discovery of innovative 
lipid-based therapeutic strategies for the treatment of neurodegenerative disorders.  
 
 
 66 
 
 
 
 
 
 
 
 
 
 
 
  
 67 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 68 
 
 
 
 
 
 
 
 
 
 
 
 
Objectives 
  
 69 
 
 
 
Objectives 
 
70 
 
Objectives 
 
 The basal forebrain cholinergic pathways are progressively affected in 
Alzheimer´s disease, leading to a decline in cognitive functions and irreversible 
impairment of memory and thinking abilities. Neurolipidic systems, such as the 
endocannabinoid system, regulate different physiological processes including learning 
and memory. Endocannabinoid signaling becomes altered during the progression of 
AD, and there is increasing evidence that a deregulation of lipid metabolism may 
underlie the onset or contribute to the progression of several neurodegenerative 
disorders, including AD.  
 On the other hand, the synthesis of endocannabinoids is stimulated by 
muscarinic receptor activation and CB1 cannabinoid receptor activation modulates the 
release of ACh. Furthermore, the synthesis of the endogenous ligands of both systems 
may share common metabolic pathways and membrane phospholipid precursors. 
Therefore, to further understand the relationship between the basal forebrain 
cholinergic neurotransmission and CB1 receptor-mediated signaling in the pathways 
which arise in the basal forebrain, the objectives of the present study are: 
 
I. To develop an ex vivo model of specific impairment of the basal forebrain cholinergic 
neurons (BFCN) by using the immunotoxin 192IgG-saporin in hemibrain organotypic 
cultures and to evaluate the effect of the cannabinoid agonist WIN55,212-2 by using 
immunohistochemistry. 
 
II. To improve the in vivo model of specific BFCN lesion in the nucleus basalis 
magnocellularis in the adult rat by the intraparenchymal administration of 192IgG-
saporin, to evaluate the behavioral outcomes related to learning and memory of an 
aversive stimulus by using the passive avoidance test, to verify the specificity and 
severity of the lesion and to analyze the cholinergic signaling mediated by M2/M4 
muscarinic receptors.  
 
III. To analyze CB1 receptor-mediated endocannabinoid signaling in the in vivo model of 
BFCN lesion by using autoradiography and to analyze the cellular distribution of CB1 
receptors by using immunohistochemistry. 
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IV. To obtain the lipid profile by means of MALDI-IMS in the in vivo model of 192IgG-
saporin-induced lesion, focusing on the analysis of membrane phospholipid precursors 
for both the de novo synthesis of choline and the synthesis of eCB. 
 
V. To evaluate in a 7 month-old 3xTg-AD mice model of AD learning and memory of an 
aversive stimulus, to analyze CB1 and M2/M4 receptor-mediated signaling by using 
autoradiography and to analyze the cellular distribution of these receptors by using 
immunohistochemistry.  
 
VI. To evaluate the effects on the above mentioned behavioral and neurochemical 
parameters of the subchronic activation of the eCB system, following the administration 
of a direct (WIN55,212-2) and an indirect (JZL-184) cannabinoid agonist in 7 month-old 
3xTg-AD mice.  
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1. Animals 
 
 1.1. Sprague-Dawley rats (Manuscript I) 
 We used male Sprague-Dawley rat pups at postnatal day 7 (P7) which weighed 
14-20 g at the start of the experiments. Every effort was made to minimize animal 
suffering and to use the minimum number of animals. All procedures were performed in 
accordance with European animal research laws (Directive 2010/63/EU) and the 
Spanish National Guidelines for Animal Experimentation (RD 53/2013, Law 32/2007). 
Experimental protocols were approved by the Local Ethical Committee for Animal 
Research of the University of the Basque Country (CEEA 388/2014). The number of 
animals and organotypic cultures used is detailed in the manuscript. 
 These animals were used for the immunohistochemical detection of p75NTR in 
fixed tissue and the ex vivo experiments based on hemibrain organotypic cultures 
containing BFCN. 
 
1.2. Sprague-Dawley rats (Manuscripts II and III) 
 Adult male Sprague-Dawley rats weighing 200-250 g and ranging from 8 to 10 
weeks at the start of the experiment were used for the studies in manuscripts II and III. 
Rats were housed four per cage (50 cm length x 25 cm width x 15 cm height) at a 
temperature of 22ºC and in a humidity-controlled (65%) room with a 12:12 hours 
light/dark cycle, with access to food and water ad libitum. Every effort was made to 
minimize animal suffering and to use the minimum number of animals. All procedures 
were performed in accordance with European animal research laws (Directive 
2010/63/EU) and the Spanish National Guidelines for Animal Experimentation (RD 
53/2013, Law 32/2007). Experimental protocols were approved by the Local Ethical 
Committee for Animal Research of the University of the Basque Country (CEEA 
388/2014). 
 These animals were used for the in vivo administration of 192IgG-saporin 
followed by behavioral tests and histochemical, immunohistochemical, 
autoradiographic or MALDI-IMS assays. The number of animals used for in vivo 
administration of 192IgG-saporin is detailed in manuscripts II and III. 
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1.3. CB1 knockout mice (Manuscript III and IV) 
 CB1 receptor knockout (CB1
-/-) and wild-type (CB1
+/+) mice were provided by Dr. 
C. Ledent. The generation of mice lacking the CB1 receptor was previously described 
as follows (Ledent et al., 1999). Briefly, the CB1 gene was cloned from the 129/Sv 
mouse genomic library, and the single coding exon was mapped and sequenced 
(EMBL/GenBank Y18374). A PGK-Neo cassette was inserted between Avr II and Sfi I 
sites located 1073 base pairs apart, replacing the first 233 codons of the gene. 
Homologous recombination in R1 cells and aggregation with CD1 eight-cell stage 
embryos were performed as described in Ledent et al (1997). A recombinant line was 
used to generate chimeras, allowing germ line transmission of the mutant gene. 
Heterozygous mice were bred for 30 generations on a CD1 background before 
generating the CB1
-/- and CB1
+/+ varieties used in these studies. 
  For this study 9 week-old male CB1
-/- and CB1
+/+ mice were used. Animals were 
housed and maintained under standard laboratory conditions (12:12 hours light/dark 
cycle, starting the light cycle at 8:00 am, with access to food and water ad libitum, 22 ± 
2 ºC, 50-60% humidity). All procedures were performed in accordance with European 
animal research laws (Directive 2010/63/EU) and the Spanish National Guidelines for 
Animal Experimentation (RD 53/2013, Law 32/2007) and the Use of Genetically 
Modified Organisms (Law 32/2007 and 9/2003). Experimental protocols were approved 
by the Local Ethical Committee for Animal Research of the University of the Basque 
Country (CEIAB/21/2010/Rodríguez Puertas and CEEA 366-1 and 2). These animals 
were used for autoradiographic studies. The number of animals used is detailed in 
manuscript IV. 
 
1.4. 3xTg-AD mice (Manuscript IV) 
 The triple transgenic mice (3xTg-AD), used as a model for familial AD , were 
obtained from the Department of Medical Psychology, Universitat Autonóma de 
Barcelona, Barcelona, Spain, in collaboration with Dr Lydia Giménez Llort. The 3xTg-
AD mice harboring PS1M146V, APPSwe and TauP301L transgenes were genetically 
modified as described below, by LaFerla and colleagues at the Department of 
Neurobiology and Behavior, University of California, Irvine (Oddo et al., 2003). Briefly, 
two independent transgenes (encoding human APPSwe and human tauP301L, both under 
control of the mouse Thy1.2 regulatory element) were co-injected into single-cell 
embryos harvested from homozygous mutant PS1M146V knock-in (PS1KI) mice. 
 For the present study 7 month-old male 3xTg-AD mice and age-matched 
controls (Non-Tg mice) sharing the same background, but without genetic 
modifications, were used. All the animals were housed and maintained under standard 
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laboratory conditions (12:12 hours light/dark cycle, starting the light cycle at 8:00 am, 
with access to food and water ad libitum, 22 ± 2 ºC, 50-60% humidity). All procedures 
were performed in accordance with European animal research laws (Directive 
2010/63/EU) and the Spanish National Guidelines for Animal Experimentation (RD 
53/2013, Law 32/2007) and the Use of Genetically Modified Organisms (Law 32/2007 
and 9/2003). Experimental protocols were approved by the Ethical Local Committee for 
Animal Research of the University of the Basque Country (CEIAB/21/2010/Rodríguez 
Puertas and CEEA 366-1 and 2). 
 These animals were used for behavioral tests, autoradiographic and 
immunofluorescence studies and synthocannabinoid-based pharmacological 
treatments. The number of animals used is detailed in manuscript IV as well as in 
Figure 11. 
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2. Materials 
 
2.1. Reagents 
 192IgG-saporin (Batch 2441969) was acquired from Millipore (Temecula, CA, 
USA), [3H]CP55,940 (131.8 Ci/mmol) and [35S]GTPγS (1250 Ci/mmol) from 
PerkinElmer (Boston MA, USA). The [3H]-microscales and [14C]-microscales used as 
standards in the autoradiographic experiments were purchased from ARC (American 
Radiolabeled Chemicals, Saint Louis, MO, USA). The β-radiation sensitive films, Kodak 
Biomax MR, bovine serum albumin (BSA), DL-dithiothreitol (DTT), adenosine 
deaminase (ADA), guanosine 5´-diphosphate (GDP), guanosine5´-O-3-
thiotriphosphate (GTPγS), ketamine, xylazine, acetylthiocholine iodide, 2-
mercaptobenzothiazole (MBT), Hoechst 33258  and tetraisopropylpyrophosphoramide 
(iso-OMPA) were all acquired from Sigma-Aldrich (St Louis, MO, USA). The 
compounds necessary for the preparation of the different buffers, the fixation and the 
treatment of slides were of the highest commercially available quality for the purpose of 
our studies.  
 
2.2. Drugs 
 R-(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-
benzoxazinyl]-(1-naphthalenyl)methanone mesylate (WIN55,212-2), (-)-cis-3-[2-
Hydroxy-4-(1,1-dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl) cyclohexanol 
(CP55,940) and (2-Carbamoyloxyethyl) trimethylammonium chloride (carbachol) were 
acquired from Sigma-Aldrich; 4-Nitrophenyl 4-(dibenzo[d][1,3]dioxol-5-
yl(hydroxy)methyl)piperidine-1-carboxylate (JZL184) and 5-(4-chloro-3-methylphenyl)-
1-[(4-methylphenyl)methyl]-N-[(1S,2S,4R)-1,3,3-trimethylbicyclo[2.2.1]hept-2-yl]-
1pyrazole3-carboxamide (SR144528) from Cayman-Chemicals (Ann Arbor, MI, USA); 
N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-
carboxamidehydrochloride (SR141716A) and 1-(2,4-Dichlorophenyl)-5-(4-iodophenyl)-
4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide (AM251) from Tocris (Bristol, 
UK). 
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3. Methods 
 
3.1. Ex vivo experiments (Manuscript I) 
 
Tissue preparation for organotypic cultures 
 To prepare hemibrain organotypic cultures, P7 Sprague-Dawley rats were 
sacrificed by decapitation and their brains were quickly dissected under aseptic 
conditions inside a laminar flow cabinet (TELSTAR, BV-30/70) (Stoppini et al., 1991). 
After removal of the olfactory bulb and the most caudal part of the cerebellum, the 
brains were placed in minimal essential Dulbecco´s modified Eagle medium (DMEM, 
Sigma-Aldrich) supplemented with 0.1% (v/v) antibiotic/antimycotic (Gibco) at 4ºC.  
 The brains were vertically positioned resting on the cerebellum by means of 
cyanoacrylate. They were then cut, from the rostral to the caudal part, into coronal 300 
µm-thick organotypic slices using a sliding vibratome (Leica VT 1.000 S, Leica 
Microsystems AG, Wetzlar, Germany). Approximately 6 slices containing the medial 
septum and another 6 slices containing the NBM were obtained from each brain and 
these were immediately transferred into cell culture inserts over membranes of 0.4 µm 
pore size (PIC50ORG, Millipore, MA, USA). The organotypic slices were then placed in 
6-well culture dishes (Falcon, BD Biosciences Discovery Labware, Bedford, MA) that 
contained 1 ml culture medium per well (Figure 9). The culture medium consisted of 
49% (v/v) Neurobasal Medium (NB, Sigma-Aldrich), 24% (v/v) Hanks‟ Balanced Salt 
Solution (HBSS, Gibco), 24% (v/v) Normal Horse Serum (NHS, Gibco), 1% (v/v) D-
glucose, 0.5% glutamine (Sigma-Aldrich), 0.5% B27 supplement serum free (Gibco) 
and 1% antibiotic/antimycotic. The culture dishes were incubated at 37ºC in a fully 
humidified atmosphere supplemented with 5% CO2 and the cell culture medium was 
replaced by fresh medium depending on each treatment protocol, but typically, on the 
second or third day. 
 
Treatments  
 Drugs and vehicle. WIN55,212-2 and AM251 were dissolved in pure ethanol 
and stored at -20ºC until used. 192IgG-saporin was dissolved directly in the culture 
medium immediately prior to the treatment. The preparations were divided into different 
groups and treated according to different treatment schedules (Figure 9). 
 192IgG-saporin. At 2 DIV, at 5 DIV or at 2 and 5 DIV, organotypic cultures were 
incubated with the immunotoxin 192IgG-saporin (50-200 ng/ml). 
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 Vehicle. Non-lesioned organotypic cultures were kept in the culture medium for 
8 days without receiving any treatments and served as controls. At 2 and 5 DIV, 
organotypic cultures were treated with the vehicle ethanol. The maximal concentration 
of ethanol in the culture medium was set at 0.01% (v/v) based on the concentration 
used in previous studies (Koch et al., 2011). 
 Agonist. At 2 and 5 DIV, organotypic cultures were incubated with the 
cannabinoid agonist WIN55,212-2 (10 nM or 1 nM).  
 Agonist + 192IgG-saporin. At 2 and 5 DIV, organotypic cultures were treated 
with the cannabinoid agonist WIN55,212,2 (10 nM or 1 nM), 2h prior to adding the 
immunotoxin (100 ng/ml). 
 Antagonist + agonist + 192IgG-saporin. At 2 and 5 DIV, organotypic cultures 
were preincubated with the CB1 receptor antagonist AM251 (1 µM) together with the 
cannabinoid agonist WIN55,212-2 (10 nM or 1 nM), 2h prior to adding the immunotoxin 
(100 ng/ml). 
 Cell death marker. After 8 DIV, organotypic cultures were incubated in the 
presence of 5 µg/ml of propidium iodide (PI) for 2 h prior to fixation. The uptake of PI 
stains the nuclei of degenerating cells bright red when observed by the appropriate 
immunofluorescence filters, identifying them in CNS organotypic cultures as previously 
described (Pozzo Miller et al., 1994; Dehghani et al., 2003; Koch et al., 2011a) (Figure 
9). 
  
Immunohistochemistry 
 After the different treatments, the organotypic cultures were gently and 
extensively rinsed with 0.9% saline solution (37ºC) followed by immersion in 4% 
paraformaldehyde and 3% picric acid in 0.1 M phosphate buffer (PB) (4ºC) for 1h. 
Then, the fixed organotypic slices were extensively rinsed in 0.1 M PB (pH 7.4) and 
simultaneously blocked and permeabilized with 4% normal goat serum (NGS) in 0.6% 
Triton X-100 in PBS (0.1 M, pH 7.4) for 2 h at 4ºC. All incubations were performed in 
free floating at 4ºC (48 h) with rabbit anti p75NTR primary antibody, diluted in 0.6% 
Triton X-100 in PBS with 5% BSA. The primary antibody was then revealed by 
incubation for 30 min at 37ºC with Alexa 488-labeled donkey anti-rabbit secondary 
antibody diluted in Triton X-100 (0.6%) in PBS. Then, organotypic slices were washed 
for 30 min by immersion in PBS and incubated for 15 min at room temperature with 
Hoechst 33258 for fluorescent counterstaining of the nuclei. Finally, slices were 
extensively rinsed with PBS and covered with p-phenylendiamine-glycerol (0.1%) in 
PBS for immunofluorescence observation. 
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Quantitative analyses of BFCN   
 200-fold magnification photomicrographs of the MS, VDB, HDB, NBM and 
cortex were acquired by means of an Axioskop 2 Plus microscope (Zeiss) equipped 
with a CCD imaging camera (SPOT Flex Shifting Pixel). All the images were acquired 
at similar brain coordinates, with as much accuracy as possible, under the same 
illumination and exposure time and contrasted to the same level. Both p75NTR 
immunoreactive BFCN and PI positive cells were manually counted by using the 
“manual cell counting and marking” tool of the ImageJ image processing program. The 
area of the images was then calculated based on the display resolution. Finally, the 
total number (N) in the whole image was obtained and the densities of BFCN or PI 
stained cells were expressed as N/mm2.   
 
 
Figure 9. Synopsis of the experimental design including the generation and maintenance of the 
organotypic cultures and treatments schedule (below) (Modified from Ullrich et al., 2011). 
Animals, Materials and Methods 
 
83 
 
3.2. In vivo experiments (Manuscript II, III and IV) 
 
192IgG-saporin infusion (Manuscripts II and III) 
 All surgery was carried out under aseptic conditions. 192IgG-saporin was also 
used in vivo to selectively eliminate BFCN in the NBM. Rats were randomly assigned 
to one of three groups: sham-operated (SHAM), artificial cerebrospinal fluid as vehicle 
(aCSF) and lesion by 192IgG-saporin (SAP). The vehicle was prepared as follows: 
0.15 M NaCl, 2.7 mM KCl, 0.85 mM MgCl2, 1.2 mM CaCl2 (pH 7.4) and sterilized by 
filtration with 0.4 µm-Ø filters (EMD Millipore, CA, USA). Rats were anesthetized with 
ketamine/xylazine (90/10 mg/kg; s.c.) and then placed in a stereotaxic instrument 
(Kopf, Tujunga, CA). After an incision was made in the skin along the midline of the 
skull, two holes were drilled. A 10-µl Hamilton syringe (NeurosTM Syringe, 1701RN; 
Bonaduz, Switzerland) with a 0.008 inches (0.210 mm) diameter needle was carefully 
used to minimize brain damage. The intraparenchymal infusions were made into the 
NBM: - 1.5 mm anteroposterior from Bregma, ± 3 mm mediolateral from midline, + 8 
mm dorsoventral from the cranial surface (Paxinos and Watson, 2005). 192IgG-saporin 
was dissolved in aCSF under aseptic conditions to a final concentration of 130 ng/µl. 
aCSF or 192IgG-saporin was bilaterally injected (1 µl/hemisphere) at a constant rate of 
0.2 µl/min. The needle was kept in for 5 min before removal to avoid a possible 
backflow and to allow complete diffusion. During surgery, the body temperature was 
controlled and the eyes were kept hydrated with warm saline solution (0.9% NaCl). 
After the administration was completed, the wounds were closed with braided silk 
sutures and a broad-spectrum intramuscular antibiotic (2.25 mg/kg oxytetracycline) 
injection was given. The choice of coordinates, the infusion rate, volume and dose of 
immunotoxin were based on previous experiments performed in our laboratory. 
 The rats were allowed to recover from surgery for seven days. On day seven 
(acquisition) and day eight (retention) the learning and memory behavior of the animals 
was tested before the dissection of the brain for use in the neurochemical studies 
(Figure 10).  
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Figure 10. Synopsis of the experimental design including surgery schedule, behavioral 
assessment and euthanasia (manuscripts II and III). 
 
Synthocannabinoid administration in 3xTg-AD mice (Manuscript IV) 
 Synthocannabinoids were administered intraperitoneally (5 ml/kg) once daily, 
for seven consecutive days. WIN55,212-2 and JZL184 were dissolved in pure DMSO 
and diluted with Kolliphor EL (Sigma-Aldrich) and 0.9% saline to a proportion of 
(1:1:18), respectively, as vehicle. Two independent sets of mice were randomly 
assigned to one of the following five groups (n = 10): [1] Non-Tg-vehicle, [2] 3xTg-AD-
vehicle, [3] 3xTg-AD-WIN55,212-2 (0.1 mg/kg), [4] 3xTg-AD-WIN55,212-2 (1 mg/kg) 
and [5] 3xTg-AD-JZL184 (8 mg/kg). During the two days following the last 
administration, the different behavioral parameters were analyzed in the PA test 
(Figure 11). 
 
Figure 11. Synopsis of the experimental design showing the treatment schedule, behavioral 
assessment and euthanasia (manuscript IV). 
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Passive avoidance test (Manuscripts II, III and IV) 
 The passive avoidance apparatus for rats consists of two methacrylate 
compartments separated by a guillotine door. The first compartment is large, white 
illuminated and open-topped: 31 cm (W) x 31 cm (D) x 24 cm (H), and the other is 
small, dark and closed: 19.5 cm (W) x 10.8 cm  (D) x 12 cm (H) (PanLab passive 
avoidance box LE870).   
 The dimensions of the compartments for mice are as follows. Large: 25 cm (W) 
x 25 cm (D) x 24 cm (H) and small: 19.5 cm (W) x 10.8 cm  (D) x 12 cm (H) (PanLab 
passive avoidance box LE872). 
 The test consists of two sessions. The first one is called “the acquisition 
session”. Each animal was gently placed in the illuminated compartment with its head 
facing the closed door and allowed to explore it for 30 sec. Then, the guillotine door 
automatically opened and the animal was allowed to enter the dark compartment for 60 
sec. When the animals cross the threshold, the guillotine door closed and the 
acquisition latency was measured, then a foot shock (0.4 mA/2 sec) was delivered. 10 
sec after the foot shock, the animal was returned to its home cage. The animals which 
did not enter the dark compartment during the acquisition session were eliminated from 
the study. The second session, called the “retention session”, was performed 24 h 
later. The animals were again placed in the illuminated compartment and allowed to 
explore for 30 sec. Then the door opened and the step-through latency time to enter 
the dark compartment was measured up to a maximum cut-off time of 300 sec. No foot 
shock was delivered in the retention session. 
 
Tissue preparation (Manuscripts I, II, III, IV) 
 P7 rats and the animals tested in the passive avoidance test were anesthetized 
with ketamine/xylazine (90/10 mg/kg; i.p.) and then sacrificed before the dissection of 
their brains. 
 Fixed tissue. Representative P7 rats, those rats from SHAM, aCSF and SAP 
groups and 3xTg-AD mice from the five treatment groups, were transcardially perfused 
via the ascending aorta with 50 ml warm (37ºC), calcium-free Tyrode‟s solution (0.15 M 
NaCl, 5 mM KCl, 1.5 mM MgCl2, 1 mM MgSO4, 1.5 mM NaH2PO4, 5.5 mM Glucose, 25 
mM NaHCO3; pH 7.4) and 0.5% heparinized, followed by 4% paraformaldehyde and 
3% picric acid in 0.1 M PB (4ºC) (100 ml/100 g b.w.). Their brains were subsequently 
removed and post-fixed in the same fixative solution for 90 min at 4ºC, and then were 
immersed in a cryoprotective solution of 20% sucrose in PB overnight at 4ºC. Then the 
tissue was frozen by immersion in isopentane and kept at -80ºC. The brains were cut 
into 10 µm coronal slices using a Microm HM550 cryostat (Thermo Scientific) equipped 
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with a freezing-sliding microtome at -25ºC and mounted onto gelatin-coated slides and 
finally stored at -25ºC until used.  
 Fresh tissue. The rest of the animals were sacrificed by decapitation after 
anesthesia. The brain samples from SHAM, aCSF and 192IgG-saporin treated rats, 
3xTg-AD/Non-Tg and CB1
-/-/CB1
+/+ mice, as well as the spleens from CB1
-/-/CB1
+/+ mice, 
were quickly removed by dissection (4ºC), fresh frozen and kept at -80ºC. Later they 
were cut into 20 µm slices and mounted onto gelatin-coated slides and stored at -25ºC 
until used. Several brain areas including that of the basal forebrain cholinergic system, 
amygdaloid nuclei, cortical and hippocampal regions, basal ganglia and olfactory 
system were analyzed in these studies (Figure 12). 
 
Histochemical methods (Manuscripts I, II, III and IV)  
Histochemistry for AChE detection in fixed and fresh tissue (Manuscripts II and III) 
 For some histochemical procedures fresh slices from SHAM, aCSF and SAP 
groups were used. The slices were air dried for 20 min at room temperature, post-fixed 
in 4% paraformaldehyde in PBS for 30 min at 4ºC and washed in 0.1 M PBS, pH 7.4 
(PBS) for 20 min.  
BFCN in the NBM and cholinergic innervations were stained using the “direct coloring” 
thiocoline method for AChE (Karnovsky and Roots, 1964). The slices were rinsed twice 
in 0.1 M Tris-maleate buffer (pH 6.0) for 10 min and incubated in complete darkness, 
with constant and gentle agitation in the AChE reaction buffer: 0.1 M Tris-maleate; 5 
mM sodium citrate; 3 mM CuSO4; 0.1 mM iso-OMPA; 0.5 mM K3Fe(CN)6 and 2 mM 
acetylthiocholine iodide as reaction substrate. The incubation times were from 30 min 
for staining cholinergic somas in NBM or 100 min for staining cholinergic fibers. Finally, 
the enzymatic reaction was stopped by two consecutive washes (2x10 min) in 0.1 M 
Tris-maleate (pH 6.0). Slices were then dehydrated in increasing concentrations of 
ethanol and covered with di-n-butyl phthalate in xylene (DPX) as the mounting 
medium. 
  
Immunohistochemistry (Manuscripts I, II, III and IV) 
 10 µm slices were simultaneously blocked and permeabilized with 4% NGS in 
0.3% Triton X-100 in PBS (0.1 M, pH 7.4) for 2 h at room temperature (22 ± 2ºC). The 
slices were incubated at 4ºC overnight with primary antibodies, diluted in 0.3% Triton 
X-100 in PBS with 5% BSA. The primary antibodies were then revealed by incubation 
for 30 min at 37ºC in the darkness with fluorophore-labeled secondary antibodies 
diluted in Triton X-100 (0.3%) in PBS. Then, slices were washed for 30 min by 
immersion in PBS and incubated with Hoechst 33258 for 15 min at room temperature. 
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Finally, slices were extensively rinsed with PBS and mounted with p-phenylendiamine-
glycerol (0.1%) in PBS for immunofluorescence. The list of primary and secondary 
antibodies as well as the supplier companies, the fluorophores, and the specific 
dilutions are shown in table 1. 
 
Immunohistochemistry for CB1 receptor with tyramide signal amplification (TSA) 
(Manuscripts III and IV) 
 To label CB1 receptors, the primary rabbit antiserum against the CB1 receptor, 
PA1-743, (Affinity BioReagents, CO, USA) was diluted [1:500] in TBS (Tris-buffered 
saline) (0.1 M Tris, 0.15 M NaCl, pH 7.4) containing 0.5% milk powder. Fixed 10 µm 
coronal slices were air dried for 20 min and washed by immersion in PBS for 15 min at 
room temperature. Then, the slices were blocked with 5% NGS in TBS buffer for 2 h at 
room temperature before being incubated with the primary antibody overnight at 4ºC. 
The tyramide signal amplification (TSA) method was used to amplify the signal 
associated with the CB1 receptor antiserum. Briefly, slices were washed for 30 min in 
TNT buffer (0.05% Tween 20 in TBS, pH 7.4) and blocked in TNB solution (10 ml TNT 
buffer, 0.05 g blocking reagent, DuPont) for 1 h at room temperature. Later, the slices 
were incubated with horseradish peroxidase (HRP) goat anti-rabbit (1:150; Perkin 
Elmer, MA, USA) for 1 h followed by a tyramide-fluorescein-based amplification (1:100, 
Perkin Elmer, MA, USA) process in complete darkness for 10 min at room temperature. 
Slices were extensively rinsed in TBS and mounted with p-phenylendiamine-glycerol 
(0.1%) in PBS for immunofluorescence. 
 
Colocalization studies 
 630-fold magnification images for colocalization were acquired on an Axioskop 
Observer A1 inverted microscope (Carl Zeiss) by optical sectioning (0.24 µm/X-Y-Z-
resolution) using structured illumination (ApoTome, Carl Zeiss). Colocalization images 
were created by using ZEN2014 software (Carl Zeiss) and were defined as immuno-
signals without physical signal separation. 
 
Quantitative analyses of BFCN and AChE positive fibers (Manuscripts II and III)  
 200-fold magnification photomicrographs of the NBM were acquired by means 
of an Axioskop 2 Plus microscope (Carl Zeiss) equipped with a CCD imaging camera 
SPOT Flex Shifting Pixel. Both AChE stained and p75NTR immunoreactive BFCN were 
counted independently by two observers at three different stereotaxic levels (-1.08 mm, 
-1.56 mm and -2.04 mm from Bregma), and the total number of BFCN (N) in the whole 
image was obtained. The density of BFCN was expressed as N/mm3.  
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 The stained slices were scanned at 600 ppi of resolution, the images were 
converted to 8-bit gray-scale mode and AChE positive fiber density was quantified by 
using Image J software (NIH, Bethesda, MD, USA). This software defines the optical 
density (O.D.) of an anatomical area and the background from 0 (white) to 256 (black). 
The intensity values in arbitrary units (A.U.) were defined in the selected equivalent 
areas from both hemispheres of all the animals. Background or non-specific staining 
values were substracted from AChE positive signals to obtain the net AChE O.D. in 
each area. AChE staining values in the striatum served as control, and data were 
expressed as percentages of O.D. in striatum for each area. 
 
Semiquantitative analyses of GAD65 immunoreactivity (Manuscript III) 
 200-fold magnification photomicrographs were acquired by using an Axioskop 2 
Plus microscope (Carl Zeiss). All the images were acquired at the same brain 
coordinates with the same illumination and exposure time and contrasted to the same 
level. The immunoreactivity was measured as arbitrary units (AU) of optical density 
(O.D.) by using Image J software. We applied the same brightness and contrast to all 
images. Mean intensity values were defined by the software in the selected equivalent 
areas from both hemispheres of all the animals. The average value from both 
hemispheres was calculated for each animal. 
 
Table 1. Details of primary and secondary antibodies used for immunohistochemistry. 
Host Primary ab Source  Dilut Host Secondary ab Fluorophore Dilution TSA 
Rabbit P75
NTR
 
Cell Signaling, 
MA, USA 
 
[1:750] Donkey Anti-rabbit Alexa fluor-488 [1:250] NO 
Goat ChAT 
Millipore, CA, 
USA 
 
[1:200] Donkey Anti-goat Rhodamine [1:80] NO 
Mouse GAD65 
Millipore, CA, 
USA 
 
[1:750] Donkey Anti-mouse Alexa fluor-555 [1:250] NO 
Guinea pig VGLUT3 
Millipore, CA, 
USA 
 
[1:750] Donkey Anti-guinea pig Alexa fluor-555 [1:250] NO 
Rabbit M2AChR 
Millipore, CA, 
USA 
 
[1:400] Donkey Anti-rabbit Alexa fluor-488 [1:250] NO 
Mouse M4AChR 
Millipore, CA, 
USA 
 
[1:250] Donkey Anti-mouse Alexa fluor-488 [1:250] NO 
Rabbit CB1 
Affinity BioReag, 
USA 
 
[1:500] Goat Anti-rabbit (HRP) Tyramide-FITC [1:150] YES 
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Figure 12. Different rodent brain sections in the coronal plane including the olfactory bulb 
structures (A), the basal forebrain cholinergic system and basal ganglia (B and C), cortical and 
dorsal hippocampal regions and amygdaloid nuclei (C and D), ventral hippocampal regions, 
subiculum, substantia nigra (E) and dorsal raphe and periaqueductal grey (F). Modified from 
Paxinos and Watson, 2005. 
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Autoradiographic studies (Manuscripts II, III and IV) 
 
Cannabinoid receptor autoradiography (Manuscripts III and IV) 
 Fresh 20 µm brain slices from SHAM, aCSF and 192IgG-saporin treated rats, 
3xTg-AD/Non-Tg and CB1
-/-/CB1
+/+ mice, as well as spleen slices from CB1
-/-/CB1
+/+ mice 
were air-dried and submerged in 50 mM Tris-HCl buffer containing 1% of BSA (pH 7.4) 
for 30 min at room temperature to remove the endogenous ligands. They were then 
incubated in the same buffer but in the presence of the CB1/CB2 receptor radioligand, 
[3H]CP55,940 (3 nM) for 2 h at 37ºC. Nonspecific binding was measured by 
competition with non-labeled CP55,940 (10 µM) in another consecutive slice. The CB1 
receptor antagonist, SR141716A (0.1 µM) and the CB2 receptor antagonist, SR144528 
(0.1 µM), were used together with [3H]CP55,940 in two consecutive slices to check for 
the CB1 or CB2 receptor binding specificity. Then, slices were washed in ice-cold (4ºC) 
50 mM Tris-HCl buffer supplemented with 1% BSA (pH 7.4) to stop radioligand binding 
and were dipped in distilled cold water and cold dried (4ºC). Autoradiograms were 
generated by exposure of the tissues for 21 days at 4ºC to β-radiation sensitive films 
together with [3H]-microscales used to calibrate the optical densities to fmol/mg tissue 
equivalent (fmol/mg t.e.). 
 
Labeling of activated Gαi/0 proteins by means of the [
35S]GTPγS binding assay 
(Manuscripts II, III and IV) 
 Fresh 20 µm slices from  SHAM, aCSF and 192IgG-saporin-treated rats and 
3xTg-AD mice (groups [1] to [5]) were dried, followed by two consecutive incubations in 
HEPES-based buffer (50 mM HEPES, 100 mM NaCl, 3 mM MgCl2, 0.2 mM EGTA and 
0.5% BSA, pH 7.4) for 30 min at 30ºC to remove the endogenous ligands. Briefly, 
slices were incubated for 2 h at 30ºC in the same buffer but supplemented with 2 mM 
GDP, 1 mM DTT, adenosine deaminase (3-Units/l) and 0.04 nM [35S]GTPγS. The 
[35S]GTPγS basal binding was determined in two consecutive slices in the absence of 
the agonist. The agonist-stimulated binding was determined in another consecutive 
slice with the same reaction buffer, but in the presence of the corresponding receptor 
agonists (e.g. WIN55,212-2 for CB1/CB2 receptors). The specific receptor antagonist, 
e.g. SR141716A (0.1 µM), was used together with WIN55,212-2 (10 µM) in one 
consecutive slice to check for the specific activation of the CB1 receptor. Nonspecific 
binding was defined by competition with GTPγS (10 µM) in another section. Then, 
slices were washed twice in cold (4ºC) 50 mM HEPES buffer (pH 7.4), dried and 
exposed to β-radiation sensitive film with a set of [14C] standards calibrated for 35S 
calibration (Figure 13). 
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 A similar procedure was followed for mAChR in the presence of the nonspecific 
agonist, carbachol (100 µM), but no BSA was used. 
 After 48 h, the films were developed, scanned and quantified by transforming 
optical densities into nCi/g tissue equivalence units using a calibration curve defined by 
the known values of the [14C] standards (NIH-IMAGE, Bethesda, MD, USA). 
Nonspecific binding values were subtracted from all experimental conditions. The 
percentages of agonist-evoked stimulation were calculated from both the net basal and 
net agonist-stimulated [35S]GTPγS binding densities according to the following formula: 
([35S]GTPγS agonist-stimulated binding  x 100/[35S]GTPγS basal binding)-100. 
 
 
Figure 13. Schematic description of [
35
S]GTPγS functional autoradiography. (Modified from 
Wettschureck and Offermanns, 2005 and Cortés et al., 2016). 
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Matrix-Assisted Laser Desorption Ionization-Imaging Mass Spectrometry 
(MALDI-IMS) (Manuscript II) 
 
Sample preparation for MALDI-IMS. Matrix deposition  
 Both lipid species composition and their anatomical distribution were analyzed 
by using matrix-assisted laser desorption/ionization (MALDI)-imaging mass 
spectrometry (MALDI-IMS) in fresh 20 µm slices from aCSF and 192IgG-saporin-
treated rats. Once the fresh tissue was sliced and mounted on gelatin-coated slides, 
the matrix 2-Mercaptobenzothiazole (MBT) was deposited on the tissue surface by a 
process of solvent-free sublimation, which allows the correct and homogenous 
deposition of the matrix and avoids lipid migration. MBT matrix reaches a good signal 
to noise ratio, both in extracts and in IMS experiments (Astigarraga et al., 2008). The 
sublimation was performed using 300 mg of MBT in a vacuum and the deposition time 
and temperature were controlled (30 min, 140ºC).  
 
Matrix re-crystallization 
 For the re-crystallization of the matrix the sample was attached face-down to 
the bottom of a glass Petri plate which was placed on another Petri plate containing a 
methanol impregnated piece of filter paper in its base. The Petri plates were then 
placed on a hot plate (1 min, 40ºC). 
 
Mass spectrometer spectra and image analysis  
 A MALDI LTQ-XL-Orbitrap (Thermo Fisher, San Jose, CA) equipped with a 
nitrogen laser (λ = 337 nm, rep. rate = 60 Hz, spot size = 80 x 120 µm) was used for 
mass analysis. Thermo´s Imagequest and Xcalibur software were used for MALDI-IMS 
data and image acquisition in both positive and negative ion mode. The positive ion 
range was 500-1000 Da and the negative ion range was 400-1100 Da, with 10 laser 
shots per pixel at a laser fluence of 15 µJ. The target plate stepping distance was set at 
150 µm for both x- and y-axes by the MSI image acquisition software. The data were 
normalized using the total ion current (TIC) values, as there may be potential 
displacement of the masses on the tissue due to experimental factors, e.g., the 
irregularities of the surface.  
 The MALDI images were generated by means of ImageQuest (Thermo 
Scientific). Each of the m/z values was plotted for signal intensity for each pixel (mass 
spectrum) across a given area (tissue section). The m/z range of interest was 
normalized using the ratio of the TIC for each mass spectrum. The intensity reached by 
each peak (m/z or molecule) was further calculated as a ratio of the peak with the 
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highest intensity, and the average was obtained using OriginPro8 (Northampton MA, 
USA) software. The most intense peak was considered to be 100%. The assignment of 
lipid species was facilitated by the use of the databases Lipid MAPS 
(http://www.lipidmaps.org/) and Madison Metabolomics (http://mmcd.nmrfam.wisc.edu), 
and 5 ppm mass accuracy was selected as the tolerance window for the assignment 
(Figure 14). 
 
 
 
Figure 14. Schematic description of MALDI-IMS procedures. From the collection of the sample 
to the identification and quantification of the relative abundance of lipids and imaging acquisition 
(Modified from Schwamborn and Caprioli, 2010).  
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Statistical analyses 
 The two-tailed unpaired Student t test was used for comparisons between aCSF 
vs 192IgG-saporin-treated rats and Non-Tg vs 3xTg-AD mice treated with vehicle. The 
one-way analysis of variance (ANOVA) and Log-Rank analyses were used for multiple 
comparisons between treatments in organotypic cultures, treatments in 3xTg-AD mice 
and when SHAM, aCSF and 192IgG-saporin-treated groups were simultaneously 
compared. The statistical significance threshold was set at p < 0.05. 
 Passive avoidance test (Manuscripts II, III and IV). The acquisition latencies 
were statistically analyzed using the two-tailed unpaired Student t test, or by one-way 
analysis of variance (ANOVA) for multiple comparisons, followed by Bonferroni´s or 
Dunn‟s post hoc tests. The step-through latencies were represented as Kaplan-Meier 
survival curves, and for comparisons the nonparametric Log-rank/Mantel-Cox test was 
used which is appropriate when censored data must be analyzed. The existence of 
animals that reached the cut-off time of 300 s was the reason to choose this rigorous 
statistical analysis. 
 Histochemical data (Manuscripts I, II and III). Propidium iodide positive cells, 
BFCN density, AChE fiber density and GAD65 optical density were statistically 
analyzed using the two-tailed unpaired Student t test or one-way analysis of variance 
(ANOVA), followed by Bonferroni´s or Dunn‟s post hoc tests.  
 Autoradiographic data (Manuscripts II, III, IV). The percentages of agonist-
evoked [35S]GTPγS binding and the [3H]CP55,940 densities were statistically analyzed 
using the two-tailed unpaired Student t test or one-way analysis of variance (ANOVA), 
followed by Bonferroni´s or Dunn‟s post hoc tests. 
 MALDI-IMS data (Manuscript III). The percentages of the relative intensity of 
lipids were statistically analyzed using the two-tailed unpaired Student t test. 
 Correlation analyses (Manuscript II, III and IV). Correlations between different 
neurochemical data were examined by linear regression analysis and the Pearson´s 
correlation coefficient was calculated.
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1. Ex vivo model of basal forebrain cholinergic lesion 
 
(Manuscript I) WIN55,212-2-mediated protective effects of basal forebrain 
cholinergic system via CB1 receptor activation in organotypic cultures 
treated with 192IgG-saporin 
 
HIGHLIGHTS 
 P7 and adult rats show a similar anatomical distribution of basal forebrain 
cholinergic neurons (BFCN). 
 The BFCN from P7 rats express somatodendritic p75NTR receptors.  
 The BFCN are selectively eliminated by 192IgG-saporin in hemibrain 
organotypic cultures. 
 WIN55,212-2, at nanomolar concentrations, protects basal forebrain cells from 
the damage induced by the elimination of BFCN. 
 
GRAPHICAL ABSTRACT 
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1.1. P75NTR immunostaining in the basal forebrain of P7 rats 
 Prior to the use of the 192IgG-saporin to mimic an ex vivo model of basal 
forebrain cholinergic dysfunction, it was necessary to determine the presence of BFCN 
expressing the immunotoxin target p75NTR in P7 rats. The immunofluorescence studies 
carried out in the basal forebrain cholinergic system from P7 rats revealed the 
presence of a high density of BFCN expressing p75NTR in the different nuclei analyzed 
(Ch1-Ch4). The BFCN perikarya were intensely stained showing the typically 
somatodendritic distribution of p75NTR. The BFCN are continuously distributed in 
partially discrete populations along the rostrocaudal axis in adult rodents as well as in 
human and non-human primates. According to this particular distribution of the BFCN, 
the Ch1 or the medial septum (MS) and the Ch2 or the vertical diagonal band of Broca 
(VDB) were first analyzed in P7 rats. The big immunoreactive BFCN from the MS and 
VDB were clearly distinguished from the smaller surrounding cells, showed a moderate 
Hoechst-staining and, moreover, were distributed along the midline (Figure 15 A) 
extending ventrally to the vertical limb of the VDB, (Figure 15 B), which revealed a 
continuum of p75NTR positive BFCN located within Ch1 and Ch2. The BFCN from the 
horizontal diagonal band of Broca (HDB) or Ch3 (Figure 15 C), were distributed 
caudally to VDB and extended ventrally to the nucleus basalis magnocellularis (NBM) 
or Ch4 (Figure 15 D). The BFCN of these nuclei displayed similar staining patterns to 
those previously mentioned, including big but moderately stained nuclei, described for 
the MS and VDB. It should also be emphasized that the BFCN from the NBM showed 
the biggest size and the most extensive dendritic arborization among all BFCN. 
 
 
Figure 15. Low magnification (2.5X) photomicrographs of Hoechst staining in 10 µm tissue 
slices from P7 rats including the MS (1-A), both VDB (1-B) and HDB (1-C) and the NBM (2-D) 
(Scale bar = 1 mm). P75
NTR 
immunofluorescence in the MS (A-A1), VDB (B-B1), HDB (C-C1) 
and NBM (D-D1). (C-D scale bar = 100 µm and C1-D1 scale bar = 50 µm). 
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1.2. 192IgG-saporin-induced BFCN death in organotypic cultures 
 The application of different doses of 192IgG-saporin to hemibrain organotypic 
cultures containing the basal forebrain cholinergic system was able to induce specific 
reductions of BFCN, in a dose-dependent manner, according to the different assayed 
treatments (Figure 16). Increasing concentrations of 192IgG-saporin (50-200 ng/ml) 
were added at day five of culture in vitro, and let the toxin do its effect during another 
three days in vitro (DIV). The effective concentration of immunotoxin, which eliminated 
approximately 50% of BFCN was set around 100 ng/ml, leading to a reduction of BFCN 
density of up to 36% in the MS, 55% in HDB, 42% in VDB and 35% in the NBM. The 
highest concentrations of 192IgG-saporin (200 ng/ml) triggered a reduction of 58% in 
the number of p75NTR positive cells/mm2 in the MS, 64% in the HDB, 61% in the VDB 
and 72% in the NBM (Figure 16 A). In another set of experiments the schedule was 
modified and the 192IgG-saporin was added at day two of culture which was let in the 
tissue acting during six additional DIV. The purpose was to evaluate more initial effects 
of the toxin for a longer period. It was observed a reduction of BFCN densities of up to 
65% in the MS, 55% in HDB, 60% in VDB and 65% in the NBM (Figure 17 A). 
Interestingly, the BFCN reduction induced by 100 ng/ml of immunotoxin during six DIV 
was comparable to that observed with the highest dose (200 ng/ml) during three DIV, 
which demonstrated not only a 192IgG-saporin-induced BFCN death in a dose-
dependent manner, but also in a time-dependent manner of exposure to the 
immunotoxin. The p75NTR-immunoreactivity showed the presence of a great deal of 
debris and a significant atrophy related to smaller somatic size and a reduced dendritic 
arborization after the application of 192IgG-saporin (Figure 17 B). Furthermore, the PI 
uptake, indicative of compromised cell viability, showed dramatic levels of cell death in 
a dose-dependent manner including BFCN and non-cholinergic cells (Figure 18). 
Finally, the double application of 100 ng/ml of 192IgG-saporin at days two and five of 
culture in vitro during 6 DIV led to comparable levels of BFCN reduction to those 
observed with the single application at day two of culture in vitro (Figure 19). However, 
the double application of 200 ng/ml of immunotoxin led to an almost total elimination of 
BFCN as revealed by the nearly complete lack of p75NTR immunoreactivity and the 
intense PI staining recorded in the different cholinergic nuclei of the basal forebrain 
which further suggested non-specific damage. 
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Figure 16. The 192IgG-saporin treatment during 3 days was able to induce a concentration 
dependent  reduction in the densities of p75
NTR
 positive cells in hemibrain organotypic cultures 
containing the MS, HDB, VDB and NBM basal forebrain cholinergic nucleus * p < 0.05; ** p < 
0.01; *** p < 0.001 vs control (0 ng/ml).  
 
 
 
Figure 17. (A) Number of p75
NTR
 immunoreactive BFCN in hemibrain organotypic cultures 
containing the different nucleus of the basal forebrain cholinergic system (MS, HDB, VDB and 
NBM) after the application of different concentrations of 192IgG-saporin according to the six 
days treatment schedule (A above). (B) P75
NTR
 immunoreactive BFCN in the MS (top row) and 
the NBM (bottom row) in the absence (control) or in the presence of 100 ng/ml of the 
immunotoxin according to the treatment schedule described in (A). Low magnification scale bar 
= 200, and high magnification scale bar in the inset = 40 µm. * p < 0.05 vs control (0 ng/ml). 
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Figure 18. (A) Densities of PI positive cells in hemibrain organotypic cultures containing the 
basal forebrain cholinergic nuclei after the application of different concentrations of 192IgG-
saporin according to the treatment schedule detailed in the green arrow graphic. (B) PI uptake 
in hemibrain organotypic cultures containing the MS (top row) and the NBM (bottom row) in the 
absence (control) or in the presence of 100 ng/ml of the immunotoxin (SAP) according to the 
treatment schedule described in (A above). Scale bar = 200 µm.  * p < 0.05; ** p < 0.01; *** p < 
0.001 vs control (0 ng/ml).  
 
 
1.3. Effects of WIN55,212-2 in 192IgG-saporin-lesioned hemibrain 
organotypic cultures 
  
P75NTR immunoreactive BFCN  
 The pharmacological treatment of hemibrain organotypic cultures with the 
synthetic agonist for CB1/CB2 receptors, WIN55,212-2, or with the ethanol used as 
vehicle, did not exert any effect on the viability of the cultures nor on the density of 
BFCN (see treatment schedule in Figure 19 A). The application of 100 ng/ml of 
192IgG-saporin at days two and five of culture in vitro during six DIV led to a 
statistically significant decrease in the density of BFCN (up to 60%), in both the MS 
(vehicle 64 ± 7.8 BFCN/mm2 vs SAP 26 ± 4.2 BFCN/mm2; p < 0.01) and NBM (vehicle 
64 ± 3.8 BFCN/mm2 vs SAP 26 ± 6.7 BFCN/mm2; p < 0.01) (Figure 19). The pre-
treatment of hemibrain organotypic cultures with either 1 nM or 10 nM of WIN55,212-2, 
2h prior the application of 192IgG-saporin, did not trigger any relevant effect on the 
viability and density of BFCN but induced an attenuation of BFCN death in both, the 
MS (1 nM WIN55,212-2: 44 ± 4.2 BFCN/mm2 and 10 nM WIN55,212-2: 43 ± 7.4 
BFCN/mm2) and NBM (1 nM WIN55,212-2: 31.56 ± 4.8 BFCN/mm2 and 10 nM 
WIN55,212-2: 40 ± 2.9 BFCN/mm2) (Figure 19 B-C). These effects were completely 
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abolished in the presence of the CB1 receptor antagonist AM251 (1 µM) leading to 
BFCN levels similar or even lower to those observed in the cultures treated with the 
immunotoxin (Figure 19 B-C). The loss of BFCN was revealed by the absence of well-
defined p75NTR immunostained magnocellular neuronal bodies (Figure 19 D). 
 
 
Figure 19. (B-C) Number of p75
NTR
 immunoreactive BFCN in hemibrain organotypic cultures in 
the absence or presence of 100 ng/ml of 192IgG-saporin, the cannabinoid agonist WIN55,212-2 
(1 or 10 nM) or the CB1 receptor antagonist AM251 (1 µM) during 6 days according to the 
treatment schedule (A). (D) P75
NTR
 immunoreactive BFCN in the MS (top row) and the NBM 
(bottom row) in the absence (vehicle) or presence of 100 ng/ml of the immunotoxin, treated with 
1 nM WIN55,212-2 and 1 µM of AM251. Scale bar = 40 µm. * p < 0.05; ** p < 0.01; *** p < 0.001 
vs control untreated tissues. 
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Cell death evaluated as PI positive cells   
 The PI uptake was also measured and the cell death quantified in the MS, NBM 
and cortex. The pharmacological treatment of the hemibrain organotypic cultures with 
the cannabinoid agonist for CB1/CB2 receptors, WIN55,212-2, or with the vehicle, did 
not exert any effect on the density of PI positive cells (Figure 20 A; see treatment 
schedule in figure 19 A). The application of 100 ng/ml of 192IgG-saporin during six DIV 
led to a statistically significant increase in the density of PI stained cells (approximately 
up to 300%) in the MS (vehicle 16.76 ± 2.3 cells/mm2 vs SAP 70.26 ± 7.7 cells/mm2; p 
< 0.001), NBM (14 ± 2.3 cells/mm2 vs SAP 59 ± 7.5 cells/mm2; p < 0.001) and cortex 
(18 ± 3.8 cells/mm2 vs SAP 61.63 ± 8 cells/mm2; p < 0.001) (Figure 20 A). The pre-
treatment of hemibrain organotypic cultures with 1 nM or 10 nM of WIN55,212-2, prior 
to the application of 192IgG-saporin, induced protective effects on cell viability in the 
MS and in the NBM but no effects were observed in the cortex. A statistically significant 
decrease of cell death was observed as compared with 192IgG-saporin-treated 
hemibrain organotypic cultures in the MS (1 nM WIN55,212-2: 38 ± 4.2 PI cells/mm2 
and 10 nM WIN55,212-2: 39 ± 2.2 PI cells/mm2; p < 0.01 vs SAP data above 
described), in the NBM (1 nM WIN55,212-2; 33 ± 4.9 PI cells/mm2; p < 0.05 vs SAP 
data above described, and 10 nM: WIN55,212-2 41 ± 2.8 PI cells/mm2; p < 0.01 vs 
SAP data above described) (Figure 20 A). The specific CB1 receptor antagonist, 
AM251, was able to block the protective effects elicited by WIN55,212-2 leading to cell 
death levels similar to those observed in the cultures treated with the immunotoxin 
(Figure 20 A-C). 
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Figure 20. (A) Number of PI positive cells in hemibrain organotypic cultures containing the MS 
(i), the NBM (ii) and the cortex (iii) in the absence or presence of 100 ng/ml of 192IgG-saporin, 
the cannabinoid agonist WIN55,212-2 (1 or 10 nM) or the CB1 receptor antagonist AM251 (1 
µM) during 6 days according to the treatment schedule (see Figure 19 A). (B) PI uptake in the 
MS (top row) and the NBM (bottom row) in the absence (vehicle) or presence of 100 ng/ml of 
the immunotoxin, treated with WIN55,212-2 (1 nM) and of AM251 (1 µM). Scale bar = 200 µm. 
** p < 0.01; *** p < 0.001 vs control and # p < 0.05; ## p < 0.01 vs 192IgG-saporin. 
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2. In vivo model of basal forebrain cholinergic lesion 
 
(Manuscript II) Muscarinic neurotransmission and lipid profile changes in 
a rat model of cholinergic dysfunction 
 
 HIGHLIGHTS 
 The 192IgG-saporin lesion model of basal forebrain cholinergic damage has 
been improved minimizing artifactual impairment. 
 The intraparenchymal infusion of 192IgG-saporin in the NBM specifically 
eliminates BFCN leading to a dramatic reduction of cortical cholinergic 
innervation and deficits in learning and memory. 
 M2/M4 mAChR-mediated muscarinic cholinergic signaling is altered in the NBM 
and hippocampus where these receptors show specific distribution patterns. 
 Changes in the phospholipid composition observed in this model contribute 
to understand their relation with the BFCN.  
 
GRAPHICAL ABSTRACT 
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2.1. The specific loss of BFCN in the NBM leads to learning and memory 
impairment  
 To examine learning and memory behavior, the rats were trained and tested 
using the passive avoidance test. Seven days after the intraparenchymal infusion of 
192IgG-saporin in the NBM we evaluated the acquisition latency parameter as the time 
that rats stayed in the open compartment before entering the dark and closed 
compartment where the aversive stimulus was then produced as an electrical foot-
shock. No differences in acquisition latency were observed between the three groups 
(SHAM, aCSF and SAP: 10.2 ± 1 sec, 10.4 ± 0.9 sec and 11.14 ± 1.4 sec; respectively) 
(Figure 21 A). 24 h later, all trained animals were tested again to evaluate learning and 
memory. The step-through latency time was measured and represented as Kaplan-
Meier survival curves to determine the estimated probability of a positive response; i.e., 
to reach the cut-off time. When the groups were compared, 100% of the SHAM, and 
78% of the aCSF-treated rats, remembered the aversive stimulus and displayed a 
positive response. However, only the 40% of the 192IgG-saporin-treated rats 
remembered the aversive stimulus (p = 0.0006 vs aCSF; Log-Rank/Mantel-Cox test) 
(Figure 21 B). No statistically significant differences were observed between SHAM 
and aCSF-treated animals, which revealed the absence of a significant damage due to 
the needle or the vehicle used. The median latency was determined as the time where 
50% of the animals cross the doorway. The median step-through latency could only be 
calculated for 192IgG-saporin-treated rats, which showed a median latency of 102 s.   
 On the other hand, the degree of the lesion was estimated by using the AChE 
enzymatic assay to stain BFCN somas and cholinergic fibers in the projecting areas. 
The p75NTR immunofluorescence assay was also used to stain the surviving target 
BFCN after the administration of 192IgG-saporin. The intraparenchymal infusion of 
192IgG-saporin in the NBM resulted in an extensive reduction of both AChE stained 
(1032 ± 50 cells/mm3 in aCSF group and 270 ± 23 cells/mm3 in SAP group; p < 0.0001) 
and p75NTR immunoreactive BFCN (973 ± 53 cells/mm3 in aCSF group and 226 ± 25 
cells/mm3 in 192IgG-saporin-treated rats, respectively; p < 0.0001)  (Figure 21 C-D). 
Interestingly, correlation analysis between the step-through latencies and the number 
of BFCN in the NBM of those rats infused with the immunotoxin, revealed that the 
animals with higher reductions in BFCN density spent significantly less time to access 
the dark compartment; i.e., had a higher impairment in learning and memory behavior 
(R2 = 0.5127; p = 0.0199) (Figure 21 E). 
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Figure 21. (A) Acquisition latency times in the learning trial of the passive avoidance test. (B) 
Step-through latency times of passive avoidance test represented as Kaplan-Meier survival 
curves (p < 0.0001 vs aCSF, Log-Rank/Mantel-Cox test). (C) Number of BFCN in the NBM of 
aCSF and 192IgG-saporin treated animals. (D) AChE enzymatic staining and p75
NTR
 
immunofluorescence in the NBM. (E) Correlation analysis between the step-through latencies 
and the density of BFCN in the NBM. Scale bars = 500 and 100 µm, respectively. Data are 
means ± SEM; ***p < 0.001 vs aCSF-AChE and vs aCSF-p75
NTR
. 
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2.2. The specific loss of BFCN leads to a decrease of cholinergic 
innervations 
 The loss of BFCN in the NBM triggers a dramatic reduction in the AChE positive 
fibers in the brain areas innervated by the basal forebrain cholinergic system (Figure 
22). The highest loss of cholinergic afferents was observed in the motor (60%), 
somatosensory (65%) and entorhinal (40%) cortices (p < 0.001 vs aCSF). A moderate 
loss of cholinergic fibers was recorded in other cortical areas such as the cingulate 
(20%) and piriform (15%) (p < 0.05 vs aCSF) (Figure 22 C-D). The AChE staining was 
also decreased in the amygdaloid complex, showing a significant reduction in the 
anterior (30%) (p < 0.05 vs aCSF), lateral (19%) (p < 0.05 vs aCSF) and medial (40%) 
(p < 0.05 vs aCSF) amygdaloid nuclei. In the hippocampus a significant cholinergic 
dennervation was also observed in CA3 (10%) and dentate gyrus (15%) (p < 0.05 vs 
aCSF) (Figure 22 D). 
 
 
 
Figure 22. (A-B) AChE staining in brain slices at three different levels of aCSF and 192IgG-
saporin-treated rats. (C) Microphotographs from different cortical regions of both groups at 400-
fold magnification, revealing the decrease in AChE positive fibers induced by the immunotoxin 
(scale bar = 20 µm). (D) The histograms show the optical density of AChE expressed as 
percentages of the striatal levels (used as control area) in aCSF (n = 13) and SAP (n = 13) 
treated rats. *p < 0.05; **p < 0.01 and ***p < 0.001 vs aCSF-treated rats. MS: medial septum; 
Cg: cingular cortex; Mot: motor cortex; Ss: somatosensory cortex; Pir: piriform cortex; Ent: 
entorhinal cortex; Amyg: amygdala; DG: dentate gyrus. 
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2.3. The specific loss of BFCN positively correlates with reduced 
cholinergic innervation  
 As expected, the loss of BFCN in the NBM induced a significant decrease in 
AChE staining in projection areas. The linear regression analysis confirmed the 
relationship between the loss of BFCN and the reduction in AChE fiber densities in the 
cortex, including cingular (R2 = 0.4886, p < 0.001), motor (R2 = 0.8370; p < 0.001), 
piriform (R2 = 0.3667, p < 0.05), somatosensory (R2 = 0.8148, p < 0.001) and entorhinal 
(R2 = 0.5536, p < 0.001) cortices. The same effect was measured in the amygdala, 
including the anterior (R2 = 0.4245, p < 0.01), lateral (R2 = 0.2296, p < 0.05) and medial 
(R2 = 0.3134, p < 0.05) nuclei, and in the hippocampus, including the CA3 (R2 = 0.4926, 
p < 0.01) and the dentate gyrus (R2 = 0.3274, p < 0.05) regions (Figure 23). 
 
 
 
Figure 23. The plots show the number of AChE stained BFCN in the NBM (number of 
cells/mm
3
) and the density of AChE stained fibers (arbitrary units) in different basal forebrain 
cholinergic projections including the cortex (top row), the amygdala (middle row) and the 
hippocampus (bottom row) from aCSF and 192IgG-saporin-treated rats. The regression 
analyses reveal a decrease in the density of AChE stained fibers directly related to the depletion 
of BFCN. 
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2.4. The specific loss of BFCN in the NBM leads to altered mAChR 
functionality 
 To examine M2/M4 mAChR-mediated signaling, the activity of Gi/o-coupled 
mAChR was analyzed by means of [35S]GTPγS autoradiography assay. Basal binding 
values were similar in both groups (aCSF and SAP) in all the brain areas analyzed. 
The anatomical analysis of carbachol-induced [35S]GTPγS binding stimulation revealed 
differences in the functional coupling of mAChR to G i/o proteins in several brain areas 
in 192IgG-saporin-treated animals (See tables 2-3). Thus, carbachol-induced 
stimulation of M2/M4 mAChR was decreased in the NBM (aCSF 45 ± 9.7% and SAP 15 
± 6.2%; p < 0.05) from 192IgG-saporin-treated rats. Despite the massive loss of the 
presynaptic cortical cholinergic innervation demonstrated in the previous section, no 
changes were found in any of the cortical areas (Figure 24 A). However, in the 
hippocampus, the lesion induced an enhancement of carbachol-induced [35S]GTPγS 
binding in the pyramidal layer of the CA3 (aCSF 11 ± 5.6% and SAP 32 ± 4.2%; p < 
0.05) and in the granular layer of the dentate gyrus (aCSF 27 ± 6% and SAP 62 ± 
6.7%; p < 0.05) (Figure 24 B). On the contrary, a decrease of M2/M4 mAChR activity 
was recorded in the lateral nucleus of the amygdaloid complex (aCSF 41 ± 9.3% and 
SAP 36 ± 7.2%; p < 0.05) (Table 2). 
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Figure 24. [
35
S]GTPγS carbachol-evoked (100 µM) stimulation in representative brain coronal 
slices including the NBM (A) and the ventral hippocampus (B), obtained from aCSF and 
192IgG-saporin-treated rats. NBM: nucleus basalis magnocellularis; Granular DG: granular 
dentate gyrus; CA3: CA3 region of hippocampus. [
14
C]-microscales used as standards, values 
in nCi/g t.e. Scale bar: 5 mm. 
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2.5. Microscopic distribution of M2 and M4 mAChR  
 To examine the subcellular localization of M2 and M4 mAChR, 
immunofluorescence studies were performed in the basal forebrain cholinergic system, 
hippocampal dentate gyrus and CA3 and somatosensory cortex by using two different 
antibodies against i3 intercellular loop of human M2 and M4 mAChR. Taken together 
the distribution patterns obtained for M2 and M4 mAChR were similar to that observed 
for the M2/M4 mAChR activity. The highest level of M2 mAChR expression was 
observed in the striatum, in the basal forebrain and in the pyramidal layers of different 
hippocampal subfields, and more moderate in the cortex (Figure 25). M2 mAChR 
displayed a somatodendritic immunostaining in the NBM with the presence of a dense 
network of fibers surrounding the somas of ChAT positive cells, probably revealing 
presynaptic M2 mAChR contacts (Figure 25 A-I-IV). ChAT enzyme is preferentially 
distributed in the somatodendritic compartment of BFCN which encloses the total area 
of these neurons. In the figure 25B, the surviving ChAT positive BFCN from 192IgG-
saporin infused rats show somatic and nucleus shrinkage, together with reduced 
dendritic arborisation and almost a total absence of M2 mAChR-immunoreactivity in the 
basal forebrain (Figure 25 B). On the other hand, M4 mAChR immunoreactivity was 
distributed mainly in somatodendritic compartments in NBM which reveal a typically 
postsynaptic localization (Figure 26 A). 192IgG-saporin-treated rats showed a dramatic 
decrease in M4 mAChR-immunoreactivity in the basal forebrain as a consequence of 
the loss of BFCN, as revealed by ChAT immunostaining (Figure 26 B).  
 In the hippocampal formation, M2 mAChR-immunoreactivity was distributed 
throughout the large pyramidal neurons from CA1, CA3 and dentate gyrus as a dense 
network of fibers delineating the perikarya in basket-like formations, without 
immunoreactivity in the soma (Figure 27 A). In the somatosensory cortex, M2 mAChR 
displayed a scattered distribution in presumably presynaptic compartments (Figure 27 
C). The somatodendritic distribution of M4 mAChR was also observed in the perikarya 
of hippocampal ChAT positive neurons (Figure 27 B) as well as in the cortex, where M4 
mAChR is distributed in a similar pattern to that observed in CA3 (Figure 27 D). 
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Figure 25. Confocal microscope images which show double immunofluorescence labeling in 
slices containing the NBM from representative aCSF (A) and 192IgG-saporin-treated (B) rats. 
ChAT (red) and M2 mAChR (green) can be observed at 200-fold magnification (A, B). 192IgG-
saporin induced a reduction in BFCN density and in M2 mAChR immunoreactivity. Scale bar = 
40 µm. High magnification images reveal a particular M2 mAChR-immunostaining pattern 
surrounding the perikarya (A-II) of the large BFCN (A-I), which show a M2 mAChR presumable 
presynaptic localization and a distribution in contact with plasmatic membrane, but with a 
modest degree of co-localization (A-IV). Interestingly, 192IgG-saporin-treated rats showed the 
presence of few shrunken ChAT-ir BFCN (B-I), whereas the loss of M2 mAChR 
immunoreactivity is evident (B-II). Scale bar = 10 µm. 
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Figure 26. Double labeling in slices containing NBM from a representative aCSF (A) and 
192IgG-saporin-treated rat (B). The immunofluorescence for ChAT (red) and M4 mAChR 
(green) can be observed at the 200-fold magnification images obtained in a confocal 
microscope. 192IgG-saporin induced a reduction in BFCN density and in M4 mAChR-
immunoreactivity. Scale bar = 40 µm. High magnification images reveal a somatodendritic M4 
mAChR-immunostaining pattern surrounding the perikarya (A-II) of the large BFCN (A-I) with a 
high degree of co-localization. In 192IgG-saporin-treated rats there was a reduction of M4 
mAChR-immunoreactivity (B-II) but ChAT labeling still remained in surviving BFCN (B-I). Scale 
bar = 10 µm. 
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Figure 27. Confocal microscope images which show the double labeling of consecutive slices 
containing hippocampal CA3 pyramidal region (A and B) and somatosensory cortex (C and D) 
from a representative aCSF-treated rat, stained for ChAT (red), M2 mAChR (A and C in green) 
and M4 mAChR (B and D in green) at 630-fold magnification. The images show a presumable 
presynaptic distribution of M2 mAChR, delineating the perikarya of the large CA3 pyramidal 
neurons in basket-like formations (A) and the somatodendritic distribution of M4 mAChR in the 
perikarya of the same neurons (B). In the cortex, both M2 (C) and M4 (D) mAChR display a 
similar distribution pattern to that observed in CA3. Scale bar = 10 µm. 
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2.6. The specific loss of BFCN in the NBM leads to changes in lipid 
composition  
 The matrix-assisted laser desorption ionization-imaging mass spectrometry 
(MALDI-IMS) technique allows to anatomically localize lipid species in tissue slices. 
Furthermore, MALDI-IMS is a semiquantitative technique. In the present study we 
analyzed the complex lipid composition in both positive and negative ion detection 
modes of coronal slices from both aCSF and 192IgG-saporin-treated rat brains, 
including the NBM and cortical projections.  
 Firstly, MALDI-IMS was performed in positive ion detection mode and more 
than 300 peaks were obtained but the analyses were focused on those lipid species 
which may serve as precursors for the synthesis of choline in both the NBM and 
cortical innervation areas.  
 The relative intensities of different phosphatidylcholine (PC) species were found 
to be modified in the NBM and cortex of 192IgG-saporin-treated rats. Thus, increased 
levels of PC (36:1) + Na+ (aCSF 14.62 ± 0,30% vs SAP 21.64 ± 1.53%, p < 0.01), PC 
(36:4) + K+ (aCSF 10.32 ± 1.01% vs SAP 18.61 ± 2.71%, p < 0.05) and PC (40:6) + 
Na+ (aCSF 0.88 ± 0.17% vs SAP 2.25 ± 0.40%, p < 0.01) were observed in the NBM of 
192IgG-saporin-treated rats. However, in the cortex of 192IgG-saporin-treated rats, 
there was found a decrease in the level of PC (36:1) + Na+ (aCSF 10.62 ± 0.48% vs 
SAP 8.95 ± 0.63%, p < 0.05) and increased levels of two species, the PC (36:4) + K+ 
(aCSF 13.17 ± 0.99% vs SAP 15.63 ± 0.48%, p < 0.05) and PC (40:6) + Na+ (aCSF 
0,75 ± 0.11% vs SAP 1.14 ± 0.09%, p < 0.05). Furthermore, the levels of other clases 
of lipids were also found modified in the NBM of the injured rats, such as PE 
(14:1/20:4) + H+ (aCSF 15.21 ± 0.70% vs SAP 11.87 ± 1.35%, p < 0.05), PE (40:4) 
(aCSF 0.82 ± 0.13 vs SAP 1.35  ±  0.17; p < 0.05) SM (d18:1/18:0) + H+ (aCSF 7,11 ± 
1,13% vs SAP 4,15 ± 0,80%, p < 0.05), SM (d18:1/16:0) + K+ (aCSF 0.96 ± 0.14% vs 
SAP 10.53 ± 3.33%, p < 0.01) (Table 4 and Figure 28 A-B).  
 In negative ion detection mode, additional lipid species were found modified in 
the NBM including SM (d18:0/18:1) (aCSF 1.26 ± 0.24% vs SAP 6.44 ± 1.50%, p < 
0.01) and PS (18:0/18:1) (aCSF 11.04 ± 2.16% vs SAP 3.95 ± 0.99%, p < 0.01). The 
intensity of PG (22:6/22:6) was also increased in 192IgG-saporin-treated rats (aCSF 
0.06 ± 0.01% vs SAP 0.86 ± 0.24%; p < 0.05 and aCSF 0.04 ± 0.01% vs SAP 0.16 ± 
0.05%; p < 0.05, in NBM and cortex, respectively) (Table 4 and Figure 28 A-B). 
Results 
 
120 
 
 
Results 
 
121 
 
 
Figure 28. (A) The histograms show the relative abundance of different lipid species in the NBM 
(left) and cortex (right), expressed as percentages of the values obtained in the aCSF-treated 
group. (B) Matrix-assisted laser desorption ionization-imaging mass spectrometry (MALDI-IMS) 
of different lipids in brain slices containing the NBM and cortical projections from representative 
aCSF and 192IgG-saporin-treated rats. The intensities were measured in the areas marked with 
black squares of the somatosensory cortex and the NBM. *p < 0.05; **p < 0.01 and ***p < 0.001 
vs aCSF-treated rats. PC: phosphatidylcholines; PE: phosphatidylethanolamines; PS: 
phosphatidylserines; SM: sphingomyelin; PG: phosphoglycerol. Scale bar = 5 mm. 
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(Manuscript III) Increase of cortical endocannabinoid signaling in a rat 
model of basal forebrain cholinergic dysfunction 
 
HIGHLIGHTS 
 A crosstalk between cholinergic and cortical endocannabinoid signaling is 
proposed. 
 The loss of basal forebrain cholinergic input decreases cortical GABAergic 
tone. 
 CB1 receptor-mediated signaling adaptation in response to cholinergic 
dysfunction. 
 The activation of the endocannabinoid system may restore cholinergic 
deficits in Alzheimer's disease. 
 
 
GRAPHICAL ABSTRACT 
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2.7. The specific loss of BFCN in the NBM leads to endocannabinoid 
signaling adaptation  
 
CB1 receptor density after basal forebrain cholinergic lesion 
 The density and activity of CB1 receptors was analyzed by means of 
autoradiography. Despite of the massive loss of basal forebrain cholinergic terminals 
(up to 65%, as measured by AChE staining) arising from the NBM to cortical and 
subcortical brain areas, the 192IgG-saporin-treated rats showed no changes in 
[3H]CP55,940 binding in the cortex (Table 5). However, [3H]CP55,940 binding was 
increased in the NBM (180 ± 13 fmol/mg and 364 ± 63 fmol/mg, in aCSF and 192IgG-
saporin-treated rats, respectively, p < 0.05). On the contrary, in some hippocampal 
subregions, we found a down regulation (oriens CA1: aCSF 1057 ± 67 fmol/mg, and 
SAP 721 ± 92 fmol/mg, p < 0.05; molecular dentate gyrus: aCSF 900 ± 63 fmol/mg, 
and SAP 603 ± 71 fmol/mg, p < 0.01) (Figure 29 B, tables 5-6). CP55,940 shows high 
affinity for both CB1 and CB2 receptors. Therefore, using two different cannabinoid 
antagonists we checked the specificity of the radioligand binding. SR141716A, a CB1 
antagonist, completely blocked the binding of [3H]CP55,940 (Figure 29 C) while 
SR144528, a CB2 antagonist, failed to do so (Figure 29 D), providing evidence that the 
changes in [3H]CP55,940 binding are specifically related to CB1 receptors. See also the 
Figure 37 for further details of the specificity of both antagonists. 
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Table 5. Autoradiographic densities of CB1 receptors 
expressed in fmol/mg t.e., obtained as specific binding of 
[
3
H]CP55.940 in different gray and white matter regions from 
vehicle (aCSF) and 192IgG-saporin (SAP) treated rats. 
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Table 6. Autoradiographic densities of CB1 receptors expressed 
in fmol/mg t.e., obtained as specific binding of [
3
H]CP55.940 in 
different hippocampal regions and amygdaloid nuclei from 
vehicle (aCSF) and 192IgG-saporin (SAP) treated rats. 
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Figure 29. (A) AChE staining in representative fixed hemibrain slices at two different levels 
(right and left columns) from aCSF and 192IgG-saporin-treated rats. (B) [
3
H]CP55,940 (3 nM) 
binding in hemibrain coronal slices from aCSF and 192IgG-saporin-treated rats. (C) The 
specificity of the binding was determined blocking the radioligand binding in the presence of the 
specific CB1 receptor antagonist, SR141716A (0.1 µM) (D) The specific CB2 antagonist 
SR144528 (0.1 µM) was not able to inhibit the [
3
H]CP55,940 (3 nM) binding to rat brain slices 
(D) . DG: dentate gyrus; CA3: layer CA3 of hippocampus. Bottom, [
3
H] standards (µCi/g tissue 
equivalent), tissue scale bar: 5 mm. 
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Endocannabinoid signaling deregulation in areas of cholinergic innervation 
 To study whether the changes in receptor density are reflected by CB1 receptor 
activity mediated by Gi/o protein signaling, we used the functional autoradiography 
technique analyzing the binding of [35S]GTPγS. Basal binding values were similar in the 
both groups, aCSF and SAP, in all of the brain areas analyzed (Tables 7-9, Figures 30 
A and C). The anatomical analysis of [35S]GTPγS binding induced by the CB1/CB2 
receptor agonist, WIN55,212-2 (10 µM), revealed changes in the functional coupling of 
cannabinoid receptors to Gi/o proteins. Despite of the absence of changes in cortical 
CB1 receptor density, agonist-induced stimulation of [
35S]GTPγS binding was enhanced 
in several cortical regions (entorhinal: aCSF 156 ± 17% vs SAP 277 ± 30%, p < 0.01; 
motor: aCSF 127 ± 20% vs SAP 203 ± 14%, p < 0.05; piriform: aCSF 72 ± 10% vs SAP 
122 ± 9%, p < 0.001; somatosensory: aCSF 131 ± 29% vs SAP 218 ± 11%, p < 0.05), 
and was more evident in the internal layers, such as the layer VI of the entorhinal 
cortex (Table 7, Figures 30 B and D), which indicates a hyperactivity of cortical eCB 
signaling. 
 Also, in the striatum (aCSF 178 ± 28% vs SAP 252 ± 19%, p < 0.05) and in the 
NBM (aCSF 103 ± 18% vs SAP 142 ± 9%, p<0.05) there was an increase in 
WIN55,212-2-induced functional coupling of CB1 receptors to Gi/o proteins (Figure 31 B, 
tables 8-9). However, in the hippocampus and, in accordance with the results related to 
CB1 receptor density, we found a decrease of the activity in the molecular layer of 
dentate gyrus (aCSF 299 ± 37% vs SAP 166 ± 25%, p < 0.05) (Figure 30 B, table 8). 
SR141716A almost completely blocked WIN55,212-2-evoked binding of [35S]GTPγS, 
which indicates that the changes in eCB signaling were specifically through CB1 
receptors (Figure 31 C). 
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Figure 30. Representative autoradiograms including both dorsal (A, B) and ventral 
hippocampus (C, D) obtained from aCSF and SAP-treated rats that show [
35
S]GTPγS basal 
binding (A and C) and WIN55,212-2 (10 µM) evoked activation of cannabinoid receptors (B and 
D). DG: dentate gyrus; Ss cx: somatosensory cortex; Ent cx: entorhinal cortex. Bottom, [
14
C] 
standards (nCi/g tissue equivalent), tissue scale bar: 5 mm. 
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Figure 31. Autoradiographic images showing [
35
S]GTPγS basal binding in sagittal slices from 
aCSF and 192IgG-saporin-treated rats (A), stimulated by WIN55,212-2 (10 µM) (B), and 
WIN55,212-2 (10 µM) stimulation antagonized by SR141716A (1 µM) (C). Mot cx: motor cortex; 
Str: striatum. Scale bar: 1 cm. 
 
 
Linear regression analysis between CB1 receptor changes and the number of 
surviving BFCN 
 To examine the relation between the results of the autoradiographic assays and 
the degree of lesion, firstly we correlated [3H]CP55,940 binding (fmol/mg) with the 
number of basal forebrain cholinergic neurons in the NBM by using a regression 
analysis. These analyses showed that 40% in NBM (p = 0.011), 29% in the dentate 
gyrus (p = 0.047) and 36% in CA1 (p = 0.018) of the variation in the density of CB1 
receptors could be attributable to the loss of BFCN. The lower the BFCN density, the 
higher the CB1 density in NBM and the lower in hippocampus, showing a different 
modulation depending on the brain area studied (Figure 32 A). Then, we correlated the 
number of BFCN with CB1 receptor activity, and similar results were obtained. Thus, 
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the regression models showed that 39% in NBM (p = 0.007), 63% in striatum (p = 
0.0002) and 40% in dentate gyrus (p = 0.009) of the variation in the functional coupling 
of cannabinoid receptors to Gi/o proteins might be related to the loss of BFCN (Figure 
32 B). When the entire cortical mantle was analyzed we found the lower the number of 
BFCN, the higher the CB1 receptor activity. The regression models showed that 28% in 
motor (p = 0.02), 40% in somatosensory (p = 0.0025), 24% in entorhinal (p = 0.0349) 
and 43% in piriform cortices (p = 0.002), of the increase in the CB1 activity could be 
related to the basal forebrain cholinergic lesion (Figure 32 C). 
 
 
Figure 32. (A) The plots show the number of BFCN in the NBM (number of cells/mm
3
) and the 
density of CB1 receptors (fmol/mg) from aCSF and 192IgG-saporin-treated rats in different brain 
areas. The regression analyses reveal a decrease in the density of CB1 receptor related to the 
depletion of BFCN in the dentate gyrus (R
2
 = 0.29; p = 0.047) and CA1 (R
2
 = 0.36; p = 0.018) 
and an increase in the NBM (R
2
 = 0.40; p = 0.011). (B and C) The plots show the number of 
BFCN in the NBM and WIN55,212-2 (10 µM)-evoked stimulation of CB1 receptors (% activity 
over basal) from aCSF and SAP treated rats in different brain areas.  (B) The regression 
analyses reveal a hyperactivity of CB1 receptors in the NBM (R
2 
= 0.38; p = 0.007) and in the 
striatum (R
2
 = 0.63; p = 0.0002), but a decrease in the dentate gyrus (R
2
 = 0.4; p = 0.0089) 
related to the loss of BFCN. (C) The regression analyses reveal a hyperactivity of CB1 receptors 
in cortical areas: motor (R
2
 = 0.28; p = 0.0202), somatosensory (R
2 
= 0.41; p = 0.0025), 
entorhinal (R
2
 = 0.24; p = 0.0349) and piriform (R
2
 = 0.43; p = 0.0018) cortices, related to the 
depletion of BFCN. 
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2.8. Anatomical distribution of CB1 receptor  
 The subcellular localization of CB1 receptors was determined by 
immunofluorescence studies using an antiserum against the C-terminus of the human 
CB1 receptor. The regional distribution pattern of immunostaining was similar to that 
observed in the autoradiographic studies. Some areas exhibited very high CB1 receptor 
expression, such as the olfactory bulb, globus pallidus, substantia nigra, amygdala and 
hippocampus. The different hippocampal layers exhibited differential CB1 receptor-
immunostaining patterns and were clearly defined. We studied the co-localization of 
CB1 receptors with GAD65, the smaller isoform of the enzyme glutamate 
decarboxylase, which is mainly associated with nerve terminals (Kash et al., 1999), 
and with VGLUT3, the third subtype of glutamate vesicular transporter, which is mainly 
expressed in synaptic boutons, but also in somatodendritic compartments (Herzog et 
al., 2004). The abundant and dense CB1 receptor immunoreactive puncta observed 
suggested a predominant localization of CB1 receptors in presynaptic terminals with 
similar densities in both groups of animals. Immunofluorescence assays for GAD65 
and VGLUT3 and the subsequent co-localization studies, allowed us to confirm the 
inhibitory nature of presynaptic boutons, which express CB1 receptors in the 
hippocampus (Figure 33 A). Although, GAD65 and VGLUT3 had different patterns of 
distribution, no differences in the immunostaining pattern were observed between the 
two groups studied and therefore the immunofluorescence images shown in Figure 33 
correspond to rats treated with 192IgG-saporin. Thus, GAD65 immunoreactivity was 
seen as a dense plexus of immunoreactive puncta around the pyramidal neurons and 
had a similar distribution to CB1 receptors (Figure 33 Ai), while VGLUT3 displayed a 
postsynaptic somatodendritic immunostaining (Figure 33 Aii). The studies of co-
localization that were performed in the Z-axis with a 0.24-µm resolution by using 
structured illumination, revealed an optimal penetration of the antibody in the tissue. 
The presence of CB1 receptors in presynaptic GABAergic terminals, with a high degree 
of co-immunoreactivity with GAD65 was observed (Figure 33 Ai-YZ/XZ). CB1 receptor 
immunostaining was found surrounding the VGLUT3-expressing somatodendritic 
compartment. A Z-stack analysis revealed the almost total absence of co-
immunoreactivity with VGLUT3 (Figure 33 Aii-YZ/XZ).  
 However, in the cortex, CB1 receptors were not clearly located in either 
presynaptic GABAergic or postsynaptic glutamatergic compartments (Figure 33 B). 
GAD65 was distributed presynaptically (Figure 33 Bi), while VGLUT3 displayed a 
somatodendritic distribution (Figure 33 Bii). The Z-stack analysis revealed a similar 
distribution of CB1 receptors and GAD65 but with a very low degree of co-
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immunoreactivity (Figure 33 Bi-YZ/XZ). However, a higher co-expression with VGLUT3 
was observed, despite the different cellular distribution (Figure 33 Bii-YZ/XZ). 
  
 
 
Figure 33. Immunostaining in a representative section from a rat treated with 192IgG-saporin. 
Immunoreactivity for CB1 receptors in dentate gyrus (A) and in motor cortex (B), in combination 
with GAD65 (i) or VGLUT3 (ii). Nuclei were also stained with Hoechst. In merge images note 
the CB1 co-localization in dentate gyrus with GAD65 and in cortex with VGLUT3. Triple labeling 
of tissue slices is shown at 200-fold magnification (merge) and at 630-fold magnification 
(structured illumination) in a single plane from the collecting Z-stacking. Scale bar = 50 µm and 
10 µm, respectively. 
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2.9. The specific loss of BFCN in the NBM leads to a decrease of cortical 
presynaptic GABAergic tone  
 GAD65 immunofluorescence showed a different pattern of distribution in 
different cortical layers, with the highest density being in the layer IV, as shown for 
motor cortex (Figure 34 A). There was a large decrease in GAD65 positive cortical 
terminals in those animals lesioned with 192IgG-saporin, suggesting a down-
regulation. Semiquantitative analysis in the motor cortex showed a reduction in motor 
cortex of 28%, 35% and 39% of GAD65-immunoreactivity in layers I, II-III and IV, 
respectively (p< 0.05) (Figure 34 B). The somatosensory and piriform cortices were 
also analyzed and a similar decrease of immunosignaling was found, 28%, 32% and 
32% in layers I, II-III (p < 0.01) and IV (p < 0.05) in the somatosensory cortex and 25% 
in the piriform cortex (p < 0.05) (Figure 34 B). One of the most significant decreases of 
GAD65 immunoreactivity was registered in layer V of the entorhinal cortex (21% 
decrease, p< 0.01), but it was not modified in the dentate gyrus of the hippocampus 
(2% decrease).  
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Figure 34. (A) Immunoreactivity for GAD65 in the motor cortex (layers I-VI) from representative 
rats, one treated with aCSF compared with other rat treated with 192IgG-saporin. (B) Note the 
differences in optical density of GAD65 positive presynaptic terminals in aCSF and SAP-treated 
rats, measured as arbitrary units (A.U.) of fluorescence, in motor, somatosensory and entorhinal 
cortical layers, and also in the total area of the piriform cortex and dentate gyrus. Data are 
means ± SEM; *p < 0.05; **p < 0.01. Scale bar = 150 µm. 
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3. Triple transgenic mice model of AD (3xTg-AD) 
(Manuscript IV) Relationship of the Cannabinoid and Muscarinic Signaling 
with cognitive Impairments in 3xTg-AD Mice at the Onset of Alzheimer’s 
Disease 
 
HIGHLIGHTS 
 3xTg-AD mice exhibit anxiety-like symptoms and cognitive deficits at seven 
months of age as revealed in the passive avoidance test. 
 CB1 receptor-mediated hyperactivity in the BLA correlates with higher 
acquisition latency times which may be related with anxiety-like responses.  
 Decreased muscarinic neurotransmission runs in parallel to the onset of 
cognitive decline in 3xTg-AD mice. 
 Pharmacological desensitization of CB1 receptors in 3xTg-AD mice restores 
behavioral responses.  
 Subchronic activation of CB1 receptors modulates muscarinic signaling in limbic 
areas. 
 
 
GRAPHICAL ABSTRACT 
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3.1. Learning and memory impairment in 3xTg-AD mice 
 To examine behavior, adult 3xTg-AD and matched Non-Tg mice at seven 
months of age were trained and tested on the passive avoidance test. We first 
examined the acquisition or transfer latency or the time that mice stayed under 
anxiogenic stimulus in the opened compartment, before receiving a foot-shock as an 
aversive stimulus when crossed to the closed-dark box. 24 h later, mice were tested 
evaluating the step-through latency in the retention phase and the step-through 
latencies were measured and represented as Kaplan-Meier survival curves to elucidate 
the estimated probability of showing a positive response (to reach the cut-off time). 
3xTg-AD and Non-Tg mice clearly differed during the training and testing sessions on 
the passive avoidance test. Transgenic mice took significantly longer (26.24 ± 1.8 s) to 
enter the dark compartment than Non-Tg genotype (12.28 ± 1.9 s) (p = 0.0002, two-
tailed unpaired student t test) (Figure 35 left). Not recorded observations showed 
higher periods of initial freezing in 3xTg-AD mice, immediately after placing in the 
illuminated compartment, in comparison to the control Non-Tg mice. Moreover, 40% of 
them failed to remember the foot shock as compared to the positive response shown in 
100% of Non-Tg mice (p = 0.029, Log-Rank/Mantel-Cox test) (Figure 35 right). 
 
 
Figure 35. Acquisition latency during the learning trial (left) represented as box plot and step-
through latency (right) represented as Kaplan-Meier survival curves in both genotypes and in 
the absence of treatment. *** p < 0.001 vs Non-Tg mice. 
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3.2. Deregulated endocannabinoid signaling in 3xTg-AD mice  
 
CB1 receptor density 
 To examine CB1 receptor density in 3xTg-AD mice and matched Non-Tg mice, 
cannabinoid receptor autoradiography was performed. Quantitative densitometry 
showed an increase in the BLA of transgenic mice (Non-Tg 386 ± 12 fmol/mg t.e.; 
3xTg-AD 497 ± 19 fmol/mg t.e.; p = 0.0008) and in the lateral olfactory tract nucleus 
(Non-Tg 281 ± 40 fmol/mg t.e.; 3xTg-AD 424 ± 38 fmol/mg t.e.; p = 0.0274), but a 
decrease in the glomerular olfactory bulb (Non-Tg 470 ± 8 fmol/mg t.e.; 3xTg-AD 304 ± 
9 fmol/mg t.e.; p < 0.0001) (two-tailed unpaired student t test) (Student t-test, table 10; 
Figures 36 and 41 A).  
 
 
Figure 36. [
3
H]CP55,940 binding autoradiography showed the cannabinoid receptor distribution 
in representative brain coronal slices from Non-Tg and 3xTg-AD mice. Note the increase in the 
density of cannabinoid receptors in the basolateral amygdala (BLA) of 3xTgAD mice. [
3
H]-
microscales used as standards in µCi/g t.e. 
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Specificity of [3H]CP55,940 binding 
 SR141716A and SR144528, well known selective antagonists for CB1 and CB2 
receptors respectively, were used in combination with brain and spleen samples from 
CB1
+/+ and CB1
-/- mice to check the specific subtype of cannabinoid receptor involved in 
the observed changes. SR141716A blocked [3H]CP55,940 binding in brain slices from 
3xTg-AD and CB1
+/+ mice, but failed in spleen. SR144528 completely blocked 
[3H]CP55,940 binding in spleen slices but failed in brain samples. CB1
-/- mice displayed 
similar binding levels in the spleen to those obtained in CB1
+/+ mice, demonstrating the 
selectivity of both antagonists and the specific deregulation of the CB1 receptor subtype 
in 3xTg-AD mice (Figure 37). 
 
 
 
Figure 37. [
3
H]CP55,940 binding autoradiography showing the cannabinoid receptor distribution 
in brain and spleen samples from 3xTg-AD, CB1 receptor knockout (CB1
-/-
) and wild type 
(CB1
+/+
) mice. The total binding is shown in the top row (A), displaying the characteristic and 
well-described distribution of cannabinoid receptors in the brain, and surrounding the lymphatic 
nodules (white pulp) in the spleen. In the presence of SR141716A (0.1 µM) (rimonabant), a CB1 
specific antagonist, binding is almost completely blocked in the brain but not in the spleen (B). 
SR144528 (0.1 µM), a CB2 specific antagonist, completely displaced the [
3
H]CP55,940 binding 
in the spleen without affecting the binding in the brain (C). Note the absence of binding in the 
brain from CB1
-/-
 and the identical distribution in the spleen from both Non-Tg and knockout 
mice, revealing the preponderance of CB1 receptors in the brain and CB2 receptors in spleen 
tissue, and the specificity of the cannabinoid antagonists. Scale bar = 5 mm. 
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3.3. Subchronic cannabinoid administration restores acquisition latency 
to control Non-Tg levels 
 The subchronic administration of direct or indirect cannabinoid agonists in 3xTg-
AD mice reduced the increase in acquisition latencies observed in the vehicle-treated 
3xTg-AD group (one-way ANOVA, Dunn‟s multiple comparison test), restoring the 
latencies to Non-Tg levels (Figure 38). Thus, WIN55,212-2 elicited a behavioral dose-
response with slight (0.1 mg/kg, reduction 35%) and marked (1 mg/kg, reduction 50%, 
p < 0.05) reductions in the acquisition latency as compared with those observed in the 
vehicle-treated 3xTg-AD animals. JZL184 (8 mg/kg), a monoacylglycerol lipase 
(MAGL) inhibitor, also induced such an effect (reduction 42%, p < 0.05) (Figure 38 left). 
The treatments elicited subtle variations in learning and memory (step-through latency) 
in 3xTg-AD mice, as shown in the Kaplan-Meier representation, although they did not 
reach statistical significance (Figure 38 right). 
  
 
 
Figure 38. The subchronic administration of WIN55,212-2 (1 mg/kg) and JZL184 (8 mg/kg) for 
seven consecutive days triggered a statistically significant decrease in the acquisition latency 
(left) compared to that obtained in the Non-Tg group (as previously shown in Figure 34). Step-
through latency in 3xTg-AD mice represented as Kaplan-Meier survival curves (right). The 
probability is plotted over the step-through latencies in 3xTg-AD mice after different 
cannabinoid-based treatments. 
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3.4. CB1 receptor desensitization induced by direct and indirect 
cannabinoids  
 [3H]CP55,940 autoradiography revealed specific modifications in cerebral CB1 
receptor density following the subchronic eCB system activation. WIN55,212-2 (0.1 
mg/kg) did not modify CB1 receptor density, but WIN55,212-2 (1 mg/kg) induced a 
significant decrease in BLA (22%) (Figures 39 and 41 C). Furthermore, the 
administration of JZL184 dramatically down-regulated CB1 receptor, including cortical, 
hippocampal and amygdaloid regions (Tables 10-11, Figure 39 and 41 C). Functional 
[35S]GTPγS autoradiography of CB1 receptor activation showed a decrease of 24% and 
32% in the BLA following treatment with WIN55,212-2 (1 mg/kg) and JZL184 (8 
mg/kg), respectively (Table 12, Figure 40 C-D and 42 C). The basal binding of 
[35S]GTPγS was not modified by the different cannabinoid compounds, which probably 
indicates the absence of changes in the constitutive activity of G-protein coupled 
receptors (GPCR). 
 
 
Figure 39. (A) 3xTg-AD mice treated with different cannabinoid agonists. [
3
H]CP55,940 binding 
autoradiography in representative brain sagittal (top images) and coronal (bottom images) slices 
from 3xTg-AD mice administered with vehicle (A), WIN55,212-2 (1 mg/kg) (B), and JZL184 (8 
mg/kg) (C). Note that both pharmacological treatments decreased the density of receptors in the 
whole grey matter including the BLA (boxed area). [
3
H]-microscales used as standards in µCi/g 
t.e. Scale bar: 5 mm. 
Results 
 
144 
 
 
Results 
 
145 
 
 
 
 
  
Results 
 
146 
 
3.5. CB1 receptor functionality 
 To check for a presumed modification of eCB signaling, [35S]GTPγS 
autoradiography assay was performed. This technique represents a powerful functional 
approach to anatomically localize and quantify the receptor-dependent Gi/o protein 
activity directly in tissue slices. Basal Gi/o protein activity was firstly examined and no 
differences between genotypes were observed. The activity of CB1 receptors evoked 
by WIN55,212-2 (10 µM), was higher in the BLA of 3xTg-AD (p = 0.0303) but lower in 
several areas such as the striatum (p = 0.0285), the glomerular olfactory bulb (p = 
0.0043), and the molecular layer of hippocampal dentate gyrus (p = 0.0040; Student t-
test) (Tables 12-13; Figures 40 and 42 A). 
 
 
 
Figure 40. [
35
S]GTPγS autoradiography evoked by WIN55,212-2 (10 µM) for cannabinoid 
receptors in representative coronal brain slices from Non-Tg (A) and 3xTg-AD mice treated with 
vehicle (B) and cannabinoid agonists (C-D). The highest CB1 receptor stimulation was found in 
the hippocampus, the most caudal portion of the globus pallidus, the deeper layers of the 
cortex, and the amygdaloid complex. Thus, in the amygdala, the latero-basolateral region 
(boxed area) seems to be the most activated, displaying a hyperactivation in 3xTg-AD mice (B) 
which is attenuated with both cannabinoids (C-D). [
14
C]-microscales used as standards in µCi/g 
t.e. Scale bar: 5 mm. 
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Data are expressed as mean ± S.E.M. 
*p < 0.05; **p < 0.01 vs Non-Tg  (vehicle)                                         
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Data are expressed as mean ± S.E.M. 
*p < 0.05 vs Non-Tg (vehicle)                                                     
# p < 0.05 vs 3xTg-AD (vehicle) 
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3.6. CB1 receptor up-regulation positively correlates with the acquisition 
latencies  
 The regression analyses showed that the greater the density of CB1 receptors 
the higher the acquisition latencies estimating that 50% and 33% of the variation in the 
acquisition latencies was related to changes in CB1 receptors density at BLA (Figure 41 
A) (r2 = 0.5096, p = 0.0091; Figure 41 C) and/or to changes in CB1 receptor activity 
(evoked by WIN55,212-2) (Figure 42 A) (r2 = 0.3299, p = 0.0508; Figure 42 C). No 
statistically significant correlations were found when other brain areas were compared 
such as the lateral olfactory tract nucleus and glomerular olfactory bulb (p = ns). Both 
treatments, JZL184 (8 mg/kg) and WIN55,212-2 (1 mg/kg), decreased the acquisition 
latencies of 3xTg-AD mice to Non-Tg mice control values due to the pharmacological 
down-regulation of CB1 receptors to levels even lower than those observed in Non-Tg 
mice (Figure 41 B). When the groups were compared all together, a positive and 
statistically significant correlation between CB1 receptor density in the BLA (Figure 41 
B) and acquisition latencies was found, showing that 25% of the acquisition latencies 
variation was explained by changes in CB1 density (r
2 = 0.2499, p = 0.013; Figure 41 
D), but not by changes in CB1 activity (Figure 42 D).  
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Figure 41. (A) CB1 receptor density in the BLA in both genotypes (3xTg-AD vs Non-Tg) without 
any pharmacological treatment and (B) in 3xTg-AD mice seven days after the administration of 
WIN55,212-2 (0.1 and 1 mg/kg) or JZL184 (8 mg/kg). (C) Correlation analyses between the CB1 
density in the BLA and the acquisition latencies between both genotypes and (D) in 3xTg-AD 
mice after cannabinoid administration. Note that data are grouped according to both genotype 
and cannabinoid-based treatment *p < 0.05; **p < 0.01 and *** p < 0.001. 
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Figure 42. (A) Quantification of CB1 receptor stimulation (% over basal activity) evoked by 
WIN55,212-2 (10 µM) in the BLA in both genotypes (Non-Tg vs 3xTg-AD) and (B) in 3xTg-AD 
mice seven days after the administration of different doses of WIN55,212-2 (0.1 mg/kg and 1 
mg/kg) or JZL184 (8 mg/kg). (C) Correlation analysis between the eCB signaling in the BLA and 
the acquisition latencies in both genotypes and (D) in 3xTg-AD mice after cannabinoid 
administration. Note that data are grouped according to genotype but not to treatment *p < 0.05 
vs Non-Tg; two-tailed unpaired Student t test. 
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3.7. Decreased M2/M4 mAChR-mediated activity in 3xTg-AD is modulated 
by cannabinoid administration  
 We analyzed the functional coupling of mAChR to G i/o proteins evoked by 
carbachol (100 µM) in both genotypes and in cannabinoid treated 3xTg-AD mice. 
Transgenic mice showed decreased functional coupling in the BLA (Non-Tg 102 ± 
13.7% and 3xTg-AD 55 ± 10.5%; p = 0.0258), in the lateral amygdala (Non-Tg 96 ± 
18.3% and 3xTg-AD 41 ± 11.3%; p = 0.0303) and hippocampal pyramidal CA1 (Non-
Tg 30 ± 6% and 3xTg-AD 16 ± 6.8%; p = 0.0227). Moreover, increased M2/M4 mAChR 
receptor activity was found in the glomerular olfactory bulb (Non-Tg 193 ± 25.9% and 
3xTg-AD 295 ± 14.9%; p = 0.0095). The administration of 1 mg/kg of WIN55,212-2 was 
able to increase the M2/M4 mAChR-mediated activity to similar values of Non-Tg mice; 
up to 60% in the BLA (97 ± 12.6%; p < 0.05) and up to 100% in the lateral amygdala 
(84 ± 9.1%; p < 0.01). No modulation of M2/M4 mAChR-mediated activity was observed 
in other brain areas (Tables 14-15; Figure 43 C-D). 
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Figure 43. [35S]GTPγS autoradiography evoked by carbachol (100 µM) for M2/M4 mAChR, in 
representative coronal brain slices from Non-Tg (A) and 3xTg-AD mice treated with vehicle (B) 
and cannabinoid agonists (C-D). A deregulation of mAChR functionality in 3xTg-AD mice was 
found. Note the decrease in the latero-basolateral region and in the pyramidal layer of the 
hippocampal CA1 region (boxed areas) (B) and the potentiation of muscarinic signaling in the 
amygdala following the subchronic administration of 1 mg/kg of WIN55,212-2 (C). [
14
C]-
microscales used as standards in µCi/g t.e. Scale bar: 5 mm. 
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Data are expressed as mean ± S.E.M. 
*p < 0.05 vs Non-Tg (vehicle)                                                     
#p < 0.05; ##p < 0.01 vs 3xTg-AD (vehicle) 
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Data are expressed as mean ± S.E.M. 
*p < 0.05 vs Non-Tg (vehicle)                                                     
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3.8. CB1 receptors in BLA and M2 mAChR in hippocampus colocalize with 
GABAergic terminals  
 The different nuclei of the amygdala exhibited distinct CB1-immunostaining 
patterns and were clearly defined (Figure 44 B). The dense CB1 immunoreactive 
puncta observed in the BLA (Figures 44 A1 and B1), suggested a presynaptic 
localization of CB1. Immunofluorescence assays for VGLUT3 (Figure 44 A2) and 
GAD65 (Figure 44 B2), and the subsequent colocalization studies, allowed us to 
confirm the inhibitory nature of CB1 receptor containing presynaptic boutons (Figure 44 
B-merge and D4).  
 M2 immunoreactivity was differentially localized in the hippocampus (Figure 45 
A-B). The pyramidal neurons of CA1-CA3 displayed a dense network of fibers 
delineating the perikarya in basket-like formations (Figure 45 A2 and B2). VGLUT3 
(Figure 45 A1) displayed a somato-dendritic immunostaining, whereas GAD65 (Figure 
45 B1) was present as a dense plexus of fibers around pyramidal neurons with a 
similar distribution to M2 mAChR. Colocalization studies showed the presence of M2 
mAChR (Figure 45 B-merge) in presynaptic GABAergic terminals with a high degree of 
co-immunoreactivity with GAD65 (Figure 45 D4), and an almost total absence of 
expression on VGLUT3 positive cells (Figure 45 C4). 
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Figure 44. Double labeling of tissue slices including the amygdaloid complex from seven 
month-old 3xTg-AD mice processed for CB1 receptor (in green) and VGLUT3 (A2 and C2 in 
red) as a glutamatergic marker, and GAD65 (B2 and D2 in red) as a GABAergic presynaptic 
marker. The different amygdaloid nuclei exhibited specific CB1-immunostaining patterns. 
VGLUT3 was distributed presumably in post-synaptic somatodendritic compartment (A2 and 
C2) while GAD65 immunostaining was clearly delineated presynaptic inhibitory boutons (B2 and 
D2). In low magnification images, note the distribution of CB1 receptors surrounding positive 
glutamatergic neurons (A3) and sharing localization with GAD65 (B3); scale bar: 150 µm. High 
magnification images showed the intracellular localization of VGLUT3 (C2) closely surrounding 
the nuclei stained with Hoechst (C3 in blue) revealing the almost complete lack of colocalization 
with CB1 (C4). Conversely, CB1 was located on GAD65-positive terminals (D4), revealing its 
presynaptic localization on inhibitory synaptic boutons. Scale bar = 10 µm. Bregma -1.82 mm. 
CeL: central amygdaloid nucleus, lateral division; La: lateral amygdaloid nucleus; BLA: 
basolateral amygdaloid nucleus, anterior part; BLP: basolateral amygdaloid nucleus, posterior 
part; BMP: basomedial amygdaloid nucleus, posterior part. 
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Figure 45. Double labeling of tissue slices including the CA1 field of the hippocampus from a 
representative 7-month-old 3xTg-AD mouse processed for M2 (in red) and VGLUT3 (A1 and C1 
in green) as a glutamatergic marker, and GAD65 (B1 and D1 in green) as a GABAergic 
presynaptic marker (B). The different hippocampal subfields exhibited specific M2-
immunostaining patterns delineating the perikarya of the large pyramidal neurons in basket-like 
formations. VGLUT3 was distributed near the nucleus (A1 and C1), presumably in the 
somatodendritic compartment of pyramidal neurons, while GAD65 immunostaining (B1 and D1) 
clearly delineated presynaptic inhibitory boutons. In low magnification images, note that M2-
immunoreactivity showed a complementary distribution to VGLUT3, surrounding the pyramidal 
neurons (A3), and was localized in GAD65-positive presynaptic terminals (B3); scale bar: 150 
µm. High magnification images revealed the intracellular localization of VGLUT3 (C1) closely 
surrounding the nuclei stained with Hoechst (C3 in blue) and the almost complete lack of 
colocalization with M2 (C4). Conversely, M2 was distributed in GAD65-positive terminals, 
revealing the presynaptic localization on inhibitory synaptic boutons (C4). Scale bar = 10 µm. 
Bregma -3.08 mm. Alv: alveus of the hippocampus; Or: oriens layer of the hippocampus; Py: 
pyramidal cell layer of the hippocampus; Rad: radiatum layer of the hippocampus; LMol: 
lacunosum molecular layer of the hippocampus. 
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 The cholinergic hypothesis of AD was postulated in the early 1980s due to a big 
deal of evidence supporting the role of central cholinergic neurotransmission in 
learning and memory processes, as well as the specific vulnerability of this 
neurotransmitter system during the progression, but probably also at the onset, of AD 
(Bartus et al., 1982). From the first reports in the mid 1970s, which described 
degenerative processes of the basal forebrain cholinergic system by means of 
histochemical analyses in postmortem samples, up to the present, with the in vivo 
neuroimaging studies in AD patients, a large quantity of data has been acquired which 
points to the cholinergic neurotransmission arising from the basal forebrain as a key 
neuromodulatory element involved in the pathophysiology of AD.  
 Potentiation of cholinergic neurotransmission in the CNS has been a consistent 
challenge which has been addressed by using different therapeutic strategies. Since 
tacrine was approved by the FDA as the first AChE inhibitor for the treatment of 
symptoms of AD in 1997, the cholinergic drugs that inhibit the breakdown of ACh, 
donepezil, galantamine and rivastigmine, are considered to be the first choice in drug 
therapy for mild to moderate AD. On the other hand, several attempts to reduce the 
deficit of ACh by the administration of cholinergic enhancers or precursors such as Ch 
or lecithin have failed, whereas treatments based on phospholipids including PC and 
PS, or based on Ch alphoscerate and citicholine, provided slight, but noticeable 
benefits (Carotenuto et al., 2017). 
 Furthermore, lipid-based signaling molecules or neurolipids, which include eCB, 
contribute to cellular communication usually involving GPCR-mediated signaling. The 
synthesis of eCB can be stimulated by cholinergic neurotransmission through 
muscarinic receptor activation, and cholinergic neurotransmission is modulated by the 
eCB signaling through the activation of CB1 receptors in several brain areas that 
control learning and memory processes. Specific membrane phospholipids may serve 
as lipid precursors for the synthesis of eCB as well as for the de novo synthesis of Ch. 
The described impairment of cholinergic neurotransmission observed in AD, together 
with altered eCB signaling and profound changes in the lipid profile, provide the clinical 
evidence in support of the general objective of this study, i.e., to analyze the 
relationship between both systems under neurodegenerative conditions by using 
different experimental models of basal forebrain cholinergic dysfunction. 
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Brain organotypic cultures lesioned with 192IgG-saporin as an ex vivo 
model of AD 
 
 Firstly, an ex vivo model of basal forebrain cholinergic lesion based on brain 
organotypic cultures was characterized and used to evaluate the effects of the 
activation of the eCB system by the synthetic cannabinoid agonist WIN55,212-2.  
Organotypic cultures of brain slices have become a useful tool with which to study the 
physiological and pharmacological properties of tissues. Brain organotypic slices can 
be maintained in culture for several weeks and represent a versatile, reproducible and 
rapid method to evaluate cellular interactions and mechanisms. Cultured brain slices 
can be treated with specific toxins to develop ex vivo models that mimic some 
neuropathological features of several neurological disorders. They can be considered 
an intermediate stage between in vitro cell cultures and in vivo models, maintaining a 
well-preserved three dimensional structure and the cytoarchitecture and the 
microenvironment of the original tissue, and they represent a powerful tool for the 
evaluation of the neuroprotective effects of different compounds (Daviaud et al., 2013).  
 Individual immunotoxins are designed in neuroscience research to eliminate 
specific cells or neuronal populations after binding to specific surface antigens. We 
have used 192IgG-saporin to specifically eliminate BFCN expressing p75NTR in 
hemibrain organotypic cultures from P7 rats. The immunotoxin-mediated depletion of 
BFCN in adult rats has been extensively described, but was first reported in the early 
90s (Wiley et al., 1991). When 192IgG-saporin is administered to adult rats it induces a 
massive and specific loss of BFCN. However, the levels of expression of p75NTR, as 
well as the cells expressing this receptor, vary during brain development and increase 
following neural injury (Ibañez and Simi, 2012). We first checked the anatomical 
distribution of the p75NTR receptor in the basal forebrain cholinergic system of formalin-
fixed P7 rats, prior to the application of the immunotoxin to hemibrain organotypic 
cultures obtained from animals of exactly the same age. The immunofluorescence 
studies clearly demonstrated the presence of p75NTR in the different nuclei of the basal 
forebrain cholinergic system, including the MS, VDB, HDB and NBM, which expressed 
the highest levels of p75NTR immunoreactivity, consistent with the patterns of 
expression in the adult brain (Kiss et al., 1988; Woolf et al., 1989). The process itself 
for obtaining and further culturing brain organotypic cultures causes a massive lesion 
and damages to the integrity of the brain tissue, which could modulate the expression 
of p75NTR, as suggested by Ibañez and Simi (2012), as well as the proliferation of glial 
cells surrounding the whole slice culture (del Rio et al., 1991). The application of 
Discussion 
 
164 
 
different concentrations of 192IgG-saporin to hemibrain organotypic cultures resulted in 
a significant loss of BFCN in a dose and time-dependent manner. It is well known that 
p75NTR mediates the retrograde transport of neurotrophins, and in a similar way 
contributes to the movement of the monoclonal antibody coupled to saporin from axon 
terminals. This process explains the loss of BFCN following the uptake of 192IgG-
saporin when it is administered by intracerebroventricular (i.c.v.) infusion in vivo 
(Schweitzer, 1987; Heckers et al., 1994). As the hemibrain organotypic cultures were 
obtained in the coronal plane and BFCN display a rostrocaudal distribution pattern of 
axonal branching travelling in the sagittal plate, it is reasonable to assume that the 
anterior, the medial and the lateral basal forebrain cholinergic pathways described for 
rodents (Kristt et al., 1985), and conserved in human brain (Selden et al., 1998), are 
transected. Therefore, the only way for the internalization of 192IgG-saporin in 
hemibrain organotypic cultures is through p75NTR located in the somatodendritic 
compartment. This process also explains how 192IgG-saporin is uptaken when the 
immunotoxin is directly infused in vivo into the basal forebrain (intraparenchymal). 
 A secondary neuronal or cellular damage critically mediates the future fate of 
the neurons and cells which survive the initial lesion (Koch et al., 2011b). The present 
results suggest that a single daily in vitro application of increasing concentrations of 
192IgG-saporin for three DIV begining on day five of in vitro culture triggers a partial 
loss of BFCN, which leads to secondary cellular damage. This secondary cell damage 
is further demonstrated by the increased levels of propidium iodide (PI) uptake when 
hemibrain organotypic cultures are treated on day two of the in vitro culture for 6 DIV. 
PI has previously been established as a marker that identifies degenerating cells in 
hemibrain organotypic cultures (Pozzo Miller et al., 1994; Dehghani et al., 2003). The 
density of PI positive cells is significantly higher than the values of p75NTR 
immunoreactive BFCN in organotypic cultures treated with 192IgG-saporin, providing 
further support of secondary neuronal or glial cell damage as a consequence of the 
initial BFCN lesion. A double application of the immunotoxin on days two and five of 
the in vitro culture was assayed to avoid the washout of the toxin when the culture 
medium was replaced, and showed more reproducible effects. The concentration of 
immunotoxin that was able to eliminate approximately 50%-60% of BFCN (EC50) was 
selected for further assays aimed at evaluating the effects of endocannabinoid system 
activation in this ex vivo model of AD. 
 The in vivo administration of 192IgG-saporin to adult rats triggers secondary 
alterations in different neurotransmitter systems such as a deregulation of the "on/off" 
glutamatergic/GABAergic signaling. Excitotoxicity could be one of the consequences 
together with cortical and hippocampal reorganization in an attempt to compensate for 
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the reduced cholinergic presynaptic input (Rossner et al., 1995a; reviewed in Rossner, 
1997; Conner et al., 2003; Lee et al., 2016; Jeong da et al., 2016). More evidence of 
secondary neuronal or cellular damage is provided by the activation of microglia 
(Rossner et al., 1995d). Furthermore, different authors have reported findings which 
range from changes in dendritic morphology (Harmon and Wellman, 2003), to 
impairment of neuronal plasticity (Wellman and Sengelaub, 1991) and a negative 
impact on the adult neurogenic processes (Cooper-Kuhn et al., 2004). The 
consequences of the partial removal of BFCN in hemibrain organotypic cultures treated 
with the immunotoxin need to be evaluated and compared with in vivo administration. 
However, this model allows us to initiate the pharmacological evaluation of compounds 
that could ameliorate the subsequent effects on cell viability.  
 
 
WIN55,212-2-mediated protective effects in the ex vivo model of basal 
forebrain cholinergic dysfunction 
 
In the present study we observed that CB1 receptors are involved in the 
WIN55,212-2-mediated reduction of PI uptake after 192IgG-saporin application 
because the protective effect of the synthetic cannabinoid agonist was blocked by the 
application of the specific CB1 receptor antagonist AM251. The density of p75
NTR 
immunoreactive neurons in the presence of WIN55,212-2 was not clearly enhanced, 
which may indicate that there is, a modest and probably indirect protective effect on the 
surviving BFCN. Therefore, the decrease in cell death observed in the presence of 
WIN55,212-2 is presumably related to secondary neuroprotective effects, and not to a 
direct protection from the toxic effects of 192IgG-saporin. On the other hand, 
WIN55,212-2 has a similar affinity for both CB1 and CB2 receptors. As mentioned 
above, the CB1 receptor antagonist, AM251, blocked neuroprotection at a micromolar 
concentration, therefore, the contribution of microglial CB2 receptors cannot be totally 
excluded. 
 The precise mechanism by which direct BFCN death induced by 192IgG-
saporin spreads out to additional BFCN or non-cholinergic cells in hemibrain 
organotypic cultures remains elusive. The deleterious effects described in the in vivo 
model of 192IgG-saporin administration suggest that the protective effects mediated by 
CB1 receptor activation in the present model could be related to the attenuation of 
excitotoxicity or to the modulation of aberrant synaptic transmission after BFCN 
degeneration, very probably involving the activation of glial cells. Excitotoxic brain 
lesions contribute to microglial activation and migration towards the sites of injury, 
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thereby increasing secondary damage (Kim and Ko, 1998; Kreutz et al., 2007). 
Neuroprotective effects of cannabinoid compounds have been previously described in 
models of excitotoxicity in organotypic cultures. Thus, 2-AG, through microglial CB2 
receptor activation or microglial abnormal-cannabidiol-sensitive receptor activation, 
triggers neuroprotective effects in hippocampal organotypic cultures, whereas Δ9-THC 
or anandamide failed to provide neuroprotection, despite the fact that there was a 
reduction in microglial cell density (Kreutz et al., 2007; Kreutz et al., 2009). On the 
other hand, palmitoylethanolamide, through the peroxisome proliferator-activated 
receptor-alpha, together with WIN55,212-2 and N-arachidonoyldopamine, through CB1 
receptor activation, were able to induce neuroprotection in the same model of 
excitotoxicity. However, these effects were blocked by specific CB1 receptor 
antagonists and were absent in mutant knockout mice (Koch et al., 2011a; Koch et al., 
2011b; Grabiec et al., 2012). Interestingly, opposite effects of the phytocannabinoid Δ9-
THC and the synthetic agonist WIN55,212-2 have been described depending on the 
dose, but probably also on the time of exposure (Acquas et al., 2001, Tzavara et al., 
2003a). The complexity of eCB signaling can be explained by the phenomenon of 
functional selectivity or biased agonism, i.e., the ability of ligands to activate a subset of 
the full repertoire of signaling cascades available to individual GPCR (Urban et al., 
2007). Thus, the binding of WIN55,212-2 to CB1 receptors significantly differs from that 
of other cannabinoids, such as 2-AG (Howlett et al., 2002). Different alternative 
signaling pathways could be activated by WIN55,212-2 in addition to classical eCB-
mediated signaling cascades. Nevertheless, neuroprotective effects have been 
described for both cannabinoids, WIN55,212-2 and 2-AG,  in different brain areas such 
as the hippocampal dentate gyrus (Koch et al., 2011b). Moreover, prolonged activation 
of the CB1 receptor results in a rapid attenuation of signaling due to desensitization 
and/or CB1 receptor internalization (Howlett et al., 2004). The internalized complex of 
phosphorylated CB1 receptors and β-arrestins mediates intracellular signaling 
pathways that control the activation of several cascades, including ERK1/2, JNK1/2/3, 
CREB and P38a, and leads to the regulation of gene expression and protein synthesis 
which most likely contribute to the protective effects of chronic activation of CB1 
receptors by WIN55,212-2 (Delgado-Peraza et al., 2016).  
 The synthesis of eCB can be stimulated by neuronal damage, and their 
protective effects are exerted through CB1 receptors, since the lack of this receptor 
increases neuronal vulnerability (Stella et al., 1997; van der Stelt et al., 2001a; 
Marsicano et al., 2003; Kallendrusch et al., 2012). The imbalance of the 
excitatory/inhibitory input described in the in vivo model of 192IgG-saporin 
administration could also contribute to an excessive glutamatergic neurotransmission 
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(Rossner et al., 1995a). A hyper-activation of glutamatergic receptors triggers an 
intracellular increase of Ca2+ levels, leading to excitotoxicity by which neurons can be 
damaged or killed (Manev et al., 1989). Interestingly, increasing levels of glutamatergic 
transmission after a 192IgG-saporin-induced lesion is prevented by the NMDA receptor 
antagonist, MK-801 (Garrett et al., 2006), and this effect is more pronounced in 
192IgG-saporin-treated young adult rats than in middle-aged and aged rats (Kim et al., 
2005), suggesting that cholinergic projections from the basal forebrain play a critical 
role in cortical plasticity, and also revealing age-related differences in the lesion-
induced expression of glutamate receptors. The fact that a reduction in glutamatergic 
neurotransmission through NMDA receptors or decreased levels of Ca2+ influx may 
confer neuroprotective effects, led to the use of memantine, a noncompetitive 
antagonist of NMDA receptors, as a therapeutic drug for AD. Pharmacological 
enhancement of CB1 receptor activity could elicit comparable effects and modulate 
excessive excitatory neurotransmission. Koch et al. (2011b) reported the 
neuroprotective effects of WIN55,212-2 in excitotoxically lesioned organotypic cultures, 
depending on the concentration of the agonist. Thus, low concentrations for three DIV 
elicited neuroprotection by directly activating CB1 receptors. We observed decreased 
levels of cell death in the MS and in the NBM with low doses of WIN55,212-2 during 6 
DIV in 192IgG-saporin-treated hemibrain organotypic cultures, and it is reasonable to 
assume that the neuroprotective effects may be related to a possible tissue or 
neurotransmission restoration by CB1 receptor activation in cells which are still 
undefined, since the localization of CB1 receptors in BFCN remains unclear. Data 
suggest that rodent BFCN in the NBM are devoid of CB1 receptors but interestingly, all 
of them contain eCB degrading enzymes and display a fine CB1 receptor fiber 
meshwork surrounding the perikarya, which suggests that BFCN may utilize eCB for 
retrograde control of cholinergic neurotransmission (Harkany et al., 2003). However, 
microscopy studies reported the existence of differentiated BFCN in the MS of the rat, 
some of which express CB1 receptors (Nyíri et al., 2005). Additional studies are 
necessary to further understand the precise mechanisms underlying 192IgG-saporin-
induced secondary cell damage, as well as the levels of expression, the precise 
location and the functionality of cannabinoid receptors under conditions of BFCN 
degeneration.  
 As mentioned above, brain organotypic cultures represent an intermediate 
stage between in vitro studies and in vivo models. The administration of 192IgG-
saporin in vivo allows us to further understand the role of BFCN in learning and 
memory processes, in several histological and biochemical parameters and in the 
crosstalk with other neurotransmitter systems. 
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Learning and memory impairment following the administration of 192IgG-
saporin in adult rats 
 
 The NBM is a neuronal nucleus which is located deeply within the brain, close 
to the border of the ventral limit. Firstly, we analyzed the mechanical lesion produced 
by the needle crossing from the dorsal cranial surface to almost the ventral border, and 
the intraparenchymal infusion of the vehicle. Previous studies from our laboratory 
demonstrated that the administration of the vehicle by using a common Hamilton 
syringe was sufficient to produce brain damage which led to learning and memory 
deficits in the control group, as observed in the passive avoidance test. Therefore, a 
new model of Hamilton neurosyringe, equipped with an ultra thin gauge needle, was 
used in order to minimize the mechanical lesion. 
 Eight days after the intraparenchymal infusion of 192IgG-saporin, 75% of BFCN 
in the NBM had disappeared leading to learning and memory impairment, as 
demonstrated by the results of the passive avoidance test. In the retention trial, 100% 
of SHAM-operated rats remembered the foot-shock and no statistically significant 
differences were observed between SHAM-operated and aCSF-treated groups. 
Moreover, the histochemical (AChE staining) and immunohistochemical (p75NTR-
immunoreactivity) studies revealed similar densities of BFCN in SHAM-operated rats 
and in those which had received aCSF used as the vehicle, thereby demonstrating that 
the intraparenchymal infusion of the vehicle by itself had no effect on the survival rate 
of BFCN. The extent of the specific basal forebrain cholinergic lesion was also 
demonstrated by the dramatic loss of AChE-positive fibers in cortical regions. The 
infusion of 192IgG-saporin had no effects on acquisition latency, suggesting that the 
motivation to explore, the level of anxiety and/or the motor functions of the rats were 
apparently unaffected. In this context, longer acquisition latency times in the passive 
avoidance test induced by BFCN depletion in the medial septum have been reported, 
showing that there are different effects on aversive learning, depending on the specific 
cholinergic nucleus lesioned (Babalola et al., 2012). As already mentioned, 192IgG-
saporin is directed against p75NTR, which is predominantly expressed in BFCN from the 
MS, VDB, HDB and NBM (Wiley et al., 1991). The specificity of the lesion in the NBM is 
demonstrated by the absence of damage in the complex MS-VDB (Ch1-Ch2) which 
mainly innervates the hippocampus, as observed by AChE staining. The evaluation of 
learning and memory behavior in the present study does not discriminate other 
parameters such as acquisition, consolidation, extinction or retrieval of new aversive 
information, but previous studies using the olfactory discrimination learning test have 
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demonstrated that 192IgG-saporin-induced lesions of the NBM impair attention 
capacity and early acquisition during a learning process (Bailey et al., 2003).  
 Kaplan-Meier survival curves were used to graphically represent the estimated 
probability of reaching the cut-off time (300 s) for each group. Then, data were 
analyzed by using the Log-rank/Mantel-Cox test to compare the survival distributions or 
the estimated probability of each group to reach the cut off time. Doing so was 
regarded as a positive response. It was found that a statistically significant higher 
percentage of immunotoxin-treated animals showed a negative behavioral response in 
comparison with those which had received aCSF.  
 The present results provide evidence that cortical cholinergic innervation arising 
from the NBM plays a pivotal role in learning and memory processes. In previous 
studies, step-through latency times were represented as histograms, evaluating 
censored latency times (cut-off time of 300 s) as threshold values, but the above-
mentioned statistical analysis is more appropriate to test the probability of reaching the 
cut-off time and eliminates the threshold bias. Based on a previous report, the 
statistical handling of data in the present study improves the analysis of the results and 
represents an alternative way to interpret behavioral responses when using the passive 
avoidance paradigm (Barreda et al., 2015).  
 The effects of cholinergic lesions on learning and memory have been 
extensively studied, but controversial data have been reported depending on the 
severity of the lesion, the dose, schedule and route of 192IgG-saporin administration, 
the specific cholinergic nucleus affected or the passive avoidance test conditions 
(reviewed in Myhrer, 2003). A previous study demonstrated that a 50% reduction of 
BFCN in the NBM produced a 25-30% decrease in ChAT activity, but was not sufficient 
to impair memory five weeks after lesioning (Wenk et al., 1994). The experimental 
design differed from ours in several aspects: lower doses of the immunotoxin, repeated 
learning trials and footshock deliveries, the post-operatory recovery period and the 
statistical analysis used. Our results are consistent with other studies which have 
demonstrated that avoidance testing is impaired after a specific lesion in the NBM with 
the excitotoxins ibotenic acid (Flicker et al., 1983; Hepler et al., 1985; Whishaw et al., 
1985), or quisqualic acid (Aaltonen et al., 1991; Riekkinen et al., 1991a,b, 1993; Zupan 
et al., 1993). In the studies using non-specific excitotoxins, the effects of the lesions 
are not restricted to BFCN, but also affect to non-cholinergic neurons in the same 
structures (Kosaka et al., 1988). However, when the lesion was induced with 192IgG-
saporin, other authors reported small, but significant deficits associated with the BFCN 
lesion in the NBM in a single learning trial of the passive avoidance test (Torres et al., 
1994). Moreover, and consistent with the present results, the relationship between the 
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severity of passive avoidance behavioral deficits and the degree of BFCN loss was 
demonstrated (Zhang et al., 1996; Martinez-Gardeazabal et al., 2017). The present 
findings unequivocally support the pivotal role of NBM-cortical cholinergic 
neurotransmission in learning and memory processes in rats.  
 
 
The loss of BFCN induces alterations in density and functionality of M2/M4 
mAChR  
   
Different alterations related to the cholinergic neurotransmission have been 
reported in postmortem samples from AD patients (Davies and Maloney, 1976; Davies, 
1979; Whitehouse et al., 1982; Rodríguez-Puertas et al., 1994 and 1997; Flynn et al., 
1995). In the present study, functional autoradiography showed a decrease in 
carbachol-induced stimulation of [35S]GTPγS binding in the NBM and an increase in 
hippocampus, but no significant change in this parameter was observed in the entire 
cortical mantle of 192IgG-saporin-treated rats. Although the cholinergic connectivity 
between these three brain areas is not fully understood, they are all areas involved in 
learning and memory.  
 BFCN from the NBM are thought to express M2 and/or M4 mAChR as 
autoreceptors in the synaptic terminals. Therefore, in the lesion model the decrease in 
M2/M4 mAChR activity recorded at the NBM may be a direct consequence of the lesion 
and indicates a loss of cholinergic interconnections within the nucleus that constitutes 
the cholinergic basal forebrain. However, despite the elimination of up to 70% of 
presynaptic basal forebrain cholinergic terminals in some cortical regions of 192IgG-
saporin-treated rats, the [35S]GTPγS autoradiographic study showed no differences in 
the functional coupling of M2/M4 mAChR to Gi/o proteins in the cortical areas analyzed. 
M2 and M4 mAChR are differentially distributed in the cortex. Thus, M2 mAChR-
immunoreactivity is dense in the deeper layers of the cortex, is located in cell bodies, 
and is associated with fibers and presumably terminals, and occasionally with 
perikarya. Using the NBM-lesioned rat model, previous studies reported a decrease in 
M2 mAChR density in frontal and parietal cortices seven days after ibotenic acid 
administration or mechanical lesioning of the NBM, by means of autoradiography and 
in situ hybridization techniques, which is in consistent with the presynaptic localization 
of M2 mAChR in BFCN terminals (Bogdanovic et al., 1993; Schliebs et al., 1994). As 
previously mentioned, mechanical or excitotoxin-based lesioning of the BFCN may 
trigger non-specific damage to non-cholinergic neurons, and this could result in 
contradictory results. Therefore, when the lesion was produced by 192IgG-saporin, as 
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observed in the study of Rossner et al. (1995b), an increase of up to 20% in M2 mAChR 
density in the parietal cortex was reported, suggesting the existence of a significant 
population of M2 mAChR located postsynaptically (reviewed in Rossner, 1997). In AD, 
the severe loss of cortical cholinergic innervation is accompanied by a depletion of M2 
mAChR, but M1 mAChR density remains relatively stable (Mash et al., 1985). It has 
been assumed that the M2 mAChR is a presynaptic autoreceptor located in all 
cholinergic axons which arise in the NBM and innervate the cerebral cortex, the NBM 
being the main source of cortical M2 mAChR. The depletion of M2 mAChR was 
therefore thought to be the consequence of the cholinergic axonal loss in AD. 
However, the expression of M2 mAChR in BFCN terminals still remains controversial. 
The interpretation of some authors was that the cholinergic axons coming from the 
NBM do not substantially contribute to the overall pool of cortical M2 mAChR, and M2 
mAChR-expressing postsynaptic neurons could be partially responsible for the 
decrease of these receptors observed in AD (Mesulam, 1998). The existence of 
cortical postsynaptic M2 mAChR and/or the possibility that they are located in non-
cholinergic terminals of either intrinsic or extrinsic origin, makes it plausible that the 
degeneration of cortical M2 mAChR-immunoreactive neurons could also be contributing 
to the described loss of M2 mAChR in AD (Mrzljak et al., 1998; Raevsky et al., 1998). 
Interestingly, electron microscopic analysis failed to reveal changes in M2 mAChR 
distribution following the intraparenchymal administration of 192IgG-saporin in the 
NBM of rhesus monkeys, and moreover, clearly showed that membrane-linked 
receptors were also located in dendritic spines of pyramidal neurons and associated 
with membranes in all cellular compartments of nonpyramidal neurons (Mrzljak et al., 
1998). Furthermore, M2 mAChR which modulate ACh release are not located in NBM 
cholinergic terminals, but are predominantly found in the membranes of postsynaptic 
sites in the NBM (Meyer et al., 1987; Pascual-Alonso and Gonzalez-Zarate, 1992; 
Decossas et al., 2003). However, the co-expression of M2 mAChR at presynaptic sites 
and VAChT has been observed by using both light and electron microscopy (Decossas 
et al., 2003).  
 On the other hand, the cortical pool of M4 mAChR is relatively small and this 
subtype is mainly located in the neuropil and in scattered perikarya (Levey et al., 
1991). The reported localization of M4 mAChR binding sites and mRNA is comparable 
in all layers of the neocortex (Buckley et al., 1988; Sugaya et al., 1997; Vilaró et al., 
1994). The present immunofluorescence assays revealed a higher density of M4 
mAChR located in somas and plasma membrane, in comparison with M2 mAChR, 
which seem to be located presynaptically, clearly showing that there is a different 
pattern of distribution. Although we did not observe changes in the activity mediated by 
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M2/M4 mAChR in cortical areas, the role of cortical M4 mAChR in this lesion model and 
their precise distribution remains unclear. Further research into the role of these 
receptors, carried out by using this model of basal forebrain cholinergic dysfunction, 
could provide valuable physiological information. 
 The immunosignal associated with both M2 and M4 mAChR was dramatically 
reduced in the basal forebrain after the lesion, thereby providing evidence of the 
contribution of both receptors to the cholinergic neurotransmission impairment in the 
NBM. As previously described, the precise anatomical distribution of M2 and M4 
mAChR in the basal forebrain still remains controversial, but present 
immunohistochemical findings suggest a mainly presynaptic localization of M2 mAChR 
and a somatodendritic distribution of M4 mAChR in the BFCN of the NBM. However, 
the expression of M2 mAChR and M4 mAChR in BFCN, including those from the MS, 
VDB, HDB and NBM, has previously been studied by using in situ hybridization, [3H]-
oxotremorine autoradiography and immunohistochemical assays (Harata et al., 1991; 
Vilaró et al., 1992 and 1994; Sugaya et al., 1997). The co-expression of these 
receptors and ChAT has also been detected in approximately 80% of BFCN by using 
light and electron microscopy (Decossas et al., 2003). In addition, dissociated NBM 
neurons are stimulated with carbachol and antagonized with the M2 mAChR 
antagonist, AF-DX-116 (Harata et al., 1991). 
 In summary, the present findings show a significant decrease in Gi/o-mediated 
muscarinic signaling in the NBM, mediated by the pool of presynaptic M2 and 
somatodendritic M4 mAChR, and the absence of changes in pre- and postsynaptic 
M2/M4 mAChR-mediated signaling in the cortex of immunotoxin-treated rats. Eight days 
after the administration of 192IgG-saporin, the loss of both the cortical source of ACh 
and the M2/M4 mAChR-mediated signaling associated with the loss of BFCN in the 
NBM could contribute to the deregulation of cortical neurotransmission responsible for 
the cognitive impairment observed in the passive avoidance test.  
 Conversely, the increased M2/M4 mAChR-mediated signaling in the dentate 
gyrus and CA3 regions of the hippocampus, cannot be directly attributed to cholinergic 
denervation from NBM because the major source of cholinergic innervation to the 
hippocampus proceeds from the MS and the VDB. In fact, the results of the 
autoradiographic assays and the AChE staining in these nuclei were similar to those 
obtained in the aCSF group, suggesting the absence of non-specific damage to other 
basal forebrain cholinergic nuclei, except that generated in the NBM. Nevertheless, 
lesions directed at the septohippocampal cholinergic projections have been used to 
evaluate the involvement of this pathway in cognition (Baxter et al., 2013; Köppen et 
al., 2016), and to explore the distribution of mAChR in the hippocampus at different 
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postsurgical times, demonstrating dynamic changes in densities of pre- and 
postsynaptic pools of M2 and M4 mAChR (Bauer et al., 1992; Wall et al., 1994; Levey et 
al., 1995).  
 Our immunofluorescence studies in the hippocampus suggest that the M2 
mAChR in the granular dentate gyrus and pyramidal CA1-CA3 are located 
presynaptically, whereas the M4 mAChR are postsynaptically distributed in the 
somatodendritic compartment of pyramidal neurons. Furthermore, presynaptic M2/M4 
mAChR inhibit ACh release (Raiteri et al., 1984; Levey et al., 1995). In this context, the 
observed increase in hippocampal cholinergic neurotransmission through M2 mAChR 
may contribute to the so-called “muscarinic long term potentiation” mediated by the 
potentiation of glutamatergic NMDA receptors, essential to explain hippocampal 
neuronal plasticity (Segal and Auerbach, 1997). Interestingly, mice lacking M2 mAChR, 
but not mice lacking M4 mAChR, showed deficits in learning and memory, as 
demonstrated by means of the passive avoidance test, together with profound 
alterations in ACh homeostasis in the hippocampus, suggesting that the M2 mAChR 
subtype plays a crucial role in cognitive processes (Tzavara et al., 2003b). Additional 
studies in M2 mAChR knockout mice reported significant deficits in the Barnes circular 
maze. In addition, this was associated with impairment in both short- and long-term 
potentiation and was completely reversed with the GABAA receptor antagonist, 
bicuculline (Seeger et al., 2004). M2 mAChR are also expressed in diverse 
hippocampal interneurons and control GABA release from presynaptic inhibitory 
terminals which leads to an increase in activity in the dendritic region of pyramidal 
neurons (Hajos et al., 1998). The increase in hippocampal muscarinic functionality 
mediated by M2 mAChR may modulate the GABAergic tone to compensate for 
excitatory-inhibitory imbalance. The M4 mAChR subtype might also be involved in 
neuronal plasticity-associated learning and memory formation, as has been reported in 
adrenalectomized rats, whereas the loss of M4 mAChR leads to dysfunction in 
hippocampal synaptic transmission (Mulugeta et al., 2006). 
 However, the influence of other neurotransmitter systems in learning and 
memory processes has been studied using the passive avoidance paradigm. 
Dopaminergic antagonists either impair (Lazarova et al., 1991; Doyle and Regan, 
1993), or improve (Chugh et al., 1991), passive avoidance performance, while 
glutamatergic and GABAergic antagonists usually impair it (Venable and Kelly, 1990; 
Anglade et al., 1994). To fully understand learning and memory processes, it is 
necessary to clarify the interaction among the different neurotransmitter systems and 
each one´s contribution to the cognitive deficits associated with aging and AD. In this 
context, the eCB system modulates the release of the above-mentioned 
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neurotransmitters (Katona et al., 2001), regulates diverse physiological processes 
including learning and memory (Busquets-García et al., 2011), and is deregulated 
under neurodegenerative conditions such as AD (Manuel et al., 2014, Mulder et al., 
2011).  
 
 
Endocannabinoid signaling is modulated in the in vivo model of BFCN 
depletion  
  
Once the model of BFCN depletion in the NBM was validated and cholinergic 
neurotransmission and cognitive impairment were demonstrated, we further explored a 
possible interaction between cholinergic neurotransmission and CB1 receptor-mediated 
eCB signaling. Some authors propose that rodent BFCN are devoid of CB1 receptors, 
but all BFCN contain eCB degrading enzymes and exhibit a fine CB1 receptor 
immunoreactive fiber meshwork surrounding the perikarya, which suggests that BFCN 
may use eCB for retrograde control of neurotransmission (Harkany et al., 2003). 
Similar results were obtained in the gray mouse lemur, revealing evolutionarily 
conserved networks (Harkany et al., 2005). However, other studies reported a dense 
labeling of CB1 receptor in ChAT positive neurons in monkey basal forebrain (Lu et al., 
1999), and the existence of BFCN expressing CB1 receptors in rat (Nyíri et al., 2005). 
The eCB compounds act as retrograde synaptic messengers on presynaptic CB1 
receptors, fine-tuning neurotransmitter release (Katona et al., 2001; Ohno-Shosaku et 
al., 2001). To further understand the role of CB1 receptors, it is important to study 
which elements of the brain‟s excitatory-inhibitory networks, i.e., GABAergic or 
glutamatergic, express this receptor. GAD65, the smaller isoform of the enzyme, 
glutamic acid decarboxylase, is associated with nerve terminals (Kash et al., 1999), 
while VGLUT3 is expressed in synaptic buttons, but mainly in somatodendritic 
compartments (Herzog et al., 2004). 
 
CB1 receptor-mediated signaling in the NBM and hippocampus of 192IgG-
saporin treated rats  
 The present findings show the loss of three quarters of BFCN in the NBM 
following the intraparenchymal infusion of 192IgG-saporin, but the autoradiographic 
studies revealed an increase in both density and activity of CB1 receptors in the NBM 
of lesioned rats. The CB1 up-regulation could indicate an activation of the system in 
order to counteract the effects of the lesion, but the precise anatomical distribution of 
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CB1 receptors and the neurophysiological relevance of this modulation still remain 
unclear. Nevertheless, our results are consistent with those obtained by Harkany et al. 
(2003), which suggests the absence of a somatodendritic distribution of CB1 receptors 
in BFCN. 
 Conversely, the decreased eCB signaling in the hippocampus cannot be 
explained as a direct consequence of cholinergic denervation since the NBM mainly 
projects to the cortex. It could be a secondary neuroadaptive process, which somehow 
either compensates for or even worsens the loss of cortical cholinergic inputs. Previous 
immunochemical studies indicated the inhibitory role of hippocampal CB1 receptor-
positive terminals which had before been described as GABAergic interneurons 
(Katona et al., 1999; Tsou et al., 1999). However, further studies demonstrated that 
CB1 receptors are also present in hippocampal glutamatergic synapses, albeit at much 
lower levels (Katona et al., 2006; Kawamura et al., 2006). In this context, despite the 
reported negative effects of cannabimimetics on memory in humans, the literature fails 
to provide strong evidence for hippocampal CB1 receptor-mediated action (reviewed in 
Davies et al., 2002) although, a recent study associates hippocampal mitochondrial 
CB1 receptors with learning and memory impairment (Hebert-Chatelain et al.,  2016). 
The present study shows a moderate decrease in CB1 receptor density and activity in 
the hippocampus of BFCN-lesioned rats and the immunofluorescence images clearly 
indicate that CB1 receptors are mainly located in GABAergic presynaptic terminals. 
Transgenic mice with enhanced GABAergic inhibition exhibit impairment in both 
hippocampal long-term potentiation (LTP) and Morris water maze performance (Gong 
et al., 2009) and, moreover, learning and memory deficits in these mice or in wild-type 
mice treated with Δ9-THC are reversed by GABAA receptor antagonists (Varvel et al., 
2005; Cui et al., 2008). In this sense, a decrease in the eCB signaling in certain 
hippocampal regions may induce an increase in the GABAergic tone and probably 
contributes to the cognitive impairment observed in the passive avoidance test. CB1 
receptor-mediated signaling is also affected in the hippocampus of patients diagnosed 
with severe AD (Manuel et al., 2014). The present animal model shows a considerable 
reduction in BFCN, which partially mimics the serious degeneration of the basal 
forebrain cholinergic pathway which innervates the hippocampus through the 
entorhinal cortex described in AD patients in the final Braak's stages (V-VI) of the 
disease (Ikonomovic et al., 2003). 
 
CB1 receptor-mediated signaling in the cortex of 192IgG-saporin treated rats  
 The dramatic reduction in cortical cholinergic projections following the infusion 
of the immunotoxin, as observed by AChE staining, was not accompanied by a similar 
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decrease in [3H]CP55,940 binding in any of the different regions of brain cortex which 
suggests the absence of synthesis of CB1 receptors in the BFCN. These results are in 
agreement with previous immunochemical studies which reported that cortical 
cholinergic terminals lack any detectable CB1 receptors (Harkany et al., 2003). 
Interestingly, the hyperactivity of cortical CB1 receptor-mediated eCB signaling that we 
found in BFCN lesioned-animals was similar to that described in human brain during 
the early stages of AD (Manuel et al., 2014). Therefore, we further explored the 
different regulation of receptors in the cortex at the subcellular level by carrying out 
immunofluorescence studies (see next section).  
 CB1 receptor activation is involved in the regulation of cortical glutamatergic 
input; CB1 receptor agonists inhibit, while the antagonist, SR141716A, enhances 
cortical glutamatergic synaptic transmission and favors LTP (Auclair et al., 2000). CB1 
receptor–dependent activation is thought to be an early step in a protective cascade 
against kainic acid-induced excitotoxicity (Marsicano et al., 2003). A CB1 receptor-
mediated decrease in TNFα-induced expression of AMPA receptors protects against 
excitotoxic neuroinflammation (Zhao et al., 2010). As mentioned above, Garrett et al. 
(2006) reported increased levels of cortical glutamatergic transmission induced by the 
infusion of 192IgG-saporin in the NBM. In addition, previous studies using a similar 
lesion in basal forebrain showed a marked reduction in NMDA, α2-and β-adrenoceptors 
and 5-HT2A receptors, an increase in AMPA, kainate and GABAA receptors and a 
decrease in high-affinity choline uptake sites in cortical regions (Rossner et al., 1994, 
1995c; Schliebs et al., 1994; Heider et al., 1997). On the basis of such compelling data, 
the 192IgG-saporin-induced lesion in the NBM clearly leads to an irreversible loss of 
cholinergic innervation in almost the entire cortical mantle, sufficient to lead to an 
excess of excitatory neurotransmission that may be controlled by the activation of CB1 
receptors present in cortical areas.  
 
 
Decreased cortical presynaptic GABAergic inputs after the BFCN lesion  
   
 Previous studies have reported that almost all CB1 receptor-positive cortical 
cells also express cholecystokinin and GAD65, confirming the existence of an inhibitory 
phenotype of CB1 receptor containing terminals (Marsicano and Lutz, 1999). By using 
optical and electron microscopy, other authors described a presynaptic localization of 
CB1 receptors in GABAergic nerve terminals, as well as a compartmental distribution of 
these receptors in cell bodies of two distinct subpopulations of cholecystokinin or 
calbindin positive interneurons in rat somatosensory cortex and in calbindin positive 
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interneurons in rat prefrontal cortex (Bodor et al., 2005; Wedzony and Chocyk, 2009). 
These studies demonstrated that, independently of the precise anatomical location, 
CB1 receptor-mediated signaling promotes specific inhibitory functions. The present 
immunofluorescence studies did not help us to determine its precise location, but a 
marked decrease of GAD65-immunoreactivity was found, suggesting either a down-
regulation of GAD65 density or a loss of inhibitory cortical inputs. The results confirm 
that the BFCN terminals are essentially devoid of CB1 receptor expression and this 
model exhibits a selective down-regulation of the presynaptic cortical GABA-
synthesizing enzyme. In this context, a reduction in brain cholinergic metabolism, 
accompanied by decreased GAD levels, was found in samples from AD patients (Perry 
et al., 1977). A recent study demonstrated that 192IgG-saporin-induced BFCN loss 
was sufficient to decrease GAD65/67 levels in the prefrontal cortex, promoting the 
overexpression of the glutamate transporter. Moreover, deep brain stimulation of the 
remaining BFCN in the NBM improved spatial memory and partially restored GAD65/67 
to control levels (Lee et al., 2016). The excessive excitatory neurotransmission 
described in this model is prevented by NMDA receptor antagonists and BFCN are 
essential for enabling plasticity mechanisms required for functional recovery after 
cortical brain injury (Conner et al., 2005; Kim et al., 2005; Garrett et al., 2006).  
 The present findings demonstrate that a BFCN lesion in the NBM impairs 
memory and triggers changes in cortical eCB signaling together with a decrease in 
cortical GABAergic immunoreactivity. BFCN represent the main source of cortical ACh 
and contribute to the inhibitory tone in cortical projections. The depletion of BFCN also 
contributes to a deregulation of excitatory neurotransmission, which probably explains 
the hyperactivation of CB1 receptors. We propose that a CB1 receptor-mediated 
regulation of the cortical eCB tone is a compensatory mechanism to regulate a 
possible BFCN death-evoked glutamatergic-GABAergic imbalance. Further studies 
should be focused on discovering wether the eCB system is being regulated in 
response to excessive glutamatergic neurotransmission or, conversely, contributes to 
its worsening. Understanding the underlying mechanisms of this regulation could lead 
to the discovery of innovative cannabinoid-based pharmacological approaches towards 
the treatment of common pathological features of different neurological disorders.   
 In summary, the results from studies using the in vivo model of basal forebrain 
cholinergic dysfunction show that the intraparenchymal administration of 192IgG-
saporin into the NBM of adult rats selectively eliminates BFCN and leads to a dramatic 
loss of cortical cholinergic innervation, accompanied by changes in the activity of M2/M4 
mAChR and CB1 receptors in the NBM-cortico-hippocampal circuitry. During the 
progression of AD, basal forebrain cholinergic pathways degenerate causing disrupted 
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supply of ACh and irreversible impairment of memory and thinking abilities, together 
with changes in lipid homeostasis and neurolipid neurotransmission, such as eCB 
signaling (Whitehouse et al., 1982; Wymann and Schneiter, 2008; Mulder et al., 2011; 
Manuel et al., 2014). The regulation of lipid composition is especially relevant in brain 
processes which require a modification of cell membranes, including the formation of 
new memories for which the genesis of dendritic spines and new synapses are 
necessary. Therefore, all deregulated levels or changes in the distribution of certain 
lipid species could be indicating adaptations, but may also be underlying mechanisms 
associated with neurodegeneration. There follows a description of the lipid profile of 
192IgG-saporin-treated rats which focuses on the analysis of the phospholipid species 
that are suspected of being used as precursors for the synthesis of both ACh or eCB 
when there is specific basal forebrain cholinergic neurodegeneration.   
 
 
Lipid profile in NBM and cortex in the rat model of BFCN lesion 
 
 MALDI-IMS analysis showed changes in the brain lipid profile of 192IgG-
saporin-treated rats. The relative intensities of different lipid species, including PC, SM, 
PE and PS were modified in the basal forebrain and in areas of cortical projection. 
 ChAT enzyme has low affinities for Ch and acetyl-CoA, and the rate of 
synthesis of ACh mainly depends on the levels of Ch (Millington and Wurtman, 1982; 
reviewed in Blusztajnn and Wurtman, 1983). As previously mentioned, the 192IgG-
saporin-induced lesion model causes a considerable reduction in the level of ACh. 
Moreover, the loss of approximately 50% of BFCN has been associated with 40-60% 
reductions in ChAT and SDHACU activities throughout the basal forebrain cholinergic 
system (Rossner et al., 1996). In this context, the membrane phospholipids become an 
important source from which Ch can be synthesized de novo. This de novo synthesis 
requires PE from any membrane pool as a substrate to be sequentially methylated to 
PC (Bremer et al., 1960a,b). PC can be hydrolyzed to free Ch by membrane-
associated phospholipase D (PLD) activation (Hattori and Kanfer, 1984; Blusztajn et 
al., 1987a; Exton, 1999). Phosphatidylinositol 4,5-bisphosphate (PIP2), protein kinase 
C (PKC) and phorbol esters stimulate PLD activity which, furthermore, has been found 
to be reduced by up to 63% in homogenates of brain tissue samples from AD patients 
(Kanfer et al., 1986; reviewed in Exton, 1999). Then, Ch can be acetylated to form ACh 
in order to sustain neurotransmission at the expense of membrane formation which 
may finally impair synaptic plasticity or compromise membrane viability (Maire and 
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Wurtman, 1985; Ulus et al., 1989). Wurtman et al. (1985) described this process as 
autocannibalism of the cholinergic cells.  
 On the other hand, the synthesis of eCB is comparable to the described 
alternative source of Ch. The eCB are not stored in intracellular compartments or 
vesicles, as are other classical neurotransmitters; they are synthesized on demand by 
receptor-stimulated cleavage of membrane lipid precursors. The pathways leading to 
the synthesis and release of AEA and 2-AG from neuronal and non-neuronal cells are 
still somewhat unclear. In this context, different authors have found a relationship 
between cannabinoid and cholinergic neurotransmission (Gifford et al., 1996; Kathman 
et al., 2001; Fukudome et al., 2004). Therefore, it is tempting to interpret the 
modifications of lipid composition in the in vivo model of basal forebrain cholinergic 
dysfunction as potential precursors for both eCB and Ch synthesis. 
 If the hydrolysis of phospholipids from membranes of presynaptic terminals 
(cortical area) and/or the somatodendritic compartment (NBM area) served for the de 
novo synthesis of Ch, one would expect a regulation of certain lipid species in both 
anatomical regions due to the loss of approximately 80% of BFCN in the NBM and 
60% of cortical cholinergic innervations.  
 
Phosphatidylcholines and phosphatidylserines 
 We found an increase in PC (36:1) + Na+ in NBM and a reduction in cortical 
regions, while PS (18:0/18:1) was found to be decreased in the NBM after the infusion 
of 192IgG-saporin. The physiological role of PC (36:1) + Na+ still remains unclear, but 
its presence in both rat and human brain, mainly in regions of white matter has been 
previously described (Jackson et al., 2005a,b; Astigarraga et al., 2008; Veloso et al., 
2011). The proliferation of glial cells and the loss of both BFCN in the NBM and in the 
cortical cholinergic axons could explain either the increase or the decrease in the levels 
of this particular species in the NBM and cortex, respectively. The characterization of 
the lipid profile of the different types of cells present in the CNS could verify this 
interpretation. Moreover, these changes may also be an indication of an adaptive 
process with which to reconstruct the axonal branching following lesioning of the 
BFCN, rather than an alternative source for de novo synthesis of Ch. On the other 
hand, under normal physiological conditions, PS (18:0/18:1) is preferentially located in 
the inner leaflet of the plasma membrane, but the loss of asymmetry is an early 
indicator of apoptosis and/or glia-mediated synaptic pruning to remodel the neural 
circuit (Fadok et al., 1992; reviewed in Bevers and Williamson, 2016). The loss of PS 
asymmetry with increased externalization to the outer leaflet of the lipid bilayer has 
been described in samples from AD patients (Bader Lange et al., 2008). 18 h after the 
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internalization of saporin, apoptosis is induced, and apoptotic activity is enhanced 
when the toxin is bound to immunoglobulins such as 192IgG (Bergamaschi et al., 
1996). These findings suggest that the loss of PS (18:0/18:1) in the NBM may be a 
consequence of the immunotoxin-induced depletion of BFCN and, therefore, is 
probably not related to phospholipid hydrolysis for eCB or Ch synthesis.  
 In addition, PC (40:6) + Na+ and PC (36:4) + K+, which are mainly present in the 
gray matter of rat CNS, were also found to be increased in the NBM and in the cortex. 
PC (40:6) + Na+ is probably composed of stearic acid (18:0) and docosahexaenoic acid 
(DHA; 22:6), the latter being a polyunsaturated fatty acid (PUFA) which, when added to 
the diet of hypertensive rats, restores both their cerebral Ch and ACh levels and their 
performance in the passive avoidance test (Minami et al., 1997). Furthermore, there is 
a large body of evidence which indicates that DHA has important biological functions in 
neuronal homeostasis, mostly linked to its role in neurogenesis, synaptogenesis, 
neuronal differentiation, neurite outgrowth and maintenance of membrane fluidity, and 
this could be consistent with the need to repair the structural brain damage induced by 
192IgG-saporin (Belkouch et al., 2016). The most probable acyl chain composition of 
PC (36:4) + K+, is palmitic acid (16:0) and AA (20:4). Interestingly, AA is a well-known 
pro-inflammatory precursor but, indeed, phospholipids containing AA are the most 
suitable candidates as precursors for the synthesis of the eCB, AEA and 2-AG (Di 
Marzo et al., 1994; Sugiura et al., 1995). Moreover, the synthesis of eCB can be 
stimulated not only by neuronal damage (Stella et al., 1997; Marsicano et al., 2003; 
van der Stelt et al., 2001a) but also by the activation of Gαq/11-coupled mAChR (Kim et 
al., 2002), and the suppression of CB1 receptors increases neuronal vulnerability 
(Marsicano et al., 2003). By using genetically modified mice lacking any of the 
subtypes of mAChR, it was demonstrated that Gαq/11-coupled mAChR activation is 
responsible for the PLCβ-mediated stimulation of 2-AG synthesis which finally induces 
short-term plasticity at cholinergic synapses (Fukudome et al., 2004).  
 The study of lipids in samples from AD patients reveals an enhancement of 
plasmatic levels of PC (40:6) which has been found to positively correlate with CSF tau 
concentrations in AD patients carrying the presenilin1 mutation (Chatterjee et al., 
2015). In contrast, plasmatic levels of PC (36:4) and PC (40:6) have been found to be 
decreased in AD and have been proposed as biomarkers of phenoconversion to either 
amnestic mild cognitive impairment or late-onset AD (Mapstone et al., 2014; Fiandaca 
et al., 2015). Reduced relative densities of PC species have been found in AD brains 
and attributed to a pathological hyperactivation of phospholipase A2 (PLA2) (Nitsch et 
al., 1992; Klein, 2000). The result of this is an increase in the breakdown of certain 
phospholipids and a variation in the ratio of saturated and unsaturated fatty acids in PC 
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and PE (Mulder et al., 2003). These findings suggest a different regulation in the 
biosynthesis, turnover, and acyl chain remodeling of phospholipids in AD. Essential 
PUFA, such as AA and DHA, provide the structural functionality of the membranes, but 
lipid catabolism (e.g., during neurodegeneration, neuroinflammation or autophagy) 
generates intermediate metabolites that are not usually recycled, and increased 
demands are made on the bloodstream (Fiandaca el al., 2015). This could explain the 
decreased levels of PC (36:4) and PC (40:6) recorded in plasma from AD patients, in 
contrast with the increase observed in 192IgG-saporin-treated rat brains. Additional 
lipidomic studies of brain samples from AD patients are necessary to further elucidate if 
the plasmatic levels of certain lipid-based biomarkers correlate in some way with those 
levels observed directly in the brain tissue by means of imaging techniques such as 
MALDI-IMS. 
 
Sphingomyelins 
 There was a significant increase in the levels of SM (d18:1/16:0) + K+ in the 
NBM, but the SM (d18:0/18:1) + H+ was found to be significantly decreased in the 
same region. Sphingolipid metabolism is essential for tissue homeostasis and 
regulates the synthesis of several bioactive lipids and second messengers that are 
critical in cellular signaling (Wymann and Schneiter, 2008). The sphingomyelinase–
driven catabolism of sphingolipids triggers the release and accumulation of Cer which 
are directly involved in neurodegenerative disorders and contribute to AD pathology 
(Han et al., 2011). Interestingly, the CB1 receptor-driven breakdown of SM with 
ceramide production has been previously described in glial cells independently of Gi/o 
protein activation, which indeed, was blocked by using the CB1 receptor antagonist 
SR141716A (reviewed in Guzmán et al., 2001b; Sanchez et al., 2001; Velasco et al., 
2005). Cer participate in cell differentiation, proliferation or apoptosis. The intracellular 
accumulation of Cer has been described in neurodegenerative disorders including AD, 
Parkinson‟s disease, epilepsy and ischemia. Thus, the upregulated levels of SM 
(d18:1/16:0) + K+ observed may be a consequence of the necessary basal forebrain 
remodeling following the immunotoxin-induced apoptosis of BFCN rather than being 
related to Ch metabolism or eCB signaling. Recent studies have found a depletion of 
SM (d18:1/16:0) in CSF and a reduction in acid sphingomyelinase activity together with 
reduced levels of amyloid β42 in AD patients (Fonteh et al., 2015). However, SM 
(d18:0/18:1) was found to be decreased in the NBM following the immunotoxin-induced 
lesion. The fact that CB1 receptor-mediated endocannabinoid signaling increases 
following the lesion allows us to speculate that CB1 receptor activation in the NBM 
could be stimulating the hydrolysis of this specific SM species. In samples from AD 
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patients, SM (d18:0/18:1) levels are increased in both the hippocampal gray matter and 
CSF, and positively correlate with the total CSF tau level, but negatively with the CSF 
amyloid β42 level (Mendis et al., 2016; Koal et al., 2015). The relationship between the 
observed regulation in SM species with previous findings which indicate a CB1-
receptor-mediated regulation of hippocampal endocannabinoid signaling in AD patients 
must be further explored (Manuel et al., 2014). Moreover, additional studies focused on 
the quantification of Cer in this lesion model will contribute to a better understanding of 
the link between BFCN degeneration, CB1 receptor-mediated endocannabinoid 
signaling and deregulation of specific SM species. In the meantime, the significance of 
the specific regulation of lipid species and their physiological role in the CNS remain 
elusive, but their lipid mapping by IMS in both normal and diseased human brain and in 
models of disease would help to clarify these questions (Martínez-Gardeazabal et al., 
2017; González de San Román et al., 2017). 
  
 Phosphatidylethanolamines 
 Interestingly, PE (14:1/20:4) and PE (40:4), both of which may be composed of 
a molecule of arachidonic acid (AA; 20:4), were found to be deregulated in the NBM, 
revealing a possible membrane phospholipid source for the synthesis of Ch since PE 
are considered as precursors for PC synthesis in the ACh synthetic pathway, as 
explained above (Blusztajn et al., 1987a). Moreover, PE have diverse cellular functions 
and are involved in autophagy (reviewed in Calzada et al., 2016). PE are also the main 
substrate for the synthesis of eCB. The AEA precursor, NAPE, which is produced from 
the transfer of an acyl group (e.g. AA) from membrane phospholipids (e.g. PC) to the 
N-position of a PE, is catalyzed by a Ca2+-dependent trans-acylase, which correlates 
with the biosynthesis of AEA in the CNS after depolarization (Di Marzo et al., 1994). 
Thus, PE (14:1/20:4) is decreased, whereas there is an increase in PE (40:4) in the 
NBM, and it is reasonable to hypothesize that these particular phospholipids could be 
used for the synthesis of eCB since the CB1 receptor-mediated signaling in this brain 
area is up-regulated, as demonstrated by autoradiographic studies, which may 
increase the demand for their membrane lipid precursors. Since eCB are not 
apparently stored in vesicles, the generation of pools of lipids for further synthesis of 
eCB is difficult to understand and one would expect to observe a reduction in any 
possible PE precursors for eCB synthetic processing, pointing to PE (14:1/20:4) as a 
plausible candidate. However, the increase in the relative density of a specific lipid 
such as PE (40:4) allows us to hypothesize that a reservoir is created by an unknown 
storing mechanism from which to further synthesize eCB. 
 
Discussion 
 
183 
 
Sulfatides 
 Finally, the changes observed in certain species of sulfatides following the loss 
of BFCN indicate a pathological link similar to that found in the brains of AD patients. 
Certainly, one of the most consistent lipid changes described in these patient´s brains 
is the decrease in sulfatides during the early stages of disease (Han et al., 2002; 
Cheng et al., 2013). 
 
 
Summary of findings in the in vivo model of NBM lesion  
  
The M2/M4 mAChR-mediated muscarinic neurotransmission coupled to Gi/o 
proteins is not modified in cortical projection areas from the lesioned NBM. However 
other authors using a similar animal model have described that M1 and M2 mAChR 
density was increased (Rossner et al., 1995b). The relationship between muscarinic 
neurotransmission and phospholipid metabolism has also previously been studied, 
showing that the stimulation of cortical synaptosomes by cholinergic agonists was able 
to increase PLD activity, which was also dependent on PKC activity involving PIP2 and 
DAG, which led to the accumulation of free Ch (Qian et al., 1989). The muscarinic 
signaling-induced PLD activity was antagonized by atropine (Dolezal and Tucek, 
1984). Furthermore, eCB signaling is enhanced in cortical regions and in the NBM of 
192IgG-saporin-infused rats, areas with a marked reduction in cholinergic innervation. 
The relative intensities of phospholipid species containing AA, such as PE (14:1/20:4), 
PE (40:4) and PC (36:4) + K+, are also modulated in these same areas, suggesting a 
metabolic link between cholinergic neurotransmission and the eCB system. In 
summary, it would appear that Gq-11 protein-coupled mAChR such as M1 and/or M3 
subtypes, may be key modulatory elements of the phospholipid-related regulation 
observed in this model. Detailed analysis of the different phospholipases activities 
mediated by mAChR (mainly M1 and/or M3 subtypes) in this lesion model will contribute 
to a better understanding of the underlying processes that could link the changes in 
lipid profile to the cholinergic-cannabinoid crosstalk. The 192IgG-saporin-induced 
modulation could be related to a compensatory mechanism for the loss of cortical ACh 
supply, or conversely, represent a pathological consequence of the massive death of 
BFCN in the NBM, regardless of muscarinic signaling. Several attempts to reduce the 
deficit of ACh in AD patients by the administration of cholinergic enhancers or 
precursors such as Ch or lecithin have failed, while treatments based on AChE 
inhibitors, phosphatidylserine, Ch alphoscerate and CDP-Ch have provided slight, but 
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noticeable benefits (reviewed in Amenta et al., 2001). Perhaps future treatments aimed 
at potentiating cholinergic neurotransmission should be based on the modulation of the 
complex enzymatic machinery, which so finely regulates lipid metabolism through 
mAChR-mediated signaling. In this context, the mAChR-driven eCB-mediated 
modulation of cholinergic neurotransmission at excitatory (Straiker and Mackie, 2007) 
and inhibitory synapses through the activation of CB1 receptors (Narushima et al., 
2007) is well known. Further research focused on muscarinic-eCB crosstalk may be 
useful for the discovery of innovative therapeutic treatments for neurodegenerative 
disorders.  
 
 
3xTg-AD mice   
 
The study of AD requires the use of well established models which include 
transgenic mice of AD (e.g., 3xTg-AD). Regarding the cholinergic neurotransmission, 
hippocampal and cortical cholinergic neuritic dystrophy, a decrease in the density of 
BFCN in the medial septum and deficits in the length of hippocampal cholinergic axons 
starting at 4 months, as well as a significant reduction in the number of ChAT-
immunoreactive neurons in the NBM together with a loss of cholinergic fibers in cortical 
and hippocampal areas have been previously described in 3xTg-AD mice (Perez et al., 
2011; Girão da Cruz et al., 2012; Orta-Salazar et al., 2014). This model recapitulates 
some classical histopathological markers of AD, leading to deficits in synaptic plasticity 
and impaired learning and memory (Oddo et al., 2003). Similarly to the changes found 
in AD patients, changes in CB1 receptors have recently been described in several brain 
areas of 3xTg-AD mice rendering this model a suitable tool for the study of the 
relationship between both cholinergic and eCB systems (Bedse et al., 2014; Manuel et 
al., 2016). 
 
Altered cannabinoid and muscarinic signaling is correlative to emotional 
learning and memory impairment in seven month-old 3xTg-AD mice 
 Changes in CB1 receptors have recently been described in several brain areas 
of 3xTg-AD mice which are similar to the changes found in the brains of AD patients, 
rendering this model suitable for the study of the neuronal correlates (Bedse et al., 
2014; Manuel et al., 2016). In the present study, we provide evidence of 
neuroanatomical and neurochemical modifications related to the eCB neuromodulatory 
system and muscarinic cholinergic signaling in the 3xTg-AD mice model, and of 
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behavioral modifications at the onset of disease (7 months of age), when cognitive 
impairment is clearly established and is concurrent with limbic system mediated 
symptoms. The results point to the eCB system as a key element controlling neuronal 
homeostasis as well as the limbic component of cognition. 
 The results of behavioral assessment during the passive avoidance test, one 
typically used to evaluate learning and memory under anxiogenic conditions, may also 
indicate the presence of fear and diminished motivation to explore as shown in a lesion 
rat model of AD (Babalola et al., 2012). 3xTg-AD mice had higher acquisition latency 
times than did controls. This is in agreement with the reduced exploratory activity and 
increased freezing behavior shown in the contextual fear-conditioning test, in the open 
field and in the passive avoidance test in this same transgenic mouse model of AD at 6 
months of age (Gimenez-Llort et al., 2007; España et al., 2010; Filali et al., 2012). In 
addition, anxiety, fear, agitation and phobias may help to create a state of confusion 
which contributes to other behavioral disorders observed in AD patients, including 
learning and memory impairment (Ferretti et al., 2001; Aso and Ferrer, 2014).  
 The eCB system has emerged as a promising target for the treatment of several 
neurodegenerative disorders and has received a good deal of attention in AD. In this 
study, we report specific changes in density and in activity of CB1 receptors, indicative 
of a potentiation of cannabinoid signaling in the BLA and an attenuation in the olfactory 
bulb and hippocampal dentate gyrus of transgenic mice. The specificity for CB1 
receptors was demonstrated by the anatomical pattern of distribution of [3H]CP55,940 
binding sites in brain, in comparison with that of spleen. [3H]CP55,940 binding in 3xTg-
AD and CB1
+/+ mice was blocked by SR141716A and totally absent in CB1
-/- mouse 
brain. Indeed, SR144528, a specific CB2 receptor antagonist, failed to block the binding 
in the brain but completely inhibited it in the spleen (where the CB2 subtype is 
predominant) of both CB1
+/+ and CB1
-/- mice. On the other hand, up-regulation of CB2 
receptors is reported to occur during neuroinflammation associated with 
neurodegenerative processes (Benito et al., 2003; Tolón et al., 2009; Schmöle et al., 
2015). Therefore, the absence of a CB2 receptor-mediated signal in the CNS of seven 
month-old 3xTg-AD mice, is in agreement with the lack of neuritic plaque-associated 
neuroinflammation at the onset of disease. Our results coincide with those of studies 
which report a significant increase in CB1 receptor density in BLA when only 
intracellular Aβ accumulation can be detected, and which may be related to the 
symptoms of fear and anxiety observed in these mice (España et al., 2010; Bedse et 
al., 2014). 
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Behavioral outcomes of 3xTg-AD mice after the subchronic administration of 
synthetic cannabinoids. Possible functional interplay with muscarinic cholinergic 
signaling 
 The present study examines for the first time the neurochemical effects of 
cannabinoid agonism in 3xTg-AD mice and their behavioral correlates in a learning and 
memory task, which may be relevant in terms of clinical interventions in humans at the 
onset of disease. The results provide evidence that CB1 receptor activation, following 
repeated cannabinoid administration, was able to decrease the acquisition latency 
times in 3xTg-AD mice to Non-Tg levels during the learning trial, which may be related 
to the CB1 receptor density desensitization recorded in the BLA. Stressing factors can 
result in a modulation of the endocannabinoid levels in the amygdala, and can also 
induce a subsequent CB1 receptor-mediated suppression of GABA release in the BLA 
(Jenniches et al., 2015; Di et al., 2016; Morena et al., 2016). Interestingly, we observed 
both a down-regulation of CB1 receptors and an attenuation of their functional coupling 
to Gi/o proteins induced by the subchronic administration of JZL-184, comparable to the 
results obtained in a previous study, but at different doses (Kinsey et al., 2013). 
Moreover, the administration of WIN55,212-2 (1 mg/kg), decreases the acquisition 
latency times without significantly changing CB1 receptor functionality in the BLA. Our 
results confirm previous findings which showed that JZL184 selectively increased brain 
2-AG and also indicated that the inhibition of MAGL could be promising as a way to 
indirectly potentiate the activation of CB1 or CB2 receptors (Busquets-Garcia et al., 
2011; Kinsey et al., 2011). In this context, the pharmacological blockade or genetic 
deletion of MAGL dramatically raises brain 2-AG levels, down-regulates CB1 receptor, 
and modulates synaptic plasticity, learning, memory and anxiety-like behavior (Pan et 
al., 2011). Accordingly, URB597, an AEA degrading enzyme inhibitor, induced CB1 
receptor-mediated anxiolytic effects in the elevated plus maze (Moise et al., 2008). 
Moreover, a recent study shows that the intra-BLA administration of both AEA and 2-
AG hydrolysis inhibitors is able to attenuate anxiety-like responses, which are 
dependent on deregulated levels of eCB in the amygdala (Morena et al., 2016). 
Conversely, chronic CB1 receptor blockade induced up-regulation of CB1 receptor 
expression, down-regulation in hippocampus, and modified anxiety-like behavior 
(Tambaro et al., 2013). 
 Depending on the specific location of CB1 receptors in inhibitory or excitatory 
neurons, the functional and physiological outcomes of this deregulated 
endocannabinoid signaling may be useful to understand the present results. In order to 
address this issue, immunochemical studies were performed and we found that in the 
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BLA, CB1 receptor are more frequently located in GABAergic than in glutamatergic 
compartments, even though they have previously been detected in both of them 
(Kodirov et al., 2009; Ruehle et al., 2013; Shonesy et al., 2014; Robinson et al., 2016). 
The CB1 receptors in BLA were located in the proximity of GAD65 (the enzyme 
glutamate decarboxylase; GAD, associated with inhibitory nerve termini) (Kash et al., 
1999). In addition, the detection of VGLUT3 (the third subtype of glutamate vesicular 
transporter) has been used to identify both excitatory presynaptic boutons and 
glutamatergic somatodendritic compartments (Herzog et al., 2004). Although CB1 
receptors are present in both GABAergic and glutamatergic cellular compartments in 
areas such as the hippocampus, their activity could be lower in the inhibitory terminals 
(Steindel et al., 2013). However, in the BLA, CB1 receptors are highly expressed in 
axon terminals of GABAergic neurons which modulate GABA release via a presynaptic 
mechanism (Katona et al., 2001). Some authors have related a long-lasting increase in 
anxiety-like behavior with a hyperactivity of BLA, as a consequence of a decrease in 
the inhibitory synaptic transmission (Almeida-Suhett et al., 2014). Thus, eCB-mediated 
suppression of inhibitory inputs to BLA neurons is involved in the cellular mechanism 
for stress-induced increases in anxiety-like behavior (Roozendaal et al., 2009). The 
genetic deletion of MAGL or GAD65 triggers an excitatory-inhibitory imbalance leading 
to increased anxiety-like responses (Imperatore et al., 2015; Müller et al., 2015). The 
glucocorticoid-induced suppression of inhibitory synaptic inputs to BLA principal 
neurons has recently been proposed as playing a pivotal role in the regulation of 
emotional disorders (Di et al., 2016). Globally, the present findings suggest that an up-
regulation of the eCB tone in areas such as the BLA alters the local excitatory–
inhibitory balance, and may be an underlying mechanism involved in the observed 
differences in cognitive behavior. Furthermore, a reversion to Non-Tg mice behavioral 
parameters was recorded after the attenuation of eCB signaling mediated by a 
pharmacological desensitization of CB1 receptors. We propose that there is a CB1 
receptor-induced enhancement of the excitatory drive in brain areas such as the BLA 
due to the suppression of inhibition mediated by up-regulated CB1 receptor signaling, 
which, by decreasing GABAergic neurotransmission, is an important component of the 
neurobiological mechanisms that control some cognitive deficits observed in 3xTg-AD 
mice (acquisition latency). 
 Moreover, the administration of WIN55,212-2 (1 mg/kg), but not JZL-184, was 
able to induce a significant increase in the activity mediated by mAChR in the BLA, 
revealing a possible interaction between both systems in limbic areas. This specific 
CB1 receptor-driven modulation of cholinergic neurotransmission in the amygdala could 
also be involved in the behavioral outcomes recorded with the passive avoidance test. 
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In addition, these results support those of previous studies in which the role of the BLA 
cholinergic system, via mAChR, in memory retrieval during fear-induced learning was 
described (Malin et al., 2006; Nazarinia et al., 2017). Further behavioral studies are 
necessary in order to understand the meaning of CB1 receptor-induced modulation of 
muscarinic control and its influence on acquisition latency, and to verify its validity as a 
possible indicator of anxiety, attention, agitation or states of confusion. 
Regarding memory, step-through latency clearly distinguished the cognitively 
impaired AD-phenotype of 3xTg-AD mice, in accordance with previous studies (Clinton 
et al., 2007; Filali et al., 2012). Thus, 40% of 3xTg-AD mice did not remember the 
aversive stimulus received, while all the Non-Tg control mice did. However, under the 
present experimental conditions, we cannot rule out the possibility that the differences 
found in acquisition, or even putatively in consolidation, may also contribute to the 
performance of step-through latency. The desensitization of CB1 receptors by means of 
subchronic administration of direct and indirect agonists failed to induce significant 
modifications in this variable. On the other hand, the analgesic effects of CB1 receptor 
activation are well known (Meng et al., 1998). Subsequently, the pain threshold of the 
foot-shock in the passive avoidance test may be increased (Abush and Akirav, 2010). 
Therefore, the subtle variations in step-through latencies recorded after cannabinoid 
administration could be biased by the cannabinoid-induced analgesia. Further 
behavioral analyses by means of non-aversive stimulus-based learning and memory 
tests will help to clarify this question since 3xTg-AD mice do not seem to differ from 
Non-Tg in terms of pain thresholds (Filali et al., 2012; Baeta-Corral et al., 2015). 
However, the limbic system which is involved in cholinergic neurotransmission may be 
controlling specifically the consolidation and extinction of aversive or traumatic 
memories (Vazdarjanova and McGaugh, 1999).  
3xTg-AD mice present deficits in cognition and synaptic plasticity associated 
with intraneuronal Aβ accumulation (Oddo et al., 2003). Muscarinic activation, through 
the M2 mAChR subtype, promotes a rise in AMPA receptor sensitivity to glutamate, 
which finally leads to the so-called „muscarinic long term potentiation‟ essential to 
explain hippocampal neuronal plasticity (Segal and Auerbach, 1997). Behavioral and 
neurochemical studies in M2
 mAChR knockout mice showed that the lack of receptors 
was accompanied by cognitive impairment in the passive avoidance test (Tzavara et 
al., 2003). The present immunofluorescence studies revealed the presynaptic 
localization of M2 mAChR in GABAergic terminals, presumably making contact with 
postsynaptic VGLUT3 immunoreactive pyramidal neurons in CA1-CA3. The present 
findings in 3xTg-AD mice are similar to those reported in rat brain, suggesting that ACh 
via M2 mAChR may reduce GABA release from presynaptic inhibitory terminals, 
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leading to increased activity in the dendritic region of pyramidal neurons (Levey et al., 
1995; Hájos et al., 1998). The significant reduction in choline acetyltransferase activity 
described in hippocampus from middle-aged 3xTg-AD mice, but not associated with 
the loss of cholinergic neurons, may be related to the observed decrease in mAChR 
functionality (Perez et al., 2011). We suggest that intraneuronal accumulation of Aβ, 
beginning at 4 months of age, may trigger an early deregulation of the hippocampal 
muscarinic neurotransmission at the onset of disease, as observed in seven month-old 
3xTg-AD mice, thereby contributing to the cognitive impairment observed in this model 
(Billings et al., 2005). Moreover, an excitatory/inhibitory imbalance mediated by a 
deregulated presynaptic muscarinic neurotransmission in the hippocampus may 
underlie the impaired synaptic plasticity, i.e., the neurobiological substrate for creating 
and maintaining new memories. 
 
In summary, we provide evidence that muscarinic and cannabinoid signaling is 
altered in seven month-old 3xTg-AD mice, showing a specific regional and neuronal 
distribution in vulnerable limbic areas at the onset of disease. CB1 receptor-mediated 
hyperactivity in some specific brain areas may have behavioral correlates that 
correspond with the restoration to control levels after direct and indirect 
pharmacological desensitization of CB1 receptors. Finally, decreased muscarinic 
neurotransmission may be involved in memory-related impairment in 3xTg-AD mice. 
We propose that CB1 receptor desensitization is a plausible strategy to palliate specific 
behavioral impairment associated with genetic variants of AD. 
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I. The specific removal of basal forebrain cholinergic neurons in organotypic cultures by 
the immunotoxin 192IgG-saporin leads to secondary cell damage in non-cholinergic 
cells. The same immunotoxin causes a dramatic loss of cortical cholinergic innervation 
in adult rats which is associated with deficits in learning and memory. Both ex vivo and 
in vivo models of basal forebrain cholinergic dysfunction are valid to identify therapeutic 
targets for the development of new pharmacological treatments aimed at restoring 
cholinergic neurotransmission. 
 
II. The loss of basal forebrain cholinergic neurons in the nucleus basalis magnocellularis 
of adult rats causes a reduction in both the density and activity of muscarinic receptors 
coupled to Gi/o proteins in the basal forebrain, but does not modify either of these 
parameters in cortical projections. M2 and M4 muscarinic receptors are not located in 
cortical presynaptic terminals which arise from basal forebrain cholinergic neurons. 
However, the increase in muscarinic neurotransmission recorded in the hippocampus 
could be interpreted as a compensatory mechanism. 
 
III. Basal forebrain cholinergic dysfunction does not modify CB1 receptor density which 
indicates the lack of CB1 receptors in cortical terminals arising from basal forebrain, but 
increases the endocannabinoid signaling together with a reduction of GABAergic 
terminals in cortical projections. The activation of cortical endocannabinoid signaling 
could be regulating the glutamatergic-GABAergic imbalance induced by the dramatic 
loss of cortical cholinergic input.  
 
IV. Different phosphatidylethanolamines and phosphatidylcholines containing arachidonic 
acid which, after the lesion, are regulated in the baso-cortical cholinergic pathway, 
might be precursors for de novo synthesis of both choline and endocannabinoids and 
may indicate the existence of a metabolic link between both systems in the CNS when 
there is basal forebrain cholinergic neurodegeneration. 
 
V. The triple transgenic mice model of AD (3xTg-AD) shows altered CB1 receptor and 
M2/M4 muscarinic receptor-mediated signaling associated with learning and memory 
deficits. The increased endocannabinoid tone recorded in 3xTg-AD mice mediates the 
hyperactivation of principal neurons in the basolateral amygdala which correlates with 
anxiety-like behavioral response.  
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VI. The subchronic administration of direct or indirect synthetic cannabinoids to 3xTg-AD 
mice leads to CB1 receptor desensitization, which normalizes anxiety-like behavior and 
restores local endocannabinoid signaling. These effects together with the potentiation 
of muscarinic cholinergic signaling in limbic areas may contribute to improve learning 
and memory. 
 
VII. In summary, the different experimental models used show that basal forebrain 
cholinergic dysfunction modulates the endocannabinoid system. Understanding the 
signaling mechanisms could lead to the discovery of innovative cannabinoid-based 
pharmacological approaches for the treatment of neurodegenerative disorders such as 
AD. 
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2-AG  2-Arachidonoylglycerol 
[3H] NMS  [3H]-N-methylscopolamine  
[3H] QNB   [3H]-quinuclidinyl benzilate 
3xTg-AD  Triple transgenic mice model 
5-HT  5-hydroxytryptamine receptor/serotonin receptor 
Δ9-THC  (--)-Δ9-tetrahydrocannabinol 
AA   Arachidonic acid 
ABHD12  Alpha/beta-hydrolase domain containing 12 
ABHD6  Alpha/beta-hydrolase domain containing 6  
Acetyl-CoA Acetyl coenzyme A 
ACh  Acetylcholine 
AChE  Acetylcholinesterase 
aCSF  Artificial cerebrospinal fluid 
AD   Alzheimer´s disease 
AEA  Anandamide 
AMPA  α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor 
APP  Amyloid precursor protein 
APPSwe  Swedish mutation in amyloid precursor protein  
AU   Arbitrary units 
Aβ   Amyloid-beta 
BDNF  Brain-derived neurotrophic factor 
BFCN  Basal forebrain cholinergic neurons 
BSA  Bovine serum albumin 
cAMP  Cyclic adenosine monophosphate  
CB1 receptor Subtype one of cannabinoid receptors 
CB1
-/-  CB1 receptor knockout mice 
CB1
+/+  CB1 receptor wild type mice 
CB2 receptor Subtype two of cannabinoid receptors 
CCD  Charge-coupled device 
Cer  Ceramides 
Ch   Choline 
ChAT  Choline acetyltransferase 
CNS  Central nervous system 
CREB  cAMP response element-binding 
CSF  Cerebrospinal fluid 
DAG  Diacylglycerol 
DAGL  Diacylglycerol lipase 
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DIV  Days in vitro 
DSE  Depolarization-Induced suppression of excitation 
DSI  Depolarization-Induced suppression of Inhibition 
DTT  DL-dithiothreitol 
eCB  Endocannabinoid 
FAAH  Fatty acid amide hydrolase 
FITC  Fluorescein 
GABA  Gamma aminobutyric acid 
GAD65  Glutamic acid decarboxylase 65kDa 
GAD67  Glutamic acid decarboxylase 67kDa 
GDP  Guanosine 5′-diphosphate 
GFAP  Glial fibrilar acidic protein 
GPCR  G protein-coupled receptor 
GPR55  G Protein-coupled receptor 55 
GTPγS  Guanosine 5'-O-(3-thiotriphosphate) 
HBSS  Hanks‟ balanced salt solution 
HC-3  Hemicholinium-3  
HDB  Horizontal diagonal band of Broca 
HOC  Hemibrain organotypic cultures 
HRP  Horseradish peroxidase 
I.c.v.  Intracerebroventricular 
IMS  Imaging mass spectrometry 
IP3   Inositol trisphosphate 
Iso-OMPA  Tetraisopropylpyrophosphoramide 
LDTg  Laterodorsal tegmental area 
LTD  Long-term depression 
mAChR  Muscarinic acetylcholine receptor 
MAGL  Monoacylglycerol lipase 
MALDI  Matrix assisted laser desorption ionization 
MAPK  Mitogen-activated protein kinase 
MBT  2-mercaptobenzothiazole 
MCI  Mild cognitive impairment 
mGluR  Metabotropic glutamate receptors 
MMSE  Mini-mental state examination 
mNGF  Mature nerve growth factor 
MRI  Magnetic resonance imaging 
MS  Medial septal nucleus/medial septum 
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nAChR  Nicotinic acetylcholine receptors 
NAPE  N-acyl-phosphatidylethanolamines 
NArPE  N-arachidonoyl-phosphatidylethanolamine 
NB   Neurobasal medium 
NBM  Nucleus basalis magnocellularis 
nbM  Nucleus basalis of Meynert 
NGF  Nerve growth factor 
NGS  Normal goat serum 
NHS  Normal horse serum 
NMDA  N-methyl D-aspartate 
Non-Tg  Non transgenic mice 
O.D.  Optical density 
P7   7-day-old postnatal rats 
P75NTR  Low affinity nerve-growth factor receptor 
PB   Phosphate buffer 
PBS  Phosphate-buffered saline 
PC   Phosphatidylcholine 
PE   Phosphatidylethanolamine 
PET  Positron emission tomography 
PI   Propidium iodide 
PI3K  Phosphatidylinositol-4,5-bisphosphate 3-kinase 
PIP2  Phosphatidylinositol 4,5-bisphosphate 
PKA  Protein kinase A 
PKC  Protein kinase C 
PLA1  Phospholipase A1 
PLA2  Phospholipase A2 
PLC  Phospholipase C 
PLD  Phospholipase D 
Ppi   Pixels per inch 
PPTg  Pedunculopontine tegmental area 
ProNGF  Precursor nerve growth factor 
PSIM146V M 146V mutation in presenilin1  
RT-PCR  Reverse transcription polymerase chain reaction 
SAP  192IgG-saporin-treated group 
S.c.  Subcutaneous 
SDHACU  Sodium dependent-high affinity choline uptake 
ST   Sulfatides 
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SM  Sphingomyelins 
STD  Short-term depression 
TauP301L  P301L mutation in tau protein 
TBS  Tris-buffered saline 
T.E.  Tissue equivalent 
TIC  Total ion current 
TM   Transmembrane  
TNB  Tris-NaCl-Tween blocking buffer 
TNT  Tris-NaCl-Tween buffer 
TrkA  Tyrosine kinase 
VAChT  Vesicular Acetylcholine transporter 
VDB  Vertical diagonal band of Broca 
VGLUT3  Vesicular glutamate transporter subtype 3 
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Glossary 
2-AG: 2-arachidonoylglycerol; AD: Alzheimer´s disease; BFCN: Basal forebrain 
cholinergic neurons; CB1 receptor: Subtype 1 of cannabinoid receptors; CB2 receptor: 
Subtype 2 of cannabinoid receptors; DIV: Days in vitro; HDB: Horizontal diagonal band 
of Broca; MS: Medial septum; NBM: Nucleus basalis magnocellularis; P7: 7-day-old 
postnatal rats; P75NTR: Low-affinity nerve growth factor receptor p75NTR; PI: Propidium 
iodide; SAP: 192IgG-saporin treated cultures; VDB: Vertical diagonal band of Broca.  
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Abstract 
 
In the present study hemibrain organotypic cultures containing basal forebrain 
cholinergic nuclei were treated with the immunotoxin 192IgG-saporin, which specifically 
eliminates basal forebrain cholinergic neurons expressing the low-affinity nerve growth 
factor receptor p75NTR in a dose and time of exposure-dependent manner. The most 
effective dose of immunotoxin, which eliminated approximately 50% (EC50) of basal 
forebrain cholinergic neurons, was set to 100 ng/ml. The effects of CB1 receptor 
activation in the ex vivo model of basal forebrain cholinergic dysfunction were 
evaluated by using the synthetic cannabinoid agonist WIN55,212-2, that at nanomolar 
concentrations was able to induce protective effects on secondary cells in the medial 
septum and the nucleus basalis magnocellularis. The CB1 receptor antagonist AM251 
blocked the protective effects mediated by the cannabinoid agonist. Present findings 
support the protective role of cannabinoid system through the specific activation of CB1 
receptors during specific cholinergic damage. 
Keywords: 192IgG-saporin, cholinergic, cannabinoid, organotypic. 
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Introduction 
 
 One of the main common pathological features underlying the course of 
neurodegenerative diseases is the neuronal damage and glial proliferation. In 
Alzheimer´s disease (AD), a specific vulnerability of basal forebrain cholinergic neurons 
(BFCN) has been described (Davies and Maloney, 1976). This vulnerability contributes 
to the progressive loss of memory and thinking abilities which led to the “cholinergic 
hypothesis of geriatric memory dysfunction” proposed by Bartus et al. (1982). The loss 
of basal forebrain cholinergic innervation may indirectly trigger an excitatory/inhibitory 
imbalance further contributing to secondary neuronal or cell damage. This 
phenomenon is the result of neurotoxic and neuroprotective events which involves 
complex interactions between neurons and activated glial cells (Kreutz et al., 2007). 
 192IgG-saporin consists of a monoclonal antibody (192IgG), which is armed 
with a ribosome inactivating protein (saporin) and specifically directed to the low-affinity 
nerve growth factor receptor (p75NTR). P75NTR is abundantly and specifically expressed 
on BFCN in the basal forebrain during the whole life of the rodents (Springer et al., 
1987; Woolf et al., 1989). Following receptor binding and internalization, saporin 
enzymatically inactivates the large ribosomal subunit, thereby blocking protein 
synthesis and ultimately resulting in BFCN death by apoptosis (Wrenn and Wiley, 
1998).The basal forebrain cholinergic degeneration partially mimics the cholinergic 
dysfunction described in AD. The loss of BFCN in rodents has been associated with 
deregulated levels of cortical and hippocampal glutamate and GABA receptors as well 
as a reduction in the GABA synthesizing enzyme levels, probably leading to an excess 
of glutamatergic neurotransmission and revealing secondary alterations due to the loss 
of basal forebrain cholinergic inputs. (Rossner et al.,1995a; reviewed in Rossner, 1997; 
Lee et al., 2016)  
 The endocannabinoid signaling, which is altered in AD (Manuel et al., 2014; 
Mulder et al., 2011), fine tunes the neuronal transmission at both excitatory (Kreitzer 
and Regehr, 2001), and inhibitory synapses (Wilson and Nicoll, 2001) leading to a 
transient suppression of excitatory or inhibitory transmission by a presynaptic 
mechanism mediated by the subtype 1 of cannabinoid receptors (CB1 receptor). 
Moreover, pharmacological and histological evidences support the endocannabinoid-
driven modulation of cholinergic neurotransmission through CB1 receptor activation 
(Gifford et al., 1996). The activation of the endocannabinoid system has also been 
associated with neuroprotective effects in vitro (Skaper et al., 1996), in vivo (van der 
Stelt et al., 2001a, b) and ex vivo (Kreutz et al., 2007; Koch et al., 2011a, b). The 
neurochemical mechanisms involve the activation of CB1 but also CB2 receptors mainly 
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in glial cells. The ex vivo model of organotypic culture comprises functional cellular 
networks involving neurons and glial cells (Hailer et al., 2001). This type of tissue 
culture allows to induce specific neuronal damage with toxins but also to evaluate the 
effects of pharmacological treatments. In the present study, the role of CB1 receptor 
activation has been analyzed in the ex vivo model of 192IgG-saporin-induced BFCN 
dysfunctionin hemibrain organotypic cultures of 7-day-old postnatal male Sprague-
Dawley rats (P7). The aim is to further understand the crosstalk between the 
endocannabinoid and cholinergic systems in the Alzheimer's disease. 
 
 
Experimental procedures 
 
Animals 
 P7 (n = 25) weighing 14-20 g at the onset of the experiments were used. Every 
effort was made to minimize animal suffering and to use the minimum number of 
animals. All procedures were performed in accordance with European animal research 
laws (Directive 2010/63/EU) and the Spanish National Guidelines for Animal 
Experimentation (RD 53/2013, Law 32/2007). Experimental protocols were approved 
by the Local Ethical Committee for Animal Research of the University of the Basque 
Country (CEEA 388/2014). 
 
Fixed tissue preparation 
 Two representative P7 rats, were anesthetized with ketamine/xylazine (90/10 
mg/kg; i.p.) and transcardially perfused with 0.1 M phosphate buffer (PB), 0.5% 
heparinized (37ºC, pH 7.4) followed by 4% paraformaldehyde and 3% picric acid in 
0.1M PB (4ºC) (10 ml/10 g b.w.). Their brains were subsequently removed and post-
fixed in the same fixative solution for 90 min at 4ºC, followed by immersion in a 
cryoprotective solution of 20% sucrose in PB during 8h at 4ºC. Then the tissue was 
frozen by immersion in isopentane and kept at -80ºC. The brains were coronally cut 
into 10 µm slices containing the basal forebrain cholinergic neurons (BFCN) from the 
different nuclei of the basal forebrain cholinergic system; Ch1 or medial septum (MS); 
Ch2 or vertical diagonal band of Broca (VDB); Ch3 or horizontal diagonal band of 
Broca (HDB) and Ch4 or nucleus basalis magnocellularis (NBM) according to the 
classification proposed by Mesulam et al. (1983) using a Microm HM550 cryostat 
(Thermo Scientific) equipped with a freezing-sliding microtome at -25ºC and mounted 
onto gelatin-coated slides and finally stored at -25ºC until used.  
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Hemibrain organotypic cultures 
 To prepare hemibrain organotypic cultures, P7 rats were sacrificed by 
decapitation and their brains were quickly dissected under aseptic conditions inside a 
laminar flow cabinet (TELSTAR, BV-30/70). After removal of the olfactory bulbs and 
the most caudal part of the cerebellum, the brains were placed in minimal essential 
Dulbecco´s Modified Eagle Medium (DMEM, Sigma-Aldrich) supplemented with 0.1% 
(v/v) antibiotic/antimycotic (Gibco) at 4ºC and incubated according to the method 
proposed by Stoppini et al. (1991). Briefly, the brains were vertically positioned resting 
on the cerebellum by means of cyanocrylate on a teflon stage. These preparations 
were rostro-caudally cut into coronal 300 µm-thick vibrosections using a sliding 
vibratome (Leica VT 1,000 S, Leica Microsystems AG, Wetzlar, Germany). 
Approximately, 10 hemibrain vibrosections containing the MS-VDB subregions and 
additional 10 vibrosections containing the HDB-NBM were obtained from each brain, 
which were immediately transferred into cell culture inserts (3 vibrosections per insert) 
(PIC50ORG, Millipore), fitted with a membrane of 0.4 µm pore size. The hemibrain 
organotypic cultures were then placed in 6-well culture dishes (Falcon, BD Biosciences 
Discovery Labware, Bedford, MA) that contained 1 ml culture medium per well. The 
culture medium consisted of 49% (v/v) Neurobasal Medium (NB, Sigma-Aldrich), 24% 
(v/v) Hanks‟ Balanced Salt Solution (HBSS, Gibco), 24% (v/v) Normal Horse Serum 
(NHS, Gibco), 1% (v/v) D-glucose, 0.5% glutamine (Sigma-Aldrich), 0.5% B27 
supplement serum free (Gibco) and 1% antibiotic/antimycotic. The culture dishes were 
incubated at 37ºC in a fully humidified atmosphere supplemented with 5% CO2 and the 
cell culture medium was replaced by fresh medium depending on the treatment 
protocol but typically, the second or third day. 
 
Immunotoxin, drugs and vehicle  
 192IgG-saporin (batch 2441969) was acquired from Millipore (Temecula, CA, 
USA) and dissolved directly in culture medium immediately prior to the treatment. R-
(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl) methyl]pyrrolo [1,2,3-de]-1,4-benzoxazinyl]-
(1-naphthalenyl)methanone mesylate (WIN55,212-2, from Sigma-Aldrich, St Louis, 
MO, USA) and 1-(2,4-Dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-(piperidin-1-yl)-1H-
pyrazole-3-carboxamide (AM251, from Tocris, Bristol, UK) were dissolved in pure 
ethanol and stored at -20ºC until use.  
 
192IgG-saporin (SAP) treatment schedules 
 [1] Nonlesioned hemibrain organotypic cultures (n = 6) were kept in culture 
medium for eight days in vitro (DIV) without any treatment and served as controls. 
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 [2] At day five of culture in vitro, the hemibrain organotypic cultures (n = 4-5 per 
condition) were incubated with 192IgG-saporin (50-200 ng/ml) during three DIV. 
 [3] At day two of culture in vitro, the hemibrain organotypic cultures (n = 4-5 per 
condition) were incubated with 192IgG-saporin (50-200 ng/ml) during six DIV. 
 [4] At day two and five of culture in vitro, the hemibrain organotypic cultures (n = 
4-5 per condition) were incubated with 192IgG-saporin (100 or 200 ng/ml) during six 
DIV. 
 
Cannabinoid treatment schedules 
 Vehicle. Nonlesioned hemibrain organotypic cultures (n = 6 including the SM + 
6 including the NBM) were kept in culture medium for eight DIV without any treatment 
and served as controls. At 2 and 5 DIV, the organotypic cultures were treated with the 
vehicle ethanol. The maximal final solvent ethanol concentration in culture medium was 
set at 0.01% (v/v), according to previous reports (Koch et al., 2011a). 
 Agonist. At day two and five of culture in vitro, hemibrain organotypic cultures 
(n = 5 including the SM + 5 including the NBM) were incubated with the cannabinoid 
agonist WIN55,212,2 (10 nM or 1 nM) during six DIV. 
 192IgG-saporin. At day two and five of culture in vitro, hemibrain organotypic 
cultures (n = 7 including the SM + 7 including the NBM) were incubated with the 
immunotoxin 192IgG-saporin (100 ng/ml) during six DIV. 
 Agonist + 192IgG-saporin. At day two and five of culture in vitro, hemibrain 
organotypic cultures (n = 6 including the SM + 6 including the NBM) were treated with 
the cannabinoid agonist WIN55,212,2 (10 nM or 1 nM) during six DIV, 2h prior the 
addition of the immunotoxin 192IgG-saporin (100 ng/ml). 
 Antagonist + agonist + 192IgG-saporin. At day two and five of culture in vitro, 
hemibrain organotypic cultures (n = 5 including the SM + 5 including the NBM) were 
preincubated with the CB1 receptor antagonist AM251 (1 µM) immediately prior to the 
treatment with the cannabinoid agonist WIN55,212,2 (10 nM or 1 nM). 2h later the 
immunotoxin 192IgG-saporin was added (100 ng/ml) to the culture medium during six 
DIV. 
 Cell death marker. At day eight of culture in vitro, hemibrain organotypic 
cultures were incubated in the presence of 5 µg/ml of propidium iodide (PI) for 2 h prior 
to fixation. Uptake of PI stains the nuclei of degenerating cells intensely red and its use 
for identifying degenerating cells in CNS organotypic cultures has been previously 
established (Pozzo Miller et al., 1994; Dehghani et al., 2003; Koch et al., 2011a). 
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Immunohistochemical studies 
 After the different treatments, the hemibrain organotypic cultures were 
processed for the immunohistochemical localization of BFCN.  Briefly, they were gently 
and extensively rinsed with 0.9% saline solution (37ºC) followed by immersion in 4% 
paraformaldehyde and 3% picric acid in 0.1M PB (4ºC) for 1h. Then, the fixed 
vibroslices were extensively rinsed in 0.1M PB (pH 7.4) and simultaneously blocked 
and permeabilized with 4% normal goat serum (NGS) in 0.6% Triton X-100 in PBS (0.1 
M, pH 7.4) for 2 h at 4ºC. The incubation was performed in free floating at 4ºC (48 h) 
with rabbit anti p75NTR primary antibody, diluted to [1:500] in 0.6% Triton X-100 in PBS 
with 5% BSA. The primary antibody was then revealed by incubation for 30 min at 37ºC 
in the darkness with Alexa488-labeled donkey anti-rabbit secondary antibody diluted to 
[1:250] in Triton X-100 (0.6%) in PBS. Then, were washed for 30 min by immersion in 
PBS and incubated with Hoechst 33258 for 15 min at room temperature. Finally, slices 
were extensively rinsed with PBS and mounted with p-phenylendiamine-glycerol 
(0.1%) in PBS for immunofluorescence. 
 Fixed 10 µm slices were extensively rinsed in 0.1M PB (pH 7.4), simultaneously 
blocked and permeabilized with 4% NGS in 0.3% Triton X-100 in PBS (0.1 M, pH 7.4) 
for 2 h at 4ºC in PBS with 5% BSA and incubated with rabbit anti p75NTR primary 
overnight diluted as previously mentioned. The rest of the process was carried out in a 
similar way as for the hemibrain organotypic cultures.  
 
Quantification 
 200-fold magnification photomicrographs of the Ch1-Ch4 nuclei were acquired 
by means of an Axioskop 2 Plus microscope (Zeiss) equipped with a CCD imaging 
camera (SPOT Flex Shifting Pixel). Both p75NTR immunoreactive BFCN and PI positive 
cells were counted and the total number (N) in the whole image was obtained. The 
population of p75NTR immunoreactive BFCN or PI stained cells was expressed as 
N/mm2.   
 
Statistical analyses 
 The average number of BFCN density and PI positive stained cells was 
calculated for each experimental group. Then, data were statistically analyzed by 
means of one-way analysis of variance (ANOVA) to determine whether the effect of the 
different concentrations of 192IgG-saporin in each area or the effect of the cannabinoid 
treatment on the density of p75NTR immunoreactive BFCN or PI stained cells. If 
significant differences were detected, the one-way ANOVA test was followed by 
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Bonferroni´s post hoc test for multiple comparisons. Data are means ± SEM and the 
statistical significance threshold was set at p < 0.05. 
 
 
Results 
P75NTR immunostaining of BFCN in the basal forebrain cholinergic system of P7 rats 
 Prior to the use of the 192IgG-saporin to mimic an ex vivo model of cholinergic 
dysfunction, it was important to determine the presence of BFCN expressing the 
immunotoxin target p75NTR, in P7 rats. The immunofluorescence studies carried out in 
the basal forebrain cholinergic system from P7 rats revealed the presence of a high 
density of BFCN expressing p75NTR in the different nuclei analyzed (Ch1-Ch4). The 
BFCN perikarya were intensely stained showing the typically somatodendritic 
distribution of p75NTR. The BFCN are continuously distributed in partially discrete 
populations along the rostrocaudal axis in adult rodents as well as in human and non-
human primates. According to this particular distribution of the BFCN, the Ch1 or the 
MS and the Ch2 or the VDB were first analyzed in P7 rats. The immunoreactive BFCN 
from the MS and VDB were clearly distinguished from the surrounding cells by showing 
big-size but moderate Hoechst-staining nuclei and were distributed along the midline 
(Figure 1A) extending ventrally to the vertical limb of the VDB, (Figure 1B), which 
revealed a continuum of p75NTR positive BFCN located within Ch1 and Ch2. The BFCN 
from the HDB or Ch3 (Figure 1C) were distributed caudally to VDB and extended 
ventrally to the NBM or Ch4 (Figure 1D). The BFCN of these nuclei displayed similar 
staining patterns to those previously mentioned, including big but moderately stained 
nuclei, described for the MS and VDB. It should also be emphasized that those BFCN 
from the NBM showed the biggest size and the most extensive dendritic arborization 
among all BFCN. 
 
192IgG-saporin-induced BFCN death in hemibrain organotypic cultures 
 The application of different doses of 192IgG-saporin to hemibrain organotypic 
cultures containing the basal forebrain cholinergic system was able to induce specific 
reductions of BFCN in a dose-dependent manner according to the different assayed 
treatments (Figure 2). Increasing concentrations of 192IgG-saporin (50-200 ng/ml) 
were administered at day five of culture in vitro, and let the toxin do its effect during 
another three days in vitro (DIV). The effective concentration of immunotoxin, which 
eliminated approximately 50% of BFCN, was set around 100 ng/ml, leading to a 
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reduction of BFCN densities of up to 36% in the MS, 55% in HDB, 42% in VDB and 
35% in the NBM. The highest concentrations of 192IgG-saporin (200 ng/ml) triggered a 
reduction of 58% in the number of p75NTR positive cells/mm2 in the MS, 64% in the 
HDB, 61% in the VDB and 72% in the NBM (Figure 2 A). In another set of experiments 
the schedule was modified and the 192IgG-saporin was administered at day two of 
culture, and let it act in the tissue during six additional DIV. The purpose was to 
evaluate more initial effects of the toxin for a longer period. It was observed a reduction 
of BFCN densities of up to 65% in the MS, 55% in HDB, 60% in VDB and 65% in the 
NBM (Figure 3 A). Interestingly, the BFCN reduction induced by 100 ng/ml of 
immunotoxin during 6 DIV was comparable to that observed with the highest dose (200 
ng/ml) during three DIV which demonstrated not only a 192IgG-saporin-induced BFCN 
death in a dose-dependent manner, but also a dependence on the time of exposure to 
the immunotoxin. The p75NTR-immunoreactivity showed the presence of a great deal of 
debris and a significant atrophy related to smaller somatic size and reduced dendritic 
arborisation after the application of 192IgG-saporin (Figure 3 B). Furthermore, the PI 
uptake, indicative of compromised cell viability, led to dramatic levels of cell death 
(Figure 4) in a dose dependent manner including BFCN and non-cholinergic cells. 
Finally, the double application of 100 ng/ml of 192IgG-saporin at days two and five of 
culture in vitro during 6 DIV led to comparable levels of BFCN reduction to those 
observed with the single application at day two of culture in vitro. However, the double 
application of 200 ng/ml of immunotoxin led to an almost total reduction of BFCN 
density accompanied by a massive cell death as revealed by the almost lack of p75NTR 
immunoreactivity and the intensely PI staining recorded in the different cholinergic 
nuclei of the basal forebrain. 
 
WIN55,212-2 treatment in 192IgG-saporin-lesioned hemibrain organotypic cultures 
 
P75NTR immunoreactive BFCN quantification  
 The pharmacological treatment of hemibrain organotypic cultures with the 
CB1/CB2 receptor cannabinoid synthetic agonist WIN55,212-2 or ethanol used as 
vehicle did not exert any effect on the viability of the cultures as well as on the density 
of BFCN (Figure 5 A).The application of 100 ng/ml of 192IgG-saporin at days two and 
five of culture in vitro during six DIV led to a statistically significant decrease in the 
density of BFCN (approximately up to 60%) in both the MS (vehicle 64 ± 7.8 
BFCN/mm2 vs SAP 26 ± 4.2 BFCN/mm2; p < 0.01) and NBM (vehicle 64 ± 3.8 
BFCN/mm2 vs SAP 26 ± 6.7 BFCN/mm2; p < 0.01) (Figure 5 A). The pre-treatment of 
hemibrain organotypic cultures with either 1 nM or 10 nM of WIN55,212-2, 2h prior the 
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application of 192IgG-saporin, did not trigger any relevant effect on the viability and 
density of BFCN but induced a modest although not statistically significant attenuation 
of BFCN death in the MS (1 nM WIN55,212-2 44 ± 4.2 BFCN/mm2 and 10 nM 
WIN55,212-2 43 ± 7.4 BFCN/mm2) and NBM (1 nM WIN55,212-2 31.56 ± 4.8 
BFCN/mm2 and 10 nM WIN55,212-2 40 ± 2.9 BFCN/mm2) (Figure 5 A). This effect was 
specifically driven through the activation of CB1 receptors since it was completely 
abolished by the specific blocking of CB1 receptors by means of the receptor antagonist 
AM251, leading to immunotoxin-induced levels of BFCN (Figure 5 A-C). The loss of 
BFCN was revealed by the absence of well-defined magnocellular neuronal bodies as 
well as by the presence of a great deal of p75NTR-immunoreactive neuronal debris 
(Figure 5 D). 
 
PI positive cells quantification  
 The PI uptake was also measured and the cell death quantified in the MS, NBM 
and cortex. The pharmacological treatment of the hemibrain organotypic cultures with 
the CB1/CB2 receptor synthetic cannabinoid agonist WIN55,212-2 or ethanol did not 
exert any effect on the viability of the cultures as well as on the density of PI positive 
cells (Figure 6 A). The application of 100 ng/ml of 192IgG-saporin at days two and five 
of culture in vitro during six DIV led to a statistically significant increase in the density of 
PI stained cells (approximately up to 300%) in the MS (vehicle 16.76 ± 2.3 cells/mm2 vs 
SAP 70.26 ± 7.7 cells/mm2; p < 0.001), NBM (14 ± 2.3 cells/mm2 vs SAP 59 ± 7.5 
cells/mm2; p < 0.001) and cortex (18 ± 3.8 cells/mm2 vs SAP 61.63 ± 8 cells/mm2; p < 
0.001) (Figure 6 A). The pre-treatment of hemibrain organotypic cultures with either 1 
nM or 10 nM of WIN55,212-2, 2h prior the application of 192IgG-saporin, induced 
protective effects on cell viability in the MS and in the NBM but no effects were 
observed in the cortex. A statistically significant decrease of cell death was observed 
as compared with 192IgG-saporin-treated hemibrain organotypic cultures in the MS (1 
nM WIN55,212-2 38 ± 4.2 PI cells/mm2 and 10 nM WIN55,212-2 39 ± 2.2 PI cells/mm2; 
p < 0.01 vs SAP), in the NBM (1 nM WIN55,212-2 33 ± 4.9 PI cells/mm2; p < 0.05 vs 
SAP and 10 nM WIN55,212-2 41 ± 2.8 PI cells/mm2; p < 0.01 vs SAP) (Figure 6 A). The 
specific CB1 receptor antagonist AM251 was able to block the protective effects elicited 
by WIN55,212-2 leading to cell death levels similar to those observed in those 
hemibrain organotypic cultures treated with the immunotoxin (Figure 6 A-C). 
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Discussion 
 Individual immunotoxins are designed in neuroscience research to eliminate 
specific cells or neuronal populations after binding to specific surface antigens. We 
have used 192IgG-saporin to specifically eliminate BFCN expressing p75NTR in 
hemibrain organotypic cultures from P7 rats. The immunotoxin-mediated depletion of 
BFCN in adult rats has been extensively described, but was first reported in the early 
90s (Wiley et al., 1991). When 192IgG-saporin is administered to adult rats it induces a 
massive and specific loss of BFCN. However, the levels of expression of p75NTR, as 
well as the cells expressing this receptor, vary during brain development and increase 
following neural injury (Ibañez and Simi, 2012). We first checked the anatomical 
distribution of this p75NTR receptor in the basal forebrain cholinergic system of formalin-
fixed P7 rats, prior to the application of the immunotoxin to hemibrain organotypic 
cultures obtained from animals of exactly the same age. The immunofluorescence 
studies clearly demonstrated the presence of p75NTR in the different nuclei of the basal 
forebrain cholinergic system, including the MS, VDB, HDB and NBM, which expressed 
the highest levels of p75NTR immunoreactivity, consistent with the patterns of 
expression in the adult brain (Kiss et al., 1988; Woolf et al., 1989). The process for 
obtaining and further culturing brain organotypic cultures causes a massive lesion and 
damages to the integrity of the brain tissue, which could modulate the expression of 
p75NTR, as suggested by Ibañez and Simi (2012), as well as the proliferation of glial 
cells surrounding the whole slice culture (del Rio et al., 1991). The application of 
different concentrations of 192IgG-saporin to hemibrain organotypic cultures resulted in 
a significant loss of BFCN in a dose and time-dependent manner. It is well known that 
p75NTR mediates the retrograde transport of neurotrophins, and in a similar way 
contributes to the movement of the monoclonal antibody coupled to saporin from axon 
terminals. This process explains the loss of BFCN following the uptake of 192IgG-
saporin when it is administered by intracerebroventricular (i.c.v.) infusion in vivo 
(Schweitzer, 1987; Heckers et al., 1994). As the hemibrain organotypic cultures were 
obtained in the coronal plane and BFCN display a rostrocaudal distribution pattern of 
axonal branching travelling in the sagittal plate, it is reasonable to assume that the 
anterior, the medial and the lateral basal forebrain cholinergic pathways described in 
rodent (Kristt et al., 1985) and conserved in human brain (Selden et al., 1998), are 
transected. Therefore, the only way for the internalization of 192IgG-saporin in 
hemibrain organotypic cultures is through p75NTR located in the somatodendritic 
compartment. This process also explains how 192IgG-saporin is uptaken when the 
immunotoxin is directly infused in vivo into the basal forebrain (intraparenchymal). 
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 A secondary neuronal or cellular damage critically mediates the future fate of 
the neurons and cells which survive the initial lesion (Koch et al., 2011b). The present 
results suggest that a single daily in vitro application of increasing concentrations of 
192IgG-saporin for three DIV begining on day five of in vitro culture triggers a partial 
loss of BFCN, which leads to secondary cellular damage. This secondary cell damage 
is further demonstrated by the increased levels of propidium iodide (PI) uptake when 
hemibrain organotypic cultures are treated on day two of the in vitro culture for 6 DIV. 
PI has previously been established as a marker that identifies degenerating cells in 
hemibrain organotypic cultures (Pozzo Miller et al., 1994; Dehghani et al., 2003). The 
density of PI positive cells is significantly higher than the values of p75NTR 
immunoreactive BFCN in organotypic cultures treated with 192IgG-saporin, providing 
further support of secondary neuronal or glial cell damage as a consequence of the 
initial BFCN lesion. A double application of the immunotoxin on days two and five of 
the in vitro culture was assayed to avoid the washout of the toxin when the culture 
medium was replaced, and showed more reproducible effects. The concentration of 
immunotoxin that was able to eliminate approximately 50%-60% of BFCN (EC50) was 
selected for further assays aimed at evaluating the effects of endocannabinoid system 
activation in this ex vivo model of AD. 
 The in vivo administration of 192IgG-saporin to adult rats triggers secondary 
alterations in different neurotransmitter systems such as a deregulation of the "on/off" 
glutamatergic/GABAergic signaling. Excitotoxicity could be one of the consequences 
together with cortical and hippocampal reorganization in an attempt to compensate for 
the reduced cholinergic presynaptic input (Rossner et al., 1995a; reviewed in Rossner, 
1997; Conner et al., 2003; Lee et al., 2016; Jeong da et al., 2016). More evidence of 
secondary neuronal or cellular damage is provided by the activation of microglia 
(Rossner et al., 1995d). Furthermore, different authors have reported findings which 
range from changes in dendritic morphology (Harmon and Wellman, 2003) to 
impairment of neuronal plasticity (Wellman and Sengelaub, 1991) and a negative 
impact on the adult neurogenic processes (Cooper-Kuhn et al., 2004). The 
consequences of the partial removal of BFCN in hemibrain organotypic cultures treated 
with the immunotoxin need to be evaluated and compared with in vivo administration. 
However, this model allows us to initiate the pharmacological evaluation of compounds 
that could ameliorate the subsequent effects on cell viability.  
 
 In the present study we observed that CB1 receptors are involved in the 
WIN55,212-2-mediated reduction of PI uptake after 192IgG-saporin application 
because the protective effect of the synthetic cannabinoid agonist was blocked by the 
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application of the specific CB1 receptor antagonist AM251. The density of p75
NTR 
immunoreactive neurons in the presence of WIN55,212-2 was not clearly enhanced, 
which may indicate that there is, a modest and probably indirect protective effect on the 
surviving BFCN. Therefore, the decrease in cell death observed in the presence of 
WIN55,212-2 is presumably related to secondary neuroprotective effects, and not to a 
direct protection from the toxic effects of 192IgG-saporin. On the other hand, 
WIN55,212-2 has a similar affinity for both CB1 and CB2 receptors. As mentioned 
above, the CB1 antagonist, AM251, blocked neuroprotection at a micromolar 
concentration, therefore, the contribution of microglial CB2 receptors cannot be totally 
excluded 
 The precise mechanism by which direct BFCN death induced by 192IgG-
saporin spreads out to additional BFCN or non-cholinergic cells in hemibrain 
organotypic cultures remains elusive. The deleterious effects described in the in vivo 
model of 192IgG-saporin administration suggest that the protective effects mediated by 
CB1 receptor activation in the present model could be related to the attenuation of 
excitotoxicity or to the modulation of aberrant synaptic transmission after BFCN 
degeneration, very probably involving the activation of glial cells. Excitotoxic brain 
lesions contribute to microglial activation and migration towards the sites of injury, 
thereby increasing secondary damage (Kim and Ko, 1998; Kreutz et al., 2007). 
Neuroprotective effects of cannabinoid compounds have been previously described in 
models of excitotoxicity in organotypic cultures. Thus, 2-Arachidonoylglycerol (2-AG), 
through microglial CB2 receptor activation or microglial abnormal-cannabidiol-sensitive 
receptor activation, triggers neuroprotective effects in hippocampal organotypic 
cultures, whereas Δ9-THC or anandamide failed to provide neuroprotection, despite the 
fact that there was a reduction in microglial cell density (Kreutz et al., 2007; Kreutz et 
al., 2009). On the other hand, palmitoylethanolamide, through the peroxisome 
proliferator-activated receptor-alpha, together with WIN55,212-2 and N-
arachidonoyldopamine, through CB1 receptor activation, were able to induce 
neuroprotection in the same model of excitotoxicity. However, these effects were 
blocked by specific CB1 receptor antagonists and were absent in mutant knockout mice 
(Koch et al., 2011a; Koch et al., 2011b; Grabiec et al., 2012). Interestingly, opposite 
effects of the phytocannabinoid Δ9-THC and the synthetic agonist WIN55,212-2 have 
been described depending on the dose, but probably also on the time of exposure 
(Acquas et al., 2001, Tzavara et al., 2003a). The complexity of eCB signaling can be 
explained by the phenomenon of functional selectivity or biased agonism, i.e., the 
ability of ligands to activate a subset of the full repertoire of signaling cascades 
available to individual GPCR (Urban et al., 2007). Thus, the binding of WIN55,212-2 to 
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CB1 receptors significantly differs from that of other cannabinoids, such as 2-AG 
(Howlett et al., 2002). Different alternative signaling pathways could be activated by 
WIN55,212-2 in addition to classical eCB-mediated signaling cascades. Nevertheless, 
neuroprotective effects have been described for both cannabinoids, WIN55,212-2 and 
2-AG,  in different brain areas such as the hippocampal dentate gyrus (Koch et al., 
2011b). Moreover, prolonged activation of the CB1 receptor results in a rapid 
attenuation of signaling due to desensitization and/or CB1 receptor internalization 
(Howlett et al., 2004). The internalized complex of phosphorylated CB1 receptors and 
β-arrestins mediates intracellular signaling pathways that control the activation of 
several cascades, including ERK1/2, JNK1/2/3, CREB and P38a,and leads to the 
regulation of gene expression and protein synthesis which most likely contribute to the 
protective effects of chronic activation of CB1 receptors by WIN55,212-2 (Delgado-
Peraza et al., 2016).  
 The synthesis of eCB can be stimulated by neuronal damage, and their 
protective effects are exerted through CB1 receptors, since the lack of this receptor 
increases neuronal vulnerability (Stella et al., 1997; van der Stelt et al., 2001a; 
Marsicano et al., 2003; Kallendrusch et al., 2012). The imbalance of the 
excitatory/inhibitory input described in the in vivo model of 192IgG-saporin 
administration may also be contributing to an excessive glutamatergic 
neurotransmission (Rossner et al., 1995a). A hyper-activation activation of 
glutamatergic receptors triggers an intracellular increase of Ca2+ levels, leading to 
excitotoxicity by which neurons can be damaged or killed (Manev et al., 1989). 
Interestingly, increasing levels of glutamatergic transmission after a 192IgG-saporin-
induced lesion is prevented by the NMDA receptor antagonist, MK-801 (Garrett et al., 
2006), and this effect is more pronounced in 192IgG-saporin-treated young adult rats 
than in middle-aged and aged rats (Kim et al., 2005), suggesting that cholinergic 
projections from the basal forebrain play a critical role in cortical plasticity, and also 
revealing age-related differences in the lesion-induced expression of glutamate 
receptors. The fact that a reduction in glutamatergic neurotransmission through NMDA 
receptors or decreased levels of Ca2+ influx may confer neuroprotective effects led to 
the use of memantine, a noncompetitive antagonist of NMDA receptors, as a 
therapeutic drug for AD. Pharmacological enhancement of CB1 receptor activity could 
elicit comparable effects and modulate excessive excitatory neurotransmission. Koch 
et al. (2011b) reported the neuroprotective effects of WIN55,212-2 in excitotoxically 
lesioned organotypic cultures, depending on the concentration of the agonist. Thus, 
low concentrations for three DIV elicited neuroprotection by directly activating CB1 
receptors. We observed decreased levels of cell death in the MS and in the NBM with 
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low doses of WIN55,212-2 during 6 DIV in 192IgG-saporin-treated hemibrain 
organotypic cultures, and it is reasonable to assume that the neuroprotective effects 
may be related to a possible tissue or neurotransmission restoration by CB1 receptor 
activation in cells which are still undefined, since the localization of CB1 receptors in 
BFCN remains unclear. Data suggest that rodent BFCN in the NBM are devoid of CB1 
receptors but interestingly, all of them contain eCB degrading enzymes and display a 
fine CB1 receptor fiber meshwork surrounding the perikarya, which suggests that BFCN 
may utilize eCB for retrograde control of cholinergic neurotransmission (Harkany et al., 
2003). However, microscopy studies reported the existence of differentiated BFCN in 
the MS of the rat, some of which express CB1 receptors (Nyíri et al., 2005). Additional 
studies are necessary to further understand the precise mechanisms underlying 
192IgG-saporin-induced secondary cell damage, as well as the levels of expression, 
the precise location and the functionality of cannabinoid receptors under conditions of 
BFCN degeneration.  
 In summary, brain organotypic cultures represent an intermediate stage 
between in vitro studies and in vivo models and represent a suitable scenario to create 
ex vivo models of neurodegeneration with which to further evaluate pharmacological 
interventions. The present work shows that 192IgG-saporin eliminates basal forebrain 
cholinergic neurons in an attempt to create an ex vivo model of AD. The initial 
immunotoxin-induced cholinergic lesion led to secondary cell damage which was 
partially reversed by the cannabinoid agonist WIN55,212-2 at nanomolar 
concentration. The agonist-mediated effects were blocked by the antagonist AM251, 
demonstrating the specific CB1 receptor–induced protective effects.  
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Figure legends 
 
Figure 1. Low magnification (2.5X) photomicrographs of Hoechst staining in 10 µm 
tissue slices from P7 rats including the medial septum (MS) (1-A) and both the vertical 
(VDB) (1-B) and horizontal diagonal band of Broca (HDB) (1-C) and the nucleus 
basalis magnocellularis (NBM) (2-D) (Scale bar = 1 mm). P75NTR immunofluorescence 
in the MS (A-A1), VDB (B-B1), HDB (C-C1) and NBM (D-D1). (C-D scale bar = 100 µm 
and C1-D1 scale bar = 50 µm). 
 
Figure 2. Number of p75NTR positive cells in hemibrain organotypic cultures containing 
the basal forebrain cholinergic system after the application of different concentrations 
of 192IgG-saporin according to the treatment schedule. (A) * p < 0.05; ** p < 0.01; *** p 
< 0.001 vs control (0 ng/ml).  
 
Figure 3. (A) Number of p75NTR immunoreactive BFCN in hemibrain organotypic 
cultures containing the basal forebrain cholinergic system after the application of 
different concentrations of 192IgG-saporin according to the treatment schedule. (B) 
P75NTR immunoreactive BFCN in the MS (top row) and the NBM (bottom row) in the 
absence (control) or in the presence of 100 ng/ml of the immunotoxin according to the 
treatment schedule described in (A). Low magnification and high magnification images 
scale bar = 200 and 40 µm, respectively. (A-B) * p < 0.05 vs control (0 ng/ml). 
 
Figure 4. (A) Number of PI positive cells in hemibrain organotypic cultures containing 
the basal forebrain cholinergic system after the application of different concentrations 
of 192IgG-saporin according to the treatment schedule. (B) PI uptake in hemibrain 
organotypic cultures containing the MS (top row) and the NBM (bottom row) in the 
absence (control) or in the presence of 100 ng/ml of the immunotoxin according to the 
treatment schedule described in (A). Scale bar = 200 µm. (A) * p < 0.05; ** p < 0.01; *** 
p < 0.001 vs control (0 ng/ml) and (B) *** p < 0.001 vs 200 ng/ml.  
Figure 5. (A-B) Number of p75NTR immunoreactive BFCN in hemibrain organotypic 
cultures in the absence or presence of 100 ng/ml of 192IgG-saporin, the cannabinoid 
agonist WIN55,212-2 (1 or 10 nM) or the CB1 receptor antagonist AM251 (1 µM) during 
6 DIV according to the treatment schedule (C). (D) P75NTR immunoreactive BFCN in 
the MS (top row) and the NBM (bottom row) in the absence (vehicle) or presence of 
100 ng/ml of the immunotoxin, treated with 1 nM WIN55,212-2 and 1 µM of AM251. 
Scale bar = 40 µm. * p < 0.05; ** p < 0.01; *** p < 0.001 vs control. 
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Figure 6. (A) Number of PI positive cells in hemibrain organotypic cultures containing 
the MS (i), the NBM (ii) and the cortex (iii) in the absence or presence of 100 ng/ml of 
192IgG-saporin, the cannabinoid agonist WIN55,212-2 (1 or 10 nM) or the CB1 
receptor antagonist AM251 (1 µM) during 6 DIV according to the treatment schedule 
(see Figure 5 C). (B) PI uptake in the MS (top row) and the NBM (bottom row) in the 
absence (vehicle) or presence of 100 ng/ml of the immunotoxin, treated with 1 nM 
WIN55,212-2 and 1 µM of AM251. Scale bar = 200 µm. ** p < 0.01; *** p < 0.001 vs 
control and # p < 0.05; ## p < 0.01 vs 192IgG-saporin. 
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Highlights 
 P7 and adult rats show a similar anatomical distribution of basal forebrain 
cholinergic neurons. 
 The basal forebrain cholinergic neurons from P7 rats express somatodendritic 
p75NTR receptors. 
 Basal forebrain cholinergic neurons are selectively eliminated by 192IgG-
saporin in hemibrain organotypic cultures. 
 WIN55,212-2, at nanomolar concentrations, protects basal forebrain cells from 
damage induced by the elimination of BFCN. 
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 Abstract 
 
Alzheimer‟s disease (AD) is associated with a selective vulnerability of cholinergic 
neurotransmission. The loss of basal forebrain cholinergic neurons (BFCN) described 
in AD leads to decreased levels of acetylcholine associated to pathological changes of 
muscarinic signaling. Under neuropathological conditions autophagy or 
autocannibalism is considered as an adaptive response to maintain cellular 
homeostasis. When choline is in short supply and the surviving BFCN are 
physiologically more active, membrane phospholipids represent a source for the 
synthesis of choline de novo, a process that can be regulated by muscarinic receptors. 
Several lipid species involved in the metabolism of choline are deregulated and serve 
as possible biomarkers of phenoconversion to AD. In the present study we used a rat 
model with basal forebrain cholinergic dysfunction, induced by the intraparenchymal 
infusion of 192IgG-saporin in the nucleus basalis magnocellularis (NBM), to evaluate 
the effects on learning and memory under the passive avoidance paradigm. In 
addition,both muscarinic signaling and lipid composition are measured by using 
autoradiography and matrix-assisted laser desorption ionization-imaging mass 
spectrometry (MALDI-IMS), respectively. The findings show that depletion of BFCN in 
the NBM leads to a dramatic loss of cortical cholinergic innervation which runs in 
parallel to learning and memory impairment. TheA decrease in muscarinic 
neurotransmission in the NBM was found, while no changes were observed in cortical 
muscarinic signaling. Finally, marked changes in the lipid profile were found in NBM 
and the innervated cortical areas, including species related to choline metabolism, 
which supports the hypothesis that the modulation of lipid metabolism could represent 
an alternative therapeutic strategy to potentiate cholinergic neurotransmission.  
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Introduction 
 
 Alzheimer‟s disease (AD), the most common cause of dementia in the elderly, is 
clinically characterized by a progressive and irreversible impairment of memory and 
thinking abilities. During the progression of AD a specific vulnerability of the cholinergic 
neurotransmission system has been extensively described. Thus, the loss of basal 
forebrain cholinergic neurons (BFCN) (Davis and Maloney, 1976; Whitehouse et al., 
1982), decreased levels of choline acetyltransferase (ChAT) activity (Davis and 
Maloney, 1976; Davis, 1979), which lead to cholinergic hypoactivity (Perry et al., 1977), 
decreased levels of high-affinity choline uptake carriers (Rodríguez-Puertas et al., 
1994) and altered distribution and impaired functionality of both muscarinic (mAChR) 
(Nordberg, 1992; Rodríguez-Puertas et al., 1997) and nicotinic receptors. (Hellstrom-
Lindahl et al., 1999) have been reported. These findings and the observation that 
muscarinic antagonists induced amnesia and cognitive impairment in healthy young 
subjects (Drachman and Leavitt, 1974), contributed to the development of the 
cholinergic hypothesis of geriatric memory dysfunction (Bartus et al., 1982). 
Furthermore, changes in cholinergic neurotransmission are involved in the short-term 
learning deficits and memory loss described at the onset of adult dementia disorders 
(Avery et al., 1997). 
 The BFCN from the nucleus basalis magnocellularis (NBM) innervate almost 
the entire cerebral cortex, provide the main source of cortical acetylcholine (ACh) and 
control learning and memory processes. 192IgG-saporin is an immunotoxin directed at 
the low affinity neurotrophin receptor p75NTR, which is abundantly expressed in BFCN, 
and represents a powerful tool with which to specifically eliminate BFCN in order to 
mimic the cholinergic degeneration described in AD patients (Wiley et al., 1991).  
 The biosynthesis of ACh is carried out by the enzyme ChAT using choline (Ch), 
which cannot be synthesized de novo in neurons, is obtained from the diet and 
delivered to the neurons via the blood stream (reviewed in Blusztajnn and Wurtman, 
1983). ACh hydrolysis provides approximately 50% of Ch and the high affinity carrier is 
responsible for its uptake. A secondary source for Ch derived from the hydrolysis of 
certain lipid species, such as membrane phospholipids, has been described leading to 
the autocannibalism (autophagy) hypothesis as an adaptative response to stress 
provoked by the cholinergic dysfunction described in AD (Wurtman et al., 1985), which 
probably involves cholinergic muscarinic neurotransmission (Qian et al., 1989; Dolezal 
and Tucek, 1984). The intraparenchymal infusion of 192IgG-saporin in the NBM 
decreases ChAT and acetylcholinesterase (AChE) levels, reduces high-affinity choline 
carrier and neurotrophins levels and contributes to alter the activity and distribution of 
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muscarinic (see review from Rossner, 1997) and nicotinic receptors (Bednar et al., 
1998; Quinlivan et al., 2007).  
 Due to the fact that lipids are the main structural components of membranes 
involved in multiple signaling pathways and in energy metabolism, one would expect to 
observe a regulation of certain species after the immunotoxin-induced death of BFCN 
in the NBM. Moreover, both the structural lipids of BFCN and those involved in the 
metabolism of ACh, including species of phosphatidylcholines (PC), 
phosphatidylethanolamines (PE), phosphatidylserines (PS) and sphingomyelins (SM) 
should be modulated in some way. Many studies have detailed dyshomeostatic levels 
of different lipid species in AD, including PC (Martın et al., 2010; Nitsch et al., 1992), 
PE (Martın et al., 2010) and PS (Pettegrew et al., 2001). Many efforts to reduce the 
deficit of ACh in AD patients following the administration of precursors such as Ch 
have failed in clinical trials (Amenta et al., 2001). The use of immunotoxins to selective 
eliminate specific neuronal populations represents a suitable scenario with which to 
mimic certain pathological features of neurodegenerative disorders.  
 The aims of the present study were to analyze learning and memory by using 
the passive avoidance test, the muscarinic-mediated cholinergic signaling and the 
distribution of muscarinic receptors by means of [35S]GTPγS autoradiography and 
immunofluorescence and the lipid profile by using matrix-assisted laser desorption 
ionization-imaging mass spectrometry (MALDI-IMS) after the specific depletion of 
BFCN in the NBM as an appropriate in vivo model of AD. 
 
 
Materials and methods 
 
Chemicals 
 192IgG-saporin (Batch 2441969) was acquired from Millipore (Temecula, CA, 
USA) and [35S]GTPγS (1250 Ci/mmol) from PerkinElmer (Boston MA, USA). The [14C]-
microscales used as standards in the autoradiographic experiments were purchased 
from ARC (American Radiolabelled Chemicals, Saint Louis, MI, USA). The β-radiation 
sensitive films Kodak Biomax MR, bovine serum albumine (BSA), DL-dithiothreitol 
(DTT), adenosine deaminase (ADA), guanosine 5´-diphosphate (GDP), guanosine5´-
O-3-thiotriphosphate (GTPγS), ketamine, xylazine, acetylthiocholine iodide, 2-
mercaptobenzothiazole (MBT) and tetraisopropylpyrophosphoramide (iso-OMPA) were 
all acquired from Sigma-Aldrich (St Louis, MO, USA). The compounds necessary for 
the preparation of the different buffers, the fixation and the treatment of slides were of 
the highest commercially available quality.  
 II: 7 
 
Animals 
 Seventy adult male Sprague-Dawley rats, weighing 225-275 g and ranging in 
age from 8 to 10 weeks at the onset of the experiment, were used in this study. Rats 
were housed four per cage in 50 cm (length) x 25 cm (width) x 15 cm (height) cages at 
a temperature of 22ºC and in a humidity-controlled (65%) room with a 12:12 hour 
light/dark cycle, with access to food and water ad libitum. All procedures were 
performed in accordance with European animal research laws (Directive 2010/63/EU) 
and the Spanish National Guidelines for Animal Experimentation (RD 53/2013, Law 
32/2007). Experimental protocols were approved by the Local Ethical Committee for 
Animal Research of the University of the Basque Country (CEEA 388/2014). 
 
Basal forebrain cholinergic lesion  
 All surgery was carried out under aseptic conditions. 192IgG-saporin was used 
to selectively eliminate basal forebrain cholinergic neurons (BFCN) in the nucleus 
basalis magnocellularis (NBM). Rats were randomly assigned to one of three groups: 
sham-operated (SHAM; n = 6), artificial cerebrospinal fluid, used as vehicle, (aCSF; n = 
32) and 192IgG-saporin (SAP; n = 32). The vehicle was prepared as follows: 0.15 M 
NaCl, 2.7 mM KCl, 0.85 mM MgCl2, 1.2 mM CaCl2 (pH = 7.4) and sterilized by filtration 
with 0.4 µm-Ø filters (EMD Millipore, CA, USA). Rats were anesthetized with 
ketamine/xylazine (90/10 mg/kg; s.c.) and then placed in a stereotaxic instrument 
(Kopf, Tujunga, CA). After an incision was made in the skin along the midline of the 
skull, two holes were drilled and by using a 10-µl Hamilton syringe (NeurosTM Syringe, 
7000 series; Bonaduz, Switzerland) with a 26-gauge needle, the intraparenchymal 
infusions were made into the NBM: - 1.5 mm anteroposterior from Bregma, ± 3 mm 
mediolateral from midline, + 8 mm dorsoventral from cranial surface (Paxinos and 
Watson, 2005). 192IgG-saporin was dissolved in aCSF to a final concentration of 130 
ng/µl. The aCSF or the immunotoxin were bilaterally injected (1 µl/hemisphere) at a 
constant rate of 0.2 µl/min. The needle was kept in for an additional 5 min before 
removal, to avoid a possible backflow and to allow complete diffusion. The SHAM 
group was treated in the same way as the aCSF group but without vehicle infusion. 
During surgery, the body temperature was controlled and the eyes were kept hydrated 
with warm saline solution (0.9% NaCl). After completing the administration, the wounds 
were closed with braided silk sutures and a broad-spectrum antibiotic injection was 
given (2.25 mg/kg oxytetracicline; i.m.). The choice of coordinates, infusion rate, 
volume and dose of the immunotoxin were based on previous experiments performed 
in our laboratory. 
 
 II: 8 
 
Passive avoidance test 
 The rats were allowed seven days to recover from surgery and were then 
subjected to the passive avoidance test (PanLab passive avoidance box LE870/872). 
The apparatus for the test consists of two methacrylate compartments separated by a 
guillotine door. The first compartment is large, white, illuminated and open-topped: (31 
cm x 31 cm x 24 cm) and the other is small, dark and closed (19.5 cm x 10.8 cm x 12 
cm. The position of the animal is detected by the use of highly sensitive weight 
transducers. The passive avoidance test involves two sessions. The first, which is 
called “the learning trial”, was performed on day 7 after surgery. Each animal was 
gently placed in the illuminated compartment and allowed to explore it for 30 sec. 
Then, the guillotine door was automatically opened and the rat was given a maximum 
of 60 sec to enter the dark compartment. When the rat crossed the door-way the door 
closed, the acquisition latency time (i.e. the time that rats remained in the open-topped 
compartment) was measured, and a foot shock (0.4 mA/2 sec) was delivered. 10 sec 
after the foot shock, the rat was returned to its home cage. The rats, which did not 
enter the dark compartment, were eliminated from the study. 24 h later, for the second 
session called “the retention trial”, the rats were again placed in the illuminated 
compartment and allowed to explore for 30 sec. Then the door opened and the time 
taken to enter the dark compartment, the step-through latency time, was measured, 
with a cut-off of 300 sec.  
 
Tissue preparation 
 Following the passive avoidance test, all the animals were anaesthetized with 
ketamine/xylazine (90/10 mg/ kg; i.p.) and sacrificed by decapitation. 
 Fresh tissue. The brains from aCSF (n = 31) and SAP (n = 32) groups were 
quickly removed by dissection, fresh frozen and kept at -80ºC. Later, they were cut into 
20 µm slices and mounted onto gelatin-coated slides and stored at -25ºC until used. 
 Fixed tissue. Representative animals from aCSF (n = 2) and SAP (n = 2) groups 
were transcardially perfused via the ascending aorta with 50 ml warm (37ºC), calcium-
free Tyrode‟s solution (0.15 M NaCl, 5 mM KCl, 1.5 mM MgCl2, 1 mM MgSO4, 1.5 mM 
NaH2PO4, 5.5 mM Glucose, 25 mM NaHCO3; pH 7.4), 0.5% heparinized, followed by 
4% paraformaldehyde and 3% picric acid in 0.1M PB (4ºC) (100 ml/100 g b.w.) (37ºC, 
pH = 7.4). Their brains were subsequently removed and post-fixed in the same fixative 
solution for 90 min at 4ºC, followed by immersion in a cryoprotective solution of 20% 
sucrose in PB overnight at 4ºC, and then frozen by immersion in isopentane and kept 
at -80ºC. At a later date the brains were coronally cut into10 µm slices using a Microm 
HM550 cryostat (Thermo Scientific) equipped with a freezing-sliding microtome at -
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25ºC and mounted onto gelatin-coated slides and finally stored at -25ºC until used for 
the immunofluorescence assays.  
 
AChE staining and quantitative analysis  
 Prior to staining procedures, fresh tissue slices containing basal forebrain and 
hippocampus from aCSF (n = 13) and SAP (n = 13) treated rats were fixed in 4% 
paraformaldehyde in PB (0.1M) for 30 min at 4ºC and washed in 0.1 M PBS, pH 7.4 for 
20 min. Cholinergic innervations were stained using the “direct coloring” thiocoline 
method for AChE (Karnovsky and Roots, 1964) as follows: the slices were rinsed twice 
in 0.1 M Tris-Maleate buffer (pH = 6.0) for 10 min and incubated for 100 min in 
complete darkness in the AChE reaction buffer (0.1 M Tris-Maleate, 5 mM sodium 
citrate, 3 mM CuSO4, 0.1 mM iso-OMPA, 0.5 mM K3Fe(CN)6
)
 and 2 mM 
acetylthiocholine iodide, as a reaction substrate), whilst being constantly and gently 
agitated.The enzymatic reaction was finally stopped by carrying out two consecutive 
washes (2 x 10 min) in 0.1 M Tris-maleate (pH = 6.0). Slices were dehydrated in 
increasing concentrations of ethanol and covered with the mounting medium, DPX.  
 The stained slices were scanned at 600 ppi and AChE positive fiber density was 
quantified by using Image J software (NIH, Bethesda, MD, USA), and the images were 
converted to 8-bit grey-scale mode. This software defines the optical density of an 
anatomical area and the background from 0 (white) to 256 (black). The intensity values 
in arbitrary units were defined in the selected equivalent areas from both hemispheres 
in all the animals. Background or non-specific staining values were substracted from 
AChE positive signals to obtain the net AChE optical density in each area. AChE 
staining values in the striatum served as control and data were expressed as 
percentages of striatum in each area.  
 
[35S]GTPγS autoradiography and quantitative analysis of autoradiograms 
 The functional coupling of muscarinic receptors to G i/o proteins was performed 
in fresh frozen 20 µm slices from each rat, aCSF (n = 10) and SAP (n = 11) groups, 
which were air dried for 30 min, followed by two consecutive pre-incubations in 
HEPES-based buffer (50 mM HEPES, 100 mM NaCl, 3 mM MgCl2 and 0.2 mM EGTA, 
pH = 7.4) for 30 min at 30ºC in a thermostatic bath in order to eliminate the 
endogenous ACh. Then, the slices were incubated for 2 h at 30ºC in the reaction 
buffer, which was similar to the pre-incubation buffer, but supplemented with 2 mM 
GDP, 1 mM DTT, ADA (3U l-1) and 0.04 nM [35S]GTPγS. The [35S]GTPγS basal binding 
was determined in two consecutive slices in the absence of the agonist. The agonist 
stimulated binding was also determined in two consecutive slices in the same reaction 
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buffer, but in the presence of 100 µM carbachol, a non-specific muscarinic receptor 
agonist. Non-specific binding was defined by competition with 10 µM of non-labelled 
cold GTPγS in another consecutive section. Later, the slices were washed twice in a 
cold (4ºC) 50 mM HEPES buffer (pH = 7.4) to stop the binding reaction and were then 
gently dipped in cold (4ºC) distilled water and dried with cold air. Finally, the slides 
were exposed to β radiation-sensitive autoradiographic films with a set of [14C] 
standards to calibrate the images (gray densities) in hermetically closed cassettes. 
 The films were developed after 48 h, scanned and quantified by transforming 
optical densities into nCi/g tissue equivalent (nCi/g t.e.) using a calibration curve 
defined by the known values of the [14C] standards (NIH-IMAGE, Bethesda, MA, USA) 
and freely available on internet at http://rsb.info.nih.gov/nih-image/). This software 
defines the optical density of an anatomical area from 0 (white) to 256 (black). The 
specific binding for each area in consecutive slices, was calculated as follows: non-
specific binding values were substracted from the values obtained in both agonist-
stimulated and basal-stimulated conditions. Then, the net basal stimulation values 
were substracted from agonist-stimulated values to obtain net agonist-stimulation 
([agonist-stimulated - nonspecific] - [basal - nonspecific]). The percentages of 
carbachol-evoked stimulation were calculated from both the net basal and net 
carbachol-stimulated [35S]GTPγS binding densities according to the following formula: 
([35S]GTPγS agonist-stimulated binding x 100/[35S]GTPγS basal binding) - 100.  
 
Double immunofluorescence studies  
In order to perform the immunofluorescence assays, the frozen tissue slices 
were dried at room temperature for 20 min. 
BFCN were located by using goat anti choline acetyltransferase (ChAT) [1:200] 
as primary antiserum. To study the cellular localization of M2 and M4 mAChR, primary 
rabbit anti M2 mAChR [1:400] and mouse anti M4 mAChR [1:250] (EMD Millipore, CA, 
USA) were used. Primary antibodies were diluted in PBS (0.1 M, pH 7.4) containing 
0.5% BSA and the tissue samples were incubated overnight at 4ºC. They were then 
washed for 30 min in PBS and incubated for 30 min at 37ºC with the appropriate 
secondary antibodies; rhodamine donkey anti-goat for ChAT [1:80], Alexa-fluor 488 
donkey anti-rabbit [1:250] for M2 mAChR and Alexa-fluor 488 donkey anti-mouse 
[1:250] for M4 mAChR. Then, the slices were washed for 30 min at room temperature 
by immersion in PBS and incubated with Hoechst 33258 [1:106] for 15 min at room 
temperature. Finally, slices were washed for 15 min by immersion in PBS and mounted 
with p-phenylendiamine-glicerol (0.1%) for immunofluorescence. 630-fold magnification 
images for colocalization (M2 mAChR-ChAT or M4 mAChR-ChAT) were acquired on an 
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Axioskop Obsever A1 inverted microscope (Carl Zeiss) by optical sectioning (0.24 
µm/X-Y-Z-resolution) using structured illumination (ApoTome, Carl Zeiss). 
Colocalization images were created by using ZEN2014 software (Carl Zeiss) and were 
defined as immunosignals without physical signal separation.  
 
Sample preparation for MALDI-IMS 
 Lipid composition and anatomical distribution were analyzed by using MALDI-
IMS in fresh 20 µm slices from each rat in the aCSF (n = 8) and SAP (n = 8) groups, 
following the recommendations of Schwartz et al (2003). Once the tissue was sliced 
and mounted on slides, the matrix (MBT) was deposited on the tissue surface by a 
process of sublimation. The sublimation was performed using 300 mg of MBT and the 
deposition time and temperature were controlled (30 min, 140ºC). For the re-
crystallization of the matrix, the sample was attached to the bottom of a glass Petri 
plate face-down, which was placed on another Petri plate containing a methanol 
impregnated piece of filter paper in its base. The Petri plates were then placed on a hot 
plate (1 min, 40ºC). 
 
Mass spectrometer and image and spectra analysis 
 A MALDI LTQ-XL-Orbitrap (Thermo Fisher, San Jose, CA) equipped with a 
nitrogen laser (λ = 337 nm, rep. rate = 60 Hz, spot size = 80 x 120 µm) was used for 
mass analysis. Thermo´s Imagequest and Xcalibur software were used for MALDI-IMS 
data and image acquisition in both positive and negative ion mode. The positive ion 
range was 500-1000 Da, and the negative ion range was 400-1100 Da, with 10 laser 
shots per pixel at a laser fluence of 15 µJ. The target plate stepping distance was set at 
150 µm for both x- and y-axes by the MSI image acquisition software. The data were 
normalized using the total ion current values, as there may be potential displacement 
of the masses on the tissue due to experimental factors e.g., the irregularities of the 
surface.  
The MALDI images were generated using ImageQuest (Thermo Scientific). Each of the 
m/z values was plotted for signal intensity for each pixel (mass spectrum) across a 
given area (tissue section). The m/z range of interest was normalized using the ratio of 
the total ion current for each mass spectrum. The intensity reached by each spectrum 
(m/z or molecule) was further calculated as a ratio of the peak with the highest 
intensity, and the average was obtained using OriginPro8 (Northampton MA, USA) 
software. The most intense peak was considered to be 100%. The assignment of lipid 
species was facilitated by the use of the databases Lipid MAPS 
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(http://www.lipidmaps.org/) and Madison Metabolomics (http://mmcd.nmrfam.wisc.edu) 
and 5 ppm mass accuracy was selected as the tolerance window for the assignment.  
 
Statistical analyses 
Step through latencies were represented as Kaplan-Meier survival curves, and 
for comparisons between groups, the Log-rank/Mantel-Cox test was used. Acquisition 
latencies, AChE densities, the percentages of agonist-evoked [35S]GTPγS stimulation, 
and the percentages of the relative intensity of lipids were statistically analyzed using 
the two-tailed unpaired Student t test. The statistical significance threshold was set at p 
< 0.05 
 
 
Results 
 
Learning and memory evaluation after basal forebrain cholinergic lesion  
 To examine learning and memory, the animals from the three groups were 
trained and tested using the passive avoidance test. One week after administration of 
the immunotoxin, the acquisition latency was measured. No differences were observed 
between the three groups (10.20 ± 0.98 s, 10.76 ± 1.2 s and 10.88 ± 1.54 s in SHAM, 
aCSF and SAP, respectively) (Figure 1A). 24 h later, rats were again tested to evaluate 
the step-through latency. This was measured and represented as Kaplan-Meier 
survival curves to determine the estimated probability of a positive response (i.e. to 
reach the cut-off time). When the three groups were compared, 100% and 78% of the 
SHAM and aCSF-treated rats, respectively (p = n.s.), remembered the aversive 
stimulus and displayed a positive response, while only 40% of the immunotoxin-treated 
rats did (p = 0.0001 vs SHAM and p = 0.0006 vs aCSF). The median latency time was 
102.9 s for 192IgG-saporin-treated rats (Figure 1B).  
 
AChE staining 
 AChE enzymatic assay was used to stain cholinergic fibers both in the 
projecting areas from the NBM, and in the somatodendritic compartment of BFCN. 
SHAM-operated rats showed equivalent levels of AChE staining to those measured in 
the aCSF-treated group (data not shown). The intraparenchymal infusion of 192IgG-
saporin in the NBM did not modify the AChE+ fiber density in the striatum (aCSF 113 ± 
3.26 vs SAP 111 ± 3.08), but resulted in a great reduction of AChE staining in the 
entire cortical mantle, ranging from 20% in cingular (aCSF 28.3 ± 1.2% vs SAP 23.5 ± 
1%, p < 0.01) and piriform (aCSF 36.1 ±1.5% vs SAP 30.6 ± 1,5%, p <0.05) cortices to 
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60-70% in motor (aCSF 21.6 ± 0.8% vs SAP 7.6 ± 0.5%, p < 0.001), somatosensory 
(aCSF 24.1 ± 0.9% vs SAP 8.6 ± 1.4%, p < 0.001) and entorhinal (aCSF 26.4 ± 1,7% 
vs SAP 16.2 ± 0.9%, p < 0.001) cortices. In the amygdaloid complex of 192IgG-
saporin-treated animals a more moderate decrease was observed in some nuclei, such 
as in the anterior (aCSF 74.7 ± 4.4% vs SAP 52.7 ± 2.9%, p < 0.001), the lateral (aCSF 
51.4 ± 3.8% vs SAP 41.3 ± 2.3%, p < 0.05) and the medial (aCSF 25.6 ± 4.5% vs SAP 
13.8 ± 0.93% p < 0.05). No differences were observed in the medial septum, revealing 
the absence of non-specific damage in other basal forebrain cholinergic nuclei, 
although the CA3 field of hippocampus showed a moderate decrease in AChE staining 
(aCSF 51.9 ± 4.4% vs SAP 49.1 ± 2.3%, p < 0.05) (Fig 2).  
 
[35S]GTPγS autoradiography 
 To examine M2/M4 mAChR-mediated signaling, the activity of Gi/o-coupled 
muscarinic receptors was measured by using [35S]GTPγS autoradiography assay. 
Basal binding values were similar in both groups (aCSF and SAP) in all the brain areas 
analyzed. The anatomical analysis of carbachol-induced [35S]GTPγS binding 
stimulation revealed differences in the functional coupling of muscarinic receptors to 
Gi/o proteins in some brain areas in immunotoxin-treated animals (See tables 1-2). 
Thus, carbachol-induced stimulation of M2/M4 mAChR was decreased in the NBM (p < 
0.05 vs SAP) from 192IgG-saporin-treated rats, but no changes were found in any of 
the cortical areas (Fig 3B). In the hippocampus an enhancement of carbachol-induced 
[35S]GTPγS binding in the pyramidal layer of the CA3 (p < 0.05 vs SAP) and in the 
granular layer of the dentate gyrus (p < 0.05 vs SAP) was found (Fig 3D). However, 
there was a hypoactivity in the lateral nucleus of the amygdaloid complex (p < 0.05 vs 
SAP) (Table 1). 
 
Immunofluorescence 
 To examine the localization of the receptors, immunofluorescence studies were 
performed using an antiserum against i3 intercellular loop of human M2 and M4 
mAChR. The pattern of distribution of M2/M4 mAChR was very similar to that observed 
in the [35S]GTPγS autoradiographic study, clearly delineating certain brain subregions. 
There was a high expression of M2 mAChR in the striatum, the basal forebrain (Figure 
4) and in the pyramidal layers of different hippocampal subfields, while it was more 
moderate in the cortex (Figure 6). BFCN of NBM displayed a modest somatodendritic 
immunostaining, but the presence of a dense network of fibers surrounding the somas 
revealed presynaptic contacts from M2 mAChR-positive axon terminals (Figure 4A-I-
IV). 192IgG-saporin-treated rats showed an almost total absence of M2 mAChR-
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immunoreactivity in the basal forebrain due to the disappearance of BFCN, as revealed 
by ChAT immunostaining (Figure 4B-I-IV). M2 mAChR-immunoreactivity was 
differentially distributed throughout the hippocampal formation. The large pyramidal 
neurons from CA1-CA3 and dentate gyrus displayed a dense network of fibers which 
delineate the perikarya in basket-like formations, without there being immunoreactivity 
in the soma (Figure 6A). In the somatosensory cortex, M2 mAChR presented a 
scattered distribution in presumably presynaptic compartments (Figure 6C). On the 
other hand, M4 mAChR-immunoreactivity was distributed mainly in somatodendritic 
compartments in NBM (Figure 5), hippocampus and cortex (Figure 6), and displayed a 
typically somatodendritic localization (Figure 5A-I-IV). Immunotoxin-treated rats 
showed a dramatic decrease in M4 mAChR-immunoreactivity in the basal forebrain, 
accompanied by the disappearance of BFCN, as revealed by ChAT immunostaining 
(Figure 5B-I-IV).  
 
Lipid species analysis by MALDI-IMS  
 The matrix-assisted laser desorption ionization-imaging mass spectrometry 
(MALDI-IMS) technique allows us to anatomically localize and semiquantify several 
lipid species in tissue slices. In this study we carried out a lipid analysis in coronal brain 
slices, which include the NBM, from aCSF or SAP-groups in both positive and negative 
ion detection modes. Firstly, IMS was performed in positive ion detection mode and 
more than 300 peaks were obtained. There were changes in the relative levels of 
several PC species in the NBM, but only the levels of three of them were also different 
in the cortex of the rats treated with the immunotoxin (Table 3 and Figure 7). Thus, in 
the NBM increased levels of PC (36:1) + Na+ (aCSF 14.62 ± 0,30% vs SAP 21.64 ± 
1.53%, p < 0.01), PC (36:4) + K+ (aCSF 10.32 ± 1.01% vs SAP 18.61 ± 2.71%, p < 
0.05) and PC (40:6) + Na+ (aCSF 0.88 ± 0.17% vs SAP 2.25 ± 0.40%, p < 0.01) were 
observed in 192IgG-saporin-treated rats. However, in the cortex there was a decrease 
in the level of a single species PC (36:1) + Na+ (aCSF 10.62 ± 0.48% vs SAP 8.95 ± 
0.63%, p < 0.05), while increased levels of two species PC (36:4) + K+ (aCSF 13.17 ± 
0.99% vs SAP 15.63 ± 0.48%, p < 0.05) and PC (40:6) + Na+ (aCSF 0,75 ± 0.11% vs 
SAP 1.14 ± 0.09%, p < 0.05) were found in 192IgG-saporin-treated rats. The levels of 
other lipids were also modified in the NBM of the lesioned rats, such as PE (14:1/20:4) 
+ H+ (aCSF 15.21 ± 0.70% vs SAP 11.87 ± 1.35%, p < 0.05), SM (d18:1/18:0) + H+ 
(aCSF 7,11 ± 1,135% vs SAP 4,15 ± 0,799%, p < 0.05) and SM (d18:1/16:0) + K+ 
(aCSF 0.96 ± 0.14% vs SAP 10.53 ± 3.33%, p < 0.01). Secondly, the negative ion 
detection mode was used and the levels of several lipid species were found to be 
modified in the NBM, such as SM (d18:0/18:1) (aCSF 1.26 ± 0.24% vs SAP 6.44 ± 
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1.50%, p < 0.01) and PS (18:0/18:1) (aCSF 11.04 ± 2.16% vs SAP 3.95 ± 0.99%, p < 
0.01). However, the level of only one species of phosphoglycerol, PG (22:6/22:6), was 
also changed in the cortex of 192IgG-saporin-treated rats (aCSF 0.06 ± 0.01% vs SAP 
0.86 ± 0.24%; p < 0.05 and aCSF 0.04 ± 0.01% vs SAP 0.16 ± 0.05%, in NBM and 
cortex, respectively; p < 0.05) (Table 3 and Figure 7). 
 
Discussion 
 
Learning and memory impairment after BFCN depletion 
 The NBM is a neuronal nucleus which is located deeply within the brain, close 
to the border of the ventral limit. Firstly, we analyzed the mechanical lesion produced 
by the needle crossing from the dorsal cranial surface to almost the ventral border, and 
the intraparenchymal infusion of the vehicle. Previous studies from our laboratory 
demonstrated that the administration of the vehicle by using a common Hamilton 
syringe was sufficient to produce brain damage which led to learning and memory 
deficits in the control group, as observed in the passive avoidance test. Therefore, a 
new model of Hamilton neurosyringe, equipped with an ultra thin gauge needle, was 
used in order to minimize the mechanical lesion. 
 Eight days after the intraparenchymal infusion of 192IgG-saporin, 75% of BFCN 
in the NBM had disappeared leading to learning and memory impairment, as 
demonstrated by the results of the passive avoidance test. In the retention trial, 100% 
of SHAM-operated rats remembered the foot-shock and no statistically significant 
differences were observed between SHAM-operated and aCSF-treated groups. 
Moreover, the histochemical (AChE staining) and immunohistochemical (p75NTR-
immunoreactivity) studies revealed similar densities of BFCN in SHAM-operated rats 
and in those which had received aCSF used as the vehicle, thereby demonstrating that 
the intraparenchymal infusion of the vehicle by itself had no effect on the survival rate 
of BFCN. The extent of the specific basal forebrain cholinergic lesion was also 
demonstrated by the dramatic loss of AChE-positive fibers in cortical regions. The 
infusion of 192IgG-saporin had no effects on acquisition latency, suggesting that the 
motivation to explore, the level of anxiety and/or the motor functions of the rats were 
apparently unaffected. In this context, longer acquisition latency times in the passive 
avoidance test induced by BFCN depletion in the medial septum have been reported, 
showing that there are different effects on aversive learning, depending on the specific 
cholinergic nucleus lesioned (Babalola et al., 2012). As already mentioned, 192IgG-
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saporin is directed against p75NTR, which is predominantly expressed in BFCN from the 
MS, VDB, HDB and NBM (Wiley et al., 1991). The specificity of the lesion in the NBM is 
demonstrated by the absence of damage in the complex MS-VDB (Ch1-Ch2) which 
mainly innervates the hippocampus, as observed by AChE staining. The evaluation of 
learning and memory behavior in the present study does not discriminate other 
parameters such as acquisition, consolidation, extinction or retrieval of new aversive 
information, but previous studies using the olfactory discrimination learning test have 
demonstrated that 192IgG-saporin-induced lesions of the NBM impair attention 
capacity and early acquisition during a learning process (Bailey et al., 2003).  
 Kaplan-Meier survival curves were used to graphically represent the estimated 
probability of reaching the cut-off time (300 s) for each group. Then, data were 
analyzed by using the Log-rank/Mantel-Cox test to compare the survival distributions or 
the estimated probability of each group to reach the cut off time. Doing so was 
regarded as a positive response. It was found that a statistically significant higher 
percentage of immunotoxin-treated animals showed a negative behavioral response in 
comparison with those which had received aCSF. The present results provide evidence 
that cortical cholinergic innervation arising from the NBM plays a pivotal role in learning 
and memory processes. In previous studies, step-through latency times were 
represented as histograms, evaluating censored latency times (cut-off time of 300 s) as 
threshold values, but the above-mentioned statistical analysis is more appropriate to 
test the probability of reaching the cut-off time and eliminates the threshold bias. Based 
on a previous report, the statistical handling of data in the present study improves the 
analysis of the results and represents an alternative way to interpret behavioral 
responses when using the passive avoidance paradigm (Barreda et al., 2015). The 
effects of cholinergic lesions on learning and memory have been extensively studied, 
but controversial data have been reported depending on the severity of the lesion, the 
dose, schedule and route of 192IgG-saporin administration, the specific cholinergic 
nucleus or the passive avoidance test conditions (reviewed in Myhrer, 2003). A 
previous study demonstrated that a 50% reduction of BFCN in the NBM produced a 
25-30% decrease in ChAT activity, but was not sufficient to impair memory five weeks 
after lesioning (Wenk et al., 1994). The experimental design differed from ours in 
several aspects: lower doses of the immunotoxin, repeated learning trials and 
footshock deliveries, the post-operatory recovery period and the statistical analysis 
used. Our results are consistent with other studies which have demonstrated that 
avoidance testing is impaired after a specific lesion in the NBM with the excitotoxins 
ibotenic acid (Flicker et al., 1983; Hepler et al., 1985; Whishaw et al., 1985) or 
quisqualic acid (Aaltonen et al., 1991; Riekkinen et al., 1991a,b, 1993; Zupan et al., 
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1993). In the studies using non-specific excitotoxins, the effects of the lesions are not 
restricted to BFCN, but also affect to non-cholinergic neurons in the same structures 
(Kosaka et al., 1988). However, when the lesion was induced with 192IgG-saporin, 
other authors reported small, but significant deficits associated with the BFCN lesion in 
the NBM in a single learning trial of the passive avoidance test (Torres et al., 1994). 
Moreover, and consistent with the present results, the relationship between the severity 
of passive avoidance behavioral deficits and the degree of BFCN loss was 
demonstrated (Zhang et al., 1996; Martinez-Gardeazabal et al., 2017). The present 
findings unequivocally support the pivotal role of NBM-cortical cholinergic 
neurotransmission in learning and memory processes in rats.  
 
BFCN lesion-induced alteration in functionality and distribution of M2/M4 mAChR 
  Different alterations to the cholinergic neurotransmission have been reported in 
postmortem samples from AD patients (Davies and Maloney, 1976; Davies, 1979; 
Whitehouse et al., 1982; Rodríguez-Puertas et al., 1994 and 1997; Flynn et al., 1995). 
In the present study, functional autoradiography showed a decrease in carbachol-
induced stimulation of [35S]GTPγS binding in the NBM and an increase in 
hippocampus, but no significant change in this parameter was observed in the entire 
cortical mantle of 192IgG-saporin-treated rats. Although the cholinergic connectivity 
between these three brain areas is not fully understood, they are all areas involved in 
learning and memory.  
 BFCN from the NBM are thought to express M2 and/or M4 mAChR as 
autoreceptors in the synaptic terminals, therefore, in the lesion model the decrease in 
M2/M4 mAChR activity recorded at the NBM may be a direct consequence of the lesion 
and indicates a loss of cholinergic interconnections within the nucleus that constitutes 
the cholinergic basal forebrain. However, despite the elimination of up to 70% of 
presynaptic basal forebrain cholinergic terminals in some cortical regions of 192IgG-
saporin-treated rats, the [35S]GTPγS autoradiographic study showed no differences in 
the functional coupling of M2/M4 mAChR to Gi/o proteins in the cortical areas analyzed. 
M2 and M4 mAChR are differentially distributed in the cortex. Thus, M2 mAChR-
immunoreactivity is dense in the deeper layers of the cortex, is located in cell bodies, 
and is associated with fibers and presumably terminals, and occasionally with 
perikarya. Using the NBM-lesioned rat model, previous studies reported a decrease in 
M2 mAChR density in frontal and parietal cortices seven days after ibotenic acid 
administration or mechanical lesioning of the NBM, by means of autoradiography and 
in situ hybridization techniques, which is in consistent with the presynaptic localization 
of M2 mAChR in BFCN terminals (Bogdanovic et al., 1993; Schliebs et al., 1994). As 
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previously mentioned, mechanical or excitotoxin-based lesioning of the BFCN may 
trigger non-specific damage to non-cholinergic neurons, and this could result in 
contradictory results. Therefore, when the lesion was produced by 192IgG-saporin, as 
observed in the study of Rossner et al. (1995b), an increase of up to 20% in M2 mAChR 
density in the parietal cortex was reported, suggesting the existence of a significant 
population of M2 mAChR located postsynaptically (reviewed in Rossner, 1997). In AD, 
the severe loss of cortical cholinergic innervation is accompanied by a depletion of M2 
mAChR, but M1 mAChR density remains relatively stable (Mash et al., 1985). It has 
been assumed that the M2 mAChR is a presynaptic autoreceptor located in all 
cholinergic axons which arise in the NBM and innervate the cerebral cortex, the NBM 
being the main source of cortical M2 mAChR. The depletion of M2 mAChR was 
therefore thought to be the consequence of the cholinergic axonal loss in AD. 
However, the expression of M2 mAChR in BFCN terminals still remains controversial. 
The interpretation of some authors was that the cholinergic axons coming from the 
NBM do not substantially contribute to the overall pool of cortical M2 mAChR, and M2 
mAChR-expressing postsynaptic neurons could be partially responsible for the 
decrease of these receptors observed in AD (Mesulam, 1998). The existence of 
cortical postsynaptic M2 mAChR and/or the possibility that thet are located in non-
cholinergic terminals of either intrinsic or extrinsic origin, makes it plausible that the 
degeneration of cortical M2 mAChR-immunoreactive neurons could also be contributing 
to the described loss of M2 mAChR in AD (Mrzljak et al., 1998; Raevsky et al., 1998). 
Interestingly, electron microscopic analysis failed to reveal changes in M2 mAChR 
distribution following the intraparenchymal administration of 192IgG-saporin in the 
NBM of rhesus monkeys and moreover, clearly showed that membrane-linked 
receptors were also located in dendritic spines of pyramidal neurons and associated 
with membranes in all cellular compartments of nonpyramidal neurons (Mrzljak et al., 
1998). Furthermore, M2 mAChR which modulate ACh release are not located in NBM 
cholinergic terminals, but are predominantly found in the membranes of postsynaptic 
sites in the NBM (Meyer et al., 1987; Pascual-Alonso and Gonzalez-Zarate, 1992; 
Decossas et al., 2003). However, the co-expression of M2 mAChR at presynaptic sites 
and VAChT has been observed by using both light and electron microscopy (Decossas 
et al., 2003).  
 On the other hand, the cortical pool of M4 mAChR is relatively small and this 
subtype is mainly located in the neuropil and in scattered perikarya (Levey et al., 
1991). The reported localization of M4 mAChR binding sites and mRNA is comparable 
in all layers of the neocortex (Buckley et al., 1988; Sugaya et al., 1997; Vilaró et al., 
1994). The present immunofluorescence assays revealed a higher density of M4 
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mAChR located in somas and plasma membrane, in comparison with M2 mAChR, 
which seem to be located presynaptically, clearly showing that there is a different 
pattern of distribution. Although we did not observe changes in the activity mediated by 
M2/M4 mAChR in cortical areas, the role of cortical M4 mAChR in this lesion model and 
their precise distribution remains unclear. Further research into the role of these 
receptors, carried out by using this model of basal forebrain cholinergic dysfunction, 
could provide valuable physiological information. 
 The immunosignal associated with both M2 and M4 mAChR was dramatically 
reduced in the basal forebrain after the lesion, thereby providing evidence of the 
contribution of both receptors to the cholinergic neurotransmission impairment in the 
NBM. As previously described, the precise anatomical distribution of M2 and M4 
mAChR in the basal forebrain still remains controversial, but present 
immunohistochemical findings suggest a mainly presynaptic localization of M2 mAChR 
and a somatodendritic distribution of M4 mAChR in the BFCN of the NBM. However, 
the expression of M2 mAChR and M4 mAChR in BFCN, including those from the MS, 
VDB, HDB and NBM, has previously been studied by using in situ hybridization, [3H]-
oxotremorine autoradiography and immunohystochemical assays (Harata et al., 1991; 
Vilaró et al., 1992 and 1994; Sugaya et al., 1997). The co-expression of these 
receptors and ChAT has also been detected in approximately 80% of BFCN by using 
light and electron microscopy (Decossas et al., 2003). In addition, dissociated NBM 
neurons are stimulated with carbachol and antagonized with the M2 mAChR 
antagonist, AF-DX-116 (Harata et al., 1991). 
 In summary, the present findings show a significant decrease in Gi/o-mediated 
muscarinic signaling in the NBM, mediated by the pool of presynaptic M2 and 
somatodendritic M4 mAChR, and the absence of changes in pre and postsynaptic 
M2/M4 mAChR-mediated signaling in the cortex of immunotoxin-treated rats. Eight days 
after the administration of 192IgG-saporin, the loss of both the cortical source of ACh 
and the M2/M4 mAChR-mediated signaling associated with the loss of BFCN in the 
NBM may be contributing to the deregulation of cortical neurotransmission responsible 
for the cognitive impairment observed in the passive avoidance test.  
 Conversely, the increased M2/M4 mAChR-mediated signaling in the dentate 
gyrus and CA3 regions of the hippocampus, cannot be directly attributed to cholinergic 
denervation from NBM because the major source of cholinergic innervation to the 
hippocampus proceeds from the MS and the VDB. In fact, the results of the 
autoradiographic assays and the AChE staining in these nuclei were similar to those 
obtained in the aCSF group, suggesting the absence of non-specific damage to other 
basal forebrain cholinergic nuclei, except that generated in the NBM. Nevertheless, 
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lesions directed at the septohippocampal cholinergic projections have been used to 
evaluate the involvement of this pathway in cognition (Baxter et al., 2013; Köppen et 
al., 2016), and to explore the distribution of mAChR in the hippocampus at different 
postsurgical times, demonstrating dynamic changes in densities of pre and 
postsynaptic pools of M2 and M4 mAChR (Bauer et al., 1992; Wall et al., 1994; Levey et 
al., 1995).  
 Our immunofluorescence studies in the hippocampus suggest that the M2 
mAChR in the granular dentate gyrus and pyramidal CA1-CA3 are located 
presynaptically, whereas the M4 mAChR are postsynaptically distributed in the 
somatodendritic compartment of pyramidal neurons. Furthermore, presynaptic M2/M4 
mAChR inhibit ACh release (Raiteri et al., 1984; Levey et al., 1995). In this context, the 
observed increase in hippocampal cholinergic neurotransmission through M2 mAChR 
may contribute to the so-called “muscarinic long term potentiation” mediated by the 
potentiation of glutamatergic NMDA receptors, essential to explain hippocampal 
neuronal plasticity (Segal and Auerbach, 1997). Interestingly, mice lacking M2 mAChR 
but not mice lacking M4 mAChR, showed deficits in learning and memory, as 
demonstrated by means of the passive avoidance test, together with profound 
alterations in ACh homeostasis in the hippocampus, suggesting that the M2 mAChR 
subtype plays a crucial role in cognitive processes (Tzavara et al., 2003b). Additional 
studies in M2 mAChR knockout mice reported significant deficits in the Barnes circular 
maze. In addition, this was associated with impairment in both short and long-term 
potentiation and was completely reversed with the GABAA receptor antagonist, 
bicuculline (Seeger et al., 2004). M2 mAChR are also expressed in diverse 
hippocampal interneurons and control GABA release from presynaptic inhibitory 
terminals which leads to an increase in activity in the dendritic region of pyramidal 
neurons (Hajos et al., 1998). The increase in hippocampal muscarinic functionality 
mediated by M2 mAChR may modulate the GABAergic tone to compensate for 
excitatory-inhibitory imbalance. The M4 mAChR subtype might also be involved in 
neuronal plasticity-associated learning and memory formation, as has been reported in 
adrenalectomized rats, whereas the loss of M4 mAChR leads to dysfunction in 
hippocampal synaptic transmission (Mulugeta et al., 2006). 
 
NBM and cortical lipid profile changes after 192IgG-saporin-induced BFCN lesion 
 MALDI-IMS analysis showed changes in the brain lipid profile of 192IgG-
saporin-treated rats. The relative intensities of different lipid species, including PC 
(phosphatidylcholines), SM (sphingomyelins), PE (phosphatidylethanolamines) and PS 
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(phosphatidylserines) were regulated in the basal forebrain and in areas of cortical 
projection. 
 ChAT enzyme has low affinities for Ch and acetyl coenzyme A, and the rate of 
synthesis of ACh mainly depends on the levels of Ch (Millington and Wurtman, 1982; 
reviewed in Blusztajnn and Wurtman, 1983). As previously mentioned, the 192IgG-
saporin-induced lesion model causes a considerable reduction in the level of ACh. 
Moreover, the loss of approximately 50% of BFCN has been associated with 40-60% 
reductions in ChAT and SDHACU activities throughout the basal forebrain cholinergic 
system (Rossner et al., 1996). In this context, the membrane phospholipids become an 
important source from which Ch can be synthesized de novo. This de novo synthesis 
requires PE from any membrane pool as a substrate to be sequentially methylated to 
PC (Bremer et al., 1960a,b). PC can be hydrolyzed to free Ch by membrane-
associated phospholypase D (PLD) activation (Hattori and Kanfer, 1984; Blusztajn et 
al., 1987a; Exton, 1999). Phosphatidylinositol 4,5-bisphosphate (PIP2), protein kinase 
C (PKC) and phorbol esters stimulate PLD activity which, furthermore, has been found 
to be reduced by up to 63% in homogenates of brain tissue samples from AD patients 
(Kanfer et al., 1986; reviewed in Exton, 1999). Then, Ch can be acetylated to form ACh 
in order to sustain neurotransmission at the expense of membrane formation which 
may finally impair synaptic plasticity or compromise membrane viability (Maire and 
Wurtman, 1985; Ulus et al., 1989). Wurtman et al. (1985) described this process as 
autocannibalism of the cholinergic cells.  
 On the other hand, the synthesis of eCB is comparable to the described 
alternative source of Ch. ECB are not stored in intracellular compartments or vesicles, 
as are other classical neurotransmitters; they are synthesized on demand by receptor-
stimulated cleavage of membrane lipid precursors. The pathways leading to the 
synthesis and release of AEA and 2-AG from neuronal and non-neuronal cells are still 
somewhat unclear. In this context, different authors have found a relationship between 
cannabinoid and cholinergic neurotransmission (Gifford et al., 1996; Kathman et al., 
2001; Fukudome et al., 2004). Therefore, it is tempting to interpret the modifications of 
lipid composition in the in vivo model of basal forebrain cholinergic dysfunction as 
potential precursors for both eCB and Ch synthesis. 
 If the hydrolysis of phospholipids from membranes of presynaptic terminals 
(cortical area) and/or the somatodendritic compartment (NBM area) served for the de 
novo synthesis of Ch, one would expect a regulation of certain lipid species in both 
anatomical regions due to the loss of approximately 80% of BFCN in the NBM and 
60% of cortical cholinergic innervations.  
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Phosphatidylcholines and phosphatidylserines 
 We found an increase in PC (36:1) + Na+ in NBM and a reduction in cortical 
regions, while PS (18:0/18:1) was found to be decreased in the NBM after the infusion 
of 192IgG-saporin. The physiological role of PC (36:1) + Na+ still remains unclear, but 
its presence in both rat and human brain, mainly in regions of white matter has been 
previously described (Jackson et al., 2005a,b; Astigarraga et al., 2008; Veloso et al., 
2011). The proliferation of glial cells and the loss of both BFCN in the NBM and in the 
cortical cholinergic axons could explain either the increase or the decrease in the levels 
of this particular species in the NBM and cortex, respectively. The characterization of 
the lipid profile of the different types of cells present in the CNS could verify this 
interpretation. Moreover, these changes may also be an indication of an adaptive 
process with which to reconstruct the axonal branching following lesioning of the 
BFCN, rather than an alternative source for de novo synthesis of Ch. 
On the other hand, under normal physiological conditions, PS (18:0/18:1) is 
preferentially located in the inner leaflet of the plasma membrane, but the loss of 
asymmetry is an early indicator of apoptosis and/or glia-mediated synaptic pruning to 
remodel the neural circuit (Fadok et al., 1992; reviewed in Bevers and Williamson, 
2016). The loss of PS asymmetry with increased externalization to the outer leaflet of 
the lipid bilayer has been described in samples from AD patients (Bader Lange et al., 
2008). 18 h after the internalization of saporin, apoptosis is induced, and apoptotic 
activity is enhanced when the toxin is bound to immunoglobulins such as 192IgG 
(Bergamaschi et al., 1996). These findings suggest that the loss of PS (18:0/18:1) in 
the NBM may be a consequence of the immunotoxin-induced depletion of BFCN and, 
therefore, is probably not related to phospholipid hydrolysis for eCB or Ch synthesis.  
 In addition, PC (40:6) + Na+ and PC (36:4) + K+, which are mainly present in the 
gray matter of rat CNS, were also found to be increased in the NBM and in the cortex. 
PC (40:6) + Na+ is probably composed of stearic acid (18:0), docosahexaenoic acid 
(DHA; 22:6), the latter being a polyunsaturated fatty acid (PUFA) which, when added to 
the diet of hypertensive rats, restores both their cerebral Ch and ACh levels and their 
performance in the passive avoidance test (Minami et al., 1997). Furthermore, there is 
a large body of evidence which indicates that DHA has important biological functions in 
neuronal homeostasis, mostly linked to its role in neurogenesis, synaptogenesis, 
neuronal differentiation, neurite outgrowth and maintenance of membrane fluidity, and 
this could be consistent with the need to repair the structural brain damage induced by 
192IgG-saporin (Belkouch et al., 2016). The most probable acyl chain composition of 
PC (36:4) + K+, is palmitic acid (16:0) and AA (20:4). Interestingly, AA is a well-known 
pro-inflammatory precursor but, indeed, phospholipids containing AA are the most 
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suitable candidates as precursors for the synthesis of the eCB, AEA and 2-AG (Di 
Marzo et al., 1994; Sugiura et al., 1995). Moreover, the synthesis of eCB can be 
stimulated not only by neuronal damage (Stella et al., 1997; Marsicano et al., 2003; 
van der Stelt et al., 2001a) but also by the activation of Gαq/11-coupled mAChR (Kim et 
al., 2002), and the suppression of CB1 receptors increases neuronal vulnerability 
(Marsicano et al., 2003). By using genetically modified mice lacking any of the 
subtypes of mAChR, it was demonstrated that Gαq/11-coupled mAChR activation is 
responsible for the PLCβ-mediated stimulation of 2-AG synthesis which finally induces 
short-term plasticity at cholinergic synapses (Fukudome et al., 2004).  
 The study of lipids in samples from AD patients reveals an enhancement of 
plasmatic levels of PC (40:6) which has been found to positively correlate with CSF tau 
concentrations in AD patients carrying the presenilin1 mutation (Chatterjee et al., 
2015). In contrast, plasmatic levels of PC (36:4) and PC (40:6) have been found to be 
decreased in AD and have been proposed as biomarkers of phenoconversion to either 
amnestic mild cognitive impairment or late-onset AD (Mapstone et al., 2014; Fiandaca 
et al., 2015). Reduced relative densities of PC species have been found in AD brains 
and attributed to a pathological hyperactivation of phospholipase A2 (PLA2) (Nitsch et 
al., 1992; Klein, 2000). The result of this is an increase in the breakdown of certain 
phospholipids and a variation in the ratio of saturated and unsaturated fatty acids in PC 
and PE (Mulder et al., 2003). These findings suggest a different regulation in the 
biosynthesis, turnover, and acyl chain remodeling of phospholipids in AD. Essential 
PUFA, such as AA and DHA, provide the structural functionality of the membranes, but 
lipid catabolism (e.g., during neurodegeneration, neuroinflammation or autophagy) 
generates intermediate metabolites that are not usually recycled, and increased 
demands are made on the bloodstream (Fiandaca el al., 2015). This could explain the 
decreased levels of PC (36:4) and PC (40:6) recorded in plasma from AD patients, in 
contrast with the increase observed in 192IgG-saporin-treated rat brains. Additional 
lipidomic studies of brain samples from AD patients are necessary to further elucidate if 
the plasmatic levels of certain lipid-based biomarkers correlate in some way with those 
levels observed directly in the brain tissue by means of imaging techniques such as 
MALDI-IMS. 
 
Sphingomyelins 
 There was a significant increase in the levels of SM (d18:1/16:0) + K+ in the 
NBM, but the SM (d18:0/18:1) + H+ was found to be significantly decreased in the 
same region. Sphingolipid metabolism is essential for tissue homeostasis and 
regulates the synthesis of several bioactive lipids and second messengers that are 
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critical in cellular signaling (Wymann and Schneiter, 2008). The sphingomyelinase–
driven catabolism of sphingolipids triggers the release and accumulation of ceramides 
which are directly involved in neurodegenerative disorders and contribute to AD 
pathology (Han et al., 2011). Interestingly, the CB1 receptor-driven breakdown of 
sphingomyelins with ceramide production has been previously described in glial cells 
(reviewed in Guzmán et al., 2001b; Velasco et al., 2005). Ceramides participate in cell 
differentiation, proliferation or apoptosis. The intracellular accumulation of ceramides 
has been described in neurodegenerative disorders including AD, Parkinson‟s disease, 
epilepsy and ischemia. Thus, the upregulated levels of SM (d18:1/16:0) + K+ observed 
may be a consequence of the necessary basal forebrain remodeling following the 
immunotoxin-induced apoptosis of BFCN rather than being related to Ch metabolism or 
eCB signaling. Recent studies have found a depletion of SM (d18:1/16:0) in CSF and a 
reduction in acid sphingomyelinase activity together with reduced levels of amyloid β42 
in AD patients (Fonteh et al., 2015). However, SM (d18:0/18:1) was found to be 
decreased in the NBM following the immunotoxin-induced lesion. The fact that CB1-
mediated endocannabinoid signaling increases following the lesion allows us to 
speculate that CB1 receptor activation in the NBM could be stimulating the hydrolysis of 
this specific SM species. In samples from AD patients, SM (d18:0/18:1) levels are 
increased in both the hippocampal gray matter and CSF, and positively correlate with 
the total CSF tau level, but negatively with the CSF amyloid β42 level (Mendis et al., 
2016; Koal et al., 2015). The relationship between the observed regulation in SM 
species with previous findings which indicate a CB1-receptor-mediated regulation of 
hippocampal endocannabinoid signaling in AD patients must be further explored 
(Manuel et al., 2014). Moreover, additional studies focused on the quantification of 
ceramides in this lesion model will contribute to a better understanding of the link 
between BFCN degeneration, CB1-mediated endocannabinoid signaling and 
deregulation of specific SM species. In the meantime, the significance of the specific 
regulation of lipid species and their physiological role in the CNS remain elusive, but 
their lipid mapping by IMS in both normal and diseased human brain and in models of 
disease would help to clarify these questions (Martínez-Gardeazabal et al., 2017; 
González de San Román et al., 2017). 
  
 Phosphatidylethanolamines 
 Interestingly, PE (14:1/20:4) and PE (40:4), both of which may be composed of 
a molecule of arachidonic acid (AA; 20:4), were found to be deregulated in the NBM, 
revealing a possible membrane phospholipid source for the synthesis of Ch since PE 
are considered as precursors for PC synthesis in the ACh synthetic pathway, as 
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explained above (Blusztajn et al., 1987a). Moreover, PE have diverse cellular functions 
and are involved in autophagy (reviewed in Calzada et al., 2016). PE are also the main 
precursor for the synthesis of eCB. The AEA precursor, NAPE, which is produced from 
the transfer of an acyl group (e.g. AA) from membrane phospholipids (e.g. PC) to the 
N-position of a PE, is catalyzed by a Ca2+-dependent trans-acylase, which correlates 
with the biosynthesis of AEA in the CNS after depolarization (Di Marzo et al., 1994). 
Thus, the relative levels of PE (14:1/20:4) are decreased, whereas PE (40:4) are 
increased in the NBM, and it is reasonable to hypothesize that these particular 
phospholipids could be being used for the synthesis of eCB since the CB1 receptor-
mediated signaling in this brain area is up-regulated, as previously demonstrated by 
autoradiographic studies, which may increase the demand for their membrane lipid 
precursors (Llorente-Ovejero et al; unpublished results). Since eCB are not apparently 
stored in vesicles, the generation of pools of lipids for further synthesis of eCB is 
difficult to understand and one would expect to observe a reduction in any possible PE 
precursors for eCB synthetic processing, pointing to PE (14:1/20:4) as a plausible 
candidate. However, the increase in the relative density of a specific lipid such as PE 
(40:4) allows us to hypothesize that a reservoir is created by an unknown storing 
mechanism from which to further synthesize eCB. 
 
 
 The muscarinic neurotransmission through M2/M4 receptors coupled to Gi/o 
proteins is not modified in cortical projection areas from the lesioned NBM. However 
other authors using a similar animal model have described that M1 and M2 mAChR 
density was increased (Rossner et al., 1995b). The relationship between muscarinic 
neurotransmission and phospholipid metabolism has also been studied previously, 
showing that the stimulation of cortical synaptosomes with cholinergic agonists was 
able to increase PLD activity, which was also dependent on PKC activity involving PIP2 
and DAG leading to the accumulation of free Ch (Qian et al., 1989). The muscarinic 
signaling-induced PLD activity was antagonized by atropine (Dolezal and Tucek, 
1984).  
 Furthermore, the eCB signaling is enhanced in cortical regions and NBM of 
192IgG-saporin-infused rats, areas with a marked decrease of cholinergic innervation. 
The relative intensities of phospholipid species containing AA, such as PE (14:1/20:4), 
PE (40:4) and PC (36:4) + K+, are also modulated in these same areas, suggesting a 
metabolic link between cholinergic neurotransmission and the eCB system. 
 In summary, it would appear that Gq-11 protein-coupled mAChR such as M1 
and/or M3 subtypes may be key modulatory elements of the phospholipid-related 
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regulation observed in this model and detailed analysis of the different phospholipases 
activities mediated by mAChR (mainly M1 and/or M3 subtypes) in this lesion model will 
contribute to further understand the underlying processes, that could link the changes 
in lipid profile with the cholinergic-cannabinoid cross-talk to compensate for the loss of 
cortical ACh supply, or conversely, represent a pathological consequence of the 
192IgG-saporin-induced massive death of BFCN in the NBM regardless of muscarinic 
signaling. 
 Several attempts to reduce the deficit of ACh in AD patients by the 
administration of cholinergic enhancers or precursors such as Ch or lecithin have 
failed, while treatments based on AChE inhibitors, phosphatidylserine, Ch alphoscerate 
and CDP-Ch provided slight, but noticeable benefits (reviewed in Amenta et al., 2001). 
Perhaps, future treatments based on potentiating cholinergic neurotransmission should 
be based on the modulation of the complex enzymatic machinery, which so finely 
regulates lipid metabolism through the mAChR-mediated signaling. In this sense, it is 
well known the mAChR-driven eCB-mediated modulation of cholinergic 
neurotransmission at excitatory synapses (Straiker and Mackie, 2007) and inhibitory 
synapses through the activation of CB1 receptors (Narushima et al., 2007). Further 
research focused on muscarinic-eCB crosstalk may be useful in the discovery of 
innovative therapeutic targets for neurodegenerative disorders.  
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Table 1. [35S]GTPγS basal and carbachol-induced (100 µM) binding in the different 
amygdaloid nuclei and hippocampus from vehicle (aCSF) and 192IgG-saporin-treated 
rats. 
 
Basal binding 
 (nCi/g t.e.) 
Carbachol  stimulation 
(% Over basal) 
 Brain region aCSF SAP aCSF SAP 
Telencephalon 
    Amygdaloid nuclei 
     Anterior  421 ± 33 402 ± 29 59 ± 9.1   47 ± 13.6 
     Basolateral 487 ± 47 390 ± 44 43 ± 6.6   48 ± 10.9 
     Central  710 ± 91 525 ± 55 27 ± 9.2 52 ± 7.8 
     Lateral  483 ± 50 425 ± 43 41 ± 9.3 36 ± 7.2 
     Medial  720 ± 94 621 ± 69 39 ± 8.5 34 ± 4.7 
Hippocampus     
CA1   
     Oriens 320 ± 40 269 ± 32 26 ± 9.4   40 ± 10.4 
     Pyramidal 527 ± 64 457 ± 50   40 ± 11.5 30 ± 6.2 
     Radiatum 363 ± 33 323 ± 36   45 ± 11.5 42 ± 9.0 
CA3   
     Oriens 317 ± 26 303 ± 38 26 ± 8.0 48 ± 6.6 
     Pyramidal 477 ± 36 453 ± 42 11 ± 5.6   32 ± 4.2* 
     Radiatum 328 ± 21 281 ± 32 28 ± 9.5    40 ± 13.0 
Dentate gyrus   
     Granular 467 ± 29 452 ± 50  27 ± 6.0    62 ± 6.7* 
     Molecular 315 ± 49 278 ± 45    34 ± 14.7  34 ± 9.5 
     Polymorphic 314 ± 58 263 ± 39    11 ± 18.2    25 ± 11.8 
 Ventral subiculum 345 ± 29 294 ± 18  37 ± 4.8  47 ± 6.7 
Data are mean ± S.E. M values from aCSF (n = 10) and SAP (n = 11) treated rats.        
* p < 0.05, when compared to aCSF group. 
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Table 2. [35S]GTPγS basal and carbachol-induced (100 µM) binding in several brain 
regions from vehicle (aCSF) and 192IgG-saporin-treated rats. 
 
Basal binding  
(nCi/g t.e.) 
Carbachol  stimulation 
 (% Over basal) 
 Brain region aCSF SAP aCSF SAP 
Cerebral cortex     
     Cingulate  304 ± 26 306 ± 20   52 ± 12.1 48 ± 6.7 
     Ectorhinal 352 ± 34 290 ± 29   66 ± 12.5 58 ± 8.0 
     Entorhinal  342 ± 35 335 ± 36   76 ± 10.5   93 ± 11.6 
     Perirhinal  338 ± 49 309 ± 29 35 ± 5.8 43 ± 3.5 
     Piriform  292 ± 27 319 ± 29   54 ± 15.2 33 ± 7.1 
     Somatosensory 355 ± 28 333 ± 20 31 ± 7.0   54 ± 10.6 
     Motor 311 ± 33 319 ± 20 21 ± 9.6 51 ± 8.2 
Basal ganglia 
335 ± 43 347 ± 36 
  
     Globus pallidus   46 ± 13.2    49 ± 12.5 
     Striatum 339 ± 26 345 ± 21   74 ± 15.4    62 ± 11.1 
Diencephalon 
535 ± 49 398 ± 31 
  
     NBM 45 ± 9.7    15 ± 6.6* 
     Horizontal diag band  310 ± 25 327 ± 31 121 ± 20.7  115 ± 17.6 
     Vertical diag band 330 ± 25 399 ± 42 135 ± 24.1  113 ± 23.2 
     Medial septum 267 ± 24 284 ± 32 152 ± 24.4  139 ± 23.7 
Rhinencephalon 
379 ± 45 324 ± 37 
  
     Lat olfactory tract   82 ± 13.1   47 ± 11.5 
Rhomboencephalon 
703 ± 103 590 ± 74 
  
     Dorsal raphe 19 ± 4.9 24 ± 4.7 
     Locus coeruleus 220 ± 36 132 ± 16   26 ± 11.9   78 ± 11.9 
Mesencephalon 
496 ± 44 469 ± 45 
  
     Periaqueductal gray   51 ± 15.0 47 ± 8.5 
     Substantia nigra 456 ± 52 399 ± 38   31 ± 10.5 37 ± 5.4 
Data are mean ± S.E. M values from aCSF (n = 10) and SAP (n = 8) treated rats.          
* p < 0.05, when compared to aCSF group. 
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Figure legends 
Figure 1. (A) Acquisition latency times in the learning trial of the passive avoidance test 
of SHAM (n = 6), aCSF (n = 32) and SAP (n = 32) rats. The figure shows the mean ± 
SEM of each group. (B) Step-through latency times in the retention trial of the passive 
avoidance test, represented as Kaplan-Meier survival curves. The median step-through 
latency or the time spent to enter the dark compartment by 50% of the immunotoxin-
treated population should be 102,9 seconds (aCSF vs SHAM p = n.s.; SAP vs aCSF p 
< 0.001, Log-rank test). 
Figure 2. (A and B) AChE staining in representative brain slices at three different levels 
of aCSF and 192IgG-saporin-treated rats. (C) Microphotographs from different cortical 
regions of aCSF and 192IgG-saporin-treated rats at 400-fold magnification, revealing 
the decrease in AChE positive fibers in immunotoxin-treated rats (scale bar = 20 µm). 
(D) The histograms show the optical density of AChE expressed as percentages of the 
striatum (used as control area) in aCSF (n = 13) and SAP (n = 13) treated rats. *p < 
0.05; **p < 0.01 and ***p < 0.001 vs aCSF-treated rats. MS: medial septum; Cg: 
cingular cortex; Mot: motor cortex; Ss: somatosensory cortex; Pir: piriform cortex; Ent: 
entorhinal cortex; Amyg: amygdala; DG: dentate gyrus. 
Figure 3. [35S]GTPγS autoradiography in representative brain coronal slices at two 
different levels (A and B) and (C and D) obtained from aCSF and 192IgG-saporin-
treated rats that show [35S]GTPγS basal binding (A and C) and carbachol-evoked (100 
µM) stimulation of muscarinic M2/M4 mAChR (B and D). NBM: nucleus basalis 
magncellularis; Granular DG: granular dentate gyrus; CA3: CA3 region of 
hippocampus. [14C]-microscales used as standards in nCi/g t.e. Scale bar: 5 mm. 
Figure 4. Double labeling in slices containing NBM from representative aCSF (A) and 
192IgG-saporin-treated (B) rats, stained for ChAT (red) and M2 mAChR (green) at 200-
fold magnification. 192IgG-saporin induced a reduction in BFCN density and in M2 
mAChR-immunoreactivity. Scale bar = 40 µm. High magnification images reveal a 
particular M2 mAChR-immunostaining pattern surrounding the perikarya (A-II) of the 
large BFCN (A-I) which show a presynaptic localization and a presumable distribution 
in plasmatic membrane, but with a modest degree of co-localization (A-IV). 
Interestingly, 192IgG-saporin-treated rats showed the presence of ChAT (B-I), whereas 
the loss of mAChR immunoreactivity is evident (B-II). Scale bar = 10 µm. 
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Figure 5. Double labeling in slices containing NBM from a representative aCSF (A) and 
192IgG-saporin-treated rat (B), stained for ChAT (red) and M4 mAChR (green) at 200-
fold magnification. 192IgG-saporin induced a reduction in BFCN density and in M4 
mAChR-immunoreactivity. Scale bar = 40 µm. High magnification images reveal a 
somatodendritic M4 mAChR-immunostaining pattern surrounding the perikarya (A-II) of 
the large BFCN (A-I) with a high degree of co-localization. There was a reduction of M4 
mAChR-immunoreactivity (B-II) but ChAT still remained in BFCN (B-I) in 192IgG-
saporin-treated rats. Scale bar = 10 µm. 
Figure 6. Double labeling of consecutive slices containing hippocampal CA3 pyramidal 
region (A and B) and somatosensory cortex (C and D) from a representative aCSF-
treated rat, stained for ChAT (red), M2 mAChR (A and C in green) and M4 mAChR (B 
and D in green) at 630-fold magnification. The images show a presumable presynaptic 
distribution of M2 mAChR, delineating the perikarya of the large CA3 pyramidal 
neurons in basket-like formations (A) and the somatodendritic distribution of M4 
mAChR in the perikarya of the same neurons (B). In the cortex, both M2 (C) and M4 (D) 
mAChR distribution displays a similar pattern to that observed in CA3. Scale bar = 10 
µm. 
Figure 7. (A) The histograms show the relative abundance of different lipid species in 
NBM (left) and cortex (right), expressed as percentages of the values obtained in the 
aCSF-treated group. (B) Matrix-assisted laser desorption ionization-imaging mass 
spectrometry (MALDI-IMS) of different lipids in brain slices containing the NBM and 
cortical projections from representative aCSF and 192IgG-saporin-treated rats. The 
intensities were measured in the black squares of the somatosensory cortex and the 
NBM. *p < 0.05; **p < 0.01 and ***p < 0.001 vs aCSF-treated rats. PC 
(phosphatidylcholines); PE (phosphatidylethanolamines); PS (phosphatidylserines); 
SM (sphingomyelin); PG (phosphoglycerol). Scale bar = 5 mm. 
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Abstract 
During the progression of Alzheimer’s disease, the basal forebrain cholinergic pathways 
progressively degenerate, leading to an irreversible impairment of memory and thinking skills. 
In the rat, a stereotaxic lesion with 192IgG-saporin removes basal forebrain cholinergic 
neurons, mimicking this process, and is used to test the effects on behavior and on 
neurotransmission. The modulation of cholinergic neurotransmission by the endocannabinoid 
system is thought to affect learning and memory processes by cannabinoid compounds. 
Therefore, we evaluated endocannabinoid signaling in relation to the memory impairment 
induced in adult male rats following a specific cholinergic bilateral lesion of the nucleus basalis 
magnocellularis. The lesion was further evaluated by histochemical studies, and the signaling 
mediated by CB1 receptors was analyzed by both receptor and functional autoradiography and 
immunofluorescence. The passive avoidance test and histochemical data revealed a relationship 
between impaired behavior and a loss of up to 75% of cholinergic neurons in the nucleus basalis 
magnocellularis, accompanied by the corresponding cortical cholinergic denervation. The 
receptor and functional autoradiographic assays showed that there was a decrease in CB1 
receptor density in the hippocampus together with hyperactivity of endocannabinoid signaling 
in the cortex. Immunofluorescence studies revealed the loss of almost a third of the presynaptic 
GABAergic terminals in cortical and subcortical areas innervated by nucleus basalis 
magnocellularis cholinergic neurons. CB1 receptors seem to be present at presynaptic 
GABAergic terminals in hippocampus, but in glutamatergic synapses in cortex. We propose that 
there is a CB1 receptor-mediated compensation of the endocannabinoid tone to modulate the 
loss of cortical inhibitory terminals induced by the basal forebrain cholinergic denervation. 
Keywords: nucleus basalis magnocellularis, 192IgG-saporin, memory, autoradiography, CB1 
receptors, GABA. 
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Abbreviations 
AChE  Acetylcholinesterase  
aCSF  Artificial cerebrospinal fluid 
AU  Arbitrary units 
BFCN  Basal forebrain cholinergic neurons 
CB1 receptor Type-1 cannabinoid receptor  
ChAT  Choline acetyltransferase 
eCB  Endocannabinoid 
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1. Introduction 
 Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that slowly but 
irreversibly impairs memory and thinking skills. Studies in humans indicate the relevance of the 
basal forebrain cholinergic pathways in the control of conscious awareness, attention, working 
memory, and a number of additional mnemonic processes (Perry et al., 1999). The first 
evidence of basal forebrain cholinergic damage in AD was reported in the 70s (Davies and 
Maloney, 1976; Perry et al., 1977; Davies, 1979; Whitehouse et al, 1982) and lead to the 
“cholinergic hypothesis of geriatric memory dysfunction” (Bartus et al., 1982). During the 
progression of AD a reduction in choline acetyltransferase (ChAT) activity (Davies, 1979) and 
in M2 muscarinic acetylcholine receptor density in cholinergic innervated areas such as the 
hippocampus and the entorhinal cortex has been reported (Rodríguez-Puertas et al., 1997). 
Notwithstanding its limited efficacy, the inhibition of acetylcholinesterase (AChE) has proven 
to be the most viable therapeutic target for symptomatic improvement. Between 60% and 90% 
of AD patients develop neuropsychiatric symptoms including hallucinations, delusions, 
agitation/aggression, dysphoria/depression, anxiety, irritability, disinhibition, euphoria, apathy, 
aberrant motor behavior, sleep disturbances, appetite and eating changes and altered sexual 
behavior, implying alterations to multiple neurotransmission systems (Cummings et al., 2016). 
In this context, the endocannabinoid (eCB) system, through the modulation of the synaptic 
signaling pathways activated by cannabinoid receptors, is a promising target for the treatment of 
several neurological disorders, including AD. Thus, several studies have reported alterations in 
postmortem AD brain samples both in CB1 (Westlake et al., 1994; Manuel et al., 2014) and CB2 
receptors (Benito et al., 2003), but also changes in the enzymatic machinery and in eCB levels 
(Mulder et al., 2011; D'Addario et al., 2012; Pascual et al., 2014). There is a great deal of 
evidence in the literature about the signaling crosstalk between cannabinoid and cholinergic 
systems both in vitro, by using cortical and hippocampal membranes (Gifford et al., 2000), and 
in vivo, by using CB1 receptor deficient mice (Kathmann et al., 2001) or after the administration 
of cannabinoid synthetic agonists (Tzavara et al., 2003). Moreover, cannabinoid administration 
specifically reduces the turnover rate of acetylcholine in the hippocampus in a dose-dependent 
manner (Revuelta et al., 1980), while muscarinic cholinergic receptor activation enhances the 
release of eCB in this area (Kim et al., 2002). The synthesis of eCB is also increased five-fold 
by the simultaneous activation of NMDA and acetylcholine receptors in cortical neurons (Stella 
and Piomelli, 2001).  
The present study analyzes eCB signaling by focusing on CB1 receptors in a useful model with 
which to test the cholinergic hypothesis of AD, i.e., after inducing the specific depletion of 
basal forebrain cholinergic neurons (BFCN) in the nucleus basalis magnocellularis (NBM) of 
adult rats with the immunotoxin 192IgG-saporin. This immunotoxin is directed against the low-
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affinity nerve growth factor receptor (P75
NTR
) which is primarily expressed on the soma and 
nerve terminals of BFCN of adult rats. Firstly, we established the validity of the model by using 
the passive avoidance test to evaluate learning and memory. This test measures the ability of 
rats to recognize and avoid an environment in which they have previously received a noxious 
stimulus (Tulving, 2002). Following the test, the extent of the lesion in the basal forebrain 
cholinergic system was established by histochemical methods and CB1 receptor-mediated eCB 
signaling was analyzed in the basal forebrain cholinergic pathways by using autoradiographic 
and immunofluorescent approaches. 
 
 
2. Materials and Methods 
 
2.1. Chemicals 
 192IgG-saporin (Batch 2441969) was acquired from Millipore (Temecula, CA, USA). 
[
35
S]GTPγS (1250 Ci/mmol) and [3H]CP55,940 (131.8 Ci/mmol) were purchased from 
PerkinElmer (Boston MA, USA), WIN55,212-2 and CP55,940 from Sigma-Aldrich (St Louis, 
MO, USA), SR141716A (rimonabant) from Tocris and SR144528 from Cayman-Chemicals 
(MI, USA). The [
14
C] and [
3
H]-microscales, used as standards in the autoradiographic 
experiments, were purchased from ARC (American Radiolabelled Chemicals, St Louis, MO, 
USA). Kodak Biomax MR β-radiation sensitive films, bovine serum albumine (BSA), DL-
dithiothreitol (DTT), adenosine deaminase, guanosine 5´-diphosphate (GDP), guanosine5´-O-3-
thiotriphosphate (GTPγS), ketamine, xylazine, oxytetracycline and Hoechst 33258 were 
acquired from Sigma-Aldrich. All the compounds necessary for the preparation of the different 
buffers, the fixation and the treatment of slides were of the highest commercially available 
quality. 
 
2.2 Animals 
 Forty six adult male Sprague-Dawley rats, weighing 225-275 g and ranging in age from 
8 to 10 weeks at the onset of the experiment, were used in this study. Rats were housed four per 
cage in individual 50 cm (length) x 25 cm (width) x 15 cm (height) cages at a temperature of 
22ºC and in a humidity-controlled (65%) room with a 12:12 hours light/dark cycle, with access 
to food and water ad libitum. All procedures were performed in accordance with European 
animal research laws (Directive 2010/63/EU) and the Spanish National Guidelines for Animal 
Experimentation (RD 53/2013, Law 32/2007). Experimental protocols were approved by the 
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Local Ethical Committee for Animal Research of the University of the Basque Country (CEEA 
388/2014). 
 
2.3 Basal forebrain cholinergic lesion  
 All surgery was carried out under aseptic conditions. 192IgG-saporin was used to 
selectively eliminate cholinergic neurons in the NBM. Rats were randomly assigned to one of 
two groups: artificial cerebrospinal fluid as vehicle (aCSF; n = 22) and 192IgG-saporin (SAP; n 
= 24). The vehicle was prepared as follows: 0.15 M NaCl, 2.7 mM KCl, 0.85 mM MgCl2, 1.2 
mM CaCl2 (pH 7.4) and sterilized by filtration with 0.4 µm-Ø filters (EMD Millipore, CA, 
USA). Rats were anesthetized with ketamine/xylazine (90/10 mg/kg; s.c.) and then placed in a 
stereotaxic instrument (Kopf, Tujunga, CA). After an incision was made in the skin along the 
midline of the skull, two holes were drilled and by using a 10-µl Hamilton syringe (Neuros
TM
 
Syringe, 7000 series; Bonaduz, Switzerland) with a 26-gauge needle, the intraparenchymal 
infusions were made into the NBM: - 1.5 mm anteroposterior from Bregma, ± 3 mm 
mediolateral from midline and + 8 mm dorsoventral from cranial surface (Paxinos and Watson, 
2005). 192IgG-saporin was dissolved in aCSF under aseptic conditions to a final concentration 
of 130 ng/µl. aCSF or 192IgG-saporin was bilaterally injected (1 µl/hemisphere) at a constant 
rate of 0.2 µl/min. The needle was kept in for 5 min before removal to avoid a possible 
backflow and to allow complete diffusion. During surgery, the body temperature was controlled 
and the eyes were kept hydrated with warm saline solution (0.9% NaCl). After the 
administration was completed, the wounds were closed with braided silk sutures and a broad-
spectrum antibiotic injection was given (oxytetracycline, 2.25 mg/kg; i.m.). The choice of 
coordinates, infusion rate, volume and dose of the immunotoxin were based on previous 
experiments performed in our laboratory. 
 
2.4 Passive avoidance test 
 The rats were allowed seven days to recover from surgery and were then subjected to 
the passive avoidance test (PanLab passive avoidance box LE870/872). The apparatus consists 
of two methacrylate compartments separated by a guillotine door; one large white, illuminated 
and open-topped compartment: 31 cm (W) x 31 cm (D) x 24 cm (H), and the other small, black 
and closed compartment: 19.5 cm (W) x 10.8 cm  (D) x 12 cm (H). Briefly, the test consists of 
two sessions. The first, called “the acquisition session”, was performed on day 7 after the 
surgery. Each animal was gently placed in the illuminated compartment and allowed to explore 
it for 30 sec. Then, the guillotine door was automatically opened and the animal was allowed to 
enter the dark compartment for 60 sec. When the rat crossed the door-way, the door closed, the 
acquisition latency was measured, and a scrambled foot shock (0.4 mA/2 sec) was delivered. 10 
sec after the foot shock, the rat was returned to its home cage. The rats that did not enter the 
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dark compartment were eliminated from the study. 24 h later, in the “retention session”, the rats 
were again placed in the illuminated compartment and allowed to explore for 30 sec. Then the 
door opened and the step through latency time to enter the dark compartment was measured up 
to a maximum cut-off time of 300 sec. 
 
2.5 Tissue preparation 
 Following the passive avoidance test, the animals were anesthetized with 
ketamine/xylazine (90/10 mg/kg; i.p.). 
 Fixed tissue. Representative animals from aCSF (n = 5) and SAP (n = 5) groups were 
transcardially perfused with 0.1 M phosphate buffer (PB), 0.5% heparinized (37ºC, pH 7.4) 
followed by 4% paraformaldehyde and 3% picric acid in 0.1M PB (4ºC) (100 ml/100 g b.w.). 
Their brains were subsequently removed and post-fixed in the same fixative solution for 90 min 
at 4ºC, followed by immersion in a cryoprotective solution of 20% sucrose in PB overnight at 
4ºC. Then the tissue was frozen by immersion in isopentane and kept at -80ºC. The brains were 
coronally cut into 10 µm slices using a Microm HM550 cryostat (Thermo Scientific) equipped 
with a freezing-sliding microtome at -25ºC, mounted onto gelatin-coated slides and stored at -
25ºC until used.  
 Fresh tissue. Another group of animals was euthanized by decapitation and the brain 
samples from aCSF (n = 17) and SAP (n = 19) groups were quickly removed by dissection, 
fresh frozen and kept at -80ºC. Later they were cut into 20 µm and mounted onto gelatin-coated 
slides and stored at -25ºC until used. 
 
2.6 Detection of BFCN in fresh tissue slices 
 Prior to histochemical or immunostaining procedures, all slices were air dried for 20 
min and fresh tissue slices were post-fixed in 4% paraformaldehyde in PBS for 30 min at 4ºC 
and washed in 0.1 M saline phosphate buffer, pH 7.4 (PBS), for 20 min.  
AChE staining and basal forebrain cholinergic neuron immunolabeling. BFCN in the 
NBM and cholinergic innervations were stained using the “direct coloring” thiocoline method 
for AChE (Karnovsky and Roots, 1964). The slices were rinsed twice in 0.1 M Tris-Maleate 
buffer (pH 6.0) for 10 min and incubated in complete darkness with constant, gentle agitation in 
the AChE reaction buffer: 0.1 M Tris-Maleate; 5 mM sodium citrate; 3 mM CuSO4; 0.1 mM 
iso-OMPA; 0.5 mM K3Fe(CN)6 and 2 mM acetylthiocholine iodide as reaction substrate. The 
incubation times were from 30 min for staining cholinergic somas in NBM and 100 min for 
staining cholinergic fibers in the areas of innervation. Finally, the enzymatic reaction was 
stopped in two consecutive washes (2x10 min) in 0.1 M Tris-maleate (pH 6.0). Slices were then 
dehydrated in increasing concentrations of ethanol and covered with DPX as the mounting 
medium. 
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P75
NTR
immunolabeling. Consecutive slices to those stained for AChE were blocked and 
permeabilized with 4% normal goat serum (NGS) in 0.3% Triton X-100 in PBS (0.1 M, pH 7.4) 
for 2 h at room temperature (22 ± 2ºC). To detect cholinergic neurons in NBM, the slices were 
incubated at 4ºC overnight with rabbit monoclonal anti-P75
NTR
 antibody (1:750) (Cell 
Signaling, MA, USA) and diluted in 0.3% Triton X-100 in PBS with 5% BSA. The primary 
antibody was then revealed by incubation for 30 min at 37ºC in darkness with Alexa-Fluor 488 
donkey-anti-rabbit (1:250) (Invitrogen, CA, USA) diluted in Triton X-100 (0.3%) in PBS. Then, 
slices were washed for 30 min by immersion in PBS and incubated with Hoechst 33258 for 15 
min at room temperature. Finally, slices were extensively rinsed with PBS and mounted with p-
phenylendiamine-glycerol (0.1%) in PBS for immunofluorescence. 
 
2.7 CB1 receptor immunofluorescence in fixed tissue 
 To label CB1 receptors, the primary rabbit antiserum against the CB1 receptor, PA1-743, 
(Affinity BioReagents, CO, USA) was diluted [1:500] in TBS (0.1 M Tris, 0.15 M NaCl, pH 
7.4) containing 0.5% milk powder. Fixed 10 µm coronal slices from aCSF and 192IgG-saporin-
infused rats were air dried for 20 min and washed by immersion in PBS for 15 min at room 
temperature. Then, the slices were blocked with 5% NGS in TBS buffer for 2 h at room 
temperature before being incubated with the primary antibody overnight at 4ºC. The tyramide 
signal amplification method was used to amplify the signal associated with the CB1 receptor 
antiserum. Briefly, slices were washed for 30 min in TNT buffer (0.05% Tween 20 in TBS, pH 
7.4) and blocked in TNB solution (10 ml TNT buffer, 0.05 g blocking reagent, DuPont) for 1 h 
at room temperature. Later, the slices were incubated with horse radish peroxidase-conjugated 
goat anti-rabbit secondary antibody (1:150; Perkin Elmer, MA, USA) for 1 h followed by 
tyramide-fluorescein-based amplification (1:100, Perkin Elmer, MA, USA) process in complete 
darkness for 10 min at room temperature. Slices were extensively rinsed in TBS.  
 
2.8 Double immunofluorescence studies  
To study the cellular localization of CB1 receptors on glutamatergic or GABAergic 
neurons, primary guinea pig monoclonal antiserum against vesicular glutamate transporter type 
3 (VGLUT3) (1:500) and mouse monoclonal anti-glutamic acid decarboxylase (GAD-65) 
(1:750) (EMD Millipore, CA, USA) were used respectively following the CB1 receptor 
immune-detection. Primary antibodies were diluted in PBS (0.1 M, pH 7.4) containing 0.5% 
BSA and two consecutive 10 µm slices were incubated overnight at 4ºC. Slices were washed for 
30 min in PBS and incubated with secondary Alexa-Fluor 555 donkey anti-guinea pig [1:250] 
or Alexa-Fluor 555 donkey anti-mouse [1:250] for 30 min at 37ºC. Then, slices were washed for 
30 min at room temperature by immersion in PBS and incubated with Hoechst 33258 [1:10
6
] for 
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15 min at room temperature. Finally, slices were washed for 15 min by immersion in PBS and 
mounted with p-phenylendiamine-glycerol (0.1%) for immunofluorescence. 
 
2.9 Quantitative analyses of BFCN and AChE positive fibers  
 200-fold magnification photomicrographs from aCSF (n = 19) and SAP (n = 21) rats 
were acquired by using an Axioskop 2 Plus microscope (Zeiss) equipped with a CCD imaging 
camera (SPOT Flex Shifting Pixel). Cholinergic neurons of NBM were counted independently 
by two observers at three different stereotaxic levels (-1.08 mm, -1.56 mm and -2.04 mm 
anteroposterior from Bregma) and the total number of BFCN (N) in the whole image was 
obtained. The population of BFCN was expressed as N/mm
3
. 200-fold magnification P75
NTR
 
immunofluorescence images were used to study BFCN density in the NBM. The quantification 
of P75
NTR 
positive cells was conducted in the same manner as that performed for the AChE 
stained samples described above.  
AChE stained slices were scanned at 600 ppi and AChE positive fiber density was quantified 
using Image J software (NIH, Bethesda, MD, USA). The images were converted to 8-bit grey-
scale mode. This software defines the OD of an anatomical area and the background from 0 
(white) to 255 (black). Background or non-specific staining values were substracted from AChE 
positive signal to obtain the net AChE OD in each area. 
 
2.10 Semiquantitative analyses of GAD65 immunoreactivity 
 200-fold magnification photomicrographs from aCSF (n = 5) and SAP (n = 5) samples 
were acquired by using an Axioskop 2 Plus microscope (Carl Zeiss) equipped with a CCD 
imaging camera (SPOT Flex Shifting Pixel). All the images were acquired at the same brain 
coordinates with the same illumination and exposure time and contrasted to the same level. The 
GAD65 immunoreactivity was measured as arbitrary units (AU) of optical density (OD) by 
using Image J software (NIH, Bethesda, MD, USA). We applied the same brightness and 
contrast to all images, and mean intensity values were defined by the software in the selected 
equivalent areas from both hemispheres in all the animals. The average value from both 
hemispheres was calculated for each animal. 
 
2.11 [
3
H]CP55,940 autoradiography 
 Fresh 20 µm brain slices from each animal in aCSF (n = 8) and SAP (n = 8) groups 
were dried and submerged in 50 mM Tris-HCl buffer containing 1% of BSA (pH 7.4) for 30 
min at room temperature, followed by incubation in the same buffer, but in the presence of the 
CB1/CB2 receptor radioligand, [
3
H]CP55,940 (3 nM) for 2 h at 37ºC. Nonspecific binding was 
measured by competition with non-labelled CP55,940 (10 µM) in another consecutive slice. The 
CB1 receptor antagonist, SR141716A (0.1 µM) and the CB2 receptor antagonist, SR144528 (0.1 
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µM), were used together with [
3
H]CP55,940 in two consecutive slices to check the CB1 or CB2 
receptor binding specificity. Then, slices were washed in ice-cold (4ºC) 50 mM Tris-HCl buffer 
supplemented with 1% BSA (pH 7.4) to stop the binding, dipped in distilled ice-cold water and 
dried (4ºC). Autoradiograms were generated by exposure of the tissues for 21 days at 4ºC to β-
radiation sensitive films and [
3
H]-microscales were used to calibrate the optical densities to 
fmol/mg tissue equivalent (fmol/mg). 
  
2.12  [
35
S]GTPγS autoradiography  
 The functional coupling of cannabinoid receptors to Gi/o proteins was performed as 
follows: fresh frozen 20 µm slices from each animal in aCSF (n = 9) and SAP (n = 11) groups 
were dried, followed by two consecutive incubations in HEPES-based buffer (50 mM HEPES, 
100 mM NaCl, 3 mM MgCl2, 0.2 mM EGTA and 0.5% BSA, pH 7.4) for 30 min at 30ºC. Then, 
slices were incubated for 2 h at 30ºC in the same buffer supplemented with 2 mM GDP, 1 mM 
DTT, adenosine deaminase (3-Units/l) and 0.04 nM [
35
S]GTPγS. The [35S]GTPγS basal binding 
was determined in two consecutive slices in the absence of the agonist. The agonist-stimulated 
binding was determined in the same reaction buffer in the presence of the CB1/CB2 receptor 
agonist, WIN55,212-2 (10 µM). The CB1 receptor antagonist, SR141716A (0.1 µM), was used 
together with WIN55,212-2 (10 µM) in one consecutive slice to check the CB1 receptor specific 
activation. Nonspecific binding was defined by competition with GTPγS (10 µM) in another 
section. Then, slices were washed twice in cold (4ºC) 50 mM HEPES buffer (pH 7.4) and dried. 
Finally, the slides were exposed to β-radiation-sensitive autoradiography films with a set of 
[
14
C] standards (nCi/g tissue equivalent) to calibrate the images (gray densities) in hermetically 
closed cassettes. Autoradiograms were generated by exposing the tissue for 48 h with [
14
C]-
microscales, which were used as calibration standards. Then, they were scanned and quantified 
and the percentages of WIN55,212-2-evoked stimulations were calculated according to the 
following formula: ([
35
S]GTPγS agonist-stimulated binding  x 100/[35S]GTPγS basal binding) - 
100.  
 
2.13 Statistical analyses 
 The step through latency was represented as Kaplan-Meier survival curves and for 
comparisons between groups the Log-rank test was used. The acquisition latency, BFCN 
density, percentages of agonist-evoked [
35
S]GTPγS stimulation, [3H]CP55,940 density and 
GAD65 OD were statistically analyzed using the two-tailed unpaired Student t test. Correlations 
between different neurochemical data were examined by linear regression analysis and the 
Pearson´s correlation coefficient was calculated. The statistical significance threshold was set at 
p < 0.05.  
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3. Results 
 
3.1 Learning and memory impairment after basal forebrain cholinergic lesion 
 AChE enzymatic assay was used to stain BFCN somas and cholinergic fibers in the 
projecting areas, while P75
NTR
 immunofluorescence assay was directed at the same target as that 
of the immunotoxin used (192IgG-saporin) and stained the somatodendritic compartment of 
BFCN. The intraparenchymal injection of 192IgG-saporin in the NBM resulted in an extensive 
reduction of AChE staining (1032 ± 50 cells/mm
3
 in aCSF group and 270 ± 23 cells/mm
3 
in 
SAP group; p < 0.0001) and P75
NTR
 immunoreactive (973 ± 53 cells/mm
3
 and 226 ± 25 
cells/mm
3
 in aCSF, and SAP group respectively; p < 0.0001) BFCN (Figs. 1A and B). The 
greatest loss of cholinergic afferents was observed in the motor (60%), somatosensory (65%) 
and entorhinal (40%) cortices (p < 0.001 vs aCSF). The linear regression analysis confirmed 
that a relationship exists between fewer BFCN and lower AChE fiber density in cortical areas, 
including the entorhinal cortex (R
2
= 0.5536, p < 0.001). There was a more modest loss of 
cholinergic fibers in other cortical areas such as the cingulate (20%) and piriform (15%) (p < 
0.05 vs aCSF) and in CA3 (10%) and dentate gyrus (15%) in the hippocampus (p < 0.05 vs 
aCSF) (data not shown). 
To examine learning and memory, the animals were trained and tested using the passive 
avoidance test. Seven days after the surgical procedure we evaluated the acquisition latency (the 
time that rats stayed in the open compartment) before being subjected to an aversive stimulus on 
entering the dark, closed compartment. No differences were observed for acquisition latency 
between the two groups (10.5 ± 1.7 sec and 9.78 ± 1.6 sec; aCSF and SAP, respectively) (Figure 
1C). 24 h later, rats were again tested to evaluate the step through latency which was measured 
and represented as Kaplan-Meier survival curves to determine the estimated probability of a 
positive response (i.e. to reach the cut-off time). When the groups were compared, 88% of the 
aCSF-treated rats remembered the aversive stimulus and displayed a positive response. 
However, only 26% of the rats treated with 192IgG-saporin remembered the aversive stimulus 
(p = 0.029; Log-Rank/Mantel-Cox test) (Figure 1D). The median latency, i.e. the time that 50% 
of the animals took to cross the doorway, was 28.4 sec for 192IgG-saporin-treated rats. 
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Figure 1 
 
 
3.2 CB1 receptor density after basal forebrain cholinergic lesion 
In this study we analyzed both the density and activity of CB1 cannabinoid receptors by 
using autoradiography. The rats treated with 192IgG-saporin showed no changes in 
[
3
H]CP55,940 binding in the cortical areas studied, but we found an increase in [
3
H]CP55,940 
binding in the NBM (180 ± 13 fmol/mg and 364 ± 63 fmol/mg in aCSF and SAP-treated rats, 
respectively, p < 0.05) and decreases in some hippocampal subregions (oriens CA1: aCSF 1057 
± 67 fmol/mg and SAP 721 ± 92 fmol/mg, p < 0.05; molecular dentate gyrus: aCSF 900 ± 63 
fmol/mg and SAP 603 ± 71 fmol/mg, p < 0.01) (Figure 2B, Table 1). CP55,940 shows high 
affinity for both CB1 and CB2 receptors. Therefore, using two different cannabinoid antagonists 
we checked the CB1 receptor specificity of the results. SR141716A, a CB1 receptor antagonist, 
completely blocked the binding of [
3
H]CP55,940 (Figure 2C) while SR144528, a CB2 receptor 
antagonist, failed to do so (Figure 2D), providing evidence that the changes in [
3
H]CP55,940 
binding are specifically related to CB1 receptors. 
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Figure 2. 
 
 
3.3 Endocannabinoid signaling deregulation in areas of cholinergic innervation 
To study whether the changes in receptor density are reflected by CB1 receptor activity 
mediated by Gi/o protein signaling, we used the [
35
S]GTPγS functional autoradiography 
technique. Basal binding values were similar in the two groups (aCSF and SAP) in all of the 
brain areas analyzed (Tables 2-3, Figure 3 A and C). The anatomical analysis of [
35
S]GTPγS 
binding induced by the CB1 receptor agonist, WIN55,212-2, revealed changes in the functional 
coupling of cannabinoid receptors to Gi/o proteins. Thus, the stimulation of [
35
S]GTPγS binding 
was enhanced in several cortical regions (entorhinal: aCSF 156 ± 17% vs SAP 277 ± 30%, p < 
0.01; motor: aCSF 127 ± 20% vs SAP 203 ± 14%, p < 0.05; piriform: aCSF 72 ± 10% vs SAP 
122 ± 9%, p < 0.001; somatosensory: aCSF 131 ± 29% vs SAP 218 ± 11%, p < 0.05), and was 
more evident in the inner layers, such as the layer VI of the entorhinal cortex (Table 2, Figure 3 
B and D). 
Also, in the striatum (aCSF 178 ± 28% vs SAP 252 ± 19%, p < 0.05) and in the NBM 
(aCSF 103 ± 18% vs SAP 142 ± 9%, p < 0.05) there was an increase in WIN55,212-2-induced 
functional coupling of CB1 receptors to Gi/o proteins (Table 3). However, in the hippocampus 
and, in accordance with the results related to CB1 receptor density, we found a decrease in the 
activity in the molecular layer of dentate gyrus (aCSF 299 ± 37% vs SAP 166 ± 25%, p < 0.05) 
(Figure 3B, Table 3). SR141716A almost completely blocked WIN55,212-2-evoked binding of 
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[
35
S]GTPγS which indicates that the changes in eCB signaling were due to CB1 receptor-
specific changes. 
 
Figure 3. 
 
 
3.4 Linear regression analysis between CB1 receptor changes and the number of surviving 
BFCN 
To examine the relation between the results of the autoradiographic assays and BFCN 
density, firstly we correlated [
3
H]CP55,940 binding (fmol/mg) with the number of cholinergic  
neurons in the NBM by using regression analyses. These analyses showed that 40% in NBM (p 
= 0.011), 29% in dentate gyrus (p = 0.047) and 36% in CA1 (p = 0.018) of the variation in the 
density of CB1 receptors could in some way be attributable to the loss of BFCN. The lower the 
BFCN density, the higher the CB1 receptor density in NBM and the lower in hippocampus, 
showing a different modulation depending on the brain area studied (Figure 4A). Then, we 
correlated the number of BFCN with CB1 receptor activity, and similar results were obtained. 
Thus, the regression models showed that 39% in NBM (p = 0.007), 63% in striatum (p = 
0.0002) and 40% in dentate gyrus (p = 0.009) of the variation in the functional coupling of 
cannabinoid receptors to Gi/o proteins might be related to the loss of BFCN (Figure 4B). When 
we analyzed the entire cortical mantle we found the lower the number of BFCN, the higher the 
CB1 receptor activity. The regression models showed that 28% in motor (p = 0.02), 40% in 
somatosensory (p = 0.0025), 24% in entorhinal (p = 0.0349) and 43% in piriform cortices (p = 
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0.002) of the increase in the CB1 receptor activity could be related to the basal forebrain 
cholinergic lesion (Figure 4C). 
 
Figure 4.  
 
 
3.5 Localization of CB1 receptor and GAD65 by immunofluorescence  
 The subcellular localization of CB1 receptors was determined by immunofluorescence 
studies using an antiserum against the C-terminus of the human CB1 receptor. The regional 
distribution pattern of immunostaining was similar to that observed in the autoradiographic 
studies. Some areas exhibited very high CB1 receptor expression, such as the olfactory bulb, 
globus pallidus, substantia nigra, amygdala and hippocampus. The different hippocampal layers 
exhibited differential CB1 receptor-immunostaining patterns and were clearly defined. We 
studied the co-localization of CB1 receptors with GAD65, the smaller isoform of the enzyme 
glutamate decarboxylase, which is mainly associated with nerve terminals (Kash et al., 1999), 
and with VGLUT3, the third subtype of glutamate vesicular transporter, mainly expressed in 
synaptic boutons, but also in somatodendritic compartments (Herzog et al., 2004). The abundant 
and dense CB1 receptor immunoreactive puncta observed suggested a predominant localization 
of CB1 receptors in presynaptic terminals with similar densities in both groups of animals. 
Immunofluorescence assays for GAD65 and VGLUT3 and the subsequent co-localization 
studies allowed us to confirm the inhibitory nature of presynaptic boutons which express CB1 
receptors in the hippocampus (Figure 5A). Although GAD65 and VGLUT3 had different 
patterns of distribution, no differences in the immunostaining pattern were observed between 
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the two groups studied and therefore, the immunofluorescent images shown in figure 5 
correspond to rats treated with 192IgG-saporin, in which GAD65 immunoreactivity was lower 
than in the aCSF-treated rats. Thus, GAD65 immunoreactivity was seen as a dense plexus of 
immunoreactive puncta around the pyramidal neurons and had a similar distribution to CB1 
receptors (Figure 5Ai), while VGLUT3 displayed a postsynaptic somatodendritic 
immunostaining (Figure 5Aii). The studies of co-localization that were performed in the Z-axis 
with a 0.24-µm resolution by using structured illumination revealed an optimal penetration of 
the antibody in the tissue. The presence of CB1 receptors in presynaptic GABAergic terminals, 
with a high degree of co-immunoreactivity with GAD65 was observed (Figure 5Ai-YZ/XZ). 
CB1 receptor immunostaining was found surrounding the VGLUT3-expressing somatodendritic 
compartment and a Z-stack analysis revealed the almost total absence of co-immunoreactivity 
with VGLUT3 (Figure 5Aii-YZ/XZ).  
However, in the cortex, CB1 receptors were not clearly located in either presynaptic GABAergic 
or postsynaptic glutamatergic compartments (Figure 5B). GAD65 was distributed 
presynaptically (Figure 5Bi), while VGLUT3 displayed a somatodendritic distribution (Figure 
5Bii). Z-stack analysis revealed a similar distribution of CB1 receptors and GAD65, but with a 
very low degree of co-immunoreactivity (Figure 5Bi-YZ/XZ). A higher co-expression with 
VGLUT3 was observed, despite the different cellular distribution (Figure 5Bii-YZ/XZ). 
GAD65 immunofluorescence showed a different pattern of distribution in different cortical 
layers, with the highest density being in layer IV, as shown for motor cortex (Figure 6A). There 
was a large decrease in GAD65 positive cortical terminals in those animals lesioned with 
192IgG-saporin, suggesting a down-regulation. Semiquantitative analysis in the motor cortex 
showed a reduction of 28%, 35% and 39% of GAD65 immunoreactivity in layers I, II-III and 
IV, respectively (p < 0.05) (Figure 6B). The somatosensory and piriform cortices were also 
analyzed and a similar decrease in immunosignaling was found, 28%, 32% and 32% in layers I, 
II-III (p < 0.01) and IV (p < 0.05) in the somatosensory cortex and 25% in the piriform cortex (p 
< 0.05) (Figure 6B). One of the most significant decreases in GAD65 immunoreactivity was 
registered in layer V of the entorhinal cortex (21% decrease, p < 0.01), but GAD65 
immunoreactivity was not modified in the dentate gyrus of the hippocampus (2% decrease). 
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Figures 5 and 6. 
 
 
 
 
 
 
 
 III: 20 
 
4. Discussion 
The rat model of cholinergic dysfunction of the basal forebrain pathway to cortical and 
subcortical brain areas by the infusion of 192IgG-saporin in the NBM described in the present 
study shows a significant loss of BFCN. This specific lesion leads to cognitive impairment 
related to learning and memory of an aversive stimulus. The CB1 receptor-mediated eCB 
signaling is modulated in the NBM and in cortical projections, which might be related to the 
loss of the inhibitory tone, as observed by a marked decrease in the expression of presynaptic 
GAD65.  
 
4.1 192IgG-saporin infusion in the NBM impairs learning and memory 
Eight days after the intraparenchymal infusion of 192IgG-saporin, at least three-quarters 
of BFCN had disappeared which led to memory impairment, as demonstrated by the results of 
the passive avoidance test. However, controversial data have been reported depending on the 
severity of the lesion, the dose of immunotoxin given, the stereotaxic coordinates, the needle 
used or the passive avoidance test conditions (see review from Myhrer, 2003). Thus, a previous 
study demonstrated that 50% of BFCN depletion in the NBM was not sufficient to impair 
memory five weeks after surgery (Wenk et al., 1994). However, our results are consistent with 
other studies reporting small but significant deficits associated with the NBM lesion (Torres et 
al., 1994). Due to the presence of censored data (cut-off time for step through latency times of 
300s), Kaplan-Meier survival curves and Log-rank analysis were used to compare the 
behavioral responses. Based on previous reports (Barreda-Gómez et al., 2015), the statistical 
analysis of data carried out in the present study is the best available to analyze this type of test 
and represents an alternative for the right interpretation of the data. Memory evaluation under 
the present experimental conditions is not enough to confirm if cognitive impairment is related 
to acquisition, consolidation, extinction or retrieval of aversive information, but present findings 
provide evidence of a pivotal contribution of the cortical cholinergic denervation to learning and 
memory deficits. The influence of other neurotransmitter systems has been studied using the 
passive avoidance test. Thus, dopaminergic antagonists either impair (Lazarova-Bakarova et al., 
1991; Doyle and Regan, 1993) or improve (Chugh et al., 1991) passive avoidance performance, 
while glutamatergic and GABAergic antagonists typically impair it (Venable and Kelly, 1990; 
Anglade et al., 1994), all of which suggests the involvement of multiple neurotransmission 
systems in cognition. In this context, the eCB system modulates the release of glutamate and 
GABA (Katona et al., 2001) and regulates a range of physiological processes including learning 
and memory (Busquets-García et al., 2011). 
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4.2 Endocannabinoid signaling is modulated after BFCN depletion  
The present model involving BFCN depletion provides a suitable scenario in which to 
further our understanding of the interaction of cholinergic neurotransmission with the eCB 
system. The presence of CB1 receptors in BFCN was previously established by using 
immunohistochemical methods. Some authors suggest that rodent BFCN are devoid of these 
receptors, but all basal forebrain cholinergic cells contain eCB-degrading enzymes and have a 
fine CB1 receptor positive fiber meshwork surrounding the perikarya, suggesting that BFCN 
may utilize eCB for retrograde control of neurotransmission (Harkany et al., 2003; 2005). 
However, light and electron microscopy studies reported a dense labeling of CB1 receptors in 
ChAT-immunoreactive neurons in monkey basal forebrain (Lu et al., 1999) and the existence of 
differentiated areas in the basal forebrain cholinergic system of the rat, some of them expressing 
CB1 receptors (Nyíri et al., 2005).  
The present autoradiographic studies revealed an increase in both density and activity of CB1 
receptors in the NBM of lesioned rats. If BFCN expresses somatodendritic CB1 receptors, one 
would expect a decrease, but the results are consistent with those obtained by Harkany et al. 
(2003) which describe the presence of CB1 receptors in the fiber meshwork surrounding the 
perikarya, but not in BFCN membranes.  
The observed decrease in eCB signaling (CB1 receptor activity) in discrete areas of the 
hippocampus could be a direct consequence of cholinergic denervation, but NBM mainly 
projects to the cortex. Immunofluorescence studies suggest an inhibitory nature of the CB1 
receptor containing GAD65 positive terminals in the hippocampus in which CB1 receptors are 
mainly expressed in GABAergic interneurons (Katona et al., 1999; Tsou et al., 1999). However, 
further studies demonstrated that CB1 receptors are also present in hippocampal glutamatergic 
synapses, albeit at much lower levels (Katona et al., 2006; Kawamura et al., 2006). In this 
context, despite the reported negative effects of cannabimimetics on memory in humans, the 
literature fails to provide strong evidence for hippocampal CB1 receptor-mediated action (see 
review from Davies et al., 2002). The decrease in CB1 receptors in the hippocampus of BFCN-
lesioned rats is moderate and located mainly in GABAergic presynaptic terminals. Transgenic 
mice with enhanced GABAergic inhibition exhibit impairment in both hippocampal long-term 
potentiation (LTP) and Morris water maze performance (Gong et al., 2009). Learning deficits in 
these mice or in wild-type mice treated with Δ9-THC were reversed by GABAA receptor 
antagonists (Varvel et al., 2005; Cui et al., 2008). Thus, the decrease in eCB signaling observed 
in certain hippocampal regions, leading to enhanced GABAergic inhibition, may be related to 
the BFCN depletion-induced cognitive impairment. CB1 receptor-mediated signaling is also 
affected in the hippocampus of patients diagnosed with severe AD (Manuel et al., 2014). The 
present animal model shows a great reduction in BFCN, which partially mimics the final 
Braak's stages (V-VI) of the disease described in patients who suffer a serious degeneration of 
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the basal forebrain cholinergic pathway which innervates the hippocampus through the 
entorhinal cortex (Ikonomovic et al., 2003). 
The dramatic reduction of cortical cholinergic projections observed by AChE staining in rats 
with a lesion in BFCN, was not represented by a similar decrease in [
3
H]CP55,940 binding in 
any of the different regions of brain cortex. These results are in agreement with previous studies 
which reported that cortical cholinergic terminals lack any detectable CB1 receptors (Harkany et 
al., 2003). However, the hyperactivity of cortical CB1 receptors that we found in BFCN 
lesioned-animals was similar to that described in human brain at early stages of AD. Therefore, 
we further explored the different regulation of CB1 receptors in hippocampus and cortex at the 
subcellular level by carrying out immunofluorescence studies (see next section). CB1 receptors 
are involved in the regulation of cortical glutamatergic input; CB1 receptor agonists inhibit, 
while the antagonist SR141716A enhances cortical glutamatergic synaptic transmission and 
favors LTP (Auclair et al., 2000). CB1 receptor–dependent activation is thought to be an early 
step in a protective cascade against kainic acid-induced excitotoxicity (Marsicano et al., 2003), 
and a CB1 receptor-mediated decrease in TNF -induced expression of AMPA receptors 
protects against excitotoxic neuroinflammation (Zhao et al., 2010). In addition, previous studies 
using a similar lesion in basal forebrain observed that there was a marked reduction of NMDA, 
2-and -adrenoceptors and 5-HT2A receptors, while AMPA, kainate and GABAA receptors 
were up-regulated and accompanied by a decrease in high-affinity choline uptake sites in 
cortical regions (Roβner et al., 1994, 1995; Schliebs et al., 1994; Heider et al., 1997). In 
summary, the 192IgG-saporin-induced lesion in the NBM leads to an irreversible loss of 
cholinergic innervation in almost the entire cortical mantle, sufficient to lead to an excess of 
excitatory neurotransmission that may be controlled by the observed activation of the CB1 
receptors present in cortical areas. 
 
4.3 Cortical GABAergic dysfunction after BFCN lesion  
Endocannabinoids act as retrograde synaptic messengers on presynaptic terminals and 
modulate the release of different neurotransmitters through the activation of CB1 receptors 
(Katona et al., 2001; Ohno-Shosaku et al., 2001). Previous studies reported that almost all CB1 
receptor-positive cortical cells also express cholecystokinin and GAD65, confirming the 
existence of an inhibitory phenotype of CB1 receptor containing terminals (Marsicano and Lutz, 
1999). Although, the present immunofluorescence studies did not establish the precise 
anatomical location of CB1 receptors in GABAergic or glutamatergic compartments, in the rat 
model of BFCN lesion we were able to measure a marked down-regulation of GAD65 
immunoreactivity in most of the cortical areas. These results suggest that the degeneration of 
cortical cholinergic terminals triggers a deregulation of GABAergic neurotransmission and 
clearly demonstrate that BFCN terminals are devoid of CB1 receptors. A partial loss of BFCN 
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induced by 192IgG-saporin was sufficient to decrease the levels of GAD65/67 and increase 
glutamate transporters in the prefrontal and cingulate cortices (Jeong et al., 2011; 2016). 
Moreover, deep brain stimulation of the remaining BFCN in the NBM improved spatial 
memory performance and partially restored GAD65/67 and glutamate to control levels (Lee et 
al., 2016). Recovery of the cortical GABAergic tone has been postulated as potentially 
therapeutic in AD patients (see review in Lanctôt et al., 2004). In summary, the present findings 
demonstrate that a 192IgG-saporin-induced BFCN lesion impairs learning and memory, 
activates cortical eCB signaling and provokes a significant decrease in cortical GABAergic 
tone.  
 
 
5. Conclusions 
BFCN not only represent the main source of cortical acetylcholine, but one may also 
speculate that they contribute to the inhibitory tone in cortical projections, and the loss of these 
neurons leads to a deregulation of excitatory neurotransmission which probably explains the 
hyperactivation of cortical CB1 receptors located on excitatory terminals. We propose a CB1 
receptor-mediated regulation of the eCB tone as a compensatory mechanism with which to 
regulate a possible BFCN death-evoked glutamatergic-GABAergic imbalance, in order to 
maintain the control of cortical neurotransmission. The understanding of the underlying 
mechanisms of this regulation, could lead to the discovery of cannabinoid-based 
pharmacological approaches towards the treatment of common pathological features of different 
neurological diseases affecting neuronal survival.  
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Table 1. Autoradiographic CB1 densities for the specific binding 
of [
3
H]CP55,940 in different brain regions from vehicle (aCSF) 
and 192IgG-saporin treated rats. 
Specific binding of [
3
H]CP55,940  (fmol/mg t.e.) 
 Brain region aCSF SAP 
Cerebral cortex     
     Cingulate   223 ± 27    202 ± 21 
     Motor   211 ± 25    197 ± 20 
     Somatosensory   164 ± 21    149 ± 16 
     Piriform   87 ± 8    112 ± 13 
     Perirhinal   131 ± 22    104 ± 16 
     Ectorhinal   155 ± 15    128 ± 26 
     Entorhinal   114 ± 26      96 ± 12 
Diencephalon     
      NBM   180 ± 13      364 ± 63* 
Rhinencephalon     
      Lat.Olfact. Tract    190 ± 28    137 ± 18 
Mesencephalon     
      Substantia nigra   3068 ± 218    2633 ± 177 
Basal ganglia 
  2878 ± 264    2756 ± 303       Globus pallidus 
      Striatum   456 ± 33    518 ± 75 
Telencephalon     
Amygdaloid nuclei     
     Anterior    126 ± 13  127 ± 6 
     Basolateral    102 ± 15      96 ± 19 
     Central    146 ± 18    138 ± 10 
     Lateral    109 ± 15      98 ± 23 
     Medial      62 ± 16      55 ± 14 
Hippocampus     
     CA1 
         Oriens  1057 ± 67      721 ± 92* 
         Pyramidal   583 ± 56    340 ± 44 
         Radiatum   520 ± 26    384 ± 52 
     CA3  
         Oriens   800 ± 64    550 ± 94 
         Pyramidal   408 ± 40    300 ± 56 
         Radiatum   537 ± 44    376 ± 67 
     Dentate gyrus  
         Molecular   900 ± 63         603 ± 71** 
         Polymorphic   454 ± 49    305 ± 48 
         Granular     72 ± 18      96 ± 20 
     Lac. Moleculare   605 ± 42    436 ± 79 
     Ventral subiculum   300 ± 37    248 ± 26 
Data are mean ± S.E.M values from 8 rats in each group. 
 *p < 0.05, ** p < 0.01 when compared to aCSF. 
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Table 2.  [
35
S]GTPγS basal binding and WIN55,212-2-induced binding (10 µM) in different cortical 
regions, rhinencephalon, rhomboencephalon and mesencephalon from vehicle (aCSF) and 192IgG-
saporin treated animals. 
Data are mean ± S.E.M values from 9 aCSF-treated and 11 SAP-treated rats. 
 *p < 0.05, **p < 0.01 when compared to aCSF. 
 
Basal binding 
(nCi/g t.e.) 
WIN55.212-2 stimulation                 
(% over basal) 
Brain region aCSF SAP aCSF SAP 
Cerebral cortex       
     Cingulate      
        Layer  I-III 351 ± 15 331 ± 20   97 ± 22 120 ± 17 
        Layer IV-V 395 ± 22 399 ± 22 104 ± 25 116 ± 19 
        Layer VI 548 ± 29 578 ± 37 187 ± 30 176 ± 19 
     Ectorhinal     
        Layer  I-III 306 ± 16 316 ± 17 122 ± 31 113 ± 14 
        Layer IV-V 352 ± 22 374 ± 22 108 ± 25 157 ± 15 
        Layer VI 386 ± 29 455 ± 22 209 ± 36 195 ± 19 
     Entorhinal     
        Layer  I-III 300 ± 25 337 ± 19 174 ± 28 169 ± 20 
        Layer IV-V 394 ± 26 470 ± 32 162 ± 24 164 ± 14 
        Layer VI 515 ± 35 531 ± 40 156 ± 17    277 ± 30** 
     Motor     
        Layer  I-III 399 ± 24 386 ± 33   71 ± 14   122 ± 13* 
        Layer IV-V 407 ± 17 420 ± 23 110 ± 25            119 ± 7 
        Layer VI 535 ± 33 521 ± 27 127 ± 20  203 ± 14* 
     Perirhinal     
        Layer  I-III 276 ± 23 289 ± 16 119 ± 23 189 ± 17 
        Layer IV-V 352 ± 21 357 ± 21 155 ± 36 167 ± 25 
        Layer VI 388 ± 21 444 ± 25 151 ± 24  218 ± 12* 
Somatosensory     
        Layer  I-III 380 ± 23 414 ± 34     74 ± 20   68 ± 11 
        Layer IV-V 436 ± 30 460 ± 30   118 ± 23            128 ± 7 
        Layer VI 495 ± 37 512 ± 34   131 ± 29   218 ± 11* 
     Piriform      458 ± 29          457 ± 30     72 ± 10   122 ± 9** 
Rhinencephalon     
     Lat.Olfact. Tract nucleus 359 ± 40 364 ± 38   55 ± 10   128 ± 13* 
Rhomboencephalon     
     Dorsal raphe 636 ± 72 665 ± 62 59 ± 8 82 ± 6 
     Locus coeruleus 254 ± 21 263 ± 40 32 ± 7   44 ± 15 
Mesencephalon     
     Periaqueductal gray 484 ± 44 503 ± 31   69 ± 12    94 ± 11 
     Substantia nigra 382 ± 31 463 ± 21   835 ± 145  744 ± 97 
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Table 3. [
35
S]GTPγS basal binding and WIN55,212-2-induced binding (10 µM) in telencephalon and 
diencephalon from vehicle (aCSF) and 192IgG-saporin treated animals. 
Data are mean ± S.E.M values from 9 aCSF-treated and 11 SAP-treated rats. 
 *p < 0.05 when compared to aCSF. 
 
 
 
 
Basal binding 
(nCi/g t.e.) 
WIN55.212-2 stimulation    
 (% over basal) 
Brain region aCSF SAP aCSF SAP 
Telencephalon     
Amygdaloid nuclei     
     Anterior 416 ± 50 460 ± 30 110 ± 18  99 ± 12 
     Basolateral  395 ± 28 457 ± 36 223 ± 24         150 ± 8 
     Central 586 ± 52 649 ± 53 100 ± 19 92 ± 4 
     Lateral  359 ± 36 442 ± 30 157 ± 24 150 ± 12 
     Medial  512 ± 61 636 ± 69 116 ± 20   50 ± 6* 
Hippocampus       
CA1  
     Oriens 308 ± 27 332 ± 26 106 ± 19   99 ± 17 
     Pyramidal 266 ± 29 264 ± 20 155 ± 14 159 ± 22 
     Radiatum 384 ± 36 418 ± 28 150 ± 28 178 ± 30 
CA3  
     Oriens 372 ± 45 377 ± 19 223 ± 28 110 ± 20 
     Pyramidal 272 ± 34 241 ± 23 198 ± 52 233 ± 53 
     Radiatum 254 ± 25 269 ± 21 219 ± 38 181 ± 28 
Dentate gyrus  
     Molecular 324 ± 42 387 ± 20 299 ± 37  166 ± 25* 
     Polymorphic 194 ± 38 200 ± 20 168 ± 29 211 ± 39 
     Granular 216 ± 32 204 ± 20 122 ± 30 116 ± 21 
Basal ganglia 
     Globus pallidus 442 ± 31 456 ± 39  986 ± 131   874 ± 126 
     Striatum 368 ± 25 352 ± 16 178 ± 28  252 ± 19* 
Diencephalon     
     NBM 496 ± 57 547 ± 34 103 ± 18 142 ± 9* 
     Horiz. diagonal band 327 ± 36 320 ± 20   91 ± 18 114 ± 21 
     Vertic. diagonal band 341 ± 27 393 ± 24 145 ± 27 119 ± 15 
     Medial septum 309 ± 27 320 ± 21 111 ± 23 114 ± 18 
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Legends 
Figure 1.  (A) Number of BFCN in the NBM of aCSF (n = 17) and SAP (n = 19) treated 
animals, quantified as AChE labelled cells and P75
 NTR
 immunoreactive neurons. (B) AChE 
enzymatic staining and P75
NTR
 immunostaining in the NBM. *** p < 0.001 vs aCSF. Scale bars 
= 500 (left) and 100 µm (center and right). (C) Acquisition latency times in the learning trial of 
the passive avoidance test. Data are means ± SEM. (D) Step through latency times of the 
passive avoidance test represented as Kaplan-Meier survival curves (p < 0.0001 vs aCSF, log-
rank test).  
Figure 2. (A) AChE staining in representative fixed hemibrain slices at two different levels 
(right and left columns) from aCSF and SAP-treated rats. (B) [
3
H]CP55,940 (3 nM) binding in 
hemibrain coronal slices from aCSF and SAP-treated rats. (C) The specificity of the binding 
was determined by blocking the radioligand binding in the presence of the specific CB1 receptor 
antagonist, SR141716A (0.1 µM) (D) The specific CB2 antagonist SR144528 (0.1 µM) was not 
able to inhibit the [
3
H]CP55,940 (3 nM) binding to rat brain slices (D). DG: dentate gyrus; CA3: 
layer CA3 of hippocampus. Bottom, [
3
H] standards (µCi/g tissue equivalent), tissue scale bar: 5 
mm. 
Figure 3. Representative autoradiograms including both dorsal (A, B) and ventral hippocampus 
(C, D) obtained from aCSF and SAP-treated rats that show [
35
S]GTPγS basal binding (A and C) 
and WIN55,212-2 (10 µM) evoked activation of cannabinoid receptors (B and D). DG: dentate 
gyrus; Ss cx: somatosensory cortex; Ent cx: entorhinal cortex. Bottom, [
14
C] standards (nCi/g 
tissue equivalent), tissue scale bar: 5 mm. 
Figure 4. (A) The plots show the number of cholinergic neurons in the NBM (Number of 
cells/mm
3
) and the density of CB1 receptors (fmol/mg) from aCSF (n = 8) and SAP (n = 8) 
treated rats in different brain areas. The regression analyses reveal a decrease in the density of 
CB1 receptor directly related to the depletion of BFCN in the dentate gyrus (R
2
 = 0.29; p = 
0.047) and CA1 (R
2
 = 0.36; p = 0.018) and an increase in the NBM (R
2
 = 0.40; p = 0.011). (B 
and C)  The plots show the number of cholinergic neurons in the NBM and WIN55,212-2 (10 
µM) evoked stimulation of CB1 receptors (% activity over basal) from aCSF (n = 9) and SAP (n 
= 11) treated rats in different brain areas.  (B) The regression analyses reveal a hyperactivity of 
CB1 receptors in the NBM (R
2 
= 0.38; p = 0.007) and in the striatum (R
2
 = 0.63; p = 0.0002) and 
a decrease in the dentate gyrus (R
2
 = 0.4; p = 0.0089) directly related to the loss of BFCN. (C) 
The regression analyses reveal a hyperactivity of CB1 receptors in cortical areas: motor (R
2
 = 
0.28; p = 0.0202), somatosensory (R
2 
= 0.41; p = 0.0025), entorhinal (R
2
 = 0.24; p = 0.0349) 
and piriform (R
2
 = 0.43; p = 0.0018) cortices, directly related to the depletion of BFCN. 
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Figure 5. Immunostaining in a representative section from a 192IgG-saporin treated rat. 
Immunoreactivity for CB1 receptors in dentate gyrus (A) and in motor cortex (B), in 
combination with GAD65 (i) or VGLUT3 (ii). Nuclei were also stained with Hoechst. In merge 
images, note the CB1 receptor co-localization in dentate gyrus with GAD65 and in cortex with 
VGLUT3. Triple labeling of tissue slices is shown at 200-fold magnification (merge) and at 
630-fold magnification (structured illumination) in a single plane from the collecting Z-
stacking. Scale bar = 50 µm and 10 µm, respectively. 
Figure 6. (A) Immunoreactivity for GAD65 in the motor cortex (layers I-VI) from a aCSF and 
a 192IgG-saporin treated rat. (B) Note the differences in optical density of GAD65 positive 
presynaptic terminals in aCSF (n = 5) and SAP (n = 5) treated rats, measured as arbitrary units 
(A.U.) of fluorescence in motor, somatosensory and entorhinal cortical layers, and also in the 
total area of the piriform cortex and dentate gyrus. Data are means ± SEM; *p < 0.05; **p < 
0.01. Scale bar = 150 µm. 
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Abstract 
Alzheimer‟s disease is characterized by a progressive decline in memory associated 
with selective impairment of cholinergic neurotransmission. Recently, the 
endocannabinoid system, which modulates emotional learning and memory through 
CB1 receptors, has also been found to be deregulated. In the present study, we used 
the 3xTg-AD mice model harboring familial AD mutations and tauP301L human 
transgene to identify the functional interplay of endocannabinoid and muscarinic 
signaling, and their cognitive behavioral correlates at the onset of disease by the 
passive avoidance test. Neurochemical correlates were studied with both receptor and 
functional autoradiography for CB1 and muscarinic receptors simultaneously analyzed 
in consecutive tissue slices and regulations at the cellular level were depicted by 
immunofluorescence analysis. 3xTg-AD mice exhibited increased acquisition latencies 
and impaired memory retention compared to age-matched non-transgenic mice at the 
onset of disease. Neurochemical analyses showed changes in the CB1 receptor 
density and functional coupling of CB1 and muscarinic receptors to Gi/o proteins in 
several brain areas, including the basolateral amygdala. Subchronic stimulation of the 
endocannabinoid system following repeated WIN55,212-2 (1 mg/kg) or JZL184 (8 
mg/kg) administration induced a CB1 receptor desensitization, normalizing acquisition 
latencies to control levels. However, cannabinoid-induced modulation of cholinergic 
neurotransmission in limbic areas did not significantly modify learning and memory. 
The CB1 receptor-mediated decrease in the GABAergic tone in the basolateral 
amygdala may be controlling the limbic component of learning and memory in 3xTg-AD 
mice. The CB1 receptor desensitization may be a plausible strategy to restore behavior 
alterations associated with genetic risk factors for developing AD. 
 
Keywords: Alzheimer, 3xTg-AD, cholinergic, endocannabinoid, learning and memory, 
basolateral amygdala, autoradiography.  
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Abbreviations and chemical compounds 
2-AG: 2-arachidonoylglycerol; 3xTg-AD: Triple transgenic mice model; Aβ: β-Amyloid; 
AD: Alzheimer´s disease; BLA: Basolateral amygdala; CB1 receptor: Type-1 
cannabinoid receptors; CB1
-/-: CB1 receptor knockout mice; eCB: Endocannabinoid; 
GAD65: Glutamic acid decarboxylase isoform 65kDa; GTPγS: Guanosine-5´-O-3-
thiotriphosphate; mAChR: Muscarinic acetylcholine receptor; M2 mAChR: Subtype-2 
muscarinic receptor; MAGL: Monoacylglycerol lipase; Non-Tg: Non transgenic mice, 
VGLUT3: Vesicular glutamate transporter type 3. 
R-(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-
(1-naphthalenyl)methanone mesylate: WIN55,212-2; (-)-cis-3-[2-Hydroxy-4-(1,1-
dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl) cyclohexanol: CP55,940; (2-
Carbamoyloxyethyl) trimethylammonium chloride: carbachol; 4-Nitrophenyl4-
(dibenzo[d][1,3]dioxol-5-yl(hydroxy)methyl)piperidine-1-carboxylate:JZL184; (Piperidin-
1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1Hpyrazole-3-carboxamide 
hydrochloride: SR141716A; 5-(4-chloro-3-methylphenyl)-1-[(4-methylphenyl)methyl]-N-
[(1S,2S,4R)-1,3,3-trimethylbicyclo[2.2.1]hept-2-yl]1pyrazole3-carboxamide: SR144528 
 
 
 
 
 
 
 IV: 6 
 
1. Introduction 
 
 Alzheimer‟s disease (AD), the most common cause of dementia in the elderly, is 
characterized by a progressive impairment of memory and thinking skills. Furthermore, 
60-90% of AD patients develop neuropsychiatric symptoms including agitation, 
psychosis, depression, apathy, disinhibition or anxiety, which are dependent on the 
cholinergic deficit described in AD (Cummings and Back, 1998; Cummings et al., 
2016). The cholinergic neurotransmission that controls learning and memory is 
specifically vulnerable in AD (Davies and Maloney, 1976; Perry et al., 1978; Bartus et 
al., 1982; Whitehouse et al., 1982; Rodríguez-Puertas et al., 1994, 1997). Impaired 
functionality of muscarinic receptors (mAChR) is found in areas that control cognitive 
processes, such as the amygdala and the hippocampus (Rodríguez-Puertas et al., 
1997). The deregulation of neuromodulators further contributes to the alteration of 
cognitive and emotional processes and final outcomes. This is the case of the 
endocannabinoid (eCB) system, which modulates emotional learning and memory 
(Busquets-Garcia et al., 2011). The eCB system is deregulated in AD patients. Thus, a 
reduction of type-1 of cannabinoid receptors (CB1) in different layers of the 
hippocampus is described at advanced Braak stages of the disease (Westlake et al., 
1994), while an increase in CB1 receptor activity and density is found at early and 
moderated stages of AD (Manuel et al., 2014). Endogenous and exogenous 
cannabinoids seem to elicit modulatory effects in multiple AD-related processes, 
although the biochemical mechanisms need to be further investigated. Therefore, eCB 
system is foreseen as a novel potential therapeutic target to counteract the disease 
(Bedse et al., 2015).  
At the translational level, hippocampal and cortical neuritic dystrophy has been 
reported in the triple-transgenic mice model of AD (3xTg-AD) (Perez et al., 2011) and 
impairment of mAChR in other AD models, in parallel with the progression of β-Amyloid 
(Aβ) plaque formation (Machová et al., 2008; Manuel et al., 2016). Also, altered CB1 
receptor expression has recently been described in the 3xTg-AD mice (Bedse et al., 
2014; Manuel et al., 2016). These mice harbor APPSwe, PS1M146V, and tauP301L 
transgenes and mimic several hallmarks of familial AD (Oddo et al., 2003). While Aβ 
and tau neuropathologies develop in middle age (12 months), deficits in synaptic 
plasticity and cognition have earlier onsets, when intraneuronal accumulation of 
oligomeric-Aβ, is clearly established at 6 months of age (Billings et al., 2005). So far, 
learning and memory deficits are apparent in several cognitive paradigms such as the 
passive avoidance, the novel-object recognition, and the Morris water maze (Giménez-
Llort et al., 2007; Filali et al., 2012). Anxiety-like behaviors have also been shown in the 
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open-field, the elevated plus maze, and the dark/light box (Nelson et al., 2007; España 
et al., 2010; Rasool et al., 2013; Pietropaolo et al., 2014). Interestingly, in 6-month-old 
3xTg-AD mice, the intraneuronal Aβ accumulation in the basolateral amygdala (BLA) 
has been shown to enhance innate and conditioned fear as assessed in fear 
conditioning paradigms (España et al., 2010).  
 In order to elucidate the functional interplay of cannabinoid and muscarinic 
signaling at the onset of AD and in relation to emotional learning and memory, we 
examined the expression, neuroanatomical distribution, and functional coupling of CB1 
receptor and mAChR to Gi/o proteins in seven month-old 3xTg-AD mice and age-
matched non-transgenic (Non-Tg) counterparts. Behavioral correlates were depicted in 
the step-through passive avoidance test. Finally, behavioral outcomes and cholinergic-
endocannabinoid crosstalk following the direct and indirect subchronic eCB system 
activation were also investigated. 
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2. Materials and methods 
 
2.1. Animals  
 Seven-month-old male 3xTg-AD and Non-Tg mice were obtained from 
Universitat Autonòma de Barcelona, in collaboration with Dr Lydia Giménez Llort. The 
3xTg-AD mice harboring PS1M146V, APPSwe, and TauP301L transgenes were genetically 
engineered as previously described (Oddo et al., 2003). Also, nine-week-old male CB1
-
/- and CB1
+/+ mice were used, provided by C. Ledent of the University of Brussels. 
 All the animals were housed (4-5 animals per cage) and maintained under 
standard laboratory conditions of 12 hours light-dark cycle with light from 8 am to 8 pm 
and availability of food/water ad libitum. All procedures were performed in accordance 
with European Directive 2010/63/EU and the Spanish National Guidelines for Animal 
Experimentation and the Use of Genetically Modified Organisms (Real Decreto 
1205/2005) and 178/2004; Ley 32/2007 and 9/2003). Experimental protocols were 
approved by the local Committee for Animal Research at the University of the Basque 
Country (CEIAB/21/2010/Rodríguez-Puertas).  
 
2.2. Drugs and treatments 
 WIN55,212-2, CP55,940 and carbachol were acquired from Sigma-Aldrich (St 
Louis, MO, USA); JZL184 and SR144528 from Cayman-Chemicals (MI, USA) and 
SR141716A from Tocris (Bristol, UK). WIN55,212-2 and JZL-184 were administered 
intraperitoneally, once daily, in a volume of 5 ml/kg for seven consecutive days. Both 
cannabinoid compounds were dissolved in pure DMSO and diluted with Kolliphor EL 
(Sigma-Aldrich) and 0.9% saline to a final proportion of (1:1:18) respectively, as 
vehicle. Two independent sets of mice were randomly assigned to one of the following 
five groups (n = 9-10): [1]-Non-Tg-vehicle, [2]-3xTg-AD-vehicle, [3]-3xTg-AD-
WIN55,212-2 (0.1 mg/kg), [4]-3xTg-AD-WIN55,212-2 (1 mg/kg) and [5]-3xTg-AD-
JZL184 (8 mg/kg) (Figure 1). 
2.3. Behavioral test 
 On the two days following the last dose, the behavioral effects of cannabinoid 
administration in the step-through passive avoidance were studied (PanLab, passive 
avoidance box LE872). During the acquisition session, the animals were placed in the 
open and illuminated compartment with heads facing the door, and then allowed to 
explore for 30 s. Then, the door was opened, allowing the mice to enter the dark 
compartment. The acquisition latency, with a cut-off time of 60 s, was recorded. When 
the animals crossed the door it was closed and a foot shock (0.4 mA/2 s) was 
delivered. Twenty-four hours later, during the retention session, the animals were 
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placed again into the illuminated chamber and allowed to explore for 30 s. Then, the 
door was opened and the step-through latency before entering the dark chamber, with 
a maximum cut-off time of 300 s, was recorded. No foot shock was delivered in the 
retention session. 
 
2.4. Tissue preparation  
 For immunohistochemical studies, Non-Tg and 3xTg-AD mice (n = 3/group) 
were anesthetized with ketamine:xylazine (90:10 mg/kg), and transcardially perfused 
via the ascending aorta with 50 ml warm (37ºC), calcium-free Tyrode‟s solution (0.15 M 
NaCl, 5 mM KCl, 1.5 mM MgCl2, 1 mM MgSO4, 1.5 mM NaH2PO4, 5.5 mM Glucose, 25 
mM NaHCO3; pH 7.4), 0.5% heparinized, followed by 4% paraformaldehyde and 3% 
picric acid in 0.1M PB (4ºC) (100 ml/100 g b.w.). Brains were removed, post-fixed for 
90 min at 4ºC, and cryoprotected in 20% phosphate buffer-sucrose solution overnight. 
The tissue was immersed in isopentane (-80ºC). 10 µm coronal slices were obtained in 
a cryostat, mounted onto gelatin-coated slides, and stored (-25ºC). The remaining brain 
samples from Non-Tg and 3xTg-AD mice (n = 7/group) and those from CB1
-/- and 
CB1
+/+ mice (including spleen samples) were removed, fresh frozen, cut into 20 µm 
slices, mounted onto gelatin-coated slides and stored (-25ºC). 
 
2.5. Radioligands and chemical reagents 
 [35S]GTPγS (1250Ci/mmol) and [3H]CP55,940 (131.8Ci/mmol) were purchased 
from PerkinElmer (Boston MA, USA). The [14C] and [3H]-microscales used as 
standards were purchased from American Radiolabelled Chemicals (Saint Louis, MO, 
USA). The β-radiation sensitive films were purchased from Carestream. Bovine Serum 
Albumine (BSA), DL-dithiothreitol (DTT), adenosine deaminase (ADD), guanosine-5´-
diphosphate (GDP), and guanosine-5´-O-3-thiotriphosphate (GTPγS) were acquired 
from Sigma-Aldrich. Finally, all the compounds necessary for the preparation of the 
different buffers were of the highest quality commercially available. 
 
2.6. Cannabinoid receptor autoradiography 
 Fresh slices from 3xTg-AD and Non-Tg mice (n = 6/group) and from CB1
-/- and 
CB1
+/+ mice (including brain and spleen) were dried and submerged in 50 mM Tris-HCl 
buffer containing 1% of BSA (pH 7.4) for 30 min at room temperature, followed by 
incubation in the same buffer in the presence of the CB1/CB2 radioligand, [
3H]CP55,940 
(3 nM) for 2 h at 37ºC. Nonspecific binding was measured by competition with non-
labelled CP55,940 (10 µM) in another consecutive slice. The CB1 receptor antagonist, 
SR141716A (0.1 µM) and the CB2 receptor antagonist, SR144528 (0.1 µM), were used 
 IV: 10 
 
together with [3H]CP55,940 in two consecutive slices to check the CB1 or CB2 receptor 
binding specificity. Then, slices were washed in ice-cold (4ºC) 50 mM Tris-HCl buffer 
supplemented with 1% BSA (pH 7.4) to stop the binding, followed by dipping in distilled 
ice-cold water and drying (4ºC). Autoradiograms were generated by exposure of the 
tissues for 21 days at 4ºC to β-radiation sensitive film together with [3H]-microscales 
used to calibrate the optical densities to fmol/mg tissue equivalent (fmol/mg t.e.). 
 
2.7. Labeling of activated Gi/o proteins by [
35S]GTPγS binding assay  
 Fresh slices (n = 7/group), were dried, followed by two consecutive incubations 
in HEPES-based buffer (50 mM HEPES, 100 mM NaCl, 3 mM MgCl2, 0.2 mM EGTA 
and 0.5% BSA, pH 7.4) for 30 min at 30ºC. Briefly, slices were incubated for 2 h at 
30ºC in the same buffer supplemented with 2 mM GDP, 1 mM DTT, ADD (3-Units/l), 
and 0.04 nM [35S]GTPγS. The [35S]GTPγS basal binding was determined in two 
consecutive slices in the absence of agonist. The agonist-stimulated binding was 
determined in the same reaction buffer in the presence of the CB1/CB2 receptor 
agonist, WIN55,212-2 (10 µM). Nonspecific binding was defined by competition with 
GTPγS (10 µM) in another section. Then, slices were washed twice in cold (4ºC) 50 
mM HEPES buffer (pH 7.4), dried, and exposed to β-radiation sensitive film with a set 
of [14C] standards. 
 A similar procedure was followed for mAChR in the presence of the non 
selective cholinergic agonist carbachol (100 µM). 
 After 48 h, the films were developed, scanned, and quantified by transforming 
optical densities into nCi/g tissue equivalence units using a calibration curve defined by 
the known values of the [14C] standards (NIH-IMAGE, Bethesda, MD, USA). 
Nonspecific binding values were subtracted from both agonist-stimulated and basal-
stimulated conditions. The percentages of agonist-evoked stimulation were calculated 
from both the net basal and net agonist-stimulated [35S]GTPγS binding densities 
according to the following formula: ([35S]GTPγS agonist-stimulated binding x 
100/[35S]GTPγS basal binding)-100. 
 
2.8. Immunofluorescence 
 Fixed 10 µm coronal slices from Non-Tg and 3xTg-AD mice were air dried for 
20 min and washed by immersion in PBS for 15 min at room temperature. Then, the 
slices were blocked with 5% normal goat serum in PBS buffer for 2 h at room 
temperature before being incubated with the primary antibody overnight at 4ºC. 
To label CB1 receptors, the primary rabbit antiserum against the CB1 receptor, PA1-
743, (Affinity BioReagents, CO, USA) was diluted [1:500] in TBS (0.1 M Tris, 0.15 M 
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NaCl, pH 7.4) containing 0.5% milk powder. The tyramide signal amplification method 
was used to amplify the signal associated with the CB1 receptor antiserum. Briefly, 
slices were washed for 30 min in TNT buffer (0.05% Tween 20 in TBS, pH 7.4) and 
blocked in TNB solution (10 ml TNT buffer, 0.05 g blocking reagent, DuPont) for 1 h at 
room temperature. Later, the slices were incubated with horse radish peroxidase-
conjugated goat anti-rabbit secondary antibody (Perkin Elmer, MA, USA) for 1 h 
followed by tyramide-fluorescein-based amplification (Perkin Elmer, MA, USA) process 
in complete darkness for 10 min at room temperature. Slices were extensively rinsed in 
TBS.  
 To label the subtype-2 muscarinic receptor (M2 mAChR), rabbit anti- M2 mAChR 
(EMD Millipore, CA, USA) was diluted in PBS (0.1 M, pH 7.4). Then, the primary 
antibody was revealed by incubation (30 min at 30ºC) with donkey anti-rabbit CY3. To 
study the cellular localization of CB1 receptor and M2 mAChR on glutamatergic or 
GABAergic neurons, tissue slices were incubated with primary guinea pig anti-vesicular 
glutamate transporter 3 (VGLUT3) and mouse anti-glutamic acid decarboxylase 
isoform 65kDa (GAD65) (EMD Millipore, CA, USA) diluted in PBS (0.1 M, pH 7.4), and 
revealed by incubation (30 min at 30ºC) with secondary Alexa488 or Alexa555 [1:250] 
donkey anti-guinea pig and FITC [1:80], or Alexa 555 donkey anti-mouse. Then, slices 
were incubated with Hoechst [1:106] for 15 min, washed, and mounted with p-
phenylendiamine-glycerol. 
Slices were screened with an Axioskop microscope (Zeiss). 630-fold magnification 
images for colocalization were acquired on an Axioskop Observer A1 inverted 
microscope (Zeiss) by optical sectioning (0.24 µm/X-Y-Z-resolution) using structured 
illumination (ApoTome-Zeiss). Images were created with ZEN2014 software (Zeiss) 
and defined as signal being present without physical separation. 
 
2.9. Statistical analysis 
 The two-tailed unpaired Student‟s t-test was used for differences between 
genotypes (Non-Tg versus 3xTg-AD) and one-way analysis of variance (ANOVA) for 
comparisons between treatments, followed by Bonferroni or Dunn‟s post hoc tests. The 
step-through latencies were represented as Kaplan-Meier survival curves, and for 
comparisons the nonparametric Log-rank/Mantel-Cox test was used which is 
appropriate when censored data must be analyzed, as explained in Barreda-Gómez et 
al., (2015). The existence of animals that reached the cut-off time of 300 s was the 
reason to choose this rigorous statistical analysis. Behavioral correlations with 
neurochemical data were analyzed with Pearson‟s correlation. Statistical significance 
was set at p < 0.05. 
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3. Results 
 
3.1. Learning and memory impairment  
 3xTg-AD and Non-Tg mice clearly differed during the training and testing 
sessions on the passive avoidance test. 3xTg-AD mice took significantly longer to enter 
the dark compartment than Non-Tg mice (p = 0.0002, Student‟s t-test) (Figure 2A). 
Moreover, 40% of them failed to remember the foot shock as compared to the positive 
response shown in 100% of Non-Tg mice (p = 0.029, Log-Rank/Mantel-Cox test) 
(Figure 2B). 
 
3.2. Deregulated endocannabinoid signaling  
 Quantitative densitometry showed increased density of CB1 receptors (specific 
[3H]CP55,940 binding sites) in the BLA of 3xTg-AD mice (p = 0.0008) and the lateral 
olfactory tract nucleus (p = 0.0274), but a decrease in the glomerular olfactory bulb (p < 
0.0001; Student‟s t-test) (Figures 2 and 5) (Tables 1 and S1). SR141716A and 
SR144528, well-known selective antagonists for CB1 and CB2 receptors respectively, 
were used in combination with brain and spleen samples from CB1
+/+ and CB1
-/- mice to 
check the specific subtype of cannabinoid receptor involved in the observed changes. 
SR141716A blocked [3H]CP55,940 binding in brain slices from 3xTg-AD and CB1
+/+ 
mice, but failed in spleen. SR144528 completely blocked [3H]CP55,940 binding in 
spleen slices but failed in brain samples. CB1
-/- mice showed an almost completely 
absence of [3H]CP55,940 binding in the brain, whereas displayed similar binding levels 
in the spleen to those obtained in CB1
+/+ mice, demonstrating the selectivity of both 
antagonists and the specific deregulation of the CB1 subtype in 3xTg-AD mice (Figure 
3). [35S]GTPγS autoradiography allows anatomically localizing and quantifying 
receptor-dependent Gi/o protein activity directly in tissue. Basal activity was similar in 
the two genotypes. The activity of CB1 receptors evoked by WIN55,212-2 (10 µM), was 
higher in the BLA of 3xTg-AD (p = 0.0303) but lower in several areas such as the 
striatum (p = 0.0285), the glomerular olfactory bulb (p = 0.0043), and the molecular 
layer of hippocampal dentate gyrus (p = 0.0040; Student‟s t-test) (Figure 4) (Tables 2 
and S2). 
 
3.3. Subchronic cannabinoid administration restores acquisition latencies 
 The subchronic administration of direct or indirect cannabinoid agonists in 3xTg-
AD mice reduced the increase in acquisition latencies observed in the vehicle-treated 
3xTg-AD group (one-way ANOVA, Dunn‟s multiple comparison test), restoring the 
latencies to Non-Tg levels (see Figure 2A). Thus, WIN55,212-2 elicited a behavioral 
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dose-response with slight (0.1 mg/kg, reduction 35%) and marked (1 mg/kg, reduction 
50%, p < 0.05) reductions in acquisition latency as compared with those observed in 
the vehicle-treated 3xTg-AD animals. JZL184 (8 mg/kg), a monoacylglycerol lipase 
(MAGL) inhibitor, also induced such an effect (reduction 42%, p < 0.05) (Figure 2C). 
The treatments elicited subtle variations in memory (step-through latency) in 3xTg-AD 
mice, as shown in the Kaplan-Meier representation, although they did not reach 
statistical significance (Figure 2D). 
 
3.4. CB1 receptor desensitization induced by direct and indirect cannabinoids 
 [3H]CP55,940 autoradiography revealed specific modifications in cerebral CB1 
receptor density following the subchronic eCB system activation. WIN55,212-2 (0.1 
mg/kg) did not modify CB1 receptor density, but WIN55,212-2 (1 mg/kg) induced a 
significant decrease in BLA (22%). Furthermore, the administration of JZL184 
dramatically reduced the CB1 receptor density, including cortical, hippocampal, and 
amygdaloid regions (Figures 2 and 5) (Tables 1 and S1). Functional [35S]GTPγS 
autoradiography of CB1 receptor activation showed a decrease of 24% and 32% in the 
BLA following treatment with WIN55,212-2 (1 mg/kg) and JZL184 (8 mg/kg), 
respectively (Figures 4 and 5) (Tables 2 and S2). The basal binding of [35S]GTPγS was 
not modified by the different cannabinoid compounds, which probably indicates the 
absence of changes in the constitutive activity of G protein-coupled receptors (GPCR). 
 The regression analyses showed that 50% and 33% of the variation in the 
acquisition latencies recorded in 3xTg-AD mice were related to changes in CB1 
receptor density ([3HCP55,940 binding) in the BLA (r2 = 0.5096, p = 0.0091) and/or to 
changes in CB1 receptor activity (evoked by WIN55,212-2) (r
2 = 0.3299, p = 0.0508), 
respectively (Figure 5). No statistically significant correlations were found when other 
brain areas were compared such as the lateral olfactory tract nucleus and glomerular 
olfactory bulb (p = ns). Both treatments, JZL184 (8 mg/kg) and WIN55,212-2 (1 mg/kg), 
decreased the acquisition latencies of 3xTg-AD mice to Non-Tg mice control values 
due to the pharmacological desensitization of CB1 receptors to levels even lower than 
those observed in Non-Tg mice. When the groups were compared all together, a 
positive and statistically significant correlation between CB1 receptor density in the BLA 
and acquisition latencies was found, showing that 25% of the acquisition latency 
variation may be explained by changes in CB1 receptor density (r
2 = 0.2499, p = 0.013), 
but not by changes in CB1 receptor activity (Figure 5). 
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3.5. Decreased M2/M4 mAChR-mediated activity in 3xTg-AD is modulated by 
cannabinoid administration  
 We analyzed the functional coupling of mAChR to G i/o proteins evoked by 
carbachol (100 µM) in both genotypes and in cannabinoid-based treated 3xTg-AD 
mice. Transgenic mice showed decreased functional coupling in the BLA (p = 0.0258), 
in the lateral amygdala (p = 0.0303) and hippocampal pyramidal CA1 (p = 0.0227). 
Moreover, increased M2/M4 mAChR receptor activity was found in the glomerular 
olfactory bulb (p = 0.0095) of 3xTg-AD mice. The administration of 1 mg/kg of 
WIN55,212-2 was able to increase the M2/M4 mAChR-mediated activity to similar 
values of Non-Tg mice; up to 60% in the BLA (p < 0.05 vs 3xTg-AD vehicle) and up to 
100% in the lateral amygdala (p < 0.01 vs 3xTg-AD vehicle)  (Figure 4). No modulation 
of M2/M4 mAChR-mediated activity was observed in other brain areas (Tables 3 and 
S3). 
 
3.6. CB1 receptors in BLA and M2 mAChR in hippocampus colocalize with GABAergic 
terminals 
 The different nuclei of the amygdala exhibited distinct CB1 receptor 
immunostaining patterns and were clearly defined. The dense CB1 receptor 
immunoreactive puncta observed at the BLA suggested a presynaptic localization of 
CB1 receptor. Immunofluorescence assays for VGLUT3 and GAD65 and the 
subsequent colocalization studies suggested the inhibitory nature of CB1 receptor 
containing presynaptic boutons (Figure 6). 
 M2 mAChR immunoreactivity was differentially localized along the hippocampal 
formation. The pyramidal neurons of CA1-CA3 displayed a dense network of fibers 
delineating the perikarya in basket-like formations. VGLUT3 displayed a somato-
dendritic immunostaining, but GAD65 immunoreactivity was present as a dense plexus 
of fibers around pyramidal neurons with a similar distribution to M2 mAChR. 
Colocalization studies showed the presence of M2 mAChR in presynaptic GABAergic 
terminals with a high degree of co-immunoreactivity with GAD65, and an almost total 
absence of expression on VGLUT3 positive cells (Figure 7). 
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4. Discussion  
 
Altered cannabinoid and muscarinic signaling is correlative to emotional learning and 
memory impairment in seven month-old 3xTg-AD mice 
 Changes in CB1 receptors have recently been described in several brain areas 
of 3xTg-AD mice which are similar to the changes found in the brains of AD patients, 
rendering this model suitable for the study of the neuronal correlates (Bedse et al., 
2014; Manuel et al., 2016). In the present study, we provide evidence of 
neuroanatomical and neurochemical modifications related to the eCB neuromodulatory 
system and muscarinic cholinergic signaling in the 3xTg-AD mice model, and of 
behavioral modifications at the onset of disease (7 months of age), when cognitive 
impairment is clearly established and is concurrent with limbic system mediated 
symptoms. The results point to the eCB system as a key element controlling neuronal 
homeostasis as well as the limbic component of cognition. 
 The results of behavioral assessment during the passive avoidance test, one 
typically used to evaluate learning and memory under anxiogenic conditions, may also 
be indicating the presence of fear and diminished motivation to explore as shown in a 
lesion rat model of AD (Babalola et al., 2012). 3xTg-AD mice had higher acquisition 
latency times than did controls. This is in agreement with the reduced exploratory 
activity and increased freezing behavior shown in the contextual fear-conditioning test, 
in the open field and in the passive avoidance test in this same transgenic mouse 
model of AD at 6 months of age (Gimenez-Llort et al., 2007; España et al., 2010; Filali 
et al., 2012). In addition, anxiety, fear, agitation and phobias may help to create a state 
of confusion which contributes to other behavioral disorders observed in AD patients, 
including learning and memory impairment (Ferretti et al., 2001; Aso and Ferrer, 2014).  
 The eCB system has emerged as a promising target for the treatment of several 
neurodegenerative disorders and has received a good deal of attention in AD. In this 
study, we report specific changes in density and in activity of CB1 receptors, indicative 
of a potentiation of cannabinoid signaling in the BLA and an attenuation in the olfactory 
bulb and hippocampal dentate gyrus of transgenic mice. The specificity for CB1 
receptors was demonstrated by the anatomical pattern of distribution of [3H]CP55,940 
binding sites in brain, in comparison with that of spleen. [3H]CP55,940 binding in 3xTg-
AD and CB1
+/+ mice was blocked by SR141716A and totally absent in CB1
-/- mouse 
brain. Indeed, SR144528, a specific CB2 receptor antagonist, failed to block the binding 
in the brain but completely inhibited it in the spleen (where the CB2 subtype is 
predominant) of both CB1
+/+ and CB1
-/- mice. On the other hand, up-regulation of CB2 
receptors is reported to occur during neuroinflammation associated with 
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neurodegenerative processes (Benito et al., 2003; Tolón et al., 2009; Schmöle et al., 
2015). Therefore, the absence of a CB2 receptor-mediated signal in the CNS of seven 
month-old 3xTg-AD mice, is in agreement with the lack of neuritic plaque-associated 
neuroinflammation at the onset of disease. Our results coincide with those of studies 
which report a significant increase in CB1 receptor density in BLA when only 
intracellular Aβ accumulation can be detected, and which may be related to the 
symptoms of fear and anxiety observed in these mice (España et al., 2010; Bedse et 
al., 2014). 
 
Behavioral outcomes of 3xTg-AD mice after the subchronic administration of synthetic 
cannabinoids. Possible functional interplay with muscarinic cholinergic signaling 
 The present study examines for the first time the neurochemical effects of 
cannabinoid agonism in 3xTg-AD mice and their behavioral correlates in a learning and 
memory task, which may be relevant in terms of clinical interventions in humans at the 
onset of disease. The results provide evidence that CB1 receptor activation, following 
repeated cannabinoid administration, was able to decrease the acquisition latency 
times in 3xTg-AD mice to Non-Tg levels during the learning trial, which may be related 
to the CB1 receptor density desensitization recorded in the BLA. Stressing factors can 
result in a modulation of the endocannabinoid levels in the amygdala, and can also 
induce a subsequent CB1 receptor-mediated suppression of GABA release in the BLA 
(Jenniches et al., 2015; Di et al., 2016; Morena et al., 2016). Interestingly, we observed 
both a down-regulation of CB1 receptors and an attenuation of their functional coupling 
to Gi/o proteins induced by the subchronic administration of JZL-184, comparable to the 
results obtained in a previous study, but at different doses (Kinsey et al., 2013). 
Moreover, the administration of WIN55,212-2 (1 mg/kg), decreases the acquisition 
latency times without significantly changing CB1 receptor functionality in the BLA. Our 
results confirm previous findings which showed that JZL184 selectively increased brain 
2-AG and also indicated that the inhibition of MAGL could be promising as a way to 
indirectly potentiate the activation of CB1 receptors or CB2 receptors (Busquets-Garcia 
et al., 2011; Kinsey et al., 2011). In this context, the pharmacological blockade or 
genetic deletion of MAGL dramatically raises brain 2-AG levels, down-regulates CB1 
receptor, and modulates synaptic plasticity, learning, memory and anxiety-like behavior 
(Pan et al., 2011). Accordingly, URB597, an AEA degrading enzyme inhibitor, induced 
CB1 receptor-mediated anxiolytic effects in the elevated plus maze (Moise et al., 2008). 
Moreover, a recent study shows that the intra-BLA administration of both AEA and 2-
AG hydrolysis inhibitors is able to attenuate anxiety-like responses, which are 
dependent on deregulated levels of eCB in the amygdala (Morena et al., 2016). 
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Conversely, chronic CB1 receptor blockade induced up-regulation of CB1 receptor 
expression, down-regulation in hippocampus, and modified anxiety-like behavior 
(Tambaro et al., 2013). 
 Depending on the specific location of CB1 receptors in inhibitory or excitatory 
neurons, the functional and physiological outcomes of this deregulated 
endocannabinoid signaling may be useful to understand the present results. In order to 
address this issue immunochemical studies were performed and we found that in the 
BLA CB1 receptor are more frequently located in GABAergic than in glutamatergic 
compartments, even though they have previously been detected in both of them 
(Kodirov et al., 2009; Ruehle et al., 2013; Shonesy et al., 2014; Robinson et al., 2016). 
The CB1 receptors in BLA were located in the proximity of GAD65 (the enzyme 
glutamate decarboxylase; GAD, associated with inhibitory nerve termini) (Kash et al., 
1999). In addition, the detection of VGLUT3 (the third subtype of glutamate vesicular 
transporter) has been used to identify both excitatory presynaptic boutons and 
glutamatergic somatodendritic compartments (Herzog et al., 2004). Although CB1 
receptors are present in both GABAergic and glutamatergic cellular compartments in 
areas such as the hippocampus, their activity could be lower in the inhibitory terminals 
(Steindel et al., 2013). However, in the BLA, CB1 receptors are highly expressed in 
axon terminals of GABAergic neurons which modulate GABA release via a presynaptic 
mechanism (Katona et al., 2001). Some authors have related a long-lasting increase in 
anxiety-like behavior with a hyperactivity of BLA, as a consequence of a decrease in 
the inhibitory synaptic transmission (Almeida-Suhett et al., 2014). Thus, eCB-mediated 
suppression of inhibitory inputs to BLA neurons is involved in the cellular mechanism 
for stress-induced increases in anxiety-like behavior (Roozendaal et al., 2009). The 
genetic deletion of MAGL or GAD65 triggers an excitatory-inhibitory imbalance leading 
to increased anxiety-like responses (Imperatore et al., 2015; Müller et al., 2015). The 
glucocorticoid-induced suppression of inhibitory synaptic inputs to BLA principal 
neurons has recently been proposed as playing a pivotal role in the regulation of 
emotional disorders (Di et al., 2016). Globally, the present findings suggest that an up-
regulation of the eCB tone in areas such as the BLA alters the local excitatory–
inhibitory balance, and may be an underlying mechanism involved in the observed 
differences in cognitive behavior. Furthermore, a reversion to Non-Tg mice behavioral 
parameters was recorded after the attenuation of eCB signaling mediated by a 
pharmacological desensitization of CB1 receptors. We propose that there is a CB1 
receptor-induced enhancement of the excitatory drive in brain areas such as the BLA 
due to the suppression of inhibition mediated by up-regulated CB1 receptor signaling, 
which, by decreasing GABAergic neurotransmission, is an important component of the 
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neurobiological mechanisms that control some cognitive deficits observed in 3xTg-AD 
mice (acquisition latency). 
 Moreover, the administration of WIN55,212-2 (1 mg/kg), but not JZL-184, was 
able to induce a significant increase in the activity mediated by mAChR in the BLA, 
revealing a possible interaction between both systems in limbic areas. This specific 
CB1 receptor-driven modulation of cholinergic neurotransmission in the amygdala could 
also be involved in the behavioral outcomes recorded with the passive avoidance test. 
In addition, these results support those of previous studies in which the role of the BLA 
cholinergic system, via mAChR, in memory retrieval in fear-induced learning was 
described (Malin et al., 2006; Nazarinia et al., 2017). Further behavioral studies are 
necessary in order to understand the meaning of CB1 receptor-induced modulation of 
muscarinic control and its influence on acquisition latency, and to verify its validity as a 
possible indicator of anxiety, attention, agitation or states of confusion. 
Regarding memory, step-through latency clearly distinguished the cognitively 
impaired AD-phenotype of 3xTg-AD mice, in accordance with previous studies (Clinton 
et al., 2007; Filali et al., 2012). Thus, 40% of 3xTg-AD mice did not remember the 
aversive stimulus received, while all the Non-Tg control mice did. However, under the 
present experimental conditions, we cannot rule out the possibility that the differences 
found in acquisition, or even putatively in consolidation, may also contribute to the 
performance of step-through latency. The desensitization of CB1 receptors by means of 
subchronic administration of direct and indirect agonists failed to induce significant 
modifications in this variable. However, the analgesic effects of CB1 receptor activation 
are well known (Meng et al., 1998). Subsequently, the pain threshold of the foot-shock 
in the passive avoidance test may be increased (Abush and Akirav, 2010). Therefore, 
the subtle variations in step-through latencies recorded after cannabinoid 
administration could be biased by the cannabinoid-induced analgesia. Further 
behavioral analyses by means of non-aversive stimulus-based learning and memory 
tests will help to clarify this question since 3xTg-AD mice do not seem to differ from 
Non-Tg in terms of pain thresholds (Filali et al., 2012; Baeta-Corral et al., 2015). 
However, the limbic system which is involved in cholinergic neurotransmission may be 
controlling specifically controls the consolidation and extinction of aversive or traumatic 
memories (Vazdarjanova and McGaugh, 1999).  
3xTg-AD mice present deficits in cognition and synaptic plasticity associated 
with intraneuronal Aβ accumulation (Oddo et al., 2003). Muscarinic activation, through 
the M2 mAChR subtype, promotes a rise in AMPA receptor sensitivity to glutamate, 
which finally leads to the so-called „muscarinic long term potentiation‟ essential to 
explain hippocampal neuronal plasticity (Segal and Auerbach, 1997). Behavioral and 
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neurochemical studies in M2
 mAChR knockout mice showed that the lack of receptors 
was accompanied by cognitive impairment in the passive avoidance test (Tzavara et 
al., 2003). The present immunofluorescence studies revealed the presynaptic 
localization of M2 mAChR in GABAergic terminals, presumably making contact with 
postsynaptic VGLUT3 immunoreactive pyramidal neurons in CA1-CA3. The present 
findings in 3xTg-AD mice are similar to those reported in rat brain, suggesting that ACh 
via M2 mAChR may reduce GABA release from presynaptic inhibitory terminals, 
leading to increased activity in the dendritic region of pyramidal neurons (Levey et al., 
1995; Hájos et al., 1998). The significant reduction in choline acetyltransferase activity 
described in hippocampus from middle-aged 3xTg-AD mice, but not associated with 
the loss of cholinergic neurons, may be related to the observed decrease in mAChR 
functionality (Perez et al., 2011). We suggest that intraneuronal accumulation of Aβ, 
beginning at 4 months of age, may trigger an early deregulation of the hippocampal 
muscarinic neurotransmission at the onset of disease, as observed in seven month-old 
3xTg-AD mice, thereby contributing to the cognitive impairment observed in this model 
(Billings et al., 2005). Moreover, an excitatory/inhibitory imbalance mediated by a 
deregulated presynaptic muscarinic neurotransmission in the hippocampus may 
underlie the impaired synaptic plasticity, i.e. the neurobiological substrate for creating 
and maintaining new memories. 
 
Conclusions. 
We provide evidence that muscarinic and cannabinoid signaling is altered in 
seven month-old 3xTg-AD mice, showing a specific regional and neuronal distribution 
in vulnerable limbic areas at the onset of disease. CB1 receptor-mediated hyperactivity 
in some specific brain areas may have behavioral correlates that correspond with the 
restoration to control levels after direct and indirect pharmacological desensitization of 
CB1 receptors. Finally, decreased muscarinic neurotransmission may be involved in 
memory-related impairment in 3xTg-AD mice. We propose that CB1 receptor 
desensitization is a plausible strategy to palliate specific behavioral impairment 
associated with genetic variants of AD. 
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6. Tables 
Table 1. [3H]CP55,940 binding in different brain areas of seven month-old Non-Tg and 
3xTg-AD mice expressed in fmol/mg t.e. of CB1 receptors. 
 Non-Tg 3xTg-AD  3xTg-AD  3xTg-AD   3xTg-AD 
  Vehicle Vehicle  WIN55,212-2 WIN55,212-2    JZL184 
                [0.1 mg/kg] [1 mg/kg]    [8 mg/kg] 
Telencephalon 
Amygdala      
   Anterior     209 ± 16      269 ± 16      240 ± 20     244 ± 19    209 ± 11 
   Basolateral     386 ± 12      497 ± 19***      469 ± 20     385 ± 32
$
    247 ± 14
###a,b,c,d
 
   Central     169 ± 6      216 ± 17      190 ± 27     211 ± 24    172 ± 12 
   Lateral     230 ± 10      253 ± 10      272 ± 29     246 ± 23    182 ± 16
#c
 
   Medial     121 ± 8      174 ± 16      155 ± 23     178 ± 24    122 ± 14 
Hippocampus     
CA1   593 ± 38 607 ± 28 542 ± 30     473 ± 32    410 ± 25 
   Oriens   541 ± 36 592 ± 37  584 ± 30     486 ± 18    366 ± 28**
b,c
 
   Pyramidal   924 ± 75 909 ± 69  878 ± 42     679 ± 47$    529 ± 56**b,c 
   Radiatum   603 ± 56 613 ± 51 559 ± 29     482 ± 34    434 ± 44 
CA3   591 ± 40 599 ± 19 543 ± 36     496 ± 24    396 ± 27 
   Oriens   545 ± 51 481 ± 39 499 ± 59     378 ± 32    394 ± 27 
   Pyramidal   885 ± 70 818 ± 65 763 ± 80     618 ± 67    599 ± 26*a,b 
   Radiatum   630 ± 89 596 ± 43 591 ± 58     487 ± 59    419 ± 45 
Dentate gyrus   473 ± 37 487 ± 17 454 ± 26     434 ± 40    348 ± 22 
   Granular   922 ± 75 855 ± 49 836 ± 50     711 ± 27    574 ± 35**
a,b,c
 
   Molecular   569 ± 55 544 ± 48 489 ± 32     404 ± 30    371 ± 32 
   Polymorphic   272 ± 25 267 ± 33 224 ± 25     233 ± 19    189 ± 11 
Subiculum   861 ± 86 909 ± 38 866 ± 53     712 ± 48    449 ± 56***
a,b,c;*d 
Cerebral cortex     
   Cingular     286 ± 17  316 ± 15  332 ± 25      308 ± 15    247 ± 10*
c
 
   Ectorhinal      291 ± 28  321 ± 17  331 ± 32      308 ± 31    220 ± 16*b, c 
   Entorhinal     254 ± 21  276 ± 18  271 ± 17      254 ± 19    164 ± 12*
b, c
 
   Frontal     499 ± 17  427 ± 16  501 ± 22      415 ± 17    310 ± 10**a, c 
   Motor   340 ± 8  314 ± 13  347 ± 24      317 ± 20    241 ± 11**
a, c; *b, d 
   Perirhinal     278 ± 32 302 ± 9  280 ± 23      271 ± 32    195 ± 13*b 
Rhinencephalon     
Lat. olf. tract N      281 ± 40      424 ± 38*      389 ± 32     327 ± 22    239 ± 17
##b,#c
 
Glom. olf. bulb      470 ± 8      304 ± 9***      293 ±15***      308 ± 19***    276 ± 12*** 
Data are expressed as mean ± S.E.M. *p<0.05, ***p<0.001 vs Non-Tg (vehicle).                                                                                                                                                                                                        
#p<0.05, ##p<0.01, ###p<0.001 vs Non-Tg (vehicle) (a); 3xTg-AD (vehicle) (b); 3xTg-AD 
(0.1 mg/kg WIN55,212-2) (c); 3xTg-AD (1 mg/kg WIN55,212-2) (d). $p<0.05 vs 3xTg-
AD (vehicle).           
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Table 2. [35S]GTPγS binding in different brain areas of seven-month-old Non-Tg 
and 3xTg-AD mice evoked by WIN55,212-2 (10 µM) expressed as percentage 
of stimulation over the basal binding. 
  Non-Tg 3xTg-AD  3xTg-AD  3xTg-AD   3xTg-AD 
   Vehicle Vehicle  WIN55,212-2 WIN55,212-2    JZL184 
                 [0.1 mg/kg] [1 mg/kg]    [8 mg/kg] 
Brain region           
Telencephalon           
Amygdala           
      Anterior   82 ± 16   79 ± 16  68 ± 14   98 ± 16   89 ± 24 
      Basolateral 168 ± 24  281 ± 41* 311 ±  42 213 ± 25 191 ± 31 
      Central   76 ± 28   61 ± 14   66 ± 17  58 ± 19   63 ± 21 
      Lateral 156 ± 26 197 ± 36 167 ± 45 159 ± 26 123 ± 23 
      Medial   35 ± 13 56 ± 9 100 ± 15  77 ± 20   89 ± 20 
Hippocampus           
CA1 114 ± 17 63 ± 13 64 ± 6   61 ± 9.9 59 ± 8 
      Oriens 183 ± 40 164 ± 14 132 ± 11 178 ± 16 110 ± 19 
      Pyramidal 142 ± 23 165 ± 49 157 ± 15 151 ± 20 112 ± 22 
      Radiatum 144 ± 32 141 ± 34 105 ± 16 109 ± 16  53 ± 7
#
 
CA3 154 ± 14 104 ± 19 105 ± 11   96 ± 15 116 ± 25 
      Oriens 143 ± 18 161 ± 17 134 ± 21 143 ± 16 121 ± 21 
      Pyramidal  94 ± 21 117 ± 22 135 ± 25 141 ± 23   82 ± 13 
      Radiatum 189 ± 51 123 ± 35   94 ± 19   89 ± 13   93 ± 13 
Dentate gyrus 119 ± 17 70 ± 8 65 ± 8   62 ± 10   68 ± 12 
      Granular 293 ± 71 143 ± 20 193 ± 12 186 ± 36 152 ± 25 
      Molecular 199 ± 34  108 ± 18*   99 ± 13 113 ± 8 112 ± 20 
      Polymorphic 261 ± 24 146 ± 20 104 ± 14 134 ± 13 112 ± 13 
Ventral subiculum 162 ± 37 130 ± 21 106 ± 15 125 ± 18 127 ± 19 
Cerebral cortex           
      Cingular   90 ± 10 110 ± 14 102 ± 14   98 ± 10 69 ± 7 
      Ectorhinal 159 ± 37 131 ± 12 141 ± 21 115 ± 25   93 ± 19 
      Entorhinal 154 ± 27 165 ± 36 135 ± 22 180 ± 17 149 ± 20 
      Frontal 101 ± 14 114 ± 20   99 ± 13 115 ± 17 107 ± 15 
      Motor 108 ± 10 127 ± 18   93 ± 17 88 ± 6 87 ± 5 
      Perirhinal 168 ± 41 146 ± 29 127 ± 21 107 ± 21   85 ± 12 
Striatum    134 ± 19       81 ± 8*        80 ± 6      102 ± 10       73 ± 13 
Rhinencephalon           
Lat. olf. tract N 221 ± 58 232 ± 71 230 ± 44   325 ± 61 326 ± 60 
Glom. olf. bulb 580 ± 61     343 ± 18** 317 ± 41   391 ± 50 331 ± 22 
Data are expressed as mean ± S.E.M.                                                                                                    
*p < 0.05 vs NonTg-vehicle; **p < 0.01 vs NonTg (vehicle).                                                                
# p < 0.05 when compared to 3xTg-AD (vehicle).                                                
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Table 3. [35S]GTPγS binding in different brain areas of seven-month-old Non-Tg 
and 3xTg-AD mice evoked by carbachol (100 µM) expressed as percentage of 
stimulation over the basal binding. 
  NonTg 3xTg-AD 3xTg-AD 3xTg-AD 3xTg-AD 
  Vehicle Vehicle WIN55.212-2 WIN55.212-2 JZL-184 
      [0.1 mg/kg] [1 mg/kg] [8 mg/kg] 
Brain region           
Telencephalon           
Amygdala           
      Anterior    89 ± 18.0     92 ± 21.1     128 ± 19.9    116 ± 9.7  82 ± 17.4 
      Basolateral  102 ± 13.7      55 ± 10.5*       68 ± 16.0      97 ± 12.6
#
  71 ± 11.0 
      Central  43 ± 7.6  31 ± 9.5       40 ± 8.5      43 ± 5.9  53 ± 15.1 
      Lateral    96 ± 18.3      41 ± 11.3*       43 ± 11.9      84 ± 9.1
##
 55 ± 8.1 
      Medial  66 ± 5.8    49 ± 14.6       31 ± 6.7      54 ± 10.0  46 ± 11.2 
Hippocampus           
CA1  42 ± 6.6   21 ± 3.0*       38 ± 8.5      39 ± 12.0 28 ± 7.6 
      Oriens  33 ± 6.9 29 ± 9.2       36 ± 7.6      59 ± 11.0 26 ± 8.7 
      Pyramidal  30 ± 6.0   16 ± 6.8*       23 ± 6.1      34 ± 7.0 14 ± 4.8 
CA3  43 ± 9.1 33 ± 6.4       43 ± 5.4      47 ± 15.1 46 ± 9.3 
      Oriens     30 ± 11.9 24 ± 9.9       27 ± 8.0      49 ± 11.7 27 ± 4.6 
      Pyramidal     34 ± 14.4 29 ± 5.2       28 ± 10.2      53 ± 15.0 33 ± 7.3 
Dentate gyrus  34 ± 7.6 21 ± 4.7       28 ± 6.4      21 ± 5.2 21 ± 4.1 
      Granular  23 ± 8.8 26 ± 9.4       32 ± 10.5      19 ± 5.6 21 ± 6.4 
      Molecular  21 ± 6.2 19 ± 4.4       16 ± 13.2      17 ± 4.2  8 ± 3.1 
      Polymorphic    16 ± 15.1 24 ± 5.2         3 ± 12.3      23 ± 13.2 11 ± 5.7 
Cerebral cortex           
      Cingular    62 ± 12.2 64 ± 13.0       54 ± 9.6      68 ± 10.9 58 ± 9.5 
      Ectorhinal    39 ± 14.8 42 ± 11.7       38 ± 12.8      46 ± 8.7 37 ± 5.2 
      Entorhinal    41 ± 12.9 30 ± 13.6       27 ± 9.2      37 ± 11.3 34 ± 8.8 
      Frontal    54 ± 17.9 57 ± 11.8       42 ± 8.9      68 ± 11.9 57 ± 9.6 
      Motor    59 ± 10.9 56 ± 12.1       50 ± 10.7      59 ± 11.5 46 ± 8.5 
      Perirhinal  46 ± 6.7 40 ± 4.7       43 ± 9.8      45 ± 5.4   51 ± 12.5 
Rhinencephalon           
Lat. olf. tract N  173 ± 22.3   107 ± 15.9*     125 ± 14.3    140 ± 19.9 112 ± 8.2 
Glom. olf. bulb  193 ± 25.9   295 ± 14.9*     312 ± 45.0     279 ± 53.7   266 ± 37.6 
Data are expressed as mean ± S.E.M.                                                                                                               
*p < 0.05 compared to Non-Tg (vehicle)                                                                                                    
#p < 0.05; ##p < 0.01 when compared to 3xTg-AD (vehicle).           
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9. Figure captions 
 
Figure 1. Synopsis of the experimental design including treatment schedule and 
behavioral assessment. 
 
Figure 2. Passive avoidance test and CB1 receptor binding sites. (A) Acquisition 
latency times during the learning trial in both genotypes in the absence of treatment; 
***p < 0.01 vs Non-Tg. (B) Step-through latency times in both genotypes represented 
as Kaplan-Meier survival curves. (C) 3xTg-AD mice treated with different cannabinoid 
agonists. The subchronic administration of WIN55,212-2 (1 mg/kg) and JZL184 (8 
mg/kg) for seven consecutive days triggered a statistically significant decrease in the 
acquisition latency compared to that obtained in the Non-Tg group; * p < 0.05 vs 3xTg-
AD mice treated with vehicle. (D) Step-through latency times in 3xTg-AD mice 
represented as Kaplan-Meier survival curves. The probability is plotted over the step-
through latency in 3xTg-AD mice after different cannabinoid-based treatments. (E) 
[3H]CP55,940 binding autoradiography in representative brain coronal slices from both 
genotypes treated with vehicle and from 3xTg-AD treated with either WIN55,212-2 (1 
mg/kg) or JZL184 (8 mg/kg). Note that both pharmacological treatments decreased the 
density of receptors in the whole grey matter including the basolateral amygdala (BLA) 
(boxed area). [3H]-microscales used as standards in µCi/g t.e. (n = 9-10 mice/group). 
Scale bar: 5 mm. 
 
Figure 3. [3H]CP55,940 binding autoradiography in brain and spleen. The image 
show the cannabinoid receptor distribution in brain and spleen samples from 3xTg-AD, 
CB1 receptor knockout (CB1
-/-) and wild type (CB1
+/+) mice. The total binding is shown in 
the top row, displaying the characteristic and well-described distribution of cannabinoid 
receptors in the brain, and surrounding the lymphatic nodules (white pulp) in the 
spleen. In the presence of 0.1 µM of SR141716A, a CB1 receptor specific antagonist, 
binding is almost completely blocked in the brain but not in the spleen (middle row) 
while 0.1 µM of SR144528, a CB2 receptor specific antagonist, completely displaced 
the [3H]CP55,940 binding in the spleen without affecting the binding in the brain 
(bottom row). Note the absence of binding in the brain from CB1
-/- and the identical 
distribution in the spleen from both Non-Tg and knockout mice, revealing the 
preponderance of CB1 receptors in the brain and CB2 receptors in spleen tissue, and 
the specificity of the cannabinoid antagonists. Scale bar = 5 mm. 
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Figure 4. [35S]GTPγS autoradiography. [35S]GTPγS binding evoked by both 
WIN55,212-2 (10 µM) for cannabinoid receptors (A-D) and carbachol (100 µM) for 
M2/M4 muscarinic acetylcholine receptors (mAChR) (E-H), in representative coronal 
brain slices from Non-Tg and 3xTg-AD mice treated with vehicle and cannabinoid 
agonists. The highest CB1 receptor stimulation was found in the hippocampus, the 
most caudal portion of the globus pallidus, the deeper layers of the cortex, and the 
amygdaloid complex. Thus, in the amygdala, the latero-basolateral region (boxed area) 
(A-D) seems to be the most activated, displaying a hyperactivation in 3xTg-AD (B) 
mice, which is attenuated with both cannabinoids (C-D). Moreover, deregulation of 
mAChR functionality in 3xTg-AD mice was found. Note the decrease in the latero-
basolateral region and in the pyramidal layer of the hippocampal CA1 region (boxed 
areas) (F) and the potentiation of muscarinic signaling in the amygdala following the 
subchronic administration of 1 mg/kg of WIN55,212-2 (G). [14C]-microscales used as 
standards in µCi/g t.e. Scale bar: 5 mm. 
 
Figure 5. CB1 receptor-mediated signaling and behavior. [
3H]CP55,940 binding in 
the BLA in both genotypes treated with vehicle (A) and in 3xTg-AD mice treated with 
WIN55,212-2 (0.1 mg/kg or 1 mg/kg) or JZL184 (8 mg/kg) (B). Correlation analyses 
between the CB1 receptor density in the BLA and the acquisition latency times of both 
genotypes (C) and of 3xTg-AD mice after cannabinoid treatments (D). Note that data 
are grouped according to both, genotype and treatment. Quantification of CB1 receptor 
stimulation (% over basal activity) evoked by WIN55,212-2 (10 µM) in the BLA of both 
genotypes (E) and of 3xTg-AD mice treated with WIN55,212-2 (0.1 mg/kg or 1 mg/kg) 
or JZL184 (8 mg/kg) (F). Correlation analyses between the endocannabinoid signaling 
in the BLA and the acquisition latency times of both genotypes (G) and of 3xTg-AD 
mice after cannabinoid treatments (H). Note that data are grouped according to 
genotype and not to treatment (n = 6 mice/group). *p < 0.05; **p < 0.01 and ** p < 
0.001; two-tailed unpaired Student‟s t test. 
 
Figure 6. Localization of CB1 receptors in the BLA. Double labeling of tissue slices 
including the amygdaloid complex from seven month-old 3xTg-AD mice processed for 
CB1 receptor (in green) and vesicular glutamate transporter type 3 (VGLUT3) (A2 and 
C2 in red) as a glutamatergic marker, and glutamic acid decarboxylase isoform 65kDa 
(GAD65) (B2 and D2 in red) as a GABAergic presynaptic marker. The different 
amygdaloid nuclei exhibited specific CB1 receptor-immunostaining patterns. VGLUT3 
was distributed presumably in postsynaptic somatodendritic compartment (A2 and C2) 
while GAD65 immunostaining was clearly delineated presynaptic inhibitory boutons (B2 
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and D2). In low magnification images, note the distribution of CB1 receptors 
surrounding positive glutamatergic neurons (A3) and sharing localization with GAD65 
(B3); scale bar: 150 µm. High magnification images showed the intracellular 
localization of VGLUT3 (C2) closely surrounding the nuclei stained with Hoechst (C3 in 
blue) revealing the almost complete lack of colocalization with CB1 receptors (C4). 
Conversely, CB1 receptors were located on GAD65-positive terminals (D4), revealing 
its presynaptic localization on inhibitory synaptic boutons. Scale bar = 10 µm. Bregma -
1.82 mm. CeL central amygdaloid nucleus, lateral division; La lateral amygdaloid 
nucleus; BLA basolateral amygdaloid nucleus, anterior part; BLP basolateral 
amygdaloid nucleus, posterior part; BMP basomedial amygdaloid nucleus, posterior 
part. 
Figure 7. Localization of M2 mAChR in the hippocampus.  Double labeling of tissue 
slices including the CA1 field of the hippocampus from a representative 7-month-old 
3xTg-AD mouse processed for M2 mAChR (in red) and VGLUT3 (A1 and C1 in green) 
as a glutamatergic marker, and GAD65 (B1 and D1 in green) as a GABAergic 
presynaptic marker (B). The different hippocampal subfields exhibited specific M2 
mAChR-immunostaining patterns delineating the perikarya of the large pyramidal 
neurons in basket-like formations. VGLUT3 was distributed near the nucleus (A1 and 
C1), presumably in the somatodendritic compartment of pyramidal neurons, while 
GAD65 immunostaining (B1 and D1) clearly delineated presynaptic inhibitory boutons. 
In low magnification images, note that M2 mAChR-immunoreactivity showed a 
complementary distribution to VGLUT3, surrounding the pyramidal neurons (A3), and 
was localized in GAD65-positive presynaptic terminals (B3); scale bar: 150 µm. High 
magnification images revealed the intracellular localization of VGLUT3 (C1) closely 
surrounding the nuclei stained with Hoechst (C3 in blue) and the almost complete lack 
of colocalization with M2 mAChR (C4). Conversely, M2 mAChR was distributed in 
GAD65-positive terminals, revealing the presynaptic localization on inhibitory synaptic 
boutons (C4). Scale bar = 10 µm. Bregma -3.08 mm. Alv alveus of the hippocampus; 
Or oriens layer of the hippocampus; Py pyramidal cell layer of the hippocampus; Rad 
radiatum layer of the hippocampus; LMol lacunosum molecular layer of the 
hippocampus.  
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